<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="utf-8">
    </meta>
    <title>Metadata reference</title>
  </head>

  <body>
    <h1>Metadata reference</h1>
    <div id="tocContainer">
      <ul>
        <li><a href="#package">Package ID</a></li>
        <li><a href="#trackedEntityTypes">Tracked Entity Types</a></li>
        <li><a href="#trackedEntityAttributes">Tracked Entity Attributes</a></li>
        <li><a href="#programs">Programs</a></li>
        <li><a href="#programRules">Program Rules</a></li>
        <li><a href="#programIndicators">Program Indicators</a></li>
        <li><a href="#constants">Constants</a></li>
        <li><a href="#dataElements">Data Elements</a></li>
        <li><a href="#dataElementGroups">Data Element Groups</a></li>
        <li><a href="#categoryCombos">Category Combos</a></li>
        <li><a href="#categories">Categories</a></li>
        <li><a href="#categoryOptions">Category Options</a></li>
        <li><a href="#categoryOptionCombos">Category Option Combos</a></li>
        <li><a href="#optionSets">Option Sets</a></li>
        <li><a href="#options">Options</a></li>
        <li><a href="#indicatorGroups">Indicator Groups</a></li>
        <li><a href="#indicators">Indicators</a></li>
        <li><a href="#indicatorTypes">Indicator Types</a></li>
        <li><a href="#programIndicatorGroups">Program Indicator Groups</a></li>
        <li><a href="#dashboards">Dashboards</a></li>
        <li><a href="#visualizations">Visualizations</a></li>
        <li><a href="#maps">Maps</a></li>
        <li><a href="#eventReports">Event Reports</a></li>
        <li><a href="#documents">Resources</a></li>
        <li><a href="#userGroups">User Groups</a></li>
      </ul>
    </div>
    <h2>Package info</h2>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Code</th>
        <td>TB</td>
      </tr>
      <tr>
        <th>Type</th>
        <td>DRS</td>
      </tr>
      <tr>
        <th>Version</th>
        <td>TRACKER</td>
      </tr>
      <tr>
        <th>DHIS2 version</th>
        <td>V0.9.0</td>
      </tr>
      <tr>
        <th>Created</th>
        <td>DHIS2.34</td>
      </tr>
      <tr>
        <th>Identifier</th>
        <td>TB_DRS_TRACKER_V0.9.0_DHIS2.34_2021-02-05T15:48</td>
      </tr>
    </table>
    <h2 id="trackedEntityTypes">Tracked entity types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>2021-01-20</td>
        <td>MCPQUTHX1Ze</td>
      </tr>
    </table>
    <h3>Tracked Entity Type - Tracked Entity Type Attributes</h3>
    <table>
      <tr>
        <th>Tracked Entity Type</th>
        <th>Tracked Entity Type Attribute</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>gqLw62UZlrD</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>hKZ9AJpnVcG</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>loHxNJH4IvV</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>qb8PkSObwqh</td>
      </tr>
    </table>
    <h2 id="trackedEntityAttributes">Tracked entity attributes</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Code</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Cluster ID</td>
        <td></td>
        <td></td>
        <td>2020-06-26</td>
        <td>aOrGt5JE0gV</td>
      </tr>
      <tr>
        <td>Family name</td>
        <td></td>
        <td>Family name of the patient</td>
        <td>2021-01-22</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Patient DRS ID</td>
        <td></td>
        <td></td>
        <td>2020-11-06</td>
        <td>BdvE9shT6GX</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td></td>
        <td>Sex of Person</td>
        <td>2021-01-22</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>Location of Residence (GPS)</td>
        <td></td>
        <td>The location (coordinates) of the place of residence</td>
        <td>2020-12-10</td>
        <td>f038nOc9uRF</td>
      </tr>
      <tr>
        <td>Administrative area of residence</td>
        <td></td>
        <td></td>
        <td>2021-01-22</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td></td>
        <td>Date of birth plus calculated age</td>
        <td>2021-02-05</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td></td>
        <td></td>
        <td>2021-01-14</td>
        <td>ntelZthDPpR</td>
      </tr>
      <tr>
        <td>Country of origin</td>
        <td></td>
        <td>Patient's country of origin</td>
        <td>2020-06-26</td>
        <td>PBdqXh8Nvuj</td>
      </tr>
      <tr>
        <td>DELETE_Patient DRS Serial Number</td>
        <td></td>
        <td></td>
        <td>2020-12-10</td>
        <td>Qj7EXFIXcyc</td>
      </tr>
      <tr>
        <td>Health Facility Code</td>
        <td></td>
        <td>From master facility list</td>
        <td>2021-01-28</td>
        <td>sWn0CERcUYj</td>
      </tr>
      <tr>
        <td>Given name</td>
        <td></td>
        <td>The name of the patient or initials</td>
        <td>2021-01-31</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Address (current)</td>
        <td></td>
        <td>Current home address of the patient/case </td>
        <td>2021-01-31</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td></td>
        <td></td>
        <td>2021-02-05</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
    </table>
    <h2 id="programs">Programs</h2>
    <h3>Anti-Tuberculosis Drug Resistance Survey (DRS)</h3>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Name</th>
        <td>Anti-Tuberculosis Drug Resistance Survey (DRS)</td>
      </tr>
      <tr>
        <th>Tracked Entity Type:</th>
        <td>Person</td>
      </tr>
      <tr>
        <th>Last updated:</th>
        <td>2020-10-16</td>
      </tr>
      <tr>
        <th>UID:</th>
        <td>KYzHf1Ta6C4</td>
      </tr>
    </table>
    <h4>Program Stages</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>2020-12-04</td>
        <td>GcwlzpdiI9M</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>2020-12-04</td>
        <td>GkWDp4w0oLP</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>2021-01-12</td>
        <td>mKxKBtIDl6q</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>2020-12-04</td>
        <td>oHeGGP8b2jT</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>2020-12-04</td>
        <td>ucGVfFax931</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>2020-12-04</td>
        <td>Y6qhyXKY6k5</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>2020-12-04</td>
        <td>ZVfK21voZUN</td>
      </tr>
    </table>
    <h4>Program Stage - Program Stage Section - Data Element</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Program Stage Section</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Screening Test Results for HIV</td>
        <td>TB DRS CRF: HIV test date</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Screening Test Results for HIV</td>
        <td>TB DRS CRF: HIV test result</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CRF: Bacteriological Confirmation - microscopy</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CRF: Bacteriological Confirmation - Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CRF: Specimen 1 microscopy test result</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CRF: Specimen 2 microscopy test result</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CRF: Date of Xpert MTB/RIF initial screening test</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CRF: Xpert MTB/RIF initial screening result</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - control question</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - Injections for TB</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - length of sickness - weeks</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - names of drugs</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - other symptoms of lung disease</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - prior symptoms</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - sputum examinations</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CRF: Treatment history - TB drugs</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Based on Medical Records</td>
        <td>TB DRS CRF: Treatment history - prior TB registration</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Treatment History Based on Medical Records</td>
        <td>TB DRS CRF: Treatment history - previous TB registration number</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CRF: Treatment history - Treatment over 1 month</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CRF: Treatment history - outcome</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CRF: Treatment history - officer name</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CRF: Treatment history - regimen</td>
      </tr>
      <tr>
        <td>Case report form</td>
        <td>Final Treatment History Decision</td>
        <td>Previous treatment initiation date</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Date samples arrived at NRL</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Date samples shipped to NRL</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 collection date</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 additive</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 collection date</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 additive</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 collection date</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 additive</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Specify other (Sample 1)</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Specify other (Sample 2)</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Specify other (Sample 3)</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Specify other (Sample 4)</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 collection date</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>Sample collection and shipment to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 additive</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Final microscopy result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Final culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Final culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample rejected or lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Storage Only</td>
        <td>TB Lab: Storage only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: Targeted gene sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Comments and Remarks</td>
        <td>TB Lab: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample rejected or lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Final microscopy result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Final culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Final culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: Targeted gene sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Storage Only</td>
        <td>TB Lab: Storage only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Comments and Remarks</td>
        <td>TB Lab: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample rejected or lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Final microscopy result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Final culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Final culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: Targeted gene sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Storage Only</td>
        <td>TB Lab: Storage only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Comments and Remarks</td>
        <td>TB Lab: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample rejected or lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sample Rejected or Lost</td>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Final microscopy result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Final culture result (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Final culture result (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: Targeted gene sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Date of results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Genotypic speciation results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Storage Only</td>
        <td>TB Lab: Storage only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Comments and Remarks</td>
        <td>TB Lab: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Date samples shipped to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Samples shipped to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Date samples arrived at SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: DRS ID</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Reasons for not shipping samples to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of culture result (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of culture result (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Date of results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF</td>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Final culture result (liquid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Final culture result (solid media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Final microscopy result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF</td>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Rif/Inh)</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Sample/s Rejected or Lost</td>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Sample/s Rejected or Lost</td>
        <td>TB Lab: Sample rejected or lost</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Fq/2LI)</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - LPA (Rif/Inh)</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Storage Only</td>
        <td>TB Lab: Storage only</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing</td>
        <td>TB Lab: Targeted gene sequencing</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS genotypic speciation results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Targeted Gene Sequencing</td>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Date of results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Genotypic speciation results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>File Upload Section</td>
        <td>TB DRS SRL: Import .csv</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Comments and Remarks</td>
        <td>TB DRS SRL: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Whole Genome Sequencing</td>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
      </tr>
    </table>
    <h2 id="programIndicators">Program Indicators</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Analytics Type</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Inh (CC) susceptible</td>
        <td>Sub DST SM: new patients - Inh CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>A4tOZ6DtOz6</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Pza contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Pza contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>A6hImpJUCnp</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Dlm resistant</td>
        <td>Sub DST SM: new patients - Dlm res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>A9gJNpnubW6</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Emb resistant</td>
        <td>Sub DST LM: prev patients - Emb res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AAaf1N6q9Kc</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Inh CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>abdl4RkyzwL</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lzd contaminated</td>
        <td>Sub DST LM: samples - Lzd contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ADNg2qsAAcK</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Bdq resistant</td>
        <td>Sub DST SM: samples - Bdq res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>adnY7HmKOSi</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) contaminated</td>
        <td>Sub DST LM: samples - Mfx CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ae5XHffdlOT</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>Init DST SM: prev patients - Mfx CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aEQVSqDQ91m</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Kan resistant</td>
        <td>LPA (Fq/2LI): new patients - Kan res</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>afmIU4uXULr</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Emb susceptible</td>
        <td>Sub DST LM: prev patients - Emb ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ahmEPvvLdlB</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Cfz susceptible</td>
        <td>Sub DST LM: samples - Cfz ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AhU8qnVRvyB</td>
      </tr>
      <tr>
        <td>Missing data: age</td>
        <td>Missing data: age</td>
        <td></td>
        <td>Patients with age data missing</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AIhr0Sqq0Nl</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CC) indeterminate</td>
        <td>Sub DST LM: samples - Inh CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Aiy6br5cVtS</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CC) indeterminate</td>
        <td>Init DST SM: samples - Mfx CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AJ626bsdSe7</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CC) contaminated</td>
        <td>Sub DST LM: samples - Inh CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aLoApEYPHN8</td>
      </tr>
      <tr>
        <td>Culture (solid media): previously treated patients - contaminated</td>
        <td>Culture SM: prev patients - contam</td>
        <td></td>
        <td>Previously treated patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aLyPlwg2jot</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Rif contaminated</td>
        <td>Sub DST SM: samples - Rif contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AnE9y3CTG55</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Dlm susceptible</td>
        <td>Sub DST SM: patients - Dlm ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AoNRpuKHFIA</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CC) resistant</td>
        <td>Sub DST SM: prev patients - Mfx CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ap5DhakUaof</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 1 day</td>
        <td>Culture LM: 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>apEsA0h0WnR</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Mfx (CB) susceptible</td>
        <td>Sub DST SM: new patients - Mfx CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>APrBMG15JPD</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Inh (CC) susceptible</td>
        <td>Sub DST SM: patients - Inh CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aqiSmfOO1Y8</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Rif resistant</td>
        <td>Sub DST LM: new patients - Rif res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aQYGSuGN2yc</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - Inh indeterminate</td>
        <td>LPA (Rif/Inh): patients - Inh indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aRT2098p8t3</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Pza indeterminate</td>
        <td>Sub DST LM: samples - Pza indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ASk2lczUEoC</td>
      </tr>
      <tr>
        <td>Samples: 10 days</td>
        <td>Collection arrival interval: 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>asvQqsKFI4O</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CC) resistant</td>
        <td>Sub DST LM: prev patients - Mfx CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ATlmsxFz21i</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lfx contaminated</td>
        <td>Init DST SM: samples - Lfx contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ATMaMtQexcy</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Cfz contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AUZxWKFQOIK</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Pza contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>aW1dvUXmJzF</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lfx susceptible</td>
        <td>Sub DST LM: samples - Lfx ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AxJiEHXPR4O</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CC) resistant</td>
        <td>Init DST SM: samples - Inh CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>AZuK40TqYeX</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Rif resistant</td>
        <td>Init DST LM: prev patients - Rif res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>B5d9eKm8nRR</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Lzd resistant</td>
        <td>Sub DST SM: prev patients - Lzd res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>b5ipTVVUxgZ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CB) resistant</td>
        <td>Sub DST SM: prev patients - Inh CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>B9veWJCIhm3</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Bdq contaminated/indeterminate</td>
        <td>Init DST SM: patients - Bdq contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BaMzkG7QFr3</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for subsequent DST (liquid media)</td>
        <td>Sub DST LM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BAx8oO7z3BL</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Emb resistant</td>
        <td>Init DST SM: samples - Emb res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BBfev9dl9RM</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Pza resistant</td>
        <td>Init DST LM: patients - Pza res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bbvugBgfLh0</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Cfz resistant</td>
        <td>Sub DST LM: new patients - Cfz res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Bd06WGYcdgI</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Lzd susceptible</td>
        <td>Sub DST SM: prev patients - Lzd ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BDa3bpSHQfR</td>
      </tr>
      <tr>
        <td>Samples with LPA (Rif/Inh) test result</td>
        <td>LPA (Rif/Inh): samples - result</td>
        <td></td>
        <td>Samples with result for LPA (Rif/Inh)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bE3YcdNxA3g</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Dlm resistant</td>
        <td>Init DST LM: patients - Dlm res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>belqKaig0KY</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Amk contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Amk contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bg6znd2CWYH</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Mfx (CC) susceptible</td>
        <td>Init DST SM: new patients - Mfx CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bibTiiTflBW</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CB) susceptible</td>
        <td>Sub DST LM: samples - Inh CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BifclMTmRC8</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Bdq contaminated/indeterminate</td>
        <td>Init DST LM: patients - Bdq contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bIHg1wvFPuX</td>
      </tr>
      <tr>
        <td>Culture (liquid media): new patients - NTM</td>
        <td>Culture LM: new patients - NTM</td>
        <td></td>
        <td>New patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Bl0VfF5WWxe</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>Init DST SM: patients - Inh CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bLhO4Hh4j7O</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Amk contaminated</td>
        <td>Init DST LM: samples - Amk contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bNdyJEAQZYH</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Lzd susceptible</td>
        <td>Sub DST SM: patients - Lzd ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>booODOHpIFb</td>
      </tr>
      <tr>
        <td>Samples with LPA (Fq/2LI) test result</td>
        <td>LPA (Fq/2LI): samples - result</td>
        <td></td>
        <td>Samples with result for LPA (Fq/2LI)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BP1h0h5Fcsc</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Mfx (CB) susceptible</td>
        <td>Sub DST SM: patients - Mfx CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bPfqNC7BOgJ</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Amk/Cap resistant</td>
        <td>LPA (Fq/2LI): prev patients - Amk/Cap res</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: resistant. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BpRbOc95EiZ</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Bdq contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bPWnbBZ4zc1</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Amk contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Amk contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BQ8ftQEraa4</td>
      </tr>
      <tr>
        <td>Culture (solid media): patients - contaminated</td>
        <td>Culture SM: patients - contam</td>
        <td></td>
        <td>Patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BRoeNFPYHhT</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Amk contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Amk contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bSe8cLu9vaB</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CB) resistant</td>
        <td>Init DST LM: prev patients - Mfx CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BTG0cxe1miz</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Lfx susceptible</td>
        <td>Init DST LM: prev patients - Lfx ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>btPg6w5CrOs</td>
      </tr>
      <tr>
        <td>Patients with invalid result for LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh): patients - invalid result</td>
        <td></td>
        <td>Patients with invalid LPA (Rif/Inh) result</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bUSPnAIXlHM</td>
      </tr>
      <tr>
        <td>Days from sample collection to culture inoculation (liquid media)</td>
        <td>Culture LM: collection-inoculation interval</td>
        <td></td>
        <td>Days from sample collection to inoculation. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BwTuzAmHJY2</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Emb susceptible</td>
        <td>Init DST LM: samples - Emb ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BXayDcGzAQ5</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CB) susceptible</td>
        <td>Sub DST LM: prev patients - Inh CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bxokCBL7Fa6</td>
      </tr>
      <tr>
        <td>Started culture (solid media) tests</td>
        <td>Culture SM: started tests</td>
        <td></td>
        <td>Started culture SM tests</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bXTRrrObrqh</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Inh (CB) resistant</td>
        <td>Init DST LM: patients - Inh CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bxVekLXvoG6</td>
      </tr>
      <tr>
        <td>Microscopy: previously treated patients - negative</td>
        <td>Microscopy: prev patients - negative</td>
        <td></td>
        <td>Previously treated patients with microscopy result "negative". If more than one sample is examined per patient, "negative" result is recorded if all samples are "negative". Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>by5T3Wqf1Yx</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CC) indeterminate</td>
        <td>Sub DST SM: samples - Mfx CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bYFSgzsh4y2</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Dlm resistant</td>
        <td>Sub DST LM: prev patients - Dlm res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bYO87TQdvrx</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Dlm contaminated/indeterminate</td>
        <td>Init DST LM: patients - Dlm contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BZapNkxbmGh</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Mfx CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>BzfUTfps4gS</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Bdq contaminated</td>
        <td>Init DST LM: samples - Bdq contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bZiq1qPRaJM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - invalid</td>
        <td>Xpert MTB/RIF Ultra: samples - invalid</td>
        <td></td>
        <td>Samples with result "invalid" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>bZYLsyngaPn</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Mfx (CB) susceptible</td>
        <td>Init DST LM: new patients - Mfx CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>c0Z8dcZwA9o</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Amk resistant</td>
        <td>Init DST SM: new patients - Amk res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>C2bwEfFwiBX</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Cfz susceptible</td>
        <td>Init DST SM: new patients - Cfz ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>c2PFlkVS4Zz</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 2 days</td>
        <td>LPA (Rif/Inh): 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>c2pvFmOjpxD</td>
      </tr>
      <tr>
        <td>Patients with culture inoculation date (solid media)</td>
        <td>Culture SM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>c5whDMhSvRT</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Mfx (CB) resistant</td>
        <td>Sub DST SM: new patients - Mfx CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>c7A83DBkpom</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Bdq resistant</td>
        <td>Init DST LM: new patients - Bdq res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>c9iFIVVuVMD</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - error</td>
        <td>Xpert MTB/RIF: samples - Error</td>
        <td></td>
        <td>Samples with result "error" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CBzjrquAv7v</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Rif susceptible</td>
        <td>Init DST LM: prev patients - Rif ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ccIrRzBwp6v</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Lzd contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Lzd contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CCqP9jWQpAH</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 5 days</td>
        <td>Xpert MTB/RIF Ultra: 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ccxbjmjx4DF</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Rif contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Rif contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cD6yomdezwR</td>
      </tr>
      <tr>
        <td>Culture (liquid media): samples - MTB</td>
        <td>Culture LM: samples - MTB</td>
        <td></td>
        <td>Samples with result "MTB" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CgDIb7hgosn</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - Rif susceptible</td>
        <td>LPA (Rif/Inh): patients - Rif ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: susceptible. No resistance detected by LPA (Rif/Inh) in other samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CHMTFoEGDYW</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for initial DST (solid media)</td>
        <td>Init DST SM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cJ9JXbZ0itN</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Amk/Cap indeterminate</td>
        <td>LPA (Fq/2LI): samples - Amk/Cap indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cjamO4QmiQl</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Dlm resistant</td>
        <td>Init DST LM: prev patients - Dlm res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ckCldwmEQAl</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 1 day</td>
        <td>Xpert MTB/RIF Ultra: 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CkH4cl9Ip25</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - no result</td>
        <td>Xpert MTB/RIF Ultra: samples - no result</td>
        <td></td>
        <td>Samples with result "no result" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cKlPzK4efeq</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Bdq contaminated</td>
        <td>Init DST SM: samples - Bdq contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cKpRfFeeqeK</td>
      </tr>
      <tr>
        <td>Patients with invalid result for LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI): patients - invalid result</td>
        <td></td>
        <td>Patients with invalid LPA (Fq/2LI) result</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cMcje1sf4Pn</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): previously treated patients - Inh indeterminate</td>
        <td>LPA (Rif/Inh): prev patients - Inh indet </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Rif/Inh) in other samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>coaXGRyCvbg</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Inh CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cOFUIqdayX1</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Mfx (CC) resistant</td>
        <td>Init DST LM: new patients - Mfx CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CR1sEF01MvB</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 9 days</td>
        <td>Culture LM: 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CtUD7DpDhUt</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Amk/Cap indeterminate</td>
        <td>LPA (Fq/2LI): new patients - Amk/Cap indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CVHpNLwyPw9</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Pza resistant</td>
        <td>Sub DST SM: samples - Pza res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cVY0RGqdI69</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - MTB not detected</td>
        <td>Xpert MTB/RIF: patients - MTB not detected</td>
        <td></td>
        <td>New patients with MTB not detected by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>CWCpPgb2Y2r</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Emb contaminated/indeterminate</td>
        <td>Init DST SM: patients - Emb contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cyJiS3rV7KV</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 2 days</td>
        <td>Culture LM: 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cyOnOSTFAny</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Lzd contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>cYQnmEGAuSH</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Amk contaminated</td>
        <td>Sub DST LM: samples - Amk contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>D1txAWeoz5n</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Cfz contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>d2CN7zcwQq2</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Bdq contaminated</td>
        <td>Sub DST LM: samples - Bdq contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>D2XDPZzaKjH</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Amk resistant</td>
        <td>Init DST LM: samples - Amk res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>D4I7CFxNoxO</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Dlm susceptible</td>
        <td>Init DST LM: prev patients - Dlm ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>d4K0yZYr5sf</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Emb resistant</td>
        <td>Init DST SM: prev patients - Emb res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>d5iwto9PKqu</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Dlm indeterminate</td>
        <td>Init DST LM: samples - Dlm indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>d5VDVBgpNff</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) resistant</td>
        <td>Sub DST LM: samples - Mfx CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>D74MdAoARVD</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Cfz contaminated</td>
        <td>Init DST LM: samples - Cfz contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>D9GN83zB1tB</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dBGD2K40yW9</td>
      </tr>
      <tr>
        <td>Samples: 2 days</td>
        <td>Collection arrival interval: 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DCpjfspBzJb</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lfx indeterminate</td>
        <td>Init DST LM: samples - Lfx indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dCXS1Srtvzz</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Rif susceptible</td>
        <td>Sub DST SM: samples - Rif ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dEk1wwgfnnD</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Dlm resistant</td>
        <td>Init DST SM: new patients - Dlm res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DesYHcLzFQQ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dflTpUL9TOd</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Kan indeterminate</td>
        <td>LPA (Fq/2LI): samples - Kan indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dFWU6kNKodU</td>
      </tr>
      <tr>
        <td>Days from sample collection to culture inoculation (solid media)</td>
        <td>Culture SM: collection-inoculation interval</td>
        <td></td>
        <td>Days from sample collection to inoculation. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dGKwqxO3eKj</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Inh (CC) resistant</td>
        <td>Init DST LM: new patients - Inh CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dh2mOeE0ieM</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 9 days</td>
        <td>LPA (Rif/Inh): 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Dh7a17admqQ</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Inh (CC) susceptible</td>
        <td>Init DST SM: prev patients - Inh CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dhS0qZCbUgr</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 5 days</td>
        <td>LPA (Rif/Inh): 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dIx2cpCkvtj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lfx resistant</td>
        <td>Sub DST LM: samples - Lfx res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>djuou80be4X</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) resistant</td>
        <td>Sub DST LM: samples - Mfx CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dkKIGNb3BPe</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Dlm indeterminate</td>
        <td>Sub DST SM: samples - Dlm indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dlC6LusCW5i</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DmK5rIflVja</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CC) susceptible</td>
        <td>Init DST LM: samples - Mfx CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dNbYkrR3zua</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lzd indeterminate</td>
        <td>Init DST LM: samples - Lzd indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>doQ3NVOHYPH</td>
      </tr>
      <tr>
        <td>Patients with negative HIV status</td>
        <td>HIV: negative</td>
        <td></td>
        <td>Patients with negative HIV status</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dOXNXZWb32d</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CC) indeterminate</td>
        <td>Init DST LM: samples - Mfx CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DQ6TpILpwGm</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Pza susceptible</td>
        <td>Init DST LM: patients - Pza ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DQiw76Xw1r4</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Bdq susceptible</td>
        <td>Init DST LM: samples - Bdq ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DTPsQiXmWTp</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Lfx resistant</td>
        <td>Init DST SM: new patients - Lfx res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dU8neclU24g</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Cfz indeterminate</td>
        <td>Sub DST LM: samples - Cfz indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dvBHjZYq37O</td>
      </tr>
      <tr>
        <td>Days from sample collection to date of Xpert MTB/RIF Ultra test</td>
        <td>Xpert MTB/RIF Ultra: collection-test interval</td>
        <td></td>
        <td>Days from sample collection to test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-12</td>
        <td>DVMln9sMq2c</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Rif contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>DXmiExPcVmJ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Lzd susceptible</td>
        <td>Sub DST SM: new patients - Lzd ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dZ0rHB1EkHD</td>
      </tr>
      <tr>
        <td>Samples: 8 days</td>
        <td>Collection arrival interval: 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dZ3RPo7vpmD</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Bdq susceptible</td>
        <td>Init DST SM: samples - Bdq ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>dZZHJma1Kge</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Amk contaminated/indeterminate</td>
        <td>Init DST SM: patients - Amk contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>e0cJcbD47aQ</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Rif susceptible</td>
        <td>Init DST SM: new patients - Rif ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>e0gi9i7AftL</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - Rif indeterminate </td>
        <td>Xpert MTB/RIF Ultra: patients - Rif indet</td>
        <td></td>
        <td>Patients with result "MTB, Rif indeterminate" tested by Xpert MTB/RIF Ultra. No resistance and no susceptibility detected by Xpert MTB/RIF Ultra in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>e33nRsNWbUl</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CB) susceptible</td>
        <td>Init DST SM: samples - Inh CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>E4zdpgEfh2D</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Pza susceptible</td>
        <td>Sub DST SM: new patients - Pza ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>e9RjhGOu3Fz</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Mfx (CB) susceptible</td>
        <td>Init DST LM: patients - Mfx CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EAwBFKFUQcM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 0 days</td>
        <td>Xpert MTB/RIF Ultra: 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EbYQHywJJT7</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) indeterminate</td>
        <td>Sub DST LM: samples - Mfx CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eCIxImB6qsO</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Rif contaminated</td>
        <td>Sub DST LM: samples - Rif contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ecuAlCQqOV0</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Inh (CB) susceptible</td>
        <td>Sub DST SM: new patients - Inh CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EELFTduH3M9</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Rif contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Rif contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EEQ0GjzL3Xl</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lfx indeterminate</td>
        <td>Sub DST SM: samples - Lfx indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EfhWg7dKNsv</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Lzd susceptible</td>
        <td>Init DST SM: new patients - Lzd ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EGNwXUQWIKb</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Mfx (CB) resistant</td>
        <td>Init DST SM: prev patients - Mfx CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EhnADaDfnTB</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Pza contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Pza contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eHQizAJZuXK</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Rif resistant</td>
        <td>Sub DST SM: prev patients - Rif res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EICJmQVZa2a</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CC) susceptible</td>
        <td>Sub DST LM: samples - Inh CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eId8rqyJur9</td>
      </tr>
      <tr>
        <td>Culture (liquid media): new patients - contaminated</td>
        <td>Culture LM: new patients - contam</td>
        <td></td>
        <td>New patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>elHXs7QIHeg</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Pza contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>elpk5h0qKHQ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Lzd resistant</td>
        <td>Init DST LM: prev patients - Lzd res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eLzDUToUdCS</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 6 days</td>
        <td>LPA (Fq/2LI): 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eMQxOQjYOAk</td>
      </tr>
      <tr>
        <td>Culture (liquid media): patients - no growth</td>
        <td>Culture LM: patients - no growth</td>
        <td></td>
        <td>Patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>emvCVU7nSyP</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Mfx (CC) susceptible</td>
        <td>Sub DST LM: new patients - Mfx CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>enpdoV1nHk0</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Lzd susceptible</td>
        <td>Init DST LM: patients - Lzd ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eohX6MLy3Pz</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Lzd contaminated/indeterminate</td>
        <td>Init DST SM: patients - Lzd contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ePD0F8obRs8</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CC) susceptible</td>
        <td>Sub DST LM: prev patients - Inh CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EPdS0YCH90B</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Bdq susceptible</td>
        <td>Sub DST LM: prev patients - Bdq ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EpspNpkl2xy</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Inh CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>epZELbYw3Dp</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): new patients - Inh susceptible</td>
        <td>LPA (Rif/Inh): new patients - Inh ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: susceptible. No resistance detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eqA9DYBlpOk</td>
      </tr>
      <tr>
        <td>Culture (solid media): 0 days</td>
        <td>Culture SM: 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EqAuIAkWriW</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Bdq susceptible</td>
        <td>Sub DST LM: new patients - Bdq ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>erA6BTudlqi</td>
      </tr>
      <tr>
        <td>Samples with culture inoculation date (solid media)</td>
        <td>Culture SM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eSmBD2Ihlyp</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Rif resistant</td>
        <td>Sub DST LM: prev patients - Rif res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eSVL9Sr7zpp</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for subsequent DST (solid media)</td>
        <td>Sub DST SM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EtO96EwY8GU</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Emb contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EtQJDbQppQI</td>
      </tr>
      <tr>
        <td>Culture (solid media): patients - MTB</td>
        <td>Culture SM: patients - MTB</td>
        <td></td>
        <td>Patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EU2sU2GqFEJ</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Pza resistant</td>
        <td>Init DST SM: new patients - Pza res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EUoIM0Gbjcq</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Pza resistant</td>
        <td>Sub DST SM: patients - Pza res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EvcKhBk9htx</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Dlm resistant</td>
        <td>Init DST SM: patients - Dlm res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ew0ZLYwvP0N</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Lfx resistant</td>
        <td>Init DST SM: patients - Lfx res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>exwSqqUbu1i</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Kan susceptible</td>
        <td>LPA (Fq/2LI): patients - Kan ss</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>EXziKxYBfcC</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Cfz resistant</td>
        <td>Init DST LM: new patients - Cfz res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>eZ7eIDHaYnM</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Amk indeterminate</td>
        <td>Init DST SM: samples - Amk indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>f5iJzjQNKc0</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 9 days</td>
        <td>Xpert MTB/RIF Ultra: 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>F790gdBXKhI</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Lfx contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>F7BmHiwjier</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Rif contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Rif contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>f7CKyOdJg01</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Cfz resistant</td>
        <td>Init DST SM: samples - Cfz res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>F8DmuEmfrYR</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Dlm contaminated</td>
        <td>Sub DST SM: samples - Dlm contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>f8OaQON8Jug</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Lzd contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>F9aDDuk2zH7</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Inh (CB) resistant</td>
        <td>Init DST SM: patients - Inh CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FaO1ALEZbWD</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Kan susceptible</td>
        <td>LPA (Fq/2LI): prev patients - Kan ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: susceptible. No resistance detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FBfIl9ERVVt</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Inh (CB) resistant</td>
        <td>Init DST LM: prev patients - Inh CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fcxcyNcQjzi</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Emb resistant</td>
        <td>LPA (Fq/2LI): new patients - Emb res</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fE6l4xcNtLq</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Kan indeterminate</td>
        <td>LPA (Fq/2LI): patients - Kan indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FeaSAdlKno2</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - Rif susceptible</td>
        <td>Xpert MTB/RIF: patients - RS</td>
        <td></td>
        <td>Patients with result "MTB, Rif susceptible" tested by Xpert MTB/RIF. No resistance detected by Xpert MTB/RIF in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FEiqi1Eorpi</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Inh (CB) resistant</td>
        <td>Init DST SM: prev patients - Inh CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fEZeFn8VTpk</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CC) resistant</td>
        <td>Init DST LM: samples - Inh CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FFBHhpROVU4</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Lzd contaminated/indeterminate</td>
        <td>Init DST LM: patients - Lzd contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ffqUD3Dxlfs</td>
      </tr>
      <tr>
        <td>Culture (solid media): 7 days</td>
        <td>Culture SM: 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fFuaaoUS5fC</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Lfx susceptible</td>
        <td>Sub DST LM: patients - Lfx ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Fgoss6VRywe</td>
      </tr>
      <tr>
        <td>Patients with positive HIV status</td>
        <td>HIV: positive</td>
        <td></td>
        <td>Patients with positive HIV status</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FGsZGC28X8R</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Init DST SM: patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FHU4eNjE5FD</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Kan susceptible</td>
        <td>LPA (Fq/2LI): samples - Kan ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fI46ToIG10v</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Bdq susceptible</td>
        <td>Init DST LM: prev patients - Bdq ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FI5yCrIHoow</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Pza contaminated/indeterminate</td>
        <td>Init DST SM: patients - Pza contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fIbds4Nfw1i</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CB) contaminated</td>
        <td>Init DST SM: samples - Inh CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fITjLSEGjiq</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Mfx (CC) susceptible</td>
        <td>Init DST LM: new patients - Mfx CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fkSqKvpD6PA</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Inh (CB) susceptible</td>
        <td>Init DST SM: patients - Inh CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fkva9qgQzv1</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Emb resistant</td>
        <td>LPA (Fq/2LI): samples - Emb res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FLYNb9akyHF</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Rif susceptible</td>
        <td>Sub DST LM: new patients - Rif ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fmtrEnAYaRK</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Dlm susceptible</td>
        <td>Sub DST SM: samples - Dlm ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FMvbZg2LHhV</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Amk susceptible</td>
        <td>Sub DST SM: samples - Amk ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FNMPwjQNg4U</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Amk resistant</td>
        <td>Init DST LM: patients - Amk res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FNvQMKWecPh</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Bdq resistant</td>
        <td>Sub DST LM: prev patients - Bdq res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FNYTBE2wcLm</td>
      </tr>
      <tr>
        <td>Samples: 9 days</td>
        <td>Collection arrival interval: 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fO3ji8wgXlM</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Mfx (CC) resistant</td>
        <td>Init DST LM: patients - Mfx CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fOxfV0W9xb1</td>
      </tr>
      <tr>
        <td>Patients with Xpert MTB/RIF Ultra test result</td>
        <td>Xpert MTB/RIF Ultra: patients - result</td>
        <td></td>
        <td>Patients with result for Xpert MTB/RIF Ultra</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fpV3tkYm9rn</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Lzd resistant</td>
        <td>Init DST SM: new patients - Lzd res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fpXisLGhJfK</td>
      </tr>
      <tr>
        <td>Culture (liquid media): previously treated patients - MTB</td>
        <td>Culture LM: prev patients - MTB</td>
        <td></td>
        <td>Previously treated patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fq4aooEypot</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Amk resistant</td>
        <td>Sub DST SM: patients - Amk res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FRGmGDJHpkM</td>
      </tr>
      <tr>
        <td>Culture (solid media): 8 days</td>
        <td>Culture SM: 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FrIJvXbBKJ9</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Bdq contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>frJyeMsmKYo</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Dlm resistant</td>
        <td>Sub DST LM: samples - Dlm res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fUdI3Clnew1</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Cfz susceptible</td>
        <td>Sub DST SM: patients - Cfz ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fxAlrUlm1GU</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Rif resistant</td>
        <td>Sub DST LM: samples - Rif res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>fYERuvsUVki</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Mfx (CC) resistant</td>
        <td>Sub DST LM: patients - Mfx CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>fyw7CVbbp5r</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Amk resistant</td>
        <td>Init DST SM: prev patients - Amk res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>FzvIunVITV7</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Rif susceptible</td>
        <td>Sub DST SM: prev patients - Rif ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>g3oYfS8eQAq</td>
      </tr>
      <tr>
        <td>Microscopy: patients - positive</td>
        <td>Microscopy: patients - positive</td>
        <td></td>
        <td>Patients with microscopy result "positive". If more than one sample is examined per patient, "positive" result is recorded if at least one sample is "positive". Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>G3yAX5ER7E3</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Inh (CB) susceptible</td>
        <td>Init DST LM: patients - Inh CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>G5dwFp4FeUI</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Cfz susceptible</td>
        <td>Init DST SM: prev patients - Cfz ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>g8HOqnoSNJ9</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Cfz contaminated</td>
        <td>Sub DST LM: samples - Cfz contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>g9Sp1K9EgQZ</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Emb indeterminate</td>
        <td>LPA (Fq/2LI): new patients - Emb indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GAPMlTbDkXb</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Amk susceptible</td>
        <td>Sub DST SM: prev patients - Amk ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Gc2umtqZ1lY</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Cfz indeterminate</td>
        <td>Init DST LM: samples - Cfz indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GCHhMllhJcW</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CB) susceptible</td>
        <td>Sub DST SM: samples - Mfx CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GCpLmFiy28k</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Amk resistant</td>
        <td>Sub DST LM: prev patients - Amk res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gCQxWn0enit</td>
      </tr>
      <tr>
        <td>Samples with Xpert MTB/RIF test result</td>
        <td>Xpert MTB/RIF: samples - result</td>
        <td></td>
        <td>Samples with result for Xpert MTB/RIF</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GCs58vwZsyf</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Inh (CC) resistant</td>
        <td>Sub DST SM: new patients - Inh CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GDUhrJPqy6w</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 6 days</td>
        <td>Xpert MTB/RIF: 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GGmlMcmL9hd</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Emb contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GGmrn3hUfJ1</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lzd resistant</td>
        <td>Sub DST LM: samples - Lzd res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GGor2BR1Yq1</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Bdq resistant</td>
        <td>Sub DST SM: patients - Bdq res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gHTL2er7krj</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 10+ days</td>
        <td>LPA (Fq/2LI): 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GLQZXhtNL52</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Bdq indeterminate</td>
        <td>Sub DST SM: samples - Bdq indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GLSkgEz1sfT</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CB) contaminated</td>
        <td>Init DST SM: samples - Mfx CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>glxNdJrAU4x</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Emb resistant</td>
        <td>Sub DST SM: samples - Emb res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gnJSzbNuMYw</td>
      </tr>
      <tr>
        <td>Patients with Xpert MTB/RIF test result</td>
        <td>Xpert MTB/RIF: patients - result</td>
        <td></td>
        <td>Patients with result for Xpert MTB/RIF</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gnSeNJoGz9T</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lfx indeterminate</td>
        <td>Init DST SM: samples - Lfx indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gpcKhKQvKWR</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Mfx CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GPMaGbyEjG4</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Amk/Cap resistant</td>
        <td>LPA (Fq/2LI): samples - Amk/Cap res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gSD4sqSzgGL</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Dlm contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GStm6UzOQdq</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Bdq resistant</td>
        <td>Init DST LM: patients - Bdq res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GTJ6K25PdVV</td>
      </tr>
      <tr>
        <td>Enrolled patients</td>
        <td>Enrollments - total</td>
        <td></td>
        <td>Enrollment count</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gTPmPsKLwdR</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Pza indeterminate</td>
        <td>Init DST SM: samples - Pza indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GUWNoDKwVeB</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Mfx (CC) susceptible</td>
        <td>Sub DST SM: new patients - Mfx CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gvvZUXARGg0</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Inh (CB) susceptible</td>
        <td>Init DST SM: new patients - Inh CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gwJnPsEhIvZ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - invalid</td>
        <td>Xpert MTB/RIF: samples - invalid</td>
        <td></td>
        <td>Samples with result "invalid" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GxBSEkFVnml</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Emb contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Emb contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>gYdixn3rVl7</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Bdq indeterminate</td>
        <td>Init DST LM: samples - Bdq indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>GYiY3HvV1Gy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: previously treated patients - Rif indeterminate</td>
        <td>Xpert MTB/RIF Ultra: prev patients - Rif indet</td>
        <td></td>
        <td>Previously treated patients with result "MTB, Rif indeterminate" tested by Xpert MTB/RIF Ultra. No resistance and no susceptibility detected by Xpert MTB/RIF Ultra in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>gZCthbeejQI</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Emb contaminated</td>
        <td>Sub DST SM: samples - Emb contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>H0uraA1hI5d</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Amk indeterminate</td>
        <td>Sub DST SM: samples - Amk indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>H185R6OCh9r</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>Init DST SM: prev patients - Mfx CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>H3TqQeEo9MY</td>
      </tr>
      <tr>
        <td>Culture (solid media): 10+ days</td>
        <td>Culture SM: 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>h3ZPbULlyUP</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Emb susceptible</td>
        <td>Init DST SM: samples - Emb ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>h4iCiDYGYwR</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Bdq resistant</td>
        <td>Init DST SM: samples - Bdq res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>H8hAkVy6cc6</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 4 days</td>
        <td>LPA (Fq/2LI): 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>H8hl6NVdcGi</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Emb resistant</td>
        <td>Sub DST SM: new patients - Emb res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>h8kBZ3K0T2d</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>Init DST SM: patients - Inh CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>H9pBIDDmvRF</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Bdq susceptible</td>
        <td>Init DST SM: prev patients - Bdq ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Hb3NQ6s8obq</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: new patients - Rif indeterminate</td>
        <td>Xpert MTB/RIF Ultra: new patients - Rif indet</td>
        <td></td>
        <td>New patients with result "MTB, Rif indeterminate" tested by Xpert MTB/RIF Ultra. No resistance and no susceptibility detected by Xpert MTB/RIF Ultra in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>Hbaf9zZw15P</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Inh CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hcnG8PMuECt</td>
      </tr>
      <tr>
        <td>Culture (liquid media): patients - MTB</td>
        <td>Culture LM: patients - MTB</td>
        <td></td>
        <td>Patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hDf5GZVCh6b</td>
      </tr>
      <tr>
        <td>Microscopy: patients - negative</td>
        <td>Microscopy: patients - negative</td>
        <td></td>
        <td>Patients with microscopy result "negative". If more than one sample is examined per patient, "negative" result is recorded if all samples are "negative". Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HDPycwY4BhS</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Dlm susceptible</td>
        <td>Init DST LM: patients - Dlm ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HdRTHmCBN5P</td>
      </tr>
      <tr>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>LPA (Rif/Inh): processed samples</td>
        <td></td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>henuXSapu7A</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Emb indeterminate</td>
        <td>LPA (Fq/2LI): prev patients - Emb indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HfuHrxdatgU</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): new patients - Rif susceptible</td>
        <td>LPA (Rif/Inh): new patients - Rif ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hfYRwQKgaXt</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Cfz resistant</td>
        <td>Sub DST SM: prev patients - Cfz res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hhcHMksqM3z</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - MTB, Rif indeterminate</td>
        <td>Xpert MTB/RIF Ultra: samples - Rif indet</td>
        <td></td>
        <td>Samples with result "MTB detected, Rif indeterminate" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>hHniKx89xJK</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 5 days</td>
        <td>LPA (Fq/2LI): 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HicWDsLR7Nj</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Amk contaminated/indeterminate</td>
        <td>Init DST SM: patients - Amk contam/indet - new</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HJ7yxI5uok5</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Amk/Cap susceptible</td>
        <td>LPA (Fq/2LI): samples - Amk/Cap ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HkAV7ShttEV</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CC) susceptible</td>
        <td>Sub DST SM: samples - Inh CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HkdrJSar6If</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Amk susceptible</td>
        <td>Init DST SM: patients - Amk ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hL4mwtjHRFZ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lzd resistant</td>
        <td>Sub DST SM: samples - Lzd res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HLrMymgpoqI</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hLYwIBpo278</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lfx resistant</td>
        <td>Init DST SM: samples - Lfx res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HNLM0vPGidN</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lzd indeterminate</td>
        <td>Sub DST SM: samples - Lzd indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HqO6R44DBqY</td>
      </tr>
      <tr>
        <td>RR-TB patients</td>
        <td>RR-TB patients</td>
        <td></td>
        <td>RR-TB patients</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hQP5qXsaTSB</td>
      </tr>
      <tr>
        <td>Patients with culture result (solid media)</td>
        <td>Culture SM: patients - result</td>
        <td></td>
        <td>Patients with result for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HRT8j3uimEB</td>
      </tr>
      <tr>
        <td>Samples: 10+ days</td>
        <td>Collection arrival interval: 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hSScU4CEl4x</td>
      </tr>
      <tr>
        <td>Culture (solid media): new patients - contaminated</td>
        <td>Culture SM: new patients - contam</td>
        <td></td>
        <td>New patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HT5df1hXx46</td>
      </tr>
      <tr>
        <td>Patients with error, invalid or no result for Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - invalid result</td>
        <td></td>
        <td>Patients with invalid Xpert MTB/RIF Ultra result</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HTBvmWX11N2</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CC) resistant</td>
        <td>Sub DST LM: prev patients - Inh CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>htk2PaBn9n6</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Cfz susceptible</td>
        <td>Sub DST LM: patients - Cfz ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HTYSiumflrW</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) susceptible</td>
        <td>Sub DST LM: samples - Mfx CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HuH9Wbdba4q</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Pza susceptible</td>
        <td>Sub DST LM: prev patients - Pza ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hvqTrO9xqPC</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lfx resistant</td>
        <td>Sub DST SM: samples - Lfx res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HxB1sbrTKkv</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Emb resistant</td>
        <td>Sub DST LM: patients - Emb res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>HXeaRn0AaLL</td>
      </tr>
      <tr>
        <td>Microscopy: new patients - positive</td>
        <td>Microscopy: new patients - positive</td>
        <td></td>
        <td>New patients with microscopy result "positive". If more than one sample is examined per patient, "positive" result is recorded if at least one sample is "positive". Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HxgMmSOXRO9</td>
      </tr>
      <tr>
        <td>Culture (solid media): 4 days</td>
        <td>Culture SM: 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hyoQv9Zr56m</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Bdq susceptible</td>
        <td>Sub DST LM: samples - Bdq ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hZn5S7DWqzF</td>
      </tr>
      <tr>
        <td>Samples rejected on arrival</td>
        <td>Samples rejected on arrival</td>
        <td></td>
        <td>Samples rejected on arrival</td>
        <td>EVENT</td>
        <td>2020-12-10</td>
        <td>hZP8QqW2Hgr</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) contaminated</td>
        <td>Sub DST LM: samples - Mfx CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>HZQG39GLjUK</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Emb resistant</td>
        <td>Init DST LM: samples - Emb res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>hzrdf9T71sf</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CC) contaminated</td>
        <td>Init DST SM: samples - Mfx CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>i14osWxv3vs</td>
      </tr>
      <tr>
        <td>Patients with result for subsequent DST (liquid media)</td>
        <td>Sub DST LM: patients - result</td>
        <td></td>
        <td>Patients with result for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>I4aotZJ6il4</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CB) indeterminate</td>
        <td>Init DST SM: samples - Inh CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>I64mYichCJ7</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Emb susceptible</td>
        <td>Init DST SM: patients - Emb ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>i7BNLtz6jEk</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CC) contaminated</td>
        <td>Init DST LM: samples - Inh CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IAyxc41e5Yy</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Mfx CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ibm1blKTuPA</td>
      </tr>
      <tr>
        <td>Days from sample collection to date of LPA (Fq/2LI) test</td>
        <td>LPA (Fq/2LI): collection-test interval</td>
        <td></td>
        <td>Days from sample collection to test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-12</td>
        <td>ibSDbrIrEph</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Inh (CC) resistant</td>
        <td>Init DST SM: prev patients - Inh CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ic0VoKRJi8V</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: new patients - RS</td>
        <td>Xpert MTB/RIF Ultra: new patients - RS</td>
        <td></td>
        <td>New patients with result "MTB, Rif susceptible" tested by Xpert MTB/RIF Ultra. No resistance and no susceptibility detected by Xpert MTB/RIF Ultra in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IIRJBuBrOTJ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CB) susceptible</td>
        <td>Init DST LM: samples - Inh CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ijcH0gNXBx9</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): previously treated patients - Rif indeterminate</td>
        <td>LPA (Rif/Inh): prev patients - Rif indet </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Rif/Inh) in other samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>iK1pi7QPSVA</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 10+ days</td>
        <td>LPA (Rif/Inh): 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ik9eYxKo6pQ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Dlm resistant</td>
        <td>Init DST LM: samples - Dlm res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>iKfKE7FhH9H</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Amk/Cap susceptible</td>
        <td>LPA (Fq/2LI): patients - Amk/Cap ss</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IkHjK7xP7Xf</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Emb contaminated/indeterminate</td>
        <td>Init DST LM: patients - Emb contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IMmK1P6fBva</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 1 day</td>
        <td>Xpert MTB/RIF: 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>in2GZS5lUD5</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Mfx (CB) susceptible</td>
        <td>Init DST SM: patients - Mfx CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>iNHCjhXr71r</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Emb contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IOIQueZoXmk</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Inh (CB) resistant</td>
        <td>Sub DST LM: patients - Inh CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>IpbcHr0Sl5m</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CB) resistant</td>
        <td>Sub DST SM: prev patients - Mfx CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IPCjhHOQMWl</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Emb contaminated</td>
        <td>Init DST LM: samples - Emb contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IQbtsnDkfAq</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Inh resistant</td>
        <td>LPA (Rif/Inh): samples - Inh res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IQERFALbvVz</td>
      </tr>
      <tr>
        <td>Missing data: TB treatment history</td>
        <td>Missing data: TB treatment history</td>
        <td></td>
        <td>Patients with TB treatment history data missing</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ir4RiYE3Nke</td>
      </tr>
      <tr>
        <td>Culture (liquid media): samples - contaminated</td>
        <td>Culture LM: samples - contam</td>
        <td></td>
        <td>Samples with result "contaminated" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IV7jORMyeU0</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Cfz contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IWSzulLtcRU</td>
      </tr>
      <tr>
        <td>New patients</td>
        <td>New patients</td>
        <td></td>
        <td>New patients </td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IZ05Ef30nG3</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Rif susceptible</td>
        <td>Sub DST LM: samples - Rif ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>IZmFYcpgXBt</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Pza contaminated</td>
        <td>Sub DST SM: samples - Pza contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>j1utfSEDGOO</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Cfz resistant</td>
        <td>Sub DST SM: new patients - Cfz res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>J230BlAaQlK</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Bdq resistant</td>
        <td>Init DST LM: samples - Bdq res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>J3ahtr4IVZn</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CB) contaminated</td>
        <td>Sub DST LM: samples - Inh CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>j3G2AoTFI9u</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Pza resistant</td>
        <td>Init DST LM: new patients - Pza res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>j3vGe1RQoJ3</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Lzd resistant</td>
        <td>Sub DST SM: new patients - Lzd res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>J3wjJEF8aq0</td>
      </tr>
      <tr>
        <td>Samples: 6 days</td>
        <td>Collection arrival interval: 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>j3X4YEzbRjz</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Pza contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Pza contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>j89ph75ZaX8</td>
      </tr>
      <tr>
        <td>Previously treated patients (cumulative)</td>
        <td>Previously treated patients (cumulative)</td>
        <td></td>
        <td>Previously treated patients (cumulative)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>J9VPfek4eYG</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Lfx susceptible</td>
        <td>Init DST SM: new patients - Lfx ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JBEHF7dwqbE</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Inh (CC) resistant</td>
        <td>Init DST LM: patients - Inh CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JBxsvdKtcZI</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Emb susceptible</td>
        <td>Sub DST SM: prev patients - Emb ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JCJ6UNRWuJi</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Inh CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jcm5Bo8ve5A</td>
      </tr>
      <tr>
        <td>Culture (solid media): 6 days</td>
        <td>Culture SM: 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JCsNAS3pqZZ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Mfx CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JDINMJYfpt8</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Lfx susceptible</td>
        <td>Sub DST LM: prev patients - Lfx ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Je3u7mBTONj</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Rif resistant</td>
        <td>Init DST SM: prev patients - Rif res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jEFlq5DrhmK</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Dlm contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jFmQ13LrhXY</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Mfx (CC) resistant</td>
        <td>Init DST SM: patients - Mfx CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jGOj77I7ivr</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Init DST LM: patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jgpxNB7lUtw</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 5 days</td>
        <td>Culture LM: 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JH0XVP5TaUz</td>
      </tr>
      <tr>
        <td>Patients with unknown HIV status</td>
        <td>HIV: unknown</td>
        <td></td>
        <td>Patients with unknown HIV status</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jhm47tAnQV8</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Lzd susceptible</td>
        <td>Init DST LM: new patients - Lzd ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jihuemWnruh</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Inh (CB) susceptible</td>
        <td>Sub DST LM: new patients - Inh CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jIlJF6otQaS</td>
      </tr>
      <tr>
        <td>Patients with error, invalid or no result for Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - invalid result</td>
        <td></td>
        <td>Patients with invalid Xpert MTB/RIF result</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JIZ6X5rD7OK</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CB) indeterminate</td>
        <td>Sub DST SM: samples - Inh CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jKYooU49mG4</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Inh (CB) resistant</td>
        <td>Init DST SM: new patients - Inh CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jmASgzacESm</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Bdq resistant</td>
        <td>Init DST SM: prev patients - Bdq res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JMJzISQzRK2</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Rif susceptible</td>
        <td>LPA (Rif/Inh): samples - Rif ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jnBglStivhT</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CC) resistant</td>
        <td>Sub DST SM: prev patients - Inh CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JqBF765vRaI</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Bdq susceptible</td>
        <td>Init DST LM: new patients - Bdq ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jR50rSWqk0y</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Emb susceptible</td>
        <td>LPA (Fq/2LI): patients - Emb ss</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jRlXrgXU6gg</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>Sub DST SM: prev patients - Mfx CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JsAylXp8loj</td>
      </tr>
      <tr>
        <td>Samples: 1 day</td>
        <td>Collection arrival interval: 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jtos6F8wRKV</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Lfx resistant</td>
        <td>Sub DST LM: prev patients - Lfx res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JuE3ZTRER0P</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 7 days</td>
        <td>Xpert MTB/RIF Ultra: 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jvvRyJ0orNz</td>
      </tr>
      <tr>
        <td>Culture (solid media): patients - no growth</td>
        <td>Culture SM: patients - no growth</td>
        <td></td>
        <td>Patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JxcokEnr3xj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Mfx (CB) susceptible</td>
        <td>Sub DST LM: new patients - Mfx CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JxdzwSOjm8A</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 1 day</td>
        <td>LPA (Rif/Inh): 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JXTklB80mSZ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CB) indeterminate</td>
        <td>Init DST LM: samples - Inh CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jxvva3VcMqQ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Rif susceptible</td>
        <td>Sub DST SM: patients - Rif ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jyLq8xUOZne</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Inh CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>JzIoXaU5gc7</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Fq indeterminate</td>
        <td>LPA (Fq/2LI): new patients - Fq indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jZM5koLMnTL</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Bdq susceptible</td>
        <td>Init DST LM: patients - Bdq ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>jZODNlINPVG</td>
      </tr>
      <tr>
        <td>Culture (liquid media): patients - NTM</td>
        <td>Culture LM: patients - NTM</td>
        <td></td>
        <td>Patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>K0Ni8uEHLXY</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lzd resistant</td>
        <td>Init DST SM: samples - Lzd res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>K0pjdy1M4eD</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Bdq indeterminate</td>
        <td>Init DST SM: samples - Bdq indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>k1b1mUVqTvK</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>k1YfISnKxoF</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Kan resistant</td>
        <td>LPA (Fq/2LI): prev patients - Kan res</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: resistant. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>k3dVli6pjex</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Inh CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>K3RhiJId07S</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Emb resistant</td>
        <td>Init DST SM: patients - Emb res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>K59BIxT2i6P</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Amk contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>k6SBsqcv8Pw</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 8 days</td>
        <td>LPA (Fq/2LI): 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KaGNXiu65VF</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>Sub DST LM: prev patients - Mfx CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KBbgHraFGGs</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Cfz susceptible</td>
        <td>Init DST LM: prev patients - Cfz ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KbOntu5fKTV</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Cfz contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kBPPbfaHHLL</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Fq resistant</td>
        <td>LPA (Fq/2LI): patients - Fq res</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KDdD36jnouX</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Pza susceptible</td>
        <td>Sub DST LM: new patients - Pza ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kDH4tyBM6FG</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Dlm contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Dlm contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KDMYnCVSgTk</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Inh (CB) susceptible</td>
        <td>Init DST SM: prev patients - Inh CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KeCuEyh87Ga</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Lfx resistant</td>
        <td>Sub DST LM: new patients - Lfx res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kghHkgNoh1r</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CB) resistant</td>
        <td>Sub DST SM: samples - Inh CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kGnLALoufUa</td>
      </tr>
      <tr>
        <td>Culture (solid media): 5 days</td>
        <td>Culture SM: 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kgPgADkI9De</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Emb resistant</td>
        <td>Init DST SM: new patients - Emb res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KiRnQZDm9hc</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Pza contaminated/indeterminate</td>
        <td>Init DST LM: patients - Pza contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KJe6BdMVXF3</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 4 days</td>
        <td>Xpert MTB/RIF Ultra: 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Kk7fwdFUnYo</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Pza susceptible</td>
        <td>Sub DST SM: prev patients - Pza ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Kl1ONdPznGh</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Emb contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kLiVVkPNcEG</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CB) susceptible</td>
        <td>Init DST LM: samples - Mfx CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kn7mJ4XH40C</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lzd susceptible</td>
        <td>Sub DST SM: samples - Lzd ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KNZKCM67NGi</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Dlm susceptible</td>
        <td>Init DST LM: samples - Dlm ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kqrwj0JOJon</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CB) indeterminate</td>
        <td>Init DST SM: samples - Mfx CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>kRJlr5MFMSh</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Inh CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KVMYPcUq22W</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Rif resistant</td>
        <td>Sub DST SM: patients - Rif res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KW0n6JUuqVn</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Cfz susceptible</td>
        <td>Sub DST LM: new patients - Cfz ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>KXylN7DLOAI</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 10 days</td>
        <td>Culture LM: 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l0oQQUpCe0t</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Cfz contaminated/indeterminate</td>
        <td>Init DST SM: patients - Cfz contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>L26pzli6SQ3</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Dlm contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l2og8x5vEYa</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CC) contaminated</td>
        <td>Init DST SM: samples - Inh CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>L2Sv0Lmeke5</td>
      </tr>
      <tr>
        <td>Culture (solid media): previously treated patients - NTM</td>
        <td>Culture SM: prev patients - NTM</td>
        <td></td>
        <td>Previously treated patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l3xgbTao9qK</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Amk contaminated</td>
        <td>Init DST SM: samples - Amk contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l76u70Y8RNm</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: previously treated patients - Rif susceptible</td>
        <td>Xpert MTB/RIF: prev patients - RS</td>
        <td></td>
        <td>Previously treated patients with result "MTB, Rif susceptible" tested by Xpert MTB/RIF. No resistance and no susceptibility detected by Xpert MTB/RIF in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l8EQ2Kz8HMy</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Emb resistant</td>
        <td>Sub DST LM: samples - Emb res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l9hGqsUThxS</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CC) resistant</td>
        <td>Init DST LM: prev patients - Mfx CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>l9WK4N0BUzx</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Rif resistant</td>
        <td>Init DST SM: new patients - Rif res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lAFXVyIOz59</td>
      </tr>
      <tr>
        <td>Days from sample collection to date of LPA (Rif/Inh) test</td>
        <td>LPA (Rif/Inh): collection-test interval</td>
        <td></td>
        <td>Days from sample collection to test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-12</td>
        <td>LaSMRgk7CXT</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Lfx contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Lfx contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LAsyN6saoOd</td>
      </tr>
      <tr>
        <td>Samples: 3 days</td>
        <td>Collection arrival interval: 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>Lb3IQ0ohSpp</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Lzd resistant</td>
        <td>Sub DST LM: patients - Lzd res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>Lc5HjAi5vyL</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Inh (CB) resistant</td>
        <td>Sub DST SM: new patients - Inh CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lfHTvcRzmXT</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Bdq susceptible</td>
        <td>Sub DST SM: prev patients - Bdq ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LhJkKbrTOOS</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Fq resistant</td>
        <td>LPA (Fq/2LI): samples - Fq res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lHv7SkxUIi0</td>
      </tr>
      <tr>
        <td>Culture (solid media): 10 days</td>
        <td>Culture SM: 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Lje8dx9lWYQ</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 7 days</td>
        <td>Culture LM: 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LKgEs168uwz</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Inh susceptible</td>
        <td>LPA (Rif/Inh): samples - Inh ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lmfraes6AwW</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): previously treated patients - Inh susceptible</td>
        <td>LPA (Rif/Inh): prev patients - Inh ss </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: susceptible. No resistance detected by LPA (Rif/Inh) in other samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lMxeHgDnnYU</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Inh indeterminate</td>
        <td>LPA (Rif/Inh): samples - Inh indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lNfI3Vav9ya</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CC) resistant</td>
        <td>Sub DST SM: samples - Inh CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LOLIwqxd2wm</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lfx contaminated</td>
        <td>Sub DST LM: samples - Lfx contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lopaZTLHpyB</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lzd contaminated</td>
        <td>Init DST SM: samples - Lzd contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lQnrHEMWAee</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Amk contaminated</td>
        <td>Sub DST SM: samples - Amk contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LROUBwdzaVw</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RS</td>
        <td>Xpert MTB/RIF Ultra: prrev patients - RS</td>
        <td></td>
        <td>Previously treated patients with result "MTB, Rif susceptible" tested by Xpert MTB/RIF Ultra. No resistance and no susceptibility detected by Xpert MTB/RIF Ultra in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LRW1AeEUfTs</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Lzd susceptible</td>
        <td>Init DST SM: prev patients - Lzd ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ltuLoYVJ4yN</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CC) susceptible</td>
        <td>Init DST SM: samples - Inh CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>luMcMB4YiL9</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 10 days</td>
        <td>Xpert MTB/RIF Ultra: 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>LuoF6aB4C7j</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Amk susceptible</td>
        <td>Init DST LM: samples - Amk ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lvGGYtdHr0u</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Bdq susceptible</td>
        <td>Init DST SM: new patients - Bdq ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lWEOXjxUbwf</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Lfx resistant</td>
        <td>Init DST SM: prev patients - Lfx res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lwr3AChFg30</td>
      </tr>
      <tr>
        <td>Samples with culture result(liquid media)</td>
        <td>Culture LM: samples - result</td>
        <td></td>
        <td>Samples with result for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lx4tkD2nyiv</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Inh CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>LX5Y5X1ijjJ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Inh (CB) resistant</td>
        <td>Init DST LM: new patients - Inh CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lxX3YYtafD4</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Emb susceptible</td>
        <td>Init DST LM: prev patients - Emb ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lyaTr1HCOH2</td>
      </tr>
      <tr>
        <td>Samples with culture result (solid media)</td>
        <td>Culture SM: samples - result</td>
        <td></td>
        <td>Samples with result for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>lZ1tOjYHm2t</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Mfx (CC) resistant</td>
        <td>Sub DST SM: new patients - Mfx CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>M2IinLZavHj</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Lzd contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>m5nShXZwfvl</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - MTB</td>
        <td>LPA (Fq/2LI): samples - MTB detected</td>
        <td></td>
        <td>Samples with result "MTB detected" tested by LPA (Fq/2LI). Condition: MTB detected, test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>M65WBBPkgIF</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CC) resistant</td>
        <td>Init DST SM: samples - Mfx CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>m6bgoNYcG12</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Inh CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>M74bikagdCn</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>Sub DST SM: prev patients - Mfx CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>M7Z1bApwb6J</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Inh (CC) resistant</td>
        <td>Init DST SM: new patients - Inh CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>m8N1dCCrsaT</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Amk susceptible</td>
        <td>Init DST SM: prev patients - Amk ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>M9mlpuwMiJ8</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): previously treated patients - Inh resistant</td>
        <td>LPA (Rif/Inh): prev patients - Inh res </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: resistant. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>m9N36IcoG1l</td>
      </tr>
      <tr>
        <td>Samples: 7 days</td>
        <td>Collection arrival interval: 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>M9QC4zhEcCW</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Bdq contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MAfGE8h9nR5</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Emb contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Emb contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>maRlEPKLrit</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Inh (CC) susceptible</td>
        <td>Init DST SM: new patients - Inh CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mBK3lYq8HO8</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Mfx (CB) susceptible</td>
        <td>Init DST SM: new patients - Mfx CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mdIjVH1NUaF</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CC) contaminated</td>
        <td>Init DST LM: samples - Mfx CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Me0P8Hywg5V</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Fq susceptible</td>
        <td>LPA (Fq/2LI): patients - Fq ss</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mg6xbOMevpk</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Lzd contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MGHQjfJcv8i</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Pza susceptible</td>
        <td>Init DST SM: samples - Pza ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mgyXxutltWj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Lfx susceptible</td>
        <td>Sub DST LM: new patients - Lfx ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mI5CLdPFdly</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Emb susceptible</td>
        <td>Init DST SM: new patients - Emb ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MIDce43XVMU</td>
      </tr>
      <tr>
        <td>Patients with LPA (Rif/Inh) test result</td>
        <td>LPA (Rif/Inh): patients - result</td>
        <td></td>
        <td>Patients with result for LPA (Rif/Inh)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MJ93HUyctIa</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - Rif resistant</td>
        <td>Xpert MTB/RIF: samples - RR</td>
        <td></td>
        <td>Samples with result "MTB detected, Rif resistant" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MJNbrK0Q80m</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Emb contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Emb contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MkaxSDtr5lN</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Bdq resistant</td>
        <td>Sub DST LM: patients - Bdq res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>MkpDzk0VVOn</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Bdq contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ml5TUmEp9co</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Amk susceptible</td>
        <td>Sub DST SM: patients - Amk ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MlKowimCL4m</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 1 day</td>
        <td>LPA (Fq/2LI): 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mmAog6SHRqH</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Rif indeterminate</td>
        <td>LPA (Rif/Inh): samples - Rif indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MmgqczjBy4x</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Pza contaminated</td>
        <td>Sub DST LM: samples - Pza contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MnhS9zbQTuz</td>
      </tr>
      <tr>
        <td>Culture (solid media): 2 days</td>
        <td>Culture SM: 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mNIzirHVwvO</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Rif indeterminate</td>
        <td>Sub DST LM: samples - Rif indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MNQ2cVPKts0</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Pza indeterminate</td>
        <td>Sub DST SM: samples - Pza indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mqf825wSgBW</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lzd contaminated</td>
        <td>Init DST LM: samples - Lzd contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mQmX7NJ2iWr</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Bdq resistant</td>
        <td>Sub DST SM: prev patients - Bdq res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MQz9ho7oTxM</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Mfx (CB) resistant</td>
        <td>Sub DST LM: new patients - Mfx CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MRE4oCbTgdp</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Lzd resistant</td>
        <td>Sub DST LM: new patients - Lzd res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mS4y1f2N2qr</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Fq indeterminate</td>
        <td>LPA (Fq/2LI): patients - Fq indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mSoVmSlOATC</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Rif contaminated/indeterminate</td>
        <td>Init DST SM: patients - Rif contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MT7aEWVXFBf</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for initial DST (solid media)</td>
        <td>Init DST SM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MTU6QAz2cpX</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Inh CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mU0CgKC2iWM</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Cfz contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mUmuZc4YfoA</td>
      </tr>
      <tr>
        <td>Culture (solid media): new patients - NTM</td>
        <td>Culture SM: new patients - NTM</td>
        <td></td>
        <td>New patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MuqppHWlVvW</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Pza susceptible</td>
        <td>Init DST LM: samples - Pza ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MVspOs3ajZ8</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Amk susceptible</td>
        <td>Sub DST LM: prev patients - Amk ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MwMGpZDEsVq</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Amk resistant</td>
        <td>Sub DST LM: samples - Amk res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mWVJ6NngcOg</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Pza susceptible</td>
        <td>Sub DST SM: samples - Pza ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>MX0ZgqJRARO</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Amk/Cap indeterminate</td>
        <td>LPA (Fq/2LI): patients - Amk/Cap indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mx7q7B3ZSpH</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - Inh susceptible</td>
        <td>LPA (Rif/Inh): patients - Inh ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mXnpYGKvJOJ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Inh (CC) resistant</td>
        <td>Init DST LM: prev patients - Inh CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>mZ25KRwF5Gy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - MTB not detected</td>
        <td>Xpert MTB/RIF: samples - MTB not detected</td>
        <td></td>
        <td>Samples with result "MTB not detected" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>n31mFHYciKv</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Fq susceptible</td>
        <td>LPA (Fq/2LI): samples - Fq ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>n6Rrth8edSM</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Lfx contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>N7o1Xqjimlj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CC) resistant</td>
        <td>Sub DST LM: samples - Inh CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>N8T2Ka08phP</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Rif indeterminate</td>
        <td>Init DST LM: samples - Rif indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NadcebWfg1z</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Inh CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nAG3hPJLNRZ</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Fq susceptible</td>
        <td>LPA (Fq/2LI): new patients - Fq ss</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NbEBOhJFhBx</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Pza resistant</td>
        <td>Init DST LM: samples - Pza res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nbNPEdgcXHR</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - Rif indeterminate </td>
        <td>Xpert MTB/RIF: patients - Rif indet</td>
        <td></td>
        <td>Patients with result "MTB, Rif indeterminate" tested by Xpert MTB/RIF. No resistance and no susceptibility detected by Xpert MTB/RIF in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>ncciXS4015B</td>
      </tr>
      <tr>
        <td>Patients with unknown treatment history (cumulative)</td>
        <td>DRS: unknown treatment history (cumulative)</td>
        <td></td>
        <td>Patients with unknown treatment history (cumulative)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nDbv7VbejeH</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Rif resistant</td>
        <td>Init DST SM: samples - Rif res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nea65dZOQfp</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Lzd susceptible</td>
        <td>Sub DST LM: new patients - Lzd ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NeWHeUHbtLY</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Inh (CC) resistant</td>
        <td>Sub DST SM: patients - Inh CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nFdMqXBCHgs</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Lfx susceptible</td>
        <td>Sub DST SM: new patients - Lfx ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NfZJb3KTVAO</td>
      </tr>
      <tr>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Xpert MTB/RIF: processed samples</td>
        <td></td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nhi2Mi5MXVW</td>
      </tr>
      <tr>
        <td>Samples with result for subsequent DST (solid media)</td>
        <td>Sub DST SM: samples - result</td>
        <td></td>
        <td>Samples with result for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NiZZuTnJcqI</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Pza susceptible</td>
        <td>Init DST LM: prev patients - Pza ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NJDQNJw2tGD</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 6 days</td>
        <td>Xpert MTB/RIF Ultra: 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NkcFiEE3PpA</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) indeterminate</td>
        <td>Sub DST LM: samples - Mfx CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nl8UjHDuOJp</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Rif resistant</td>
        <td>Sub DST SM: new patients - Rif res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NLogSNyPLrG</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nNgTAOUHVVf</td>
      </tr>
      <tr>
        <td>Patients with interpretable Xpert MTB/RIF Ultra result</td>
        <td>Xpert MTB/RIF Ultra: patients - interp. result</td>
        <td></td>
        <td>Patients with interpretable test result for Xpert MTB/RIF Ultra</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>nNXqEhYPq12</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 6 days</td>
        <td>LPA (Rif/Inh): 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NOwoUDobC82</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Lfx contaminated/indeterminate</td>
        <td>Init DST SM: patients - Lfx contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>npECBAtnX10</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Amk susceptible</td>
        <td>Init DST SM: samples - Amk ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nQp5mF3EWSv</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 2 days</td>
        <td>Xpert MTB/RIF Ultra: 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NqXeQze1Q7b</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Rif contaminated</td>
        <td>Init DST LM: samples - Rif contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NQXMN2Td6gk</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Dlm contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NQyWPTJyzhL</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Emb susceptible</td>
        <td>Sub DST LM: patients - Emb ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ntgkubZBIVR</td>
      </tr>
      <tr>
        <td>Culture (solid media): samples - NTM</td>
        <td>Culture SM: samples - NTM</td>
        <td></td>
        <td>Samples with result "NTM" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NuvmZiORoOd</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Bdq contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nvL2apj8ESp</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Fq resistant</td>
        <td>LPA (Fq/2LI): prev patients - Fq res</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: resistant. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nVrp5WyTpvb</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lfx susceptible</td>
        <td>Sub DST SM: samples - Lfx ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nVXSEczhAvM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 8 days</td>
        <td>Xpert MTB/RIF Ultra: 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NVZjjPEo2QI</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Fq indeterminate</td>
        <td>LPA (Fq/2LI): prev patients - Fq indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NWJoPKtoVSu</td>
      </tr>
      <tr>
        <td>Patients with culture result (liquid media)</td>
        <td>Culture LM: patients - result</td>
        <td></td>
        <td>Patients with result for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Nwoz37ThBzC</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Inh CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NXVfkJA7wg5</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Bdq susceptible</td>
        <td>Sub DST SM: patients - Bdq ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NYBeJuBeqD6</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Emb indeterminate</td>
        <td>LPA (Fq/2LI): patients - Emb indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nYuAYvmgfbs</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 10+ days</td>
        <td>Xpert MTB/RIF Ultra: 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NyyAfu95mCo</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Rif resistant</td>
        <td>Init DST LM: patients - Rif res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NyzaBaIm5jS</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Dlm susceptible</td>
        <td>Sub DST SM: prev patients - Dlm ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NzGW6C58GkF</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Lfx susceptible</td>
        <td>Init DST LM: patients - Lfx ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>nzj3O4baUVb</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: previously treated patients - Rif resistant</td>
        <td>Xpert MTB/RIF: prev patients - RR</td>
        <td></td>
        <td>Previously treated patients with result "MTB, Rif resistant" tested by Xpert MTB/RIF. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>NZul7fh2R8B</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Dlm indeterminate</td>
        <td>Init DST SM: samples - Dlm indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>O07GF4PWILB</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Bdq contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Bdq contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>o0r6wVvQT1H</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Mfx (CC) susceptible</td>
        <td>Sub DST LM: patients - Mfx CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>o2vVY3Tou4b</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Amk resistant</td>
        <td>Sub DST LM: new patients - Amk res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>o5VfgMGlYLo</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CB) resistant</td>
        <td>Sub DST LM: samples - Inh CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>O6It7XLWzij</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Bdq resistant</td>
        <td>Init DST SM: patients - Bdq res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>O6sByxTUSCg</td>
      </tr>
      <tr>
        <td>Days from sample collection to date of Xpert MTB/RIF test</td>
        <td>Xpert MTB/RIF: collection-test interval</td>
        <td></td>
        <td>Days from sample collection to test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>O81jVgPRPJZ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Pza resistant</td>
        <td>Sub DST SM: new patients - Pza res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>O9hhMPIUYZO</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CB) contaminated</td>
        <td>Init DST LM: samples - Mfx CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oaIfTkuTRsC</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 3 days</td>
        <td>Culture LM: 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oE4qleMRIsc</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Dlm resistant</td>
        <td>Sub DST LM: patients - Dlm res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>OebNebICI0h</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Dlm resistant</td>
        <td>Sub DST SM: prev patients - Dlm res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oeZepiNfmKj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Bdq susceptible</td>
        <td>Sub DST LM: patients - Bdq ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oftX0vZAM9r</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Emb susceptible</td>
        <td>Init DST LM: patients - Emb ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>OlecwgQa57o</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lzd contaminated</td>
        <td>Sub DST SM: samples - Lzd contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>OLR2G7P2KLX</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>Init DST LM: prev patients - Mfx CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Olrvc8Jhijd</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Kan indeterminate</td>
        <td>LPA (Fq/2LI): prev patients - Kan indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oLyx8mPsMUU</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Emb contaminated</td>
        <td>Sub DST LM: samples - Emb contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>onZWy5SCjZ5</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: new patients - Rif susceptible</td>
        <td>Xpert MTB/RIF: new patients - RS</td>
        <td></td>
        <td>New patients with result "MTB, Rif susceptible" tested by Xpert MTB/RIF. No resistance and no susceptibility detected by Xpert MTB/RIF in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oOTpUbHvOxn</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Cfz contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>OQeEjNs3Ho9</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Inh (CC) resistant</td>
        <td>Sub DST LM: patients - Inh CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>oqv395bpDv1</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Lfx contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Lfx contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>OSIs8OpyxVO</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Cfz resistant</td>
        <td>Init DST LM: samples - Cfz res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ou4WNqCxMuu</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CC) contaminated</td>
        <td>Sub DST SM: samples - Inh CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oUz32KzStH0</td>
      </tr>
      <tr>
        <td>Samples: 4 days</td>
        <td>Collection arrival interval: 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oViP4CReXG4</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 8 days</td>
        <td>Xpert MTB/RIF: 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>OVysV7KptVe</td>
      </tr>
      <tr>
        <td>Culture (solid media): samples - no growth</td>
        <td>Culture SM: samples - no growth</td>
        <td></td>
        <td>Samples with result "no growth" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oXa3DtiSYe0</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Kan resistant</td>
        <td>LPA (Fq/2LI): patients - Kan res</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>OxtZda8ABPq</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Cfz resistant</td>
        <td>Init DST SM: new patients - Cfz res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oyDpKH5EAxE</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Rif indeterminate</td>
        <td>Sub DST SM: samples - Rif indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>oz7eO5DDvNa</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Inh (CC) resistant</td>
        <td>Init DST SM: patients - Inh CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>P1wRsnQDSoO</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Amk/Cap resistant</td>
        <td>LPA (Fq/2LI): new patients - Amk/Cap res</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>P8GK4wGFFTE</td>
      </tr>
      <tr>
        <td>Sample collection and arrival events</td>
        <td>Collection arrival events, sum</td>
        <td></td>
        <td>Sample collection and arrival events. Added value used to calculate percentage.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>P9K7xj7hHgZ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Bdq resistant</td>
        <td>Init DST LM: prev patients - Bdq res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Pc6xpNNg7LE</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Kan susceptible</td>
        <td>LPA (Fq/2LI): new patients - Kan ss</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PCemW9SgW7M</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Emb resistant</td>
        <td>LPA (Fq/2LI): prev patients - Emb res</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: resistant. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pcyI2L4i2bS</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 0 days</td>
        <td>LPA (Fq/2LI): 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PD1r3kjNsEZ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 10 days</td>
        <td>Xpert MTB/RIF: 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>PdeRbkFtsIC</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pDF9ROzD1cb</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - Inh resistant</td>
        <td>LPA (Rif/Inh): patients - Inh res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pDr45R9KiqB</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - MTB, Rif indeterminate</td>
        <td>Xpert MTB/RIF: samples - Rif indet</td>
        <td></td>
        <td>Samples with result "MTB detected, Rif indeterminate" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>PDSh98oi6iG</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Pza resistant</td>
        <td>Init DST LM: prev patients - Pza res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pEpZ5PTUhJz</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Bdq contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Pf9TOtsHmci</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Amk susceptible</td>
        <td>Init DST LM: prev patients - Amk ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pfmjHNJ9x6R</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Cfz resistant</td>
        <td>Init DST SM: patients - Cfz res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pg04Amkdg8w</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Lzd contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PgBqxJAbupy</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Amk susceptible</td>
        <td>Init DST LM: patients - Amk ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>phffikkxLSj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Dlm susceptible</td>
        <td>Sub DST LM: patients - Dlm ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>phorDunwGXo</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Inh CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PHv62Yu06oi</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Lfx contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Pi8ayoXTRKO</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Inh CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PJZO3meSj8D</td>
      </tr>
      <tr>
        <td>New patients (cumulative)</td>
        <td>New patients (cumulative)</td>
        <td></td>
        <td>New patients (cumulative)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PK5i0N7y7Ja</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Emb contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Emb contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pkgY5FqeFjb</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Rif resistant</td>
        <td>Init DST LM: new patients - Rif res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PL2mZFknpzr</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for subsequent DST (liquid media)</td>
        <td>Sub DST LM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PldVWpl9xeq</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Pza contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Pza contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pLUGwLLLQMF</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Lzd susceptible</td>
        <td>Init DST LM: prev patients - Lzd ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>plvxpzzpVzo</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Lfx contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pMGwv0JLXEt</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Emb susceptible</td>
        <td>Init DST SM: prev patients - Emb ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pnT5LoEQyzr</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - MTB not detected</td>
        <td>Xpert MTB/RIF Ultra: patients - MTB not detected</td>
        <td></td>
        <td>New patients with MTB not detected by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Poolb0bKeix</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Dlm susceptible</td>
        <td>Sub DST SM: new patients - Dlm ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PPl4KMHIJT3</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CC) resistant</td>
        <td>Sub DST SM: samples - Mfx CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PpTb1ERfg3Q</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Pza indeterminate</td>
        <td>Init DST LM: samples - Pza indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pqKUQg6IVks</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Cfz susceptible</td>
        <td>Init DST LM: samples - Cfz ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Pr1eRaFDtRG</td>
      </tr>
      <tr>
        <td>Culture (liquid media): samples - No growth</td>
        <td>Culture LM: samples - no growth</td>
        <td></td>
        <td>Samples with result "no growth" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pTDVLacJUAm</td>
      </tr>
      <tr>
        <td>HR-TB patients</td>
        <td>HR-TB patients</td>
        <td></td>
        <td>Patients susceptible to rifampicin and resistant to isoniazid. </td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PTGtgtV5tb2</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Lzd susceptible</td>
        <td>Sub DST LM: prev patients - Lzd ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PtpSwoTHmcG</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Pza contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Pza contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PUMHNoEubMR</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Cfz contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Cfz contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pvcjXzf476j</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 5 days</td>
        <td>Xpert MTB/RIF: 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>PvKoYkm2MCX</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Amk resistant</td>
        <td>Sub DST SM: new patients - Amk res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pwDBHevJNrL</td>
      </tr>
      <tr>
        <td>Previously treated patients</td>
        <td>Previously treated patients</td>
        <td></td>
        <td>Previously treated patients</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pWkYiiBIzeI</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Inh (CB) resistant</td>
        <td>Sub DST LM: new patients - Inh CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pXysNcjM76l</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - MTB</td>
        <td>LPA (Rif/Inh): patients - MTB</td>
        <td></td>
        <td>Patients with MTB detected in at least one sample by LPA (Rif/Inh). Condition: MTB detected, test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pytuZVI0ukZ</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 4 days</td>
        <td>LPA (Rif/Inh): 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pYWJoY1zICY</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RR</td>
        <td>Xpert MTB/RIF Ultra: prev patients - RR</td>
        <td></td>
        <td>Previously treated patients with result "MTB, Rif resistant" tested by Xpert MTB/RIF Ultra. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>pzTm4eHbXdp</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - MTB</td>
        <td>LPA (Fq/2LI): patients - MTB</td>
        <td></td>
        <td>Patients with MTB detected in at least one sample by LPA (Fq/2LI). Condition: test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>q6rKTcc0b4G</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Emb susceptible</td>
        <td>Sub DST SM: samples - Emb ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>q76HsI6ClCd</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Cfz susceptible</td>
        <td>Sub DST SM: prev patients - Cfz ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>q9KghOGpcdq</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): new patients - Rif resistant</td>
        <td>LPA (Rif/Inh): new patients - Rif res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qAaqiEtHFgB</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 7 days</td>
        <td>LPA (Fq/2LI): 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QarDtlid8zk</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Lzd contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QBlVFZk3DBu</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Rif indeterminate</td>
        <td>Init DST SM: samples - Rif indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QBTDDGn35IH</td>
      </tr>
      <tr>
        <td>Enrolled patients (cumulative)</td>
        <td>Enrollments (cumulative)</td>
        <td></td>
        <td>Cumulative enrollment count</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qd9PbhmNYnR</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Dlm resistant</td>
        <td>Init DST LM: new patients - Dlm res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QEcUcHVFJho</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Emb resistant</td>
        <td>LPA (Fq/2LI): patients - Emb res</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Qfhf25Oce5X</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Rif susceptible</td>
        <td>Init DST LM: samples - Rif ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QGjAcTm4uv2</td>
      </tr>
      <tr>
        <td>Missing data: patients with no registered age, gender, HIV test result, or TB treatment history</td>
        <td>Missing data: any key demographics</td>
        <td></td>
        <td>Patients with any key demographics data missing</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qGLJdB5Qg2I</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - MTB</td>
        <td>LPA (Rif/Inh): samples - MTB</td>
        <td></td>
        <td>Samples with result "MTB detected" tested by LPA (Rif/Inh). Condition: MTB detected, test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qgRHOse57eS</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QgZ5U6ocKbS</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Mfx CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qhTaRzXxdgE</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Cfz contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QjC1EgtnJAD</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Cfz indeterminate</td>
        <td>Sub DST SM: samples - Cfz indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QLdY9WHtJDz</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Lfx susceptible</td>
        <td>Init DST SM: patients - Lfx ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QLOD6SMC2A0</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Mfx (CC) resistant</td>
        <td>Sub DST LM: new patients - Mfx CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QmGU5r5l9Ab</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>Sub DST LM: prev patients - Mfx CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qoEyqH4wwwm</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Mfx (CC) resistant</td>
        <td>Init DST SM: prev patients - Mfx CC res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qogSzR2VXkK</td>
      </tr>
      <tr>
        <td>Samples with result for initial DST (solid media)</td>
        <td>Init DST SM: samples - result</td>
        <td></td>
        <td>Samples with result for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QPGYhthplln</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - Rif resistant</td>
        <td>Xpert MTB/RIF Ultra: samples - RR</td>
        <td></td>
        <td>Samples with result "MTB detected, Rif resistant" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qQlS4yw9RaV</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - MTB not detected</td>
        <td>Xpert MTB/RIF Ultra: samples - MTB not detected</td>
        <td></td>
        <td>Samples with result "MTB not detected" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QSa605mN246</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Pza contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Pza contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qtJLBYBxHXE</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Cfz susceptible</td>
        <td>Init DST LM: patients - Cfz ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qUcV1AsyrjM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: new patients - Rif indeterminate</td>
        <td>Xpert MTB/RIF: new patients - Rif indet</td>
        <td></td>
        <td>New patients with result "MTB, Rif indeterminate" tested by Xpert MTB/RIF. No resistance and no susceptibility detected by Xpert MTB/RIF in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>QvrvOrqNR9s</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Cfz resistant</td>
        <td>Sub DST SM: samples - Cfz res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>qxFMe08GfWQ</td>
      </tr>
      <tr>
        <td>Patients with result for initial DST (liquid media)</td>
        <td>Init DST LM: patients - result</td>
        <td></td>
        <td>Patients with result for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QXiAL03hJjW</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Rif contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>QxlIXjaP09h</td>
      </tr>
      <tr>
        <td>Patients with culture inoculation date (liquid media)</td>
        <td>Culture LM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>R1AWAmtWXNh</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - MTB not detected</td>
        <td>LPA (Rif/Inh): samples - MTB not detected</td>
        <td></td>
        <td>Samples with result "MTB not detected" tested by LPA (Rif/Inh). Condition: MTB not detected, test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>r1f4FeokEfS</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Lzd susceptible</td>
        <td>Init DST SM: patients - Lzd ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>r35T9E2eN0J</td>
      </tr>
      <tr>
        <td>Culture (liquid media): previously treated patients - no growth</td>
        <td>Culture LM: prev patients - no growth</td>
        <td></td>
        <td>Previously treated patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>R3JPrdIcmjs</td>
      </tr>
      <tr>
        <td>Patients with unknown treatment history</td>
        <td>DRS: unknown treatment history</td>
        <td></td>
        <td>Patients with unknown treatment history</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>R3QrVqsFhCC</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Cfz susceptible</td>
        <td>Init DST SM: patients - Cfz ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rAIsq8tQ0rL</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Lzd resistant</td>
        <td>Init DST LM: new patients - Lzd res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rb5UEJsvHMs</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Dlm contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RBicbarJPl4</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lzd susceptible</td>
        <td>Init DST SM: samples - Lzd ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RBKOeLO8kFs</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Lfx contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rcICF38L7mE</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Rif contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Rif contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RCuCuQq8EVw</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Cfz susceptible</td>
        <td>Sub DST LM: prev patients - Cfz ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>REb86WxR7NW</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Rif resistant</td>
        <td>Init DST SM: patients - Rif res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RFUHj0EVvIW</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Emb indeterminate</td>
        <td>Init DST LM: samples - Emb indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Rfz2wpp9wsI</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lzd susceptible</td>
        <td>Init DST LM: samples - Lzd ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RK2d2KxY2ln</td>
      </tr>
      <tr>
        <td>Samples with Xpert MTB/RIF Ultra test result</td>
        <td>Xpert MTB/RIF Ultra: samples - result</td>
        <td></td>
        <td>Samples with result for Xpert MTB/RIF Ultra</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>rkXSq0Sf1Lc</td>
      </tr>
      <tr>
        <td>Culture (solid media): 1 day</td>
        <td>Culture SM: 1d</td>
        <td></td>
        <td>Samples with 1 day turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Rlbs4UiZydq</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Bdq contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Bdq contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RLMAFAjdM1P</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CC) susceptible</td>
        <td>Sub DST SM: prev patients - Inh CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rMKJMrIdwxU</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 2 days</td>
        <td>LPA (Fq/2LI): 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rnxWrZanCtV</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Bdq contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rocQB4VEATy</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Amk susceptible</td>
        <td>Init DST SM: new patients - Amk ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rq7eOFDLmQK</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Mfx (CB) resistant</td>
        <td>Init DST SM: patients - Mfx CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rQXzjEVe3c2</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Amk susceptible</td>
        <td>Init DST LM: new patients - Amk ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RsElKBSc1kB</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Amk resistant</td>
        <td>Sub DST SM: samples - Amk res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rShSocJ14lJ</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 3 days</td>
        <td>LPA (Fq/2LI): 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rSrlFohRGM1</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CB) susceptible</td>
        <td>Init DST SM: samples - Mfx CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RTLLeqWAffq</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Amk susceptible</td>
        <td>Sub DST SM: new patients - Amk ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ruLVyeypubb</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Dlm contaminated</td>
        <td>Init DST SM: samples - Dlm contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rUvdF2y3yQV</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 8 days</td>
        <td>Culture LM: 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RV2PlhWoox8</td>
      </tr>
      <tr>
        <td>Samples with microscopy result</td>
        <td>Microscopy: samples - result</td>
        <td></td>
        <td>Samples with result for microscopy</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rV8cfZVEqZK</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Dlm - contaminated</td>
        <td>Sub DST LM: samples - Dlm - contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rWJyTJVZl5s</td>
      </tr>
      <tr>
        <td>Culture (solid media): samples - contaminated</td>
        <td>Culture SM: samples - contam</td>
        <td></td>
        <td>Samples with result "contaminated" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RX5YwuS9RbM</td>
      </tr>
      <tr>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>LPA (Fq/2LI): processed samples</td>
        <td></td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>rxuYRTJZ2ej</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Pza susceptible</td>
        <td>Init DST SM: prev patients - Pza ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RyF9HEzgBBn</td>
      </tr>
      <tr>
        <td>Microscopy: previously treated patients - positive</td>
        <td>Microscopy: prev patients - positive</td>
        <td></td>
        <td>Previously treated patients with microscopy result "positive". If more than one sample is examined per patient, "positive" result is recorded if at least one sample is "positive". Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RZEpC4Mmmsp</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Amk contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>RZPj0Wrcnxn</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 7 days</td>
        <td>LPA (Rif/Inh): 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>s2MFQfmgwDR</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Pza susceptible</td>
        <td>Sub DST LM: samples - Pza ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>S33osVSK7bu</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Init DST LM: patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>s4ojXwTRVMB</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Cfz resistant</td>
        <td>Init DST SM: prev patients - Cfz res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>s560uws0IhG</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Lfx resistant</td>
        <td>Sub DST SM: new patients - Lfx res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>s8ca1kbNVCy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: previously treated patients - Rif indeterminate</td>
        <td>Xpert MTB/RIF: prev patients - Rif indet</td>
        <td></td>
        <td>Previously treated patients with result "MTB, Rif indeterminate" tested by Xpert MTB/RIF. No resistance and no susceptibility detected by Xpert MTB/RIF in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>S8lSfngoxu7</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Fq susceptible</td>
        <td>LPA (Fq/2LI): prev patients - Fq ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: susceptible. No resistance detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>s9gdW5R4nj1</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Bdq susceptible</td>
        <td>Sub DST SM: new patients - Bdq ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SARbVYz3ovb</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CB) susceptible</td>
        <td>Sub DST SM: samples - Inh CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SbfRyAQCsp4</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Mfx (CB) susceptible</td>
        <td>Sub DST LM: patients - Mfx CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SftNGftUtHI</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Inh CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sg927BRQATg</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>Init DST LM: prev patients - Mfx CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sGLpHvkrJl0</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CB) resistant</td>
        <td>Init DST LM: samples - Mfx CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SGT2z6fisYd</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - Rif susceptible</td>
        <td>Xpert MTB/RIF Ultra: samples - RS</td>
        <td></td>
        <td>Samples with result "MTB detected, Rif susceptible" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SH0iOmEe0AR</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Rif susceptible</td>
        <td>Init DST SM: patients - Rif ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sh8xXpr7SOC</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): new patients - Inh resistant</td>
        <td>LPA (Rif/Inh): new patients - Inh res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: resistant. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sHgmMnlbGOd</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - MTB</td>
        <td>Xpert MTB/RIF Ultra: patients - MTB</td>
        <td></td>
        <td>New patients with MTB detected by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SJIgoySQSL9</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Emb susceptible</td>
        <td>LPA (Fq/2LI): new patients - Emb ss</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SjJygt0PwVc</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Dlm indeterminate</td>
        <td>Sub DST LM: samples - Dlm indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sJxBmDVVRFI</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CC) contaminated</td>
        <td>Sub DST SM: samples - Mfx CC contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SkrMaOzuaOx</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Kan resistant</td>
        <td>LPA (Fq/2LI): samples - Kan res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SKYQM109VlR</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Amk resistant</td>
        <td>Init DST LM: prev patients - Amk res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>smBK9aQLZVt</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Emb susceptible</td>
        <td>LPA (Fq/2LI): prev patients - Emb ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: susceptible. No resistance detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SmerIApsjMN</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): new patients - Inh indeterminate</td>
        <td>LPA (Rif/Inh): new patients - Inh indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Rif/Inh) in other samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SMQaa2FME9m</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Pza contaminated</td>
        <td>Init DST SM: samples - Pza contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Smx6TYW3634</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Lfx resistant</td>
        <td>Init DST LM: new patients - Lfx res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Sn1Y3lTblQ2</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Mfx CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>snExB8w3Gcm</td>
      </tr>
      <tr>
        <td>Culture (solid media): patients - NTM</td>
        <td>Culture SM: patients - NTM</td>
        <td></td>
        <td>Patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>snFxSirfErx</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Inh (CB) susceptible</td>
        <td>Sub DST LM: patients - Inh CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SNTw9Vpw8qb</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - Rif resistant</td>
        <td>LPA (Rif/Inh): patients - Rif res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: resistant. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>spav9vMokn2</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - Rif indeterminate</td>
        <td>LPA (Rif/Inh): patients - Rif indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Rif/Inh) in other samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sPBdvSLlJZY</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Dlm contaminated/indeterminate</td>
        <td>Init DST SM: patients - Dlm contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sqp1Bv70e3U</td>
      </tr>
      <tr>
        <td>Culture (liquid media): previously treated patients - contaminated</td>
        <td>Culture LM: prev patients - contam</td>
        <td></td>
        <td>Previously treated patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sRaCkGSjiLt</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Lfx contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>srZG8NDtJ3h</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Inh CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ss7bHfxhLrq</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lzd susceptible</td>
        <td>Sub DST LM: samples - Lzd ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>stEHUWnoMq5</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 6 days</td>
        <td>Culture LM: 6d</td>
        <td></td>
        <td>Samples with 6 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>STuGYEEZ6o5</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CB) contaminated</td>
        <td>Init DST LM: samples - Inh CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>su6weiXSIti</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Cfz susceptible</td>
        <td>Init DST LM: new patients - Cfz ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>svpfoQw6O39</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Bdq susceptible</td>
        <td>Sub DST SM: samples - Bdq ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SwmPVQY2FJ3</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Amk resistant</td>
        <td>Sub DST SM: prev patients - Amk res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>sYiVV33usyC</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Inh (CB) resistant</td>
        <td>Sub DST SM: patients - Inh CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>SzYSBtaPujQ</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Mfx (CC) susceptible</td>
        <td>Sub DST SM: patients - Mfx CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>T1D14wQc6Pe</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CB) resistant</td>
        <td>Init DST SM: samples - Mfx CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>t2EcSOcA09t</td>
      </tr>
      <tr>
        <td>Culture (liquid media): new patients - MTB</td>
        <td>Culture LM: new patients - MTB</td>
        <td></td>
        <td>New patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>t3qthExhQKL</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lfx contaminated</td>
        <td>Init DST LM: samples - Lfx contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tA5pYtchuWU</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CB) contaminated</td>
        <td>Sub DST SM: samples - Mfx CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TAJrVlUWA15</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Lfx contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Tcq1ZiYT7Yq</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Cfz susceptible</td>
        <td>Init DST SM: samples - Cfz ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tDKHvNwKNRL</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Dlm susceptible</td>
        <td>Sub DST LM: prev patients - Dlm ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Tegm0xLM4rn</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Mfx (CB) resistant</td>
        <td>Sub DST SM: patients - Mfx CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TePspFbeIA5</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Rif contaminated/indeterminate</td>
        <td>Init DST LM: patients - Rif contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TeRX9Z45EzR</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Dlm susceptible</td>
        <td>Init DST SM: samples - Dlm ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>thTqoznl0K7</td>
      </tr>
      <tr>
        <td>Culture (liquid media): patients - contaminated</td>
        <td>Culture LM: patients - contam</td>
        <td></td>
        <td>Patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tIgRROcdrWC</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Dlm susceptible</td>
        <td>Sub DST LM: new patients - Dlm ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>titK1r1BOlH</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Fq indeterminate</td>
        <td>LPA (Fq/2LI): samples - Fq indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tiuKqMsWxrw</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Invalid</td>
        <td>LPA (Fq/2LI): samples - Invalid</td>
        <td></td>
        <td>Samples with result "invalid" tested by LPA (Fq/2LI). Condition: Result "invalid", test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-16</td>
        <td>tja5fRSuTBE</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Pza resistant</td>
        <td>Sub DST LM: new patients - Pza res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tJa81zjWUkG</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Inh (CB) susceptible</td>
        <td>Sub DST SM: patients - Inh CB ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TkKU87tvUfC</td>
      </tr>
      <tr>
        <td>Samples: 0 days</td>
        <td>Collection arrival interval: 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tLhDS5r25wt</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Emb resistant</td>
        <td>Init DST LM: new patients - Emb res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tlmQ6gisAGh</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CC) indeterminate</td>
        <td>Init DST SM: samples - Inh CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ToEpkaCnJuf</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Dlm susceptible</td>
        <td>Init DST LM: new patients - Dlm ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tois9I4EkY3</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Lfx contaminated/indeterminate</td>
        <td>Init DST LM: patients - Lfx contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TORYgaK1YUF</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CB) indeterminate</td>
        <td>Init DST LM: samples - Mfx CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TOU4KSWSS1b</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 3 days</td>
        <td>Xpert MTB/RIF Ultra: 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tqXqhNzjbLK</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Inh (CC) susceptible</td>
        <td>Init DST SM: patients - Inh CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TSS4Ymmu0qa</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Inh (CB) susceptible</td>
        <td>Init DST LM: new patients - Inh CB ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TTy1mozDhty</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Dlm resistant</td>
        <td>Init DST SM: samples - Dlm res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ttyarOal7wI</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Dlm susceptible</td>
        <td>Init DST SM: new patients - Dlm ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tuFTLk3Q0ss</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 4 days</td>
        <td>Xpert MTB/RIF: 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>TUguO2Ynxex</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CC) indeterminate</td>
        <td>Init DST LM: samples - Inh CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>tuy3A2HETxn</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Amk resistant</td>
        <td>Sub DST LM: patients - Amk res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>TXzYZ5NUzGE</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 10 days</td>
        <td>LPA (Fq/2LI): 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>tYLvtd2eq1T</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Cfz resistant</td>
        <td>Init DST LM: prev patients - Cfz res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>U0KbG9khPd5</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Mfx (CC) susceptible</td>
        <td>Init DST SM: patients - Mfx CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>U4mKeK8i4Hk</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Cfz resistant</td>
        <td>Init DST LM: patients - Cfz res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>U4YZsFclJlk</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lfx indeterminate</td>
        <td>Sub DST LM: samples - Lfx indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>U5WRXT9rtyA</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Cfz resistant</td>
        <td>Sub DST SM: patients - Cfz res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>U61I4srgNTl</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 10 days</td>
        <td>LPA (Rif/Inh): 10d</td>
        <td></td>
        <td>Samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>u7o1DWalCtg</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Emb indeterminate</td>
        <td>LPA (Fq/2LI): samples - Emb indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>u8hqJ0vFyDx</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Amk susceptible</td>
        <td>Sub DST LM: new patients - Amk ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>UBxYSphJOOI</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Lzd resistant</td>
        <td>Init DST LM: patients - Lzd res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Uchb5CJcAOn</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Rif susceptible</td>
        <td>Init DST SM: prev patients - Rif ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>UfEFCBuifbO</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CB) contaminated</td>
        <td>Sub DST SM: samples - Inh CB contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ugg2hcmNkv1</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Dlm resistant</td>
        <td>Sub DST SM: samples - Dlm res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uHVdQW61TK6</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Rif contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Rif contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ulABEq4nBsW</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CC) susceptible</td>
        <td>Init DST LM: samples - Inh CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uM6AKPkeUwQ</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 3 days</td>
        <td>LPA (Rif/Inh): 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uNBJmNEtRBF</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Emb susceptible</td>
        <td>Sub DST LM: samples - Emb ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>UnMZYDDbWef</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Emb contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Emb contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uOiAgPqfSca</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Inh (CC) indeterminate</td>
        <td>Sub DST SM: samples - Inh CC indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ur2unOu0ABe</td>
      </tr>
      <tr>
        <td>Culture (solid media): previously treated patients - MTB</td>
        <td>Culture SM: prev patients - MTB</td>
        <td></td>
        <td>Previously treated patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>UrPUE2i8GAU</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uSojnfuocie</td>
      </tr>
      <tr>
        <td>Culture (solid media): 9 days</td>
        <td>Culture SM: 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>utTgYdaTGrb</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): 9 days</td>
        <td>LPA (Fq/2LI): 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uu0066KEVEY</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Emb susceptible</td>
        <td>Sub DST SM: patients - Emb ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>UuJnpUZEIMt</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Mfx CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uvQVPvXOXSK</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - Amk/Cap resistant</td>
        <td>LPA (Fq/2LI): patients - Amk/Cap res</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uvyU5oBD2oz</td>
      </tr>
      <tr>
        <td>Patients with result for subsequent DST (solid media)</td>
        <td>Sub DST SM: patients - result</td>
        <td></td>
        <td>Patients with result for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>uXexeo22Whu</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Lzd contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Uy0fdbBkqgV</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Lfx resistant</td>
        <td>Sub DST SM: prev patients - Lfx res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>UzmVwVcCDsP</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Cfz resistant</td>
        <td>Sub DST LM: patients - Cfz res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>V0x2p9VH7D8</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Dlm resistant</td>
        <td>Sub DST SM: patients - Dlm res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>V36JWd4DEwS</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Pza susceptible</td>
        <td>Sub DST LM: patients - Pza ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>V4GWEENoVdy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - error</td>
        <td>Xpert MTB/RIF Ultra: samples - error</td>
        <td></td>
        <td>Samples with result "error" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>v4o5oChYOcF</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Amk contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>V8h0smTVb4r</td>
      </tr>
      <tr>
        <td>Patients with interpretable Xpert MTB/RIF result</td>
        <td>Xpert MTB/RIF: patients - interp. result</td>
        <td></td>
        <td>Patients with interpretable test result for Xpert MTB/RIF</td>
        <td>ENROLLMENT</td>
        <td>2020-11-13</td>
        <td>VBrNPAkO9f1</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): patients - MTB not detected</td>
        <td>LPA (Fq/2LI): patients - MTB not detected</td>
        <td></td>
        <td>Patients with MTB not detected in any samples tested by LPA (Fq/2LI). Condition: test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VCfBUEMSE8h</td>
      </tr>
      <tr>
        <td>Samples with result for initial DST (liquid media)</td>
        <td>Init DST LM: samples - result</td>
        <td></td>
        <td>Samples with result for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VCucFY6roOu</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Amk susceptible</td>
        <td>Sub DST LM: patients - Amk ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>veREteT6hlg</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lzd indeterminate</td>
        <td>Init DST SM: samples - Lzd indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VFwlYCRpKT8</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Rif contaminated</td>
        <td>Init DST SM: samples - Rif contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VIGJElSLwE6</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Rif resistant</td>
        <td>Init DST LM: samples - Rif res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VIgX0suMyw3</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Mfx (CC) resistant</td>
        <td>Init DST LM: samples - Mfx CC res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vIvpAQtmuvr</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lfx susceptible</td>
        <td>Init DST LM: samples - Lfx ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vjf4N8MCOV3</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Lfx susceptible</td>
        <td>Sub DST SM: prev patients - Lfx ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vJljhgD71Ny</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Pza resistant</td>
        <td>Sub DST LM: patients - Pza res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>VkB0mC22R4E</td>
      </tr>
      <tr>
        <td>Samples with culture inoculation date (liquid media)</td>
        <td>Culture LM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vkspdWX0mzd</td>
      </tr>
      <tr>
        <td>Culture (solid media): previously treated patients - no growth</td>
        <td>Culture SM: prev patients - no growth</td>
        <td></td>
        <td>Previously treated patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vlhg0jTKrsH</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Cfz indeterminate</td>
        <td>Init DST SM: samples - Cfz indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vMpjSJHqaNa</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Cfz contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vnRU4p2WNZH</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Mfx (CB) resistant</td>
        <td>Init DST SM: new patients - Mfx CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vpFUsKTHw7C</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Dlm susceptible</td>
        <td>Sub DST LM: samples - Dlm ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VPiRrxWIeAu</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Cfz contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Cfz contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vPjEMOUrOiA</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Amk susceptible</td>
        <td>Sub DST LM: samples - Amk ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VrkQDJXIDDP</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Amk resistant</td>
        <td>Init DST SM: patients - Amk res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VsaE6AEggjD</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Invalid</td>
        <td>LPA (Rif/Inh): samples - Invalid</td>
        <td></td>
        <td>Samples with result "invalid" tested by LPA (Rif/Inh). Condition: Result "invalid", test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-11-16</td>
        <td>VsbiIWP2J2F</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CB) resistant</td>
        <td>Sub DST LM: prev patients - Inh CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vSMBlVfDmft</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Rif contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VTQkjI3hSkm</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - MTB not detected</td>
        <td>LPA (Fq/2LI): samples - MTB not detected</td>
        <td></td>
        <td>Samples with result "MTB not detected" tested by LPA (Fq/2LI). Condition: MTB not detected, test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VVv5IQaPrdI</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>Init DST LM: patients - Inh CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VvwaGW8ihTk</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Pza resistant</td>
        <td>Sub DST SM: prev patients - Pza res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vWmY0yvNVfc</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Bdq contaminated</td>
        <td>Sub DST SM: samples - Bdq contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VxJFIFNjhb4</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Mfx (CC) resistant</td>
        <td>Init DST SM: new patients - Mfx CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>VxTMToeTQsg</td>
      </tr>
      <tr>
        <td>Missing data: sex</td>
        <td>Missing data: sex</td>
        <td></td>
        <td>Patients with sex data missing</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vXwdB7fhkW5</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Mfx (CC) susceptible</td>
        <td>Init DST SM: samples - Mfx CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>vxy56EFkTrH</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Mfx (CB) resistant</td>
        <td>Sub DST LM: patients - Mfx CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>vYwZAP4yu5U</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Emb indeterminate</td>
        <td>Sub DST SM: samples - Emb indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>W0OTsurXcBq</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Emb indeterminate</td>
        <td>Init DST SM: samples - Emb indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>w2AaUjwDGui</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Amk/Cap indeterminate</td>
        <td>LPA (Fq/2LI): prev patients - Amk/Cap indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>W2V43bhnDpW</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 8 days</td>
        <td>LPA (Rif/Inh): 8d</td>
        <td></td>
        <td>Samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>w3AZnT9pW4i</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Mfx (CC) resistant</td>
        <td>Sub DST SM: patients - Mfx CC res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>W3jcBVNTObT</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Lfx contaminated</td>
        <td>Sub DST SM: samples - Lfx contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>w4Oc9nvJwmg</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Cfz contaminated/indeterminate</td>
        <td>Init DST LM: patients - Cfz contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>W8slaPHit8G</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Emb resistant</td>
        <td>Init DST LM: prev patients - Emb res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>waI6zGdAC0L</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Lfx susceptible</td>
        <td>Init DST LM: new patients - Lfx ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WAOO1PP801X</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Lfx contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WaQFRJ0X8xv</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Amk resistant</td>
        <td>Init DST LM: new patients - Amk res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Wb7mB8gZmxS</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): 0 days</td>
        <td>LPA (Rif/Inh): 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WcDv2gi6Pek</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Amk indeterminate</td>
        <td>Sub DST LM: samples - Amk indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WdtDDovKwwJ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Amk indeterminate</td>
        <td>Init DST LM: samples - Amk indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>weuEp8gEYiA</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Lzd susceptible</td>
        <td>Sub DST LM: patients - Lzd ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wfYOu1lx6Qa</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Emb susceptible</td>
        <td>Init DST LM: new patients - Emb ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Wh5ltuI2RdR</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 3 days</td>
        <td>Xpert MTB/RIF: 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wHvQW41KS4c</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Lfx resistant</td>
        <td>Sub DST LM: patients - Lfx res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>WiIoqdGvg1M</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Lzd resistant</td>
        <td>Sub DST SM: patients - Lzd res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WjpPcWta7Gz</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Amk contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wjQ7CrAeA6p</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 10+ days</td>
        <td>Culture LM: 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WJwWEO1wLoD</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Rif contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WLH2VJO0PkN</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Dlm susceptible</td>
        <td>Init DST SM: prev patients - Dlm ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wMrYlXritKK</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Pza contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wnmc8YIahud</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Rif susceptible</td>
        <td>Init DST SM: samples - Rif ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Won3WS3jgBz</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>Init DST LM: patients - Inh CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WQ2ZlVJAL1d</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: new patients - Rif resistant</td>
        <td>Xpert MTB/RIF: new patients - RR</td>
        <td></td>
        <td>New patients with result "MTB, Rif resistant" tested by Xpert MTB/RIF. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Wq80cCyFEPj</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Emb resistant</td>
        <td>Sub DST LM: new patients - Emb res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wqHfPAv7vWy</td>
      </tr>
      <tr>
        <td>Culture (liquid media): new patients - no growth</td>
        <td>Culture LM: new patients - no growth</td>
        <td></td>
        <td>New patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wQisEHlG43c</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Mfx (CC) susceptible</td>
        <td>Init DST LM: patients - Mfx CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wSl9gzxcHBr</td>
      </tr>
      <tr>
        <td>Samples with result for subsequent DST (liquid media)</td>
        <td>Sub DST LM: samples - result</td>
        <td></td>
        <td>Samples with result for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wsLnXY7LDlA</td>
      </tr>
      <tr>
        <td>Culture (liquid media): previously treated patients - NTM</td>
        <td>Culture LM: prev patients - NTM</td>
        <td></td>
        <td>Previously treated patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WTblEFaKYPi</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Bdq contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WwLq06C7iTC</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for subsequent DST (solid media)</td>
        <td>Sub DST SM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>wxKzVyo48o2</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Lfx susceptible</td>
        <td>Init DST SM: prev patients - Lfx ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WYIKQdnWj8v</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Lfx resistant</td>
        <td>Sub DST SM: patients - Lfx res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Wyv5aIEB1Gl</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Lzd indeterminate</td>
        <td>Sub DST LM: samples - Lzd indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>WzSjzok3JLp</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Rif susceptible</td>
        <td>Sub DST LM: prev patients - Rif ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>x0BuFyVqp5G</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Lzd contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Lzd contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>X1OWCAaNwhw</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Inh (CC) resistant</td>
        <td>Sub DST LM: new patients - Inh CC res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>x2pAZdpQDUD</td>
      </tr>
      <tr>
        <td>Culture (solid media): 3 days</td>
        <td>Culture SM: 3d</td>
        <td></td>
        <td>Samples with 3 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>x9RZw5fD8fa</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>Init DST SM: patients - Mfx CB contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XbDlCbLLMWa</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: new patients - RR</td>
        <td>Xpert MTB/RIF Ultra: new patients - RR</td>
        <td></td>
        <td>New patients with result "MTB, Rif resistant" tested by Xpert MTB/RIF Ultra. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XBM747hHcXa</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Lfx resistant</td>
        <td>Init DST LM: prev patients - Lfx res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xCg1UJXJ5Yc</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Cfz contaminated</td>
        <td>Init DST SM: samples - Cfz contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XCJmxcszJ4E</td>
      </tr>
      <tr>
        <td>Culture (solid media): new patients - MTB</td>
        <td>Culture SM: new patients - MTB</td>
        <td></td>
        <td>New patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xDByzKWh8B5</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Dlm contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XdE897XapaW</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CC) susceptible</td>
        <td>Sub DST SM: samples - Mfx CC ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xDI1TZpYM8S</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Rif resistant</td>
        <td>Sub DST LM: patients - Rif res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2021-01-28</td>
        <td>xEEDBnzahPe</td>
      </tr>
      <tr>
        <td>Culture (liquid media): samples - NTM</td>
        <td>Culture LM: samples - NTM</td>
        <td></td>
        <td>Samples with result "NTM" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xFN86BRI9Z6</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Inh CB contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XGMW0GtBuNg</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Inh (CC) susceptible</td>
        <td>Init DST LM: prev patients - Inh CC ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XhNxSlnrws1</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Pza susceptible</td>
        <td>Init DST SM: patients - Pza ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xHZKn549ZRN</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XjFQ4NnAU7N</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Pza resistant</td>
        <td>Init DST SM: prev patients - Pza res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XJom38gElVN</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Dlm susceptible</td>
        <td>Init DST SM: patients - Dlm ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xjqlj9qGNwf</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Mfx (CB) resistant</td>
        <td>Init DST LM: patients - Mfx CB res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xLut6liwpel</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Bdq resistant</td>
        <td>Sub DST SM: new patients - Bdq res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xLxjI8jmbas</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Bdq resistant</td>
        <td>Sub DST LM: new patients - Bdq res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xMEWouqClFf</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Inh (CB) susceptible</td>
        <td>Init DST LM: prev patients - Inh CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xmRYHCLPMTe</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Emb resistant</td>
        <td>Init DST LM: patients - Emb res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xMXHVJ3TGdP</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): previously treated patients - Amk/Cap susceptible</td>
        <td>LPA (Fq/2LI): prev patients - Amk/Cap ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: susceptible. No resistance detected by LPA (Fq/2LI) in other samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XmzqEJb0w79</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): samples - Emb susceptible</td>
        <td>LPA (Fq/2LI): samples - Emb ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by LPA (Fq/2LI). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XNFmjjFC52a</td>
      </tr>
      <tr>
        <td>Missing data: HIV test result</td>
        <td>Missing data: HIV test result</td>
        <td></td>
        <td>Patients with HIV test result data missing</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XOE7Mzfedq4</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): previously treated patients - Rif resistant</td>
        <td>LPA (Rif/Inh): prev patients - Rif res </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: resistant. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XoQx6SJPRTV</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Rif susceptible</td>
        <td>Sub DST LM: patients - Rif ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xPHG0IoL3gy</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Bdq resistant</td>
        <td>Sub DST LM: samples - Bdq res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XqdaRwwmYFx</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Pza susceptible</td>
        <td>Init DST SM: new patients - Pza ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XQluYa6a41F</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 9 days</td>
        <td>Xpert MTB/RIF: 9d</td>
        <td></td>
        <td>Samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XqOkeUv3qn6</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) susceptible</td>
        <td>Sub DST LM: samples - Mfx CB ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xQzcgF6mGZd</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for initial DST (liquid media)</td>
        <td>Init DST LM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xRHkullgtDD</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Cfz susceptible</td>
        <td>Sub DST SM: new patients - Cfz ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XRPgDH3Z3Fq</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for initial DST (liquid media)</td>
        <td>Init DST LM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xrpPtTU0Zkc</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Rif contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Rif contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xRxkG7NLgxN</td>
      </tr>
      <tr>
        <td>RR-TB patients resistant to Fq</td>
        <td>RR-TB patients res to Fq</td>
        <td></td>
        <td>RR-TB patients resistant to Fq</td>
        <td>ENROLLMENT</td>
        <td>2020-11-12</td>
        <td>Xt0NWWZ7DNA</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Dlm resistant</td>
        <td>Sub DST LM: new patients - Dlm res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XtISOg6IH58</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Inh (CC) susceptible</td>
        <td>Sub DST LM: new patients - Inh CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Xvi6xboD8rO</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Inh CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xvIpBKT8S5R</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Lzd resistant</td>
        <td>Sub DST LM: prev patients - Lzd res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>xWTCtUoYESr</td>
      </tr>
      <tr>
        <td>Culture (solid media): new patients - no growth</td>
        <td>Culture SM: new patients - no growth</td>
        <td></td>
        <td>New patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>XZiRvxDYZTg</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): previously treated patients - Rif susceptible</td>
        <td>LPA (Rif/Inh): prev patients - Rif ss </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA (Rif/Inh). Result: susceptible. No resistance detected by LPA (Rif/Inh) in other samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>y0yp20p5Pfr</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Bdq indeterminate</td>
        <td>Sub DST LM: samples - Bdq indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Y3IoUjmY7AN</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 2 days</td>
        <td>Xpert MTB/RIF: 2d</td>
        <td></td>
        <td>Samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Y9ecVYqq2wF</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CB) susceptible</td>
        <td>Sub DST SM: prev patients - Inh CB ss</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YADgwHM5hbx</td>
      </tr>
      <tr>
        <td>Patients with LPA (Fq/2LI) test result</td>
        <td>LPA (Fq/2LI): patients - result</td>
        <td></td>
        <td>Patients with result for LPA (Fq/2LI)</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Yb4I8XsLvAC</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CB) indeterminate</td>
        <td>Sub DST SM: samples - Mfx CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yb8FgBYSj32</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Pza susceptible</td>
        <td>Sub DST SM: patients - Pza ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YCmTdM8P0s0</td>
      </tr>
      <tr>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Xpert MTB/RIF Ultra: processed samples</td>
        <td></td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ydf2CAJR8of</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Pza resistant</td>
        <td>Sub DST LM: samples - Pza res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yEIeCX7IwVi</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Emb contaminated</td>
        <td>Init DST SM: samples - Emb contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YeU707qWYqZ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Pza contaminated</td>
        <td>Init DST LM: samples - Pza contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yFUJCbawmOX</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Mfx (CB) resistant</td>
        <td>Sub DST SM: samples - Mfx CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YGAd7tN7N6e</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Inh CB contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YgU4PmqMkzP</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 4 days</td>
        <td>Culture LM: 4d</td>
        <td></td>
        <td>Samples with 4 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YhbI5N1k81G</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Pza resistant</td>
        <td>Sub DST LM: prev patients - Pza res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YhxAkBpMTmd</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Amk contaminated/indeterminate</td>
        <td>Init DST LM: patients - Amk contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yi5Rehcel7M</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Cfz susceptible</td>
        <td>Sub DST SM: samples - Cfz ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yIGqQACwPj5</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Amk resistant</td>
        <td>Init DST SM: samples - Amk res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yj67gy58tvc</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - RR</td>
        <td>Xpert MTB/RIF Ultra: patients - RR</td>
        <td></td>
        <td>Patients with result "MTB, Rif resistant" tested by Xpert MTB/RIF Ultra. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ykeijqKZSTD</td>
      </tr>
      <tr>
        <td>Microscopy: new patients - negative</td>
        <td>Microscopy: new patients - negative</td>
        <td></td>
        <td>New patients with microscopy result "negative". If more than one sample is examined per patient, "negative" result is recorded if all samples are "negative". Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YkUfHLCaQMC</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 10+ days</td>
        <td>Xpert MTB/RIF: 10+d</td>
        <td></td>
        <td>Samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YLgDcklInvQ</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Dlm contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Dlm contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yLH2B6wc2uR</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Rif resistant</td>
        <td>Sub DST SM: samples - Rif res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ylIA0CiL0uz</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): patients - MTB not detected</td>
        <td>LPA (Rif/Inh): patients - MTB not detected</td>
        <td></td>
        <td>Patients with MTB not detected in any samples tested by RIF/INH. Condition: MTB detected, test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ym7g5TyBlyV</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Amk contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Amk contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ymG3jrd4Aba</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - no result</td>
        <td>Xpert MTB/RIF: samples - no result</td>
        <td></td>
        <td>Samples with result "no result" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ymjPwXARDTy</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): samples - Rif resistant</td>
        <td>LPA (Rif/Inh): samples - Rif res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yNQDN6Y7RRv</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Inh (CB) resistant</td>
        <td>Init DST LM: samples - Inh CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YOEdyHoPgPV</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Emb susceptible</td>
        <td>Sub DST SM: new patients - Emb ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YOjNYg1yUIh</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): previously treated patients - Emb resistant</td>
        <td>Sub DST SM: prev patients - Emb res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YqnFKRIK0VQ</td>
      </tr>
      <tr>
        <td>Started culture (liquid media) tests</td>
        <td>Culture LM: started tests</td>
        <td></td>
        <td>Started culture LM tests</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yqSM0imyakl</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Dlm contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YRkeyxS2xir</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - Rif resistant</td>
        <td>Xpert MTB/RIF: patients - RR</td>
        <td></td>
        <td>Patients with result "MTB, Rif resistant" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YrnVXhFyLCd</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - Rif susceptible</td>
        <td>Xpert MTB/RIF: samples - RS</td>
        <td></td>
        <td>Samples with result "MTB detected, Rif susceptible" tested by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YsIIurLgmPo</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CB) resistant</td>
        <td>Sub DST LM: prev patients - Mfx CB res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YTfcpgyo1OW</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): samples - Cfz contaminated</td>
        <td>Sub DST SM: samples - Cfz contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by subsequent DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YVm2y4ROVLo</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Inh (CB) resistant</td>
        <td>Init DST SM: samples - Inh CB res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yw1mFlZWAMP</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 0 days</td>
        <td>Xpert MTB/RIF: 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yw1VqE1IjSk</td>
      </tr>
      <tr>
        <td>LPA (Rif/Inh): new patients - Rif indeterminate</td>
        <td>LPA (Rif/Inh): new patients - Rif indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by LPA (Rif/Inh). Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yw5erBUqN3l</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Dlm resistant</td>
        <td>Init DST SM: prev patients - Dlm res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ywEgFe3CmDN</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Dlm contaminated</td>
        <td>Init DST LM: samples - Dlm contam</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YWOxEKIW5KB</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Amk/Cap susceptible</td>
        <td>LPA (Fq/2LI): new patients - Amk/Cap ss</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA (Fq/2LI). No resistance detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>yXTY7DS9wuu</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Emb contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Emb contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YytrJOimdR2</td>
      </tr>
      <tr>
        <td>Patient's age</td>
        <td>DRS: age</td>
        <td></td>
        <td>Patient's age</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>YZSFxMBLXBq</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Kan indeterminate</td>
        <td>LPA (Fq/2LI): new patients - Kan indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA (Fq/2LI). Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA (Fq/2LI) in other samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Z0nNQL81cpK</td>
      </tr>
      <tr>
        <td>Sample processing events, total</td>
        <td>Sample processing events, total</td>
        <td>events_processing_total</td>
        <td>Sample processing events, total</td>
        <td>EVENT</td>
        <td>2020-12-10</td>
        <td>Z0pHyvWCUNG</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Lfx susceptible</td>
        <td>Init DST SM: samples - Lfx ss</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Z28tLWyehWi</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Dlm contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Z4MdCZDK7cg</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Lzd resistant</td>
        <td>Init DST SM: patients - Lzd res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>z4w7a7VHWsr</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Mfx CC contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zB5B6o1lCXQ</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Lzd contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zBFap1a5xsV</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lzd resistant</td>
        <td>Init DST LM: samples - Lzd res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZBWtuPoGXl6</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Amk contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Amk contam/indet</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZCuphHumZGJ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 7 days</td>
        <td>Xpert MTB/RIF: 7d</td>
        <td></td>
        <td>Samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZcZOvviknKv</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Lfx resistant</td>
        <td>Init DST LM: patients - Lfx res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zD5P8ROnJci</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Rif susceptible</td>
        <td>Init DST LM: new patients - Rif ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zd6SD8bbBl3</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Emb indeterminate</td>
        <td>Sub DST LM: samples - Emb indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zdHSqAwHF7w</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zdJzjF1oAzR</td>
      </tr>
      <tr>
        <td>Days from all lab sample collection to arrival, sum</td>
        <td>Collection-arrival interval - sum</td>
        <td></td>
        <td>Days from all sample collection date to arrival date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZeEskzvKb72</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Pza contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by subsequent DST LM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZEWoHGVMJHT</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Mfx (CB) resistant</td>
        <td>Init DST LM: new patients - Mfx CB res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zgKh2FOhkSv</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): new patients - Bdq resistant</td>
        <td>Init DST SM: new patients - Bdq res</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZhWUJgUGMzD</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Lfx susceptible</td>
        <td>Sub DST SM: patients - Lfx ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZiA5jXTrmaY</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Bdq susceptible</td>
        <td>Init DST SM: patients - Bdq ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: susceptible. No resistance detected by initial DST SM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Zie6OAMjczP</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Pza susceptible</td>
        <td>Init DST LM: new patients - Pza ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zIkLhe4NJc1</td>
      </tr>
      <tr>
        <td>Patients with 1+ test started, cumulative</td>
        <td>Patients with 1+ test started, (cumulative)</td>
        <td></td>
        <td>Patients with at least one test started by the end of the reporting period</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zIR9P1JOf0P</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): patients - Emb resistant</td>
        <td>Sub DST SM: patients - Emb res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZiVkPofyVfW</td>
      </tr>
      <tr>
        <td>Samples: 5 days</td>
        <td>Collection arrival interval: 5d</td>
        <td></td>
        <td>Samples with 5 days turn-around time between date of sample collection and date of arrival. Condition: date of sample collection, date of samples arrival.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZkdoPJtDiJ0</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - RS</td>
        <td>Xpert MTB/RIF Ultra: patients - RS</td>
        <td></td>
        <td>Patients with result "MTB, Rif susceptible" tested by Xpert MTB/RIF Ultra. No resistance detected by Xpert MTB/RIF Ultra in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZLg4V9cAXmw</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): new patients - Inh (CC) susceptible</td>
        <td>Init DST LM: new patients - Inh CC ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZlyejogmAYG</td>
      </tr>
      <tr>
        <td>Culture (liquid media): 0 days</td>
        <td>Culture LM: 0d</td>
        <td></td>
        <td>Samples with 0 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZM7UpCaGTY1</td>
      </tr>
      <tr>
        <td>Patients with result for initial DST (solid media)</td>
        <td>Init DST SM: patients - result</td>
        <td></td>
        <td>Patients with result for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZMo9mf0LfWt</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): samples - Pza resistant</td>
        <td>Init DST SM: samples - Pza res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zN38C55xHYZ</td>
      </tr>
      <tr>
        <td>LPA (Fq/2LI): new patients - Fq resistant</td>
        <td>LPA (Fq/2LI): new patients - Fq res</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA (Fq/2LI). Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zo63zcpBZCV</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): previously treated patients - Cfz resistant</td>
        <td>Sub DST LM: prev patients - Cfz res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZONe9AdoHYE</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Cfz resistant</td>
        <td>Sub DST LM: samples - Cfz res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zp3uN4hpm22</td>
      </tr>
      <tr>
        <td>Culture (solid media): samples - MTB</td>
        <td>Culture SM: samples - MTB</td>
        <td></td>
        <td>Samples with result "MTB" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZPXThwLCqnd</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): patients - Inh (CC) susceptible</td>
        <td>Sub DST LM: patients - Inh CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zq6n2KdR9yQ</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): samples - Inh (CB) indeterminate</td>
        <td>Sub DST LM: samples - Inh CB indet</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by subsequent DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZQk5pK5QPhu</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Rif susceptible</td>
        <td>Init DST LM: patients - Rif ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zsxVBbRRx6D</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Mfx CC contam/indet</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM in other samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Ztm42od2b6y</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): samples - Lfx resistant</td>
        <td>Init DST LM: samples - Lfx res</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZUax8mb3Fht</td>
      </tr>
      <tr>
        <td>Subsequent DST (liquid media): new patients - Emb susceptible</td>
        <td>Sub DST LM: new patients - Emb ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST LM. Result: susceptible. No resistance detected by subsequent DST LM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>Zvwpbgxmp94</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): previously treated patients - Lzd resistant</td>
        <td>Init DST SM: prev patients - Lzd res</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>zwG40huDp6Q</td>
      </tr>
      <tr>
        <td>Initial DST (solid media): patients - Pza resistant</td>
        <td>Init DST SM: patients - Pza res</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: resistant. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZWGzbjgAKMS</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - MTB</td>
        <td>Xpert MTB/RIF: samples - MTB</td>
        <td></td>
        <td>New patients with MTB detected by Xpert MTB/RIF. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZWyfaOl5ga7</td>
      </tr>
      <tr>
        <td>Patients with microscopy result</td>
        <td>Microscopy: patients - result</td>
        <td></td>
        <td>Patients with result for microscopy</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZxM3pubMWLI</td>
      </tr>
      <tr>
        <td>Initial DST (liquid media): patients - Inh (CC) susceptible</td>
        <td>Init DST LM: patients - Inh CC ss</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: susceptible. No resistance detected by initial DST LM in other samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZY5fuX5XP7P</td>
      </tr>
      <tr>
        <td>Subsequent DST (solid media): new patients - Rif susceptible</td>
        <td>Sub DST SM: new patients - Rif ss</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by subsequent DST SM. Result: susceptible. No resistance detected by subsequent DST SM in other samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-10</td>
        <td>ZZoPud9wM6I</td>
      </tr>
    </table>
    <h4 id="programRules">Program Rules</h4>
    <table>
      <tr>
        <th>Program rule</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CC) - Initial DST SM</td>
        <td>Hide Mfx (CC) from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>a2EZOnGtShT</td>
      </tr>
      <tr>
        <td>Hide "Initial DST SM" fields</td>
        <td>Hide "Initial DST SM" fields unless "Initial DST SM" is selected</td>
        <td>2020-11-09</td>
        <td>adZGFjUODor</td>
      </tr>
      <tr>
        <td>Hide "TGS - genotypic Speciation Results" fields</td>
        <td>Hide "TGS - genotypic speciation results" fields unless "Targeted Gene Sequencing" is selected</td>
        <td>2020-12-10</td>
        <td>AegsTJUK1a2</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Subsequent DST LM</td>
        <td>Make mandatory: Date of final results - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>aVO554HZRKY</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF Ultra quantitative result"</td>
        <td>Hide "Xpert MTB/RIF Ultra quantitative result" unless MTB is detected</td>
        <td>2020-08-29</td>
        <td>aZMgpoSFbJY</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Initial DST SM</td>
        <td>Hide Dlm from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>B5K6hdkZCyR</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Initial DST SM inoculation date</td>
        <td>Initial DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>B7qKWW0LA3X</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Subsequent DST SM</td>
        <td>Hide Lfx from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>b89lO4YuJ1Q</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Initial DST LM</td>
        <td>Make mandatory: Dlm - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>BacxHSLs0f3</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Initial DST SM</td>
        <td>Make mandatory: Bdq - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>bBiHx5Fodad</td>
      </tr>
      <tr>
        <td>CIF - Display guidelines for Microscopy samples in the form</td>
        <td>If initial screening is based on microscopy examination of > 2 samples then add only the 2 samples with the highest bacterial load.</td>
        <td>2020-12-10</td>
        <td>BCkatIfqdYk</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>beAbNUR3E6G</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Subsequent DST LM</td>
        <td>Hide Dlm from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>bhDFETNiD4W</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>bHJRn7iyMq3</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sample 4" stage</td>
        <td>Hide "Sample 4" stage if not used</td>
        <td>2020-12-10</td>
        <td>BIwvQ6ek8Vu</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CB) - Initial DST LM</td>
        <td>Make mandatory: Mfx (CB) - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>BJEV0tAKjxl</td>
      </tr>
      <tr>
        <td>Date validation: S1 - LPA (Fq/2LI) date</td>
        <td>LPA (Fq/2LI) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>BjqDFhRBzeS</td>
      </tr>
      <tr>
        <td>Constant: Hide Pza - Subsequent DST SM</td>
        <td>Hide Pzafrom list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>bKX5rPBfyfW</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture SM</td>
        <td>Make mandatory: Date of final results - Culture SM</td>
        <td>2020-11-09</td>
        <td>BlLwKADDmT3</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture SM</td>
        <td>Make mandatory: Date of final results - Culture SM</td>
        <td>2020-11-09</td>
        <td>bLODvaqP36S</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Subsequent DST SM</td>
        <td>Hide Cfz from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>bm4p4dc1JPN</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 2 ID</td>
        <td>Generate DRS Sample 2 ID</td>
        <td>2020-08-29</td>
        <td>bQ9VZww9wNM</td>
      </tr>
      <tr>
        <td>Date validation: S1 - LPA (Rif/Inh) date</td>
        <td>LPA (Rif/Inh) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>BSS6VeQyLqW</td>
      </tr>
      <tr>
        <td>Assign Cluster ID</td>
        <td>Assign Cluster ID if Cluster ID is used</td>
        <td>2020-12-10</td>
        <td>BTQvSqCiUl1</td>
      </tr>
      <tr>
        <td>Constant: Hide "Case report form - Cluster ID"</td>
        <td>Hide "Case report form - Cluster ID" if not used</td>
        <td>2021-02-03</td>
        <td>C0HrM84AAIB</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Initial DST LM</td>
        <td>Hide Bdq from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>c0VHXIVBluv</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Subsequent DST LM</td>
        <td>Make mandatory: Lzd - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>cdynoioBMJt</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CB) - Initial DST SM</td>
        <td>Hide Mfx (CB) from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>cqYWWBueNqe</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 1 ID</td>
        <td>Generate DRS Sample 1 ID</td>
        <td>2020-08-29</td>
        <td>cryxj5ORjxk</td>
      </tr>
      <tr>
        <td>Assign resistance status - Inh resistant</td>
        <td>Set the status of resistance to Inh</td>
        <td>2021-02-05</td>
        <td>CtFIyM0kkWi</td>
      </tr>
      <tr>
        <td>Constant: Hide Pza - Subsequent DST LM</td>
        <td>Hide Pzafrom list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>D6taGou1EWN</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Initial DST SM</td>
        <td>Make mandatory: Cfz - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>DabO92LrlbZ</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Initial DST LM</td>
        <td>Hide Lfx from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>dll60xcQXpr</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF</td>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF</td>
        <td>2020-08-29</td>
        <td>dOMPR1GfGUq</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Subsequent DST SM</td>
        <td>Hide Bdq from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>DVza0nU07P7</td>
      </tr>
      <tr>
        <td>Hide "TGS drugs tested" section</td>
        <td>Hide "LAB - Targeted Gene Sequencing Drugs Tested" section unless "TGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-12-10</td>
        <td>DW8n3TWamam</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Initial DST LM inoculation date</td>
        <td>Initial DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>dxr8QD6Cmyu</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - Microscopy</td>
        <td>Make mandatory: Date and result fields - Microscopy</td>
        <td>2020-12-10</td>
        <td>E3eIHwWlqqo</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 3</td>
        <td>Hide "Specify Other" for Sample 3 unless the Answer to "Sample 3 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>eCsM1NkAMj6</td>
      </tr>
      <tr>
        <td>Make mandatory: Emb - Subsequent DST LM</td>
        <td>Make mandatory: Emb - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>edFUeJCPxya</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Initial DST SM</td>
        <td>Make mandatory: Lzd - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>EDGMArTMHVS</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Initial DST SM</td>
        <td>Make mandatory: Date of inoculation - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>EivUtCeeRWQ</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Culture LM</td>
        <td>Make mandatory: Date of inoculation - Culture LM</td>
        <td>2020-11-09</td>
        <td>eJIAxXkWA4d</td>
      </tr>
      <tr>
        <td>Make mandatory: Emb - Initial DST SM</td>
        <td>Make mandatory: Emb - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>ejOio98LnJP</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>ESZSLZFBYDG</td>
      </tr>
      <tr>
        <td>Date validation: Culture SM date</td>
        <td>Culture SM test result date cannot be prior to inoculation date</td>
        <td>2020-11-09</td>
        <td>eWLPwEfUtwl</td>
      </tr>
      <tr>
        <td>Hide "Reasons for sample rejection or loss" fields</td>
        <td>Hide "Reasons for sample rejection or loss" unless "Sample Rejected or Lost" is selected</td>
        <td>2020-12-10</td>
        <td>EydNGX3KeUY</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CC) - Subsequent DST SM</td>
        <td>Make mandatory: Mfx (CC) - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>eyEKsDeGI6t</td>
      </tr>
      <tr>
        <td>Hide "Sputum Smear Microscopy" fields</td>
        <td>Hide "Sputum Smear Microscopy Fields" unless "Sputum Smear Microscopy" is selected</td>
        <td>2020-11-05</td>
        <td>fhJpvDBPZWN</td>
      </tr>
      <tr>
        <td>CIF - Assign "Yes" to "Previous TB treatment"</td>
        <td>Assign "Yes" to "TB DRS Treatment History - treatment >1 month" if "Treatment history" & "Prior TB Registration" or "Control Question" & "Prior TB Registration" = Yes </td>
        <td>2021-02-03</td>
        <td>fHu5DLVW1Q2</td>
      </tr>
      <tr>
        <td>Make mandatory: Drugs - LPA (Fq/2LI)</td>
        <td>Make mandatory: Drugs - LPA (Fq/2LI)</td>
        <td>2020-11-12</td>
        <td>FlBLt3Rcemi</td>
      </tr>
      <tr>
        <td>Summarise resistance</td>
        <td>Summarise resistance to Rif, Inh and Fq</td>
        <td>2020-12-09</td>
        <td>foAWLcAi42q</td>
      </tr>
      <tr>
        <td>Constant: Hide "Subsequent DST LM" section</td>
        <td>Hide "Subsequent DST LM" if not used</td>
        <td>2020-11-09</td>
        <td>fVlCUqt0Ps6</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 4 ID</td>
        <td>Generate DRS Sample 4 ID</td>
        <td>2020-02-03</td>
        <td>fVXqShjK1Ue</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Subsequent DST SM</td>
        <td>Make mandatory: Bdq - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>G0xq3NRQO5E</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 1</td>
        <td>Hide "Specify Other" for Sample 1 unless the Answer to "Sample 1 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>g5ttCkqpAas</td>
      </tr>
      <tr>
        <td>Assign previous treatment history status - new</td>
        <td></td>
        <td>2021-02-03</td>
        <td>G8LxV4AyGWa</td>
      </tr>
      <tr>
        <td>Constant: Hide Amk - Initial DST SM</td>
        <td>Hide Amk from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>GdkouxMOawY</td>
      </tr>
      <tr>
        <td>Assign resistance status - Fq resistant</td>
        <td>Set the status of resistance to Fq</td>
        <td>2021-02-05</td>
        <td>GJOM9Gnw8sA</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Culture SM inoculation date</td>
        <td>Culture SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>gJOujE07O8q</td>
      </tr>
      <tr>
        <td>Make mandatory: Amk - Initial DST LM</td>
        <td>Make mandatory: Amk - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>Glh5fxyePph</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 4</td>
        <td>Hide "Specify Other" for Sample 4 unless the Answer to "Sample 4 Treatment" is "Other"</td>
        <td>2020-12-10</td>
        <td>GN2dzpXZHFq</td>
      </tr>
      <tr>
        <td>Display treatment history</td>
        <td></td>
        <td>2020-12-10</td>
        <td>GOGFi1CdcC6</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Culture LM inoculation date</td>
        <td>Culture LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>GRoxH5Hab8n</td>
      </tr>
      <tr>
        <td>Constant: Hide "Subsequent DST SM" section</td>
        <td>Hide "Subsequent DST SM" if not used</td>
        <td>2020-11-09</td>
        <td>GwC6uvcUEdn</td>
      </tr>
      <tr>
        <td>Hide: Subsequent DST LM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>gyEgVmikOZo</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 4 ID</td>
        <td>Generate DRS Sample 4 ID</td>
        <td>2020-08-29</td>
        <td>gzN6Ya5yOFf</td>
      </tr>
      <tr>
        <td>Hide "LPA (Fq/2LI)" fields</td>
        <td>Hide "LPA (Fq/2LI)" unless "LPA (Fq/2LI)" is selected</td>
        <td>2021-01-07</td>
        <td>h8E2btTqxKM</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Initial DST SM</td>
        <td>Hide Lzd from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>H9dJ3ebaaFn</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>HH1qknkXBUG</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CC) - Subsequent DST SM</td>
        <td>Hide Mfx (CC) from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>hITJ6mxIPkN</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Subsequent DST LM</td>
        <td>Hide Bdq from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>HKS0a7Y4nHT</td>
      </tr>
      <tr>
        <td>CIF - Hide "HIV Test Date"</td>
        <td>Hide "HIV Test Date" if "HIV Test Result" = Unknown</td>
        <td>2021-02-03</td>
        <td>hpkXGVKETRq</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF" fields</td>
        <td>Hide "Xpert MTB/RIF" fields unless "Xpert MTB/RIF" is selected</td>
        <td>2020-12-10</td>
        <td>HwGNeimZpes</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>HXmFgxob7SN</td>
      </tr>
      <tr>
        <td>Constant: Hide Amk - Initial DST LM</td>
        <td>Hide Amk from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>hYQkQaPFuwT</td>
      </tr>
      <tr>
        <td>Constant: Hide Emb - Initial DST SM</td>
        <td>Hide Emb from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>hZ46pxd6j0K</td>
      </tr>
      <tr>
        <td>Assign previous treatment history status - previously treated</td>
        <td></td>
        <td>2021-02-03</td>
        <td>I1LXqwouibs</td>
      </tr>
      <tr>
        <td>Hide "WGS drugs tested" section</td>
        <td>Hide "WGS drugs tested" section unless "WGS - interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>i2OuX4baRcc</td>
      </tr>
      <tr>
        <td>Make mandatory: Pza - Initial DST LM</td>
        <td>Make mandatory: Pza - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>I5cYpaWgJ2F</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Culture SM inoculation date</td>
        <td>Culture SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>i5IhobEjIF7</td>
      </tr>
      <tr>
        <td>Hide "WGS - reasons for failed genotypic speciation Results" field</td>
        <td>Hide "WGS - reasons for failed genotypic speciation results" field if genotypic speciation results failed</td>
        <td>2020-08-29</td>
        <td>i7IJAq6Dexs</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>ICGa9EmkMyz</td>
      </tr>
      <tr>
        <td>Hide "Sample 1 Processing Status" Section </td>
        <td>Hide "Sample 1 Processing Status" Section </td>
        <td>2020-12-10</td>
        <td>IiedhV14zKD</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>IKZ3PyXzciJ</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>Imp0GenB1u6</td>
      </tr>
      <tr>
        <td>Date validation: Subsequent DST SM date</td>
        <td>Subsequent DST SM test result date cannot be prior to inoculation date</td>
        <td>2020-11-09</td>
        <td>is4YEzmgmh9</td>
      </tr>
      <tr>
        <td>Date validation: S4 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>iVonvIR1plC</td>
      </tr>
      <tr>
        <td>Constant: Hide Rif - Initial DST SM</td>
        <td>Hide Rif from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>ivrzYMSxVnO</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Subsequent DST LM</td>
        <td>Hide Lzd from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>IVZAJ5wLIPq</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>iyebVEKEkQW</td>
      </tr>
      <tr>
        <td>Hide "Culture SM" fields</td>
        <td>Hide "Culture SM" fields unless "Culture SM" is selected</td>
        <td>2020-11-09</td>
        <td>IYXGAFbCSIP</td>
      </tr>
      <tr>
        <td>Constant: Hide Emb - Subsequent DST SM</td>
        <td>Hide Emb from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>J4rPKa1u9Nl</td>
      </tr>
      <tr>
        <td>Constant: Hide "Culture SM" section</td>
        <td>Hide "Culture SM" if not used</td>
        <td>2020-11-09</td>
        <td>JD4qaeKxKoW</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Initial DST SM</td>
        <td>Make mandatory: Dlm - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>JhV2ONsXUXh</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>jJIHqnStKfp</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Subsequent DST LM inoculation date</td>
        <td>Subsequent DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>JzMOvveArd9</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Initial DST LM</td>
        <td>Make mandatory: Lzd - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>KaNYswej7JI</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CC) - Subsequent DST LM</td>
        <td>Make mandatory: Mfx (CC) - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>KCFXXYH4brB</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Culture SM</td>
        <td>Make mandatory: Date of inoculation - Culture SM</td>
        <td>2020-11-09</td>
        <td>KI03Jp6b6iV</td>
      </tr>
      <tr>
        <td>Date validation: S2 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>KIPA5MWe9lb</td>
      </tr>
      <tr>
        <td>Assign resistance status - Rif not resistant</td>
        <td>Set the status of resistance to Rif</td>
        <td>2021-02-05</td>
        <td>KjCSsrBMSMj</td>
      </tr>
      <tr>
        <td>Make mandatory: Drugs - LPA (Rif/Inh)</td>
        <td>Make mandatory: Drugs - LPA (Rif/Inh)</td>
        <td>2020-11-12</td>
        <td>kmCWnyT2VXd</td>
      </tr>
      <tr>
        <td>Make mandatory: Rif - Subsequent DST SM</td>
        <td>Make mandatory: Rif - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>KRjOBaxz4RC</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>kvcSmIKtQTe</td>
      </tr>
      <tr>
        <td>Constant: Hide "Patient TB DRS ID"</td>
        <td>Hide "Patient TB DRS ID" if 3-step entry is used.</td>
        <td>2020-12-10</td>
        <td>KXROKuIZZov</td>
      </tr>
      <tr>
        <td>Make mandatory: Amk - Subsequent DST SM</td>
        <td>Make mandatory: Amk - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>kY4e1F8QUK1</td>
      </tr>
      <tr>
        <td>Constant: Hide Rif - Subsequent DST SM</td>
        <td>Hide Rif from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>L8hrzv44viB</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CC) - Initial DST LM</td>
        <td>Hide Inh (CC) from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>lCPmmg8ANPP</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Culture SM inoculation date</td>
        <td>Culture SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>ledpI4teXIr</td>
      </tr>
      <tr>
        <td>Constant: Hide "LPA (Rif/Inh)" section</td>
        <td>Hide "LPA (Rifampicin / Isoniazid)" if not used</td>
        <td>2021-01-07</td>
        <td>Lfz435z4iQe</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CB) - Subsequent DST LM</td>
        <td>Make mandatory: Mfx (CB) - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>LHB3YSHNtlq</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Subsequent DST LM</td>
        <td>Hide Cfz from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>lHG1nvtrf4F</td>
      </tr>
      <tr>
        <td>Date validation: S3 - LPA (Rif/Inh) date</td>
        <td>LPA (Rif/Inh) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>LK8g9jJHNoc</td>
      </tr>
      <tr>
        <td>Date validation: Initial DST SM date</td>
        <td>Initial DST SM test result date cannot be prior to inoculation date</td>
        <td>2020-11-09</td>
        <td>LMK0OKT6432</td>
      </tr>
      <tr>
        <td>CIF - Hide Microscopy test result fields</td>
        <td>Hide Microscopy Test Result fields unless Sputum Smear Microscopy is selected</td>
        <td>2021-01-07</td>
        <td>LnaeeZd9aYe</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Initial DST SM</td>
        <td>Hide Bdq from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>lsbuAFe4LTe</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Initial DST LM</td>
        <td>Make mandatory: Date of final results - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>lVGTxVnDNFZ</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 3 ID</td>
        <td>Generate DRS Sample 3 ID</td>
        <td>2021-01-07</td>
        <td>LyXgAkRoTgM</td>
      </tr>
      <tr>
        <td>SRL: Hide SRL fields</td>
        <td>Hide SRL fields unless Samples shipped to SRL</td>
        <td>2021-01-07</td>
        <td>M0i7NMp24EO</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CB) - Subsequent DST SM</td>
        <td>Make mandatory: Mfx (CB) - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>m1eOx8hu8dp</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF Ultra</td>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF Ultra</td>
        <td>2021-01-07</td>
        <td>M468N9Xb9qn</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Subsequent DST LM inoculation date</td>
        <td>Subsequent DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>m4eEnHjdCeZ</td>
      </tr>
      <tr>
        <td>Date validation: S4 - LPA (Rif/Inh) date</td>
        <td>LPA (Rif/Inh) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>M6ZDn0nUt15</td>
      </tr>
      <tr>
        <td>Hide "Culture LM" fields</td>
        <td>Hide "Culture LM" fields unless "Culture LM" is selected</td>
        <td>2020-11-09</td>
        <td>M7Ohl8yE15X</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>MblpuLUQhAN</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CC) - Subsequent DST LM</td>
        <td>Hide Mfx (CC) from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>MdNdxhRQ1Ce</td>
      </tr>
      <tr>
        <td>Constant: Hide Rif - Initial DST LM</td>
        <td>Hide Rif from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>MhQJWkudWc9</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>Mjr9rbmQzXl</td>
      </tr>
      <tr>
        <td>Display Patient DRS ID</td>
        <td>Display Patient DRS ID</td>
        <td>2020-08-29</td>
        <td>mKaEauPcWxu</td>
      </tr>
      <tr>
        <td>Constant: Hide Emb - Subsequent DST LM</td>
        <td>Hide Emb from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>mKB2hn5PfNO</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Initial DST SM inoculation date</td>
        <td>Initial DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>mKsK1qsEVoF</td>
      </tr>
      <tr>
        <td>Hide "Trace" option for Xpert MTB/RIF quantitative result</td>
        <td>Hide "Trace" option for Xpert MTB/RIF quantitative result</td>
        <td>2020-10-13</td>
        <td>mL2aXhekSrU</td>
      </tr>
      <tr>
        <td>Make mandatory: Pza - Subsequent DST LM</td>
        <td>Make mandatory: Pza - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>Mm7xMwBoUil</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - LPA (Fq/2LI)</td>
        <td>Make mandatory: Date and result fields - LPA (Fq/2LI)</td>
        <td>2020-11-12</td>
        <td>Ms3vBaROHxR</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CB) - Initial DST LM</td>
        <td>Make mandatory: Inh (CB) - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>MtJMGH8LXRM</td>
      </tr>
      <tr>
        <td>CIF - Assign "Yes" to "TB DRS Treatment History - treatment >1 month"</td>
        <td>Assign "Yes" to "TB DRS Treatment History - treatment >1 month" if "Treatment history" & "Prior TB Registration" or "Control Question" & "Prior TB Registration" = Yes </td>
        <td>2021-02-05</td>
        <td>mtSkTzHDV1Z</td>
      </tr>
      <tr>
        <td>Hide "TGS - reasons for failed genotypic speciation results" field</td>
        <td>Hide "TGS - reasons for failed genotypic speciation results" field if genotypic speciation results failed</td>
        <td>2020-08-29</td>
        <td>mUWZalW1I2i</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Initial DST SM</td>
        <td>Make mandatory: Lfx - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>mzrX55hmaug</td>
      </tr>
      <tr>
        <td>Display current age ( <2) in the top bar</td>
        <td>Display Age ( <2) in the top bar</td>
        <td>2020-12-10</td>
        <td>N8z9lZls5cB</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>NAlzGYQpSvl</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF Ultra" fields</td>
        <td>Hide "Xpert MTB/RIF Ultra" fields unless "Xpert MTB/RIF Ultra" is selected</td>
        <td>2020-11-05</td>
        <td>nd0bwVElmAJ</td>
      </tr>
      <tr>
        <td>Hide "Subsequent DST LM" fields</td>
        <td>Hide "Subsequent DST LM" fields unless "Subsequent DST LM" is selected</td>
        <td>2020-11-09</td>
        <td>Nfkzw58T1On</td>
      </tr>
      <tr>
        <td>Hide "Error" and "No result" options for LPA MTB</td>
        <td></td>
        <td>2020-11-16</td>
        <td>NkELHzRIHua</td>
      </tr>
      <tr>
        <td>Hide "WGS - is interpretable genetic resistance profiling for MTBc available?" field</td>
        <td>Hide "WGS - is interpretable genetic resistance profiling for MTBc available?" field unless "WGS - genotypic speciation results" include MTBc</td>
        <td>2020-08-29</td>
        <td>NMoHHtNiIow</td>
      </tr>
      <tr>
        <td>Assign resistance status - Rif resistant</td>
        <td>Set the status of resistance to Rif</td>
        <td>2021-02-05</td>
        <td>NOsuKDnOxVz</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Initial DST LM inoculation date</td>
        <td>Initial DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>NqUFpBAMZFW</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Culture LM inoculation date</td>
        <td>Culture LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>Nw2mqRyiY1O</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>o29A6QLMT8p</td>
      </tr>
      <tr>
        <td>Constant: Hide "Culture LM" section</td>
        <td>Hide "Culture LM" if not used</td>
        <td>2020-11-09</td>
        <td>O9mMu01lgq9</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sample 2" stage</td>
        <td>Hide "Sample 2" stage if not used</td>
        <td>2020-08-29</td>
        <td>ob26R9u3bye</td>
      </tr>
      <tr>
        <td>Date validation: Initial DST LM date</td>
        <td>Initial DST LM test result date cannot be prior to inoculation date</td>
        <td>2020-11-09</td>
        <td>oiqm7VSZwLn</td>
      </tr>
      <tr>
        <td>CIF - Hide "Treatment History - previous treatment registration number"</td>
        <td>Hide "TB DRS Treatment History - previous treatment registration number" unless prior TB registration is "Yes"</td>
        <td>2020-08-29</td>
        <td>OjyDPFPlZ4L</td>
      </tr>
      <tr>
        <td>Assign Patient DRS ID</td>
        <td>Display Patient DRS ID in the Indicator Widget</td>
        <td>2020-08-29</td>
        <td>OmiDOZC8stY</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Initial DST LM</td>
        <td>Hide Lzd from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>onpLkiwFP1Y</td>
      </tr>
      <tr>
        <td>Date validation: S1 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>OObCMVzEjkl</td>
      </tr>
      <tr>
        <td>Hide "Initial DST LM" fields</td>
        <td>Hide "Initial DST LM" fields unless "Initial DST LM" is selected</td>
        <td>2020-11-09</td>
        <td>oSEcFhWKeQU</td>
      </tr>
      <tr>
        <td>Constant: Hide Pza - Initial DST LM</td>
        <td>Hide Pzafrom list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>OtODxIj253U</td>
      </tr>
      <tr>
        <td>Make mandatory: Rif - Initial DST SM</td>
        <td>Make mandatory: Rif - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>OVB1vAnuWEa</td>
      </tr>
      <tr>
        <td>Generate Patient DRS ID</td>
        <td>Generate Patient DRS ID</td>
        <td>2020-02-03</td>
        <td>OVdbdXxA4pw</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Subsequent DST LM inoculation date</td>
        <td>Subsequent DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>OZcXjJ9SSEa</td>
      </tr>
      <tr>
        <td>Date validation: S3 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>P3RSGwbipWV</td>
      </tr>
      <tr>
        <td>Hide "LPA (Rif/Inh)" Fields</td>
        <td>Hide "LPA (Rif/Inh)" unless "LPA (Rif/Inh)" is selected</td>
        <td>2021-01-07</td>
        <td>p7T5h5IhfR8</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Initial DST LM</td>
        <td>Hide Cfz from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>pbOuqeol2Wy</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sputum Smear Microscopy" section</td>
        <td>Hide "Sputum Smear Microscopy" if not used</td>
        <td>2020-08-29</td>
        <td>PcHWmirafV0</td>
      </tr>
      <tr>
        <td>Display current age ( >=2) in the top bar</td>
        <td>Display Age ( >= 2) in the top bar</td>
        <td>2020-12-10</td>
        <td>PDgCvjHcCVc</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Subsequent DST LM</td>
        <td>Make mandatory: Cfz - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>PDlfxA7ry9o</td>
      </tr>
      <tr>
        <td>Constant: Hide "Case report form - TB Bacteriological Confirmation - Sputum Smear Microscopy"</td>
        <td>Hide "Case report form - TB Bacteriological Confirmation - Sputum Smear Microscopy" if not used</td>
        <td>2021-02-03</td>
        <td>pgRQzrtyeoZ</td>
      </tr>
      <tr>
        <td>Hide "Not done" option for Microscopy test</td>
        <td>Hide "Not done" option for Microscopy test</td>
        <td>2020-11-09</td>
        <td>phbh2dN0z3l</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture LM</td>
        <td>Make mandatory: Date of final results - Culture LM</td>
        <td>2020-11-09</td>
        <td>PkFeM8yXzc9</td>
      </tr>
      <tr>
        <td>Make mandatory: Rif - Initial DST LM</td>
        <td>Make mandatory: Rif - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>q0XeuO2TB6R</td>
      </tr>
      <tr>
        <td>Constant: Hide "LPA (Fq/2LI)" section</td>
        <td>Hide "LPA (Fluoroquinolones / Second Line Injectables)" if not used</td>
        <td>2020-11-12</td>
        <td>Q2X5grtVa7h</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Subsequent DST SM</td>
        <td>Make mandatory: Dlm - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>qAtJIiAnJ2L</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - LPA (Rif/Inh)</td>
        <td>Make mandatory: Date and result fields - LPA (Rif/Inh)</td>
        <td>2020-11-12</td>
        <td>QbLVLy4wW6g</td>
      </tr>
      <tr>
        <td>Date validation: S4 - LPA (Fq/2LI) date</td>
        <td>LPA (Fq/2LI) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>QeTcwbb2vht</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF quantitative result"</td>
        <td>Hide "Xpert MTB/RIF quantitative result" unless MTB is detected</td>
        <td>2020-08-29</td>
        <td>QfW0Fzg0Gj8</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Subsequent DST SM</td>
        <td>Hide Dlm from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>QgUL7zDk98e</td>
      </tr>
      <tr>
        <td>Hide "TGS - Is Interpretable genetic resistance profiling for MTBc available?" field</td>
        <td>Hide "TGS - Is Interpretable genetic resistance profiling for MTBc available?" field unless "TGS Genotypic Speciation Results" include MTBc</td>
        <td>2020-08-29</td>
        <td>QhFwiQPkez5</td>
      </tr>
      <tr>
        <td>Assign previous treatment history status - unknown</td>
        <td></td>
        <td>2021-02-03</td>
        <td>qhpY5HIEmj1</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Subsequent DST LM</td>
        <td>Make mandatory: Lfx - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>qqaDX2cNbrZ</td>
      </tr>
      <tr>
        <td>Hide "Not done" option for Xpert MTB/RIF test</td>
        <td>Hide "Not done" option for Xpert MTB/RIF test</td>
        <td>2020-11-09</td>
        <td>qTkWofwAxS4</td>
      </tr>
      <tr>
        <td>Hide "TGS - reasons for no resistance profiling available" field</td>
        <td>Hide "TGS - reasons for no resistance profiling available" field if "TGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>qTNHmDzV7OB</td>
      </tr>
      <tr>
        <td>Make mandatory: Emb - Initial DST LM</td>
        <td>Make mandatory: Emb - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>qva46czrroD</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-12-10</td>
        <td>qW0p3UsIdxh</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Initial DST LM</td>
        <td>Make mandatory: Cfz - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>QYHfhyE0TtC</td>
      </tr>
      <tr>
        <td>CIF - Hide Xpert MTB/RIF</td>
        <td>Hide Xpert MTB/RIF Test fields unless Xpert MTB/RIF is selected</td>
        <td>2020-08-29</td>
        <td>qZ32JJQDYxp</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CC) - Initial DST SM</td>
        <td>Make mandatory: Inh (CC) - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>R0qK91POcKa</td>
      </tr>
      <tr>
        <td>Make mandatory: Rif - Subsequent DST LM</td>
        <td>Make mandatory: Rif - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>R2YTrbLLnm9</td>
      </tr>
      <tr>
        <td>Constant: Hide "Xpert MTB/RIF Ultra" section</td>
        <td>Hide "Xpert MTB/RIF Ultra" if not used</td>
        <td>2020-08-29</td>
        <td>rBHpHQHMzzY</td>
      </tr>
      <tr>
        <td>Constant: Hide "WGS" section</td>
        <td>Hide "WGS" if not used</td>
        <td>2020-08-29</td>
        <td>reQzgr6rGms</td>
      </tr>
      <tr>
        <td>SRL: Hide "Reasons for not sending results to SRL" field</td>
        <td>Hide SRL - "Reasons for not sending results to SRL" field if shipped or not applicable</td>
        <td>2020-08-29</td>
        <td>RIBNrOhnWFm</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CB) - Subsequent DST SM</td>
        <td>Make mandatory: Inh (CB) - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>RkS5eOfrRjc</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sample 3" stage</td>
        <td>Hide "Sample 3" stage if not used</td>
        <td>2020-08-29</td>
        <td>rSPDV6Kfj1x</td>
      </tr>
      <tr>
        <td>Hide: Initial DST SM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>rv5bDc0loqv</td>
      </tr>
      <tr>
        <td>Constant: Hide "Targeted Gene Sequencing" section</td>
        <td>Hide "Targeted Gene Sequencing" if not used</td>
        <td>2020-08-29</td>
        <td>rxnBSLg9bF1</td>
      </tr>
      <tr>
        <td>Constant: Hide Emb - Initial DST LM</td>
        <td>Hide Emb from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>S1mDE2iiUlk</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CB) - Subsequent DST LM</td>
        <td>Hide Inh (CB) from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>saKIwUXzmXv</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Subsequent DST LM</td>
        <td>Hide Lfx from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>SboB8RbxOjj</td>
      </tr>
      <tr>
        <td>CIF - Hide "Treatment History - Names of Drugs"</td>
        <td>Hide "TB DRS Treatment History - Names of Drugs" unless the answer for "TB DRS Treatment History - Tuberculosis Drugs" is "Yes".</td>
        <td>2020-08-29</td>
        <td>sCdmieN4lT7</td>
      </tr>
      <tr>
        <td>Constant: Hide Pza - Initial DST SM</td>
        <td>Hide Pzafrom list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>seL9DsDnIO7</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CC) - Subsequent DST LM</td>
        <td>Make mandatory: Inh (CC) - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>SHyNReZlwD7</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Subsequent DST SM</td>
        <td>Make mandatory: Date of final results - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>SUrqwc057zV</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Subsequent DST LM</td>
        <td>Make mandatory: Date of inoculation - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>sx0kyQsEg3c</td>
      </tr>
      <tr>
        <td>Date validation: Subsequent DST LM date</td>
        <td>Subsequent DST LM test result date cannot be prior to inoculation date</td>
        <td>2020-11-09</td>
        <td>sx9AorG5zM8</td>
      </tr>
      <tr>
        <td>Constant: Hide SRL stage</td>
        <td>Hide "SRL" if samples are never sent to SRL</td>
        <td>2020-08-29</td>
        <td>SYrJsO8xr6C</td>
      </tr>
      <tr>
        <td>Display previous TB Registration Number</td>
        <td>Display previous TB Registration Number</td>
        <td>2021-02-03</td>
        <td>SzhYub67ji4</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CB) - Initial DST LM</td>
        <td>Hide Mfx (CB) from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>tCbPN4u9DVh</td>
      </tr>
      <tr>
        <td>Constant: Hide Amk - Subsequent DST LM</td>
        <td>Hide Amk from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>tin0buEUJWh</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 1 ID</td>
        <td>Generate DRS Sample 1 ID</td>
        <td>2020-02-03</td>
        <td>tJq1UCrpx4p</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - initial DST LM</td>
        <td>Make mandatory: Date of inoculation - initial DST LM</td>
        <td>2020-11-09</td>
        <td>tlVFPbwLYkY</td>
      </tr>
      <tr>
        <td>Constant: Hide "Initial DST LM" section</td>
        <td>Hide "Initial DST LM" if not used</td>
        <td>2020-11-09</td>
        <td>TMFKJbuE519</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Subsequent DST LM</td>
        <td>Make mandatory: Bdq - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>tQK2uL1SHS9</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CC) - Initial DST LM</td>
        <td>Make mandatory: Mfx (CC) - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>trnwIPTQDem</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CC) - Subsequent DST LM</td>
        <td>Hide Inh (CC) from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>tWuhWCgEHBD</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Culture SM inoculation date</td>
        <td>Culture SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>txP3vA3nqWB</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CC) - Initial DST LM</td>
        <td>Make mandatory: Inh (CC) - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>U3TTAHFB1sb</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Initial DST LM inoculation date</td>
        <td>Initial DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>u8VNFez3Arg</td>
      </tr>
      <tr>
        <td>Hide: LPA (Fq/2LI) - FQ, 2LI and Emb fields</td>
        <td>Hide LPA (Fq/2LI) - results for FQ, 2LI and Emb fields unless MTBc is detected</td>
        <td>2020-11-12</td>
        <td>UCz4TkFAacz</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Culture LM inoculation date</td>
        <td>Culture LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>UDOQXveS2Uf</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CB) - Subsequent DST SM</td>
        <td>Hide Inh (CB) from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>uIOtFwtC1gH</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Initial DST LM inoculation date</td>
        <td>Initial DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>uISj7gl77sc</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Initial DST SM</td>
        <td>Hide Cfz from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>UnNaEVfXEF2</td>
      </tr>
      <tr>
        <td>Make mandatory: Pza - Subsequent DST SM</td>
        <td>Make mandatory: Pza - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>Uo4SWwUgZwU</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 3 ID</td>
        <td>Generate DRS Sample 3 ID</td>
        <td>2021-01-07</td>
        <td>UOtdRCTgYRU</td>
      </tr>
      <tr>
        <td>Assign resistance status - Fq not resistant</td>
        <td>Set the status of resistance to Fq</td>
        <td>2021-02-05</td>
        <td>USloBpR9De6</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CB) - Subsequent DST LM</td>
        <td>Make mandatory: Inh (CB) - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>UT7qmcqbuLV</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Initial DST SM</td>
        <td>Make mandatory: Date of final results - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>UYz2rgemOkh</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Culture LM inoculation date</td>
        <td>Culture LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>V5hRMgTLguM</td>
      </tr>
      <tr>
        <td>Hide "Subsequent DST SM" fields</td>
        <td>Hide "Subsequent DST SM" fields unless "Subsequent DST SM" is selected</td>
        <td>2020-11-09</td>
        <td>v6MhkRp66X4</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Subsequent DST LM inoculation date</td>
        <td>Subsequent DST LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>v6oyTdBhK6v</td>
      </tr>
      <tr>
        <td>Hide "WGS - reasons for no resistance profiling available" field</td>
        <td>Hide "WGS - reasons for no resistance profiling available" field if "WGS - interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>vDfzXrPqVKw</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Subsequent DST SM inoculation date</td>
        <td>Subsequent DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>vG5ehu9fRDu</td>
      </tr>
      <tr>
        <td>Constant: Hide Rif - Subsequent DST LM</td>
        <td>Hide Rif from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>vgqaTQVEM5r</td>
      </tr>
      <tr>
        <td>Make mandatory: Pza - Initial DST SM</td>
        <td>Make mandatory: Pza - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>VhkBA4Q9AA8</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 2</td>
        <td>Hide "Specify Other" for Sample 2 unless the Answer to "Sample 2 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>VjTyxzlQNO5</td>
      </tr>
      <tr>
        <td>Constant: Hide Amk - Subsequent DST SM</td>
        <td>Hide Amk from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>vjUK8GGhx3R</td>
      </tr>
      <tr>
        <td>Hide "WGS Genotypic Speciation Results" fields</td>
        <td>Hide "WGS - genotypic speciation results" fields unless "WGS" is selected</td>
        <td>2020-08-29</td>
        <td>VLZOl0DJLS4</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Initial DST LM</td>
        <td>Hide Dlm from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>VMe40J3NnVl</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Subsequent DST SM</td>
        <td>Make mandatory: Lfx - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>VPXrBFPYhL8</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Subsequent DST SM</td>
        <td>Make mandatory: Cfz - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>vT5dvGhswAJ</td>
      </tr>
      <tr>
        <td>Hide "WGS" fields</td>
        <td>Hide "WGS" fields unless "WGS" is selected</td>
        <td>2020-08-29</td>
        <td>W8Eq5lh30rL</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CB) - Subsequent DST LM</td>
        <td>Hide Mfx (CB) from list of drugs used for Subsequent DST LM if not used</td>
        <td>2020-11-09</td>
        <td>wBkYPnKAVOV</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CB) - Initial DST LM</td>
        <td>Hide Inh (CB) from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>wCZHu3exKHT</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CC) - Initial DST LM</td>
        <td>Hide Mfx (CC) from list of drugs used for Initial DST LM if not used</td>
        <td>2020-11-09</td>
        <td>wE0yhLXQd2Y</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Initial DST SM inoculation date</td>
        <td>Initial DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>wGuos0ZHWDk</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Subsequent DST SM</td>
        <td>Make mandatory: Date of inoculation - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>WHgSIxU1wN0</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Initial DST LM</td>
        <td>Make mandatory: Bdq - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>wI1b2t9LKQR</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CB) - Initial DST SM</td>
        <td>Make mandatory: Inh (CB) - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>wSY3LOih3gh</td>
      </tr>
      <tr>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF</td>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF</td>
        <td>2020-11-09</td>
        <td>wxBwarZREOz</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 2 ID</td>
        <td>Generate DRS Sample 2 ID</td>
        <td>2020-02-03</td>
        <td>WyhrK5pCVIr</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CC) - Subsequent DST SM</td>
        <td>Hide Inh (CC) from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>x7b5voqD5Hf</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Subsequent DST SM inoculation date</td>
        <td>Subsequent DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>X7P5bqxrcPD</td>
      </tr>
      <tr>
        <td>Constant: Hide "embB" field</td>
        <td>Hide "embB" field if Ethambutol is not being tested</td>
        <td>2020-08-29</td>
        <td>X8QIPW2W05n</td>
      </tr>
      <tr>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF Ultra</td>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF Ultra</td>
        <td>2020-11-09</td>
        <td>Xast3F5sYY8</td>
      </tr>
      <tr>
        <td>CIF - Hide "Treatment History - Regimen" and "TB DRS Treatment History - Outcome"</td>
        <td>Hide "Regimen" and "Outcome" fields unless the patient was treated for more than a month</td>
        <td>2020-12-04</td>
        <td>XBOo5soKgDT</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CC) - Initial DST SM</td>
        <td>Hide Inh (CC) from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>xdTQICXUrRr</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CB) - Initial DST SM</td>
        <td>Make mandatory: Mfx (CB) - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>xFOl7aDwQ5a</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx (CB) - Subsequent DST SM</td>
        <td>Hide Mfx (CB) from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>xly48Oj31dZ</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Subsequent DST SM inoculation date</td>
        <td>Subsequent DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>XVcJnlHXM6K</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Subsequent DST LM</td>
        <td>Make mandatory: Dlm - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>xwzc7Ek2K0p</td>
      </tr>
      <tr>
        <td>CIF - Hide treatment history provided by patient</td>
        <td>Hide "Treatment History Provided by Patient" fields if the patient was previously treated for TB</td>
        <td>2020-08-29</td>
        <td>XxpX3sJalg4</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Initial DST LM</td>
        <td>Make mandatory: Lfx - Initial DST LM</td>
        <td>2020-11-09</td>
        <td>xYFF40tZ7Qr</td>
      </tr>
      <tr>
        <td>Hide: LPA (Rif/Inh) - Rif and H result fields</td>
        <td>Hide LPA (Rif/Inh) - Rif and H result fields unless MTBc is detected</td>
        <td>2020-11-12</td>
        <td>y6QL5z3fXky</td>
      </tr>
      <tr>
        <td>Hide: Subsequent DST SM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>yhUxqzLVROr</td>
      </tr>
      <tr>
        <td>Hide: Initial DST LM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>yHzbiWa4qnF</td>
      </tr>
      <tr>
        <td>Constant: Hide "Initial DST SM" section</td>
        <td>Hide "Initial DST SM" if not used</td>
        <td>2020-11-09</td>
        <td>ykAqcJUSn6T</td>
      </tr>
      <tr>
        <td>Date validation: Culture LM date</td>
        <td>Culture LM test result date cannot be prior to inoculation date</td>
        <td>2020-11-09</td>
        <td>YmJNGBTfSM4</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Initial DST SM</td>
        <td>Hide Lfx from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>yMO3HkkVQRA</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Subsequent DST SM</td>
        <td>Make mandatory: Lzd - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>YnTxPSj9YPl</td>
      </tr>
      <tr>
        <td>Make mandatory: Inh (CC) - Subsequent DST SM</td>
        <td>Make mandatory: Inh (CC) - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>Yp1K3LvVoAV</td>
      </tr>
      <tr>
        <td>Constant: Hide "Case report form - TB Bacteriological Confirmation - Xpert MTB/RIF"</td>
        <td>Hide "Case report form - TB Bacteriological Confirmation - Xpert MTB/RIF" if not used</td>
        <td>2021-02-03</td>
        <td>yPHeTz8frbN</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Subsequent DST SM</td>
        <td>Hide Lzd from list of drugs used for Subsequent DST SM if not used</td>
        <td>2020-11-09</td>
        <td>yqL2JNGSCHi</td>
      </tr>
      <tr>
        <td>Make mandatory: Emb - Subsequent DST SM</td>
        <td>Make mandatory: Emb - Subsequent DST SM</td>
        <td>2020-11-09</td>
        <td>YSi8OAZ4TCq</td>
      </tr>
      <tr>
        <td>Make mandatory: Drugs - Emb - LPA (Fq/2LI)</td>
        <td>Make mandatory: Emb - LPA (Fq/2LI)</td>
        <td>2020-11-12</td>
        <td>yvAZGDsaVga</td>
      </tr>
      <tr>
        <td>Date validation: S3 - LPA (Fq/2LI) date</td>
        <td>LPA (Fq/2LI) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>yYnReZdcksK</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture LM</td>
        <td>Make mandatory: Date of final results - Culture LM</td>
        <td>2020-11-09</td>
        <td>yZNR57r3aIm</td>
      </tr>
      <tr>
        <td>Date validation: S2 - LPA (Rif/Inh) date</td>
        <td>LPA (Rif/Inh) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>Z53n2HnY0hP</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Initial DST SM inoculation date</td>
        <td>Initial DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>z6ngu8v0Dzy</td>
      </tr>
      <tr>
        <td>Constant: Hide "Xpert MTB/RIF" section</td>
        <td>Hide "Xpert MTB/RIF" if not used</td>
        <td>2020-08-29</td>
        <td>Zckkhc1uLyH</td>
      </tr>
      <tr>
        <td>Constant: Hide Inh (CB) - Initial DST SM</td>
        <td>Hide Inh (CB) from list of drugs used for Initial DST SM if not used</td>
        <td>2020-11-09</td>
        <td>ZcoiBN36Je1</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx (CC) - Initial DST SM</td>
        <td>Make mandatory: Mfx (CC) - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>zcyK1BiWZcE</td>
      </tr>
      <tr>
        <td>Make mandatory: Amk - Subsequent DST LM</td>
        <td>Make mandatory: Amk - Subsequent DST LM</td>
        <td>2020-11-09</td>
        <td>zLibaa5bqNy</td>
      </tr>
      <tr>
        <td>Assign resistance status - Inh not resistant</td>
        <td>Set the status of resistance to Inh</td>
        <td>2021-02-05</td>
        <td>zQRAmSJDkh6</td>
      </tr>
      <tr>
        <td>Make mandatory: Amk - Initial DST SM</td>
        <td>Make mandatory: Amk - Initial DST SM</td>
        <td>2020-11-09</td>
        <td>ZrHT0fLXE9w</td>
      </tr>
      <tr>
        <td>Date validation: S2 - LPA (Fq/2LI) date</td>
        <td>LPA (Fq/2LI) date cannot be prior to sample collection date</td>
        <td>2020-11-12</td>
        <td>ZSH50RCEsmP</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Subsequent DST SM inoculation date</td>
        <td>Subsequent DST SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-11-09</td>
        <td>ZWPmho8kwuD</td>
      </tr>
    </table>
    <h4>Program Tracked Entity Attributes</h4>
    <table>
      <tr>
        <th>Tracked Entity Attribute Name</th>
        <th>Last updated</th>
        <th>Program Tracked Entity Attribute UID</th>
        <th>Tracked Entity Attribute UID</th>
      </tr>
      <tr>
        <td>Patient DRS ID</td>
        <td>2020-10-15</td>
        <td>jf47G3ie95T</td>
        <td>BdvE9shT6GX</td>
      </tr>
      <tr>
        <td>Cluster ID</td>
        <td>2020-10-15</td>
        <td>iHuT7Jf69il</td>
        <td>aOrGt5JE0gV</td>
      </tr>
      <tr>
        <td>Given name</td>
        <td>2020-10-15</td>
        <td>YVhcTRS789c</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Family name</td>
        <td>2020-10-15</td>
        <td>yKAmutvvxlx</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-10-15</td>
        <td>mdcwEKRScEb</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td>2020-10-15</td>
        <td>jjATJmtN4T4</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td>2020-10-15</td>
        <td>oBXflxK0OPH</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td>2020-10-15</td>
        <td>FNMUKiZ2TXa</td>
        <td>ntelZthDPpR</td>
      </tr>
      <tr>
        <td>Administrative area of residence</td>
        <td>2020-10-15</td>
        <td>qObTmB2O3iw</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Location of Residence (GPS)</td>
        <td>2020-10-15</td>
        <td>tymxPk5geMN</td>
        <td>f038nOc9uRF</td>
      </tr>
      <tr>
        <td>Address (current)</td>
        <td>2020-10-15</td>
        <td>ylfC4Fjo2NN</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Country of origin</td>
        <td>2020-10-15</td>
        <td>ZSreVJc1YHl</td>
        <td>PBdqXh8Nvuj</td>
      </tr>
    </table>
    <h2 id="constants">Constants</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Amikacin</td>
        <td>Subsequent DST LM - Amk</td>
        <td>2021-02-05</td>
        <td>a4PpEfSutcV</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Pyrazinamide</td>
        <td>Initial DST SM - Pza</td>
        <td>2021-02-05</td>
        <td>aCaNdqUIDZl</td>
      </tr>
      <tr>
        <td>TB-Drugs: LPA (Fq/2Li) - Ethambutol</td>
        <td>LPA (Fq/2LI) - Emb</td>
        <td>2021-01-22</td>
        <td>AiyTLOJHMkl</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Isoniazid (CB)</td>
        <td>Initial DST SM - Inh (CB)</td>
        <td>2020-12-10</td>
        <td>anpSc1tmlft</td>
      </tr>
      <tr>
        <td>TB-DRS: SRL</td>
        <td>SRL</td>
        <td>2021-02-03</td>
        <td>AUltNkQXzdm</td>
      </tr>
      <tr>
        <td>TB-DRS: Cluster Sampling</td>
        <td>Cluster Sampling</td>
        <td>2021-02-03</td>
        <td>aYPQMlxAZsz</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Linezolid</td>
        <td>Initial DST LM - Lzd</td>
        <td>2021-02-05</td>
        <td>aZq11UuXPP6</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Levofloxacin</td>
        <td>Subsequent DST LM - Lfx</td>
        <td>2021-02-05</td>
        <td>b1KgVOel21P</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Pyrazinamide</td>
        <td>Subsequent DST SM - Pza</td>
        <td>2021-02-05</td>
        <td>bHPYGfrFNV2</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Delamanid</td>
        <td>Initial DST LM - Dlm</td>
        <td>2021-02-05</td>
        <td>BJTzi3WWjhT</td>
      </tr>
      <tr>
        <td>TB-Lab: Subsequent Phenotypic DST in Solid Media (eg. LJ)</td>
        <td>Subsequent DST SM</td>
        <td>2021-02-05</td>
        <td>BpRfvWQcvTo</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Clofazimine</td>
        <td>Subsequent DST SM - Cfz</td>
        <td>2021-02-05</td>
        <td>bywBn5DxVdi</td>
      </tr>
      <tr>
        <td>TB-Lab: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>2021-02-05</td>
        <td>cFoFDkXKcXC</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Isoniazid (CC)</td>
        <td>Initial DST LM - Inh (CC)</td>
        <td>2020-12-10</td>
        <td>cRldkiBh5xv</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Linezolid</td>
        <td>Initial DST SM - Lzd</td>
        <td>2021-02-05</td>
        <td>CVQR2ZtZWxk</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Moxifloxacin (CC)</td>
        <td>Subsequent DST SM - Mfx (CC)</td>
        <td>2020-12-10</td>
        <td>Czx5FuOqF9i</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Isoniazid (CC)</td>
        <td>Initial DST SM - Inh (CC)</td>
        <td>2020-12-10</td>
        <td>dAPAScvFPfX</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Moxifloxacin (CC)</td>
        <td>Initial DST LM - Mfx (CC)</td>
        <td>2020-12-10</td>
        <td>dgjpdQO2Iva</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Amikacin</td>
        <td>Subsequent DST SM - Amk</td>
        <td>2021-02-05</td>
        <td>dTwKm1u2VhY</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Isoniazid (CC)</td>
        <td>Subsequent DST SM - Inh (CC)</td>
        <td>2020-12-10</td>
        <td>eM3UfUO7W8O</td>
      </tr>
      <tr>
        <td>TB-Lab: LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh)</td>
        <td>2021-02-05</td>
        <td>ESUffSPwmju</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Isoniazid (CB)</td>
        <td>Subsequent DST LM - Inh (CB)</td>
        <td>2020-12-10</td>
        <td>F9DTb5zl8rS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Pyrazinamide</td>
        <td>Initial DST LM - Pza</td>
        <td>2021-02-05</td>
        <td>FDtk4otxDse</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Levofloxacin</td>
        <td>Subsequent DST SM - Lfx</td>
        <td>2021-02-05</td>
        <td>Fw8wOlTETPt</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Clofazimine</td>
        <td>Initial DST LM - Cfz</td>
        <td>2021-02-05</td>
        <td>GL5JTtBvbEC</td>
      </tr>
      <tr>
        <td>TB-Lab: LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI)</td>
        <td>2021-02-05</td>
        <td>govArZqiFzY</td>
      </tr>
      <tr>
        <td>TB-DRS: Bacteriological Confirmation of TB</td>
        <td>Bacteriological confirmation of TB</td>
        <td>2020-12-10</td>
        <td>gYj2CUoep4O</td>
      </tr>
      <tr>
        <td>TB-Lab: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td>2021-02-05</td>
        <td>H4ObQDbhnTA</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Moxifloxacin (CC)</td>
        <td>Subsequent DST LM - Mfx (CC)</td>
        <td>2020-12-10</td>
        <td>HhKitGif8RV</td>
      </tr>
      <tr>
        <td>TB-Lab: Initial Phenotypic DST in Solid Media (eg. LJ)</td>
        <td>Initial DST SM</td>
        <td>2021-02-05</td>
        <td>HjN2Bgnusyy</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Ethambutol</td>
        <td>Subsequent DST LM - Emb</td>
        <td>2021-02-05</td>
        <td>Ic5asMdbpH8</td>
      </tr>
      <tr>
        <td>TB-Lab: Culture in Solid Media (e.g. LJ)</td>
        <td>Culture SM</td>
        <td>2021-02-05</td>
        <td>iSKEqcuVAui</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Linezolid</td>
        <td>Subsequent DST SM - Lzd</td>
        <td>2021-02-05</td>
        <td>KIeI2d8xalG</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Bedaquiline</td>
        <td>Initial DST LM - Bdq</td>
        <td>2021-02-05</td>
        <td>KjvwSybuWJU</td>
      </tr>
      <tr>
        <td>TB-Lab: Targeted Gene Sequencing</td>
        <td>TGS</td>
        <td>2021-02-03</td>
        <td>KkypNdLNW1f</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Rifampicin</td>
        <td>Subsequent DST LM - Rif</td>
        <td>2021-02-05</td>
        <td>lelJEADYpeI</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Isoniazid (CB)</td>
        <td>Initial DST LM - Inh (CB)</td>
        <td>2020-12-10</td>
        <td>lqaf0KfpHGd</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Moxifloxacin (CB)</td>
        <td>Initial DST SM - Mfx (CB)</td>
        <td>2020-12-10</td>
        <td>m4c79OHEKCG</td>
      </tr>
      <tr>
        <td>TB-Lab: Whole Genome Sequencing</td>
        <td>WGS</td>
        <td>2021-02-05</td>
        <td>MC7QUDr9YKC</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Linezolid</td>
        <td>Subsequent DST LM - Lzd</td>
        <td>2021-02-05</td>
        <td>mU5iEABeF2K</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Ethambutol</td>
        <td>Initial DST LM - Emb</td>
        <td>2021-02-05</td>
        <td>n9zOOsLO0QP</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Clofazimine</td>
        <td>Subsequent DST LM - Cfz</td>
        <td>2021-02-05</td>
        <td>Nb6oHqjCCZq</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Levofloxacin</td>
        <td>Initial DST SM - Lfx</td>
        <td>2021-02-05</td>
        <td>NlOX3oV4gWe</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Moxifloxacin (CB)</td>
        <td>Subsequent DST SM - Mfx (CB)</td>
        <td>2020-12-10</td>
        <td>NvA1K4hFJbc</td>
      </tr>
      <tr>
        <td>TB-DRS: Sample 4 for NRL Processing</td>
        <td>Sample 4 for NRL Processing</td>
        <td>2021-02-03</td>
        <td>NXr7RH56Q1R</td>
      </tr>
      <tr>
        <td>TB-Lab: Initial Phenotypic DST in Liquid Media (eg. MGIT)</td>
        <td>Initial DST LM</td>
        <td>2021-02-05</td>
        <td>OQxeAIyQUeB</td>
      </tr>
      <tr>
        <td>TB-Lab: Sputum Smear Microscopy</td>
        <td>Microscopy</td>
        <td>2021-02-05</td>
        <td>q1ah12sKfG3</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Rifampicin</td>
        <td>Initial DST SM - Rif</td>
        <td>2021-02-05</td>
        <td>Q67DDsupq7v</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Bedaquiline</td>
        <td>Subsequent DST LM - Bdq</td>
        <td>2021-02-05</td>
        <td>QaioqMbO0TX</td>
      </tr>
      <tr>
        <td>TB-Lab: Culture in Liquid Media (e.g. MGIT)</td>
        <td>Culture LM</td>
        <td>2021-02-05</td>
        <td>qpAseG5vJyS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Bedaquiline</td>
        <td>Subsequent DST SM - Bdq</td>
        <td>2021-02-05</td>
        <td>r70ONQRhaHY</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Delamanid</td>
        <td>Subsequent DST SM - Dlm</td>
        <td>2021-02-05</td>
        <td>RFqmLP5W5di</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Moxifloxacin (CC)</td>
        <td>Initial DST SM - Mfx (CC)</td>
        <td>2020-12-10</td>
        <td>RJNE1o9cw7Y</td>
      </tr>
      <tr>
        <td>TB-DRS: Sample 2 for NRL Processing</td>
        <td>Sample 2 for NRL Processing</td>
        <td>2021-02-03</td>
        <td>rSS2dY6gwLJ</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Isoniazid (CB)</td>
        <td>Subsequent DST SM - Inh (CB)</td>
        <td>2020-12-10</td>
        <td>s8WPR943gGS</td>
      </tr>
      <tr>
        <td>TB-DRS: Sample 3 for NRL Processing</td>
        <td>Sample 3 for NRL Processing</td>
        <td>2021-02-03</td>
        <td>sqgp1l0s4wp</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Levofloxacin</td>
        <td>Initial DST LM - Lfx</td>
        <td>2021-02-05</td>
        <td>t7Okdm8VgDV</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Moxifloxacin (CB)</td>
        <td>Initial DST LM - Mfx (CB)</td>
        <td>2020-12-10</td>
        <td>UL61U78GWCg</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Rifampicin</td>
        <td>Initial DST LM - Rif</td>
        <td>2021-02-05</td>
        <td>uOJYEwV7XfN</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Bedaquiline</td>
        <td>Initial DST SM - Bdq</td>
        <td>2021-02-05</td>
        <td>UxcTzMRQsfa</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Delamanid</td>
        <td>Initial DST SM - Dlm</td>
        <td>2021-02-05</td>
        <td>VUlsMrm4D8k</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Pyrazinamide</td>
        <td>Subsequent DST LM - Pza</td>
        <td>2021-02-05</td>
        <td>VY15auehssY</td>
      </tr>
      <tr>
        <td>TB-Lab: Subsequent Phenotypic DST in Liquid Media (eg. MGIT)</td>
        <td>Subsequent DST LM</td>
        <td>2021-02-05</td>
        <td>W8Fm1pJuJPL</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Ethambutol</td>
        <td>Subsequent DST SM - Emb</td>
        <td>2021-02-05</td>
        <td>wNxsAieLWYc</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Amikacin</td>
        <td>Initial DST LM - Amk</td>
        <td>2021-02-05</td>
        <td>x6v8O6EZo0U</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Moxifloxacin (CB)</td>
        <td>Subsequent DST LM - Mfx (CB)</td>
        <td>2020-12-10</td>
        <td>xfltmyqC3p0</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Amikacin</td>
        <td>Initial DST SM - Amk</td>
        <td>2021-02-05</td>
        <td>XO1V9o5C95J</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Delamanid</td>
        <td>Subsequent DST LM - Dlm</td>
        <td>2021-02-05</td>
        <td>Xt5GU9kBD7q</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Ethambutol</td>
        <td>Initial DST SM - Emb</td>
        <td>2021-02-05</td>
        <td>yxPHZFwMTN6</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Isoniazid (CC)</td>
        <td>Subsequent DST LM - Inh (CC)</td>
        <td>2020-12-10</td>
        <td>ZBpqH7xJLBO</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Clofazimine</td>
        <td>Initial DST SM - Cfz</td>
        <td>2021-02-05</td>
        <td>ZDpLleSK08x</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Rifampicin</td>
        <td>Subsequent DST SM - Rif</td>
        <td>2021-02-05</td>
        <td>zJoEjvstp2d</td>
      </tr>
    </table>
    <h2 id="dataElements">Data Elements</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Categorycombo</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh)</td>
        <td></td>
        <td>LPA (Rif/Inh)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>a2I7mdEL028</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
        <td>Subsequent DST SM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>A2iF5Ix8pAf</td>
      </tr>
      <tr>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
        <td>Reasons for sample 1 rejection or loss</td>
        <td></td>
        <td>Reasons for sample 1 rejection or loss</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>A58cijzgyCn</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
        <td>TGS - Fq</td>
        <td></td>
        <td>Genotypic resistance profiling for Fluoroquinolones by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>A8MwWW7rczm</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
        <td>Subsequent DST LM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>agZKnJWKdQK</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
        <td>Subsequent DST LM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - critical concentration (Mfx CC), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>ASr2gFadIie</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
        <td>TGS - Eto</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethionamide by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>B4PXKvPqTBY</td>
      </tr>
      <tr>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
        <td>Date of subsequent DST inoculation SM</td>
        <td></td>
        <td>Date of subsequent DST inoculation (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>BMeVWBNe0Id</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM</td>
        <td></td>
        <td>Subsequent DST in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>BNkkWpCKgLR</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - previous TB registration number</td>
        <td>Previous TB registration number</td>
        <td></td>
        <td>Previous TB registration number</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>bOFQuGHR4aW</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Reasons for not shipping samples to SRL</td>
        <td>Reasons - no results to SRL</td>
        <td></td>
        <td>Why have samples not been shipped to SRL</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>bOuViG0JtyT</td>
      </tr>
      <tr>
        <td>TB Lab: Date of initial DST results (solid media)</td>
        <td>Date of initial DST SM results</td>
        <td></td>
        <td>Date of final initial DST results (solid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>bXaGYMAnfNH</td>
      </tr>
      <tr>
        <td>TB DRS CRF: HIV test date</td>
        <td>HIV test date</td>
        <td></td>
        <td>HIV test date</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>C03Ya1vvaam</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
        <td>LPA (Fq/2LI) - Amk/Cap</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Amikacin/Capreomycin</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>C2owWE9gaoe</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Xpert MTB/RIF initial screening result</td>
        <td>Xpert MTB/RIF initial screening result</td>
        <td></td>
        <td>Xpert MTB/RIF initial screening result</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>c6w0Nuei0yG</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
        <td>TGS - Inh</td>
        <td></td>
        <td>Genotypic resistance profiling for Isoniazid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>C7sLVfSD0vV</td>
      </tr>
      <tr>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
        <td>Date of initial DST inoculation SM</td>
        <td></td>
        <td>Date of initial DST inoculation (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>ck7gWJKYi8n</td>
      </tr>
      <tr>
        <td>TB Lab: Sample rejected or lost</td>
        <td>Sample rejected or lost</td>
        <td></td>
        <td>Sample rejected or lost</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>CtMCpcRTKkI</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Specimen 2 microscopy test result</td>
        <td>Specimen 2 microscopy result</td>
        <td></td>
        <td>Specimen 2 microscopy test result. If initial screening is based on microscopy examination of > 2 specimens then add only the 2 specimens with the highest bacterail load.</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>cx2xcrp1e18</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
        <td>Xpert MTB/RIF test</td>
        <td></td>
        <td>Date of Xpert MTB/RIF test</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>cxi3Lj20Zrg</td>
      </tr>
      <tr>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
        <td>Date of LPA (Rif/Inh)</td>
        <td></td>
        <td>Date of LPA (Rif/Inh)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>D4z4o6JR9M0</td>
      </tr>
      <tr>
        <td>TB Lab: Sputum smear microscopy</td>
        <td>Sputum smear microscopy</td>
        <td></td>
        <td>Sputum smear microscopy</td>
        <td>default</td>
        <td>2021-01-14</td>
        <td>Dd95Kl4aXZf</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
        <td>WGS - Pa</td>
        <td></td>
        <td>Genotypic resistance profiling for Pretomanid by WGS</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>diVqel7EsfP</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
        <td>Initial DST LM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>DjVjz7PNXJA</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
        <td>WGS - Pza</td>
        <td></td>
        <td>Genotypic resistance profiling for Pyrazinamide by WGS</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>dNgpCxvkfBa</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
        <td>TGS - Amk</td>
        <td></td>
        <td>Genotypic resistance profiling for Amikacin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Drmi6zCWAeX</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Additional comments and remarks</td>
        <td>SRL - additional comments and remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>DSvVcgTucZL</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
        <td>Subsequent DST SM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>DVEEyF5cpjB</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
        <td>Subsequent DST SM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>dwi6P6D2iFg</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
        <td>Initial DST SM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>dyqHwVB1oij</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
        <td>LPA (Fq/2LI) - Fq</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Fluoroquinolones</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>E61DoZgoPH2</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
        <td>WGS - Bdq</td>
        <td></td>
        <td>Genotypic resistance profiling for Bedaquiline by WGS</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>e7e7q0wadBs</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
        <td>Xpert MTB/RIF Ultra quantitative result</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra quantitative result</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>e838DsdVAjN</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
        <td>WGS - Rif</td>
        <td></td>
        <td>Genotypic resistance profiling for Rifampicin by WGS</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>eAAkJdj12lF</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
        <td>Subsequent DST LM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Ei5mffgPCHN</td>
      </tr>
      <tr>
        <td>TB Lab: Final microscopy result</td>
        <td>Sputum smear microscopy result</td>
        <td></td>
        <td>Final microscopy result</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>EJaXeYb8MT3</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - length of sickness - weeks</td>
        <td>Length of sickness</td>
        <td></td>
        <td>For how long has the patient been sick? (number of weeks; for periods less than a week, use decimal)</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>eKEKDJsda40</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
        <td>Initial DST LM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>ema8JjkIDTz</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - names of drugs</td>
        <td>Names of drugs</td>
        <td></td>
        <td>Specify drug/drugs taken</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>EsP0jPqdCsi</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
        <td>Initial DST LM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin CB (Mfx CB), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>F4fNZ8htdHP</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
        <td>TGS - Bdq</td>
        <td></td>
        <td>Genotypic resistance profiling for Bedaquiline by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>fhqQzSVeTR1</td>
      </tr>
      <tr>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
        <td>Date of culture inoculation SM</td>
        <td></td>
        <td>Date of culture inoculation (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>FIY3uk4J7fK</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
        <td>Subsequent DST SM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>FjsunwwqBMk</td>
      </tr>
      <tr>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI) - Specimen type</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>FKxBceeFNuR</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - outcome</td>
        <td>Outcome</td>
        <td></td>
        <td>What was the outcome of previous treatment?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>fkzW5PRBVuI</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
        <td>TGS - Lzd</td>
        <td></td>
        <td>Genotypic resistance profiling for Linezolid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>fQifcktAjNe</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 additive</td>
        <td>Sample 2 additive</td>
        <td></td>
        <td>Sample 2 additive</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>FSPdiABIisY</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
        <td>TGS - interpretable profiling for MTBc</td>
        <td></td>
        <td>Is interpretable genetic resistance profiling for MTBc available?</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>FYe5AbkFGjL</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
        <td>TGS - Pza</td>
        <td></td>
        <td>Genotypic resistance profiling for Pyrazinamide by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>G1zw1rVFH97</td>
      </tr>
      <tr>
        <td>Previous treatment initiation date</td>
        <td>Previous treatment initiation date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>G2tW5JrcAvS</td>
      </tr>
      <tr>
        <td>TB Lab: WGS</td>
        <td>WGS</td>
        <td></td>
        <td>Whole genome sequencing</td>
        <td>default</td>
        <td>2021-01-14</td>
        <td>GCEHyuCo1fA</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
        <td>LPA (Rif/Inh) - Rif</td>
        <td></td>
        <td>Final LPA (Rif/Inh) result for Rifampicin</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Gey1agRf0Kh</td>
      </tr>
      <tr>
        <td>TB Lab: Storage only</td>
        <td>Storage only</td>
        <td></td>
        <td>Storage only</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>gf1mmDm59da</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
        <td>WGS - Dlm</td>
        <td></td>
        <td>Genotypic resistance profiling for Delamanid by WGS</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>GQX1kVD3PCY</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
        <td>WGS - Amk</td>
        <td></td>
        <td>Genotypic resistance profiling for Amikacin by WGS</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>gtApUJCf41j</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
        <td>Subsequent DST SM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>GZ5Vqh8wdI1</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
        <td>WGS - Inh</td>
        <td></td>
        <td>Genotypic resistance profiling for Isoniazid by WGS</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>h0ESse3Yutp</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
        <td>Initial DST SM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>HCLjG26CmTS</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - regimen</td>
        <td>Treatment history: regimen</td>
        <td></td>
        <td>What type of regimen was the previous treatment?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>hHUDjT6cid3</td>
      </tr>
      <tr>
        <td>TB Lab: TGS genotypic speciation results</td>
        <td>TGS - genotypic speciation results</td>
        <td></td>
        <td>TGS genotypic speciation results</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>hidY602crX8</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - TB drugs</td>
        <td>Tuberculosis drugs</td>
        <td></td>
        <td>Has the patient ever taken tuberculosis drugs for more than one month?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>hkMHdJJMRkD</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
        <td>Initial DST LM</td>
        <td></td>
        <td>Initial phenotypic DST in liquid media (e.g. MGIT)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>HkZ1hGWBqlZ</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
        <td>Subsequent DST LM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>IBqX2HMQV4T</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
        <td>Subsequent DST SM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - clinical breakpoint (Mfx CB), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>iGcMnwWVhKh</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - Injections for TB</td>
        <td>Injections for TB</td>
        <td></td>
        <td>Has the patient ever had injections for TB for more than one month?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>IkDkBipcHuw</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify other (Sample 3)</td>
        <td>Specify other (Sample 3)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>IQ8pRiFktkT</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
        <td>Subsequent DST SM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>J0DefR0gJZV</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
        <td>Subsequent DST SM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>jC2yaMqEOPb</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
        <td>Initial DST SM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>jD5CwNpVmb3</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Date of Xpert MTB/RIF initial screening test</td>
        <td>Xpert MTB/RIF initial screening date</td>
        <td></td>
        <td>Date of Xpert MTB/RIF initial screening test</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>jIyPHXFmBZ3</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify other (Sample 4)</td>
        <td>Specify other (Sample 4)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>JkPoMJSKHxt</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 collection date</td>
        <td>Sample 3 collection date</td>
        <td></td>
        <td>Sample 3 collection date</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>JpAoAL6Dbmc</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
        <td>Initial DST SM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - critical concentration (Mfx CC), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>Jps4U0wxlyI</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
        <td>Subsequent DST LM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>KJ55m8WkSCO</td>
      </tr>
      <tr>
        <td>TB Lab: Additional comments and remarks</td>
        <td>Lab: Additional comments and remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>KkH3pmsTJ3M</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Bacteriological Confirmation - microscopy</td>
        <td>Confirmation - microscopy</td>
        <td></td>
        <td>Bacteriological confirmation of TB by sputum smear microscopy</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>KMP0CCj6hEC</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify other (Sample 1)</td>
        <td>Specify other (Sample 1)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>kNR9wGWUqnX</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
        <td>Initial DST LM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>KWijdprKE8o</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
        <td>Initial DST SM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - clinical breakpoint (Mfx CB), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>LgnTOBA3Fuk</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
        <td>Initial DST SM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>LRfRdS1tsMK</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
        <td>Initial DST SM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>m1qdvx91gZz</td>
      </tr>
      <tr>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
        <td>Date of culture inoculation LM</td>
        <td></td>
        <td>Date of culture inoculation (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>m7NKGHkiJps</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - officer name</td>
        <td>CRF officer name </td>
        <td></td>
        <td>Print name of officer responsible for completing the clinical information form</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>m7q2YJoRG5o</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>MAItgXvlO5L</td>
      </tr>
      <tr>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
        <td>Xpert MTB/RIF result</td>
        <td></td>
        <td>Final Xpert MTB/RIF test result</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>mdhh8AXcNMe</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - Genotypic speciation results</td>
        <td>WGS - genotypic speciation results</td>
        <td></td>
        <td>WGS - genotypic speciation results</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>MoMwVSDvenr</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 additive</td>
        <td>Sample 1 additive</td>
        <td></td>
        <td>Sample 1 additive</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>mq7gNiLqT24</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Date samples shipped to SRL</td>
        <td>Date samples shipped to SRL</td>
        <td></td>
        <td>Date samples shipped to SRL</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>mriIhfYxKhd</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 collection date</td>
        <td>Sample 1 collection date</td>
        <td></td>
        <td>Sample 1 collection date</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>Mwl0M4rvqBl</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
        <td>Initial DST SM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>Na38GSfYww7</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
        <td>Subsequent DST SM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>nBVHqtynKKg</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Samples shipped to SRL</td>
        <td>Samples to SRL</td>
        <td></td>
        <td>Samples shipped to SRL</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>ncuUAcK3obu</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
        <td>Initial DST LM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>nG3H0zGCpXg</td>
      </tr>
      <tr>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
        <td>Date of initial DST inoculation LM</td>
        <td></td>
        <td>Date of initial DST inoculation (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>ngshCLso7Qs</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
        <td>Subsequent DST SM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>NIiZmSVFoFD</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 additive</td>
        <td>Sample 3 additive</td>
        <td></td>
        <td>Sample 3 additive</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>nj5kuSbEnnm</td>
      </tr>
      <tr>
        <td>TB DRS CS: Date samples arrived at NRL</td>
        <td>Date of samples arrival at NRL</td>
        <td></td>
        <td>Date of samples arrival at NRL</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>nLJ3f34rpYm</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
        <td>Xpert MTB/RIF Ultra test</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Ultra test</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>NRUmJNJfvDc</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
        <td>Initial DST LM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>nulxcFUqHFK</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Specimen 1 microscopy test result</td>
        <td>Specimen 1 microscopy result</td>
        <td></td>
        <td>Specimen 1 microscopy test result. If initial screening is based on microscopy examination of > 2 specimens then add only the 2 specimens with the highest bacterail load.</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>nYThQIcbo27</td>
      </tr>
      <tr>
        <td>TB Lab: Date of culture result (liquid media)</td>
        <td>Date of final culture result LM</td>
        <td></td>
        <td>Date of final culture result (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>OBibApuY05j</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
        <td>TGS - Dlm</td>
        <td></td>
        <td>Genotypic resistance profiling for Delamanid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>oixCCbTWNYH</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
        <td>Initial DST LM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>oKdArKmQaar</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - other symptoms of lung disease</td>
        <td>Other symptoms of lung disease</td>
        <td></td>
        <td>Did the patient have other symptoms of lung disease prior to this episode (haemoptysis, chest pain, cough)?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>oSUHvzfAOD7</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
        <td>Subsequent DST LM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>oVK7axGLOks</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
        <td>Initial DST LM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>OXN8xMgpVvC</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
        <td>Initial DST SM</td>
        <td></td>
        <td>Initial phenotypic DST in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>OZV3tzf7bux</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
        <td>Subsequent DST LM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>P282EjwlnqS</td>
      </tr>
      <tr>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh) - Specimen type</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>p3L4HYkzU4o</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
        <td>TGS - reasons (no resistance profiling)</td>
        <td></td>
        <td>Reasons for no resistance profiling available</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>P4qS3sJtCv3</td>
      </tr>
      <tr>
        <td>TB Lab: Final culture result (solid media)</td>
        <td>Culture result SM</td>
        <td></td>
        <td>Final culture result (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Pdo9LB4lZ6H</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
        <td>Initial DST SM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>peAahjwkqNX</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Bacteriological Confirmation - Xpert MTB/RIF</td>
        <td>Confirmation: Xpert MTB/RIF</td>
        <td></td>
        <td>Bacteriological confirmation of TB by Xpert MTB/RIF</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>peo25u2dcLt</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history</td>
        <td>DRS: Treatment history</td>
        <td></td>
        <td>Has the patient been previously treated for TB?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>PjNDfgjWbFC</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
        <td>Xpert MTB/RIF quantitative result</td>
        <td></td>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>pO5nfo8ea4z</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
        <td>Subsequent DST LM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>Ps4JPDTACGB</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
        <td>Initial DST SM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>pTRWioGFFod</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
        <td>Initial DST LM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>Pvok4dVDC9n</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
        <td>Subsequent DST LM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>pXViXBpKM6Y</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - control question</td>
        <td>Control question</td>
        <td></td>
        <td>Did the patient remember previous treatment for TB after these questions?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>Q3sqPGI5Z55</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
        <td>WGS - Cfz</td>
        <td></td>
        <td>Genotypic resistance profiling for Clofazimine by WGS</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>QFU2ie7seWU</td>
      </tr>
      <tr>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
        <td>Date of subsequent DST inoculation LM</td>
        <td></td>
        <td>Date of subsequent DST inoculation (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>qJH0R9qtDoA</td>
      </tr>
      <tr>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
        <td>Culture SM</td>
        <td></td>
        <td>Culture in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>QQEolquguCi</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
        <td>LPA (Fq/2LI) - Kan</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Kanamycin</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>qt2LpZN8Hb3</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
        <td>Subsequent DST SM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>R25K2kAAG4g</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
        <td>Initial DST LM - Lzd</td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>R4Lknzhufeh</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
        <td>Initial DST SM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>RAtv78ZXQec</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
        <td>Subsequent DST LM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>rjMeZmOEivb</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
        <td>WGS - Lzd</td>
        <td></td>
        <td>Genotypic resistance profiling for Linezolid by WGS</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>RN3lGwZozL9</td>
      </tr>
      <tr>
        <td>TB Lab: Date of culture result (solid media)</td>
        <td>Date of final culture result SM</td>
        <td></td>
        <td>Date of final culture result (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>rVKthrApqAq</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
        <td>TGS - Emb</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethambutol by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>rVPpiiHMzTs</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - prior TB registration</td>
        <td>Prior TB registration</td>
        <td></td>
        <td>After extensive checking through the medical files and other documents available in the health centre, have you discovered that the patient has been registered for TB treatment before?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>rzts7X4mOUE</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - Reasons for failure</td>
        <td>WGS - reasons for failure</td>
        <td></td>
        <td>WGS - reasons for failure</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>SCWmNAXBBE7</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI)</td>
        <td></td>
        <td>LPA (Fq/2LI)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Sd91IsXISjp</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 collection date</td>
        <td>Sample 4 collection date</td>
        <td></td>
        <td>Sample 4 collection date</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>sdiW3OMXBHc</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - Date of results</td>
        <td>Date of TGS results</td>
        <td></td>
        <td>Date of targeted gene sequencing results</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>slD6pdIC4a6</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
        <td>WGS - interpretable profiling for MTBc</td>
        <td></td>
        <td>Is interpretable genetic resistance profiling for MTBc available?</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>SRB4upTdK46</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
        <td>Subsequent DST LM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - clinical breakpoint (Mfx CB), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>TJLwFGwpGFU</td>
      </tr>
      <tr>
        <td>TB DRS CRF: HIV test result</td>
        <td>HIV test result</td>
        <td></td>
        <td>HIV test result</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>tlgvzxYlF2S</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
        <td>WGS - Fq</td>
        <td></td>
        <td>Genotypic resistance profiling for Fluoroquinolones by WGS</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Tpwb8CJ8we0</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
        <td>TGS - Cfz</td>
        <td></td>
        <td>Genotypic resistance profiling for Clofazimine by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>tSe484MEuFG</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 DRS ID</td>
        <td>Sample 2 DRS ID</td>
        <td></td>
        <td>Sample 2 DRS ID</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>typK2Vw7WMj</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM</td>
        <td></td>
        <td>Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>uaewAATQgBJ</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 additive</td>
        <td>Sample 4 additive</td>
        <td></td>
        <td>Sample 4 additive</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>ucaLoGejB2M</td>
      </tr>
      <tr>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
        <td>Date of subsequent DST SM results</td>
        <td></td>
        <td>Date of final subsequent DST results (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>uEV8flIOeYI</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Date samples arrived at SRL</td>
        <td>Date of samples arrival at SRL</td>
        <td></td>
        <td>Date of samples arrival at SRL</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>uhrqXcvXURW</td>
      </tr>
      <tr>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM</td>
        <td></td>
        <td>Culture in liquid media (e.g. MGIT)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>uI7p5xLE1C8</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
        <td>LPA (Rif/Inh) - Inh</td>
        <td></td>
        <td>Final LPA (Rif/Inh) result for Isoniazid</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>UIzR3p4nlMI</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
        <td>Subsequent DST LM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>un8hXdOPwzh</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
        <td>TGS - Pa</td>
        <td></td>
        <td>Genotypic resistance profiling for Pretomanid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>uprsSY93zJA</td>
      </tr>
      <tr>
        <td>TB DRS CS: Date samples shipped to NRL</td>
        <td>Date samples shipped to NRL</td>
        <td></td>
        <td>Date samples shipped to NRL</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>vD3nvlSC6A6</td>
      </tr>
      <tr>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
        <td>Date of LPA (Fq/2LI)</td>
        <td></td>
        <td>Date of LPA (Fq/2LI)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>vezbpFOckNI</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td></td>
        <td>Xpert MTB/RIF</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>VSuQ1rwL2nA</td>
      </tr>
      <tr>
        <td>TB Lab: Final culture result (liquid media)</td>
        <td>Culture result LM</td>
        <td></td>
        <td>Final culture result (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>vTvtuUqdhSg</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
        <td>WGS - Eto </td>
        <td></td>
        <td>Genotypic resistance profiling for Ethionamide by WGS</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>VW74EEB0Ump</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 DRS ID</td>
        <td>Sample 1 DRS ID</td>
        <td></td>
        <td>Sample 1 DRS ID</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>vY0hDQBLuXA</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Import .csv</td>
        <td>Import csv</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>VYQY1CSTWHx</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - Date of results</td>
        <td>Date of WGS results</td>
        <td></td>
        <td>Date of WGS results</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>w1r7ah3H7r7</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 DRS ID</td>
        <td>Sample 3 DRS ID</td>
        <td></td>
        <td>Sample 3 DRS ID</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>w2e9rGFLNIa</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
        <td>TGS - Rif</td>
        <td></td>
        <td>Genotypic resistance profiling for Rifampicin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>w3litCy0uoa</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
        <td>WGS - reasons (no resistance profiling)</td>
        <td></td>
        <td>Reasons for no resistance profiling available</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>w7z2AXGEc5o</td>
      </tr>
      <tr>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
        <td>Xpert MTB/RIF Ultra result</td>
        <td></td>
        <td>Final Xpert MTB/RIF Ultra test result</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>w8t8k2IPqsB</td>
      </tr>
      <tr>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
        <td>Date of initial DST LM results</td>
        <td></td>
        <td>Date of final initial DST results (liquid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Wg7Df5kgpaF</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
        <td>Initial DST SM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>wgEYFWwfv7z</td>
      </tr>
      <tr>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
        <td>Date of subsequent DST LM results</td>
        <td></td>
        <td>Date of final subsequent DST results (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>wi4NRarMSuv</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
        <td>LPA (Fq/2LI) - Emb</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Ethambutol</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>WLaOsGs9ujA</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - Treatment over 1 month</td>
        <td>Treatment over 1 month</td>
        <td></td>
        <td>Has patient been previously treated for TB for more than a month?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>WlAQcyJ0xW6</td>
      </tr>
      <tr>
        <td>TB Lab: TGS - Reasons for failure</td>
        <td>TGS - reasons for failure</td>
        <td></td>
        <td>Targeted gene sequencing: Reasons for failure</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>wQqfoI8qTMX</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
        <td>Initial DST LM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>wzPWimo6vO3</td>
      </tr>
      <tr>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
        <td>WGS - Emb</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethambutol by WGS</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Xmu74LffbOV</td>
      </tr>
      <tr>
        <td>TB DRS SRL: DRS ID</td>
        <td>Patient DRS ID</td>
        <td></td>
        <td>Patient DRS ID</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>xOhEOb1qLwJ</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
        <td>Initial DST SM - Lzd</td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), initial DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>xP5C3zmYXde</td>
      </tr>
      <tr>
        <td>TB Lab: Date of microscopy</td>
        <td>Date of microscopy result</td>
        <td></td>
        <td>Date of microscopy</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>xyczZvsuaWr</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
        <td>Subsequent DST SM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - critical concentration (Mfx CC), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>xZfTs7RfeIU</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
        <td>Subsequent DST SM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>Y1VpjCBrpEc</td>
      </tr>
      <tr>
        <td>TB DRS CS: Additional comments and remarks</td>
        <td>Additional comments and remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>Y66pOFOYt6T</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
        <td>Initial DST LM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin CC (Mfx CC), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>yiGr4JTFLv3</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - prior symptoms</td>
        <td>TB prior symptoms</td>
        <td></td>
        <td>Did the patient have the same symptoms prior to this episode?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>yn0LMROuQwZ</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 DRS ID</td>
        <td>Sample 4 DRS ID</td>
        <td></td>
        <td>Sample 4 DRS ID</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>YNDJVRtDxbi</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
        <td>LPA (Fq/2LI) - MTB</td>
        <td></td>
        <td>LPA (Fq/2LI) - MTB</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>z0j1fZQHoSB</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify other (Sample 2)</td>
        <td>Specify other (Sample 2)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>z6hnMc1kBNO</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
        <td>Subsequent DST LM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2021-02-05</td>
        <td>zcmsN575vwZ</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
        <td>LPA (Rif/Inh) - MTB</td>
        <td></td>
        <td>LPA (Rif/Inh) - MTB</td>
        <td>default</td>
        <td>2021-01-22</td>
        <td>Zd7703kfnOC</td>
      </tr>
      <tr>
        <td>TB Lab: Targeted gene sequencing</td>
        <td>TGS</td>
        <td></td>
        <td>Targeted gene sequencing</td>
        <td>default</td>
        <td>2021-01-28</td>
        <td>zfF3GMpuYAP</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
        <td>Initial DST LM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), initial DST (liquid media)</td>
        <td>default</td>
        <td>2021-01-07</td>
        <td>ZSL9PI7Kbsa</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 collection date</td>
        <td>Sample 2 collection date</td>
        <td></td>
        <td>Sample 2 collection date</td>
        <td>default</td>
        <td>2020-12-10</td>
        <td>zVDnm2Bur06</td>
      </tr>
      <tr>
        <td>TB DRS CRF: Treatment history - sputum examinations</td>
        <td>Sputum examinations</td>
        <td></td>
        <td>Did the patient have sputum examinations prior to this episode?</td>
        <td>default</td>
        <td>2021-02-03</td>
        <td>ZyxsK4KWkLQ</td>
      </tr>
    </table>
    <h2>Data Element Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS</td>
        <td>2020-10-16</td>
        <td>SfwwoCbB1m3</td>
      </tr>
    </table>
    <h3>Data Element Groups - Data Elements</h3>
    <table>
      <tr>
        <th>Data Element Group</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Sample 1 - reasons for sample rejection or loss</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of subsequent DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - previous TB registration number</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Reasons for not shipping samples to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: HIV test date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Xpert MTB/RIF initial screening result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of initial DST inoculation (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Sample rejected or lost</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Specimen 2 microscopy test result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Xpert MTB/RIF test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Amk</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Xpert MTB/RIF Ultra quantitative result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final microscopy result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - length of sickness - weeks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - names of drugs</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of culture inoculation (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - outcome</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pza</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Storage only</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling- Amk</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Inh</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - regimen</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS genotypic speciation results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - TB drugs</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - Injections for TB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify other (Sample 3)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Date of Xpert MTB/RIF initial screening test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify other (Sample 4)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 collection date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Bacteriological Confirmation - microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify other (Sample 1)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of culture inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - officer name</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final Xpert MTB/RIF test result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - Genotypic speciation results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Date samples shipped to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 collection date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Samples shipped to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of initial DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Date samples arrived at NRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Xpert MTB/RIF Ultra test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Specimen 1 microscopy test result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of culture result (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - other symptoms of lung disease</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final culture result (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Bacteriological Confirmation - Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Xpert MTB/RIF quantitative result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - control question</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of subsequent DST inoculation (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of culture result (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - prior TB registration</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 collection date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - Date of results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - Is interpretable genetic resistance profiling for MTBc available?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: HIV test result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Fq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Date samples arrived at SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Pa</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Date samples shipped to NRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final culture result (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Eto</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Import .csv</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - Date of results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - genotypic resistance profiling - Rif</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - Reasons for no resistance profiling available</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final Xpert MTB/RIF Ultra test result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - Treatment over 1 month</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: TGS - Reasons for failure</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: WGS - genotypic resistance profiling - Emb</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Additional comments and remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - prior symptoms</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify other (Sample 2)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Targeted gene sequencing</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 collection date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CRF: Treatment history - sputum examinations</td>
      </tr>
    </table>
    <h2 id="categoryCombos">Category Combinations</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Categories</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2021-02-05</td>
        <td>bjDvmb4bfuf</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categories">Data Element Categories</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Category options</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2021-02-05</td>
        <td>GLevLNI9wkl</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categoryOptions">Data Element Category Options</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2021-02-05</td>
        <td>xYerKDKCefk</td>
      </tr>
    </table>
    <h2 id="categoryOptionCombos">Category Option Combination</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2021-02-05</td>
        <td>HllvX50cXC0</td>
      </tr>
    </table>
    <h2 id="optionSets">Option Sets</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Options</th>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>2020-12-10</td>
        <td>acANJTHfW9R</td>
        <td>Susceptible; Resistant; No Interpretable Result (i.e. insufficient quality); Indeterminate (i.e. mutation unknown / not graded)</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>2021-01-12</td>
        <td>bLA3AqDKdwx</td>
        <td>Yes; No; Unknown</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>2020-12-10</td>
        <td>cNBWQaZZQ8g</td>
        <td>Cured; Treatment completed; Treatment failed; Lost to follow-up; Not evaluated</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>2020-12-10</td>
        <td>EAesHOyydJi</td>
        <td>Positive; Negative; Unknown</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>2020-10-16</td>
        <td>ekhfzhURD44</td>
        <td>Susceptible; Resistant; Contaminated; Indeterminate</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>2020-12-10</td>
        <td>eUBlAbh0g2h</td>
        <td>Detected; Not detected; Error; Invalid; No result</td>
      </tr>
      <tr>
        <td>TB DRS Treatment Regimen</td>
        <td>2020-12-04</td>
        <td>hAdCLiy6j0y</td>
        <td>Drug-susceptible regimen (new); Drug-susceptible regimen (previously treated); Drug-resistant regimen (new); Drug-resistant regimen (previously treated)</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2021-01-22</td>
        <td>hiQ3QFheQ3O</td>
        <td>Male; Female</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Speciation Results</td>
        <td>2020-11-12</td>
        <td>KFLJiv8X5Uf</td>
        <td>MTBc; Mixed MTBc and Other; NTM; Contamination; Failed</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>2020-08-04</td>
        <td>oKESbY0JpLt</td>
        <td>Sputum samples or sediments; MTB culture isolates</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>2020-12-10</td>
        <td>otxN1DQ61fV</td>
        <td>MTB detected (Rifampicin susceptible); MTB detected (Rifampicin resistant); MTB detected (Rifampicin indeterminate); MTB not detected; No result; Error; Invalid; Not done</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>2020-12-10</td>
        <td>pDOu7HaMvKJ</td>
        <td>None; CPC; Ethanol; PrimeStore; Other</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>2021-02-05</td>
        <td>q75AsvLUWVp</td>
        <td>Susceptible; Resistant; Indeterminate</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>2020-12-10</td>
        <td>qIXXdwltkqk</td>
        <td>Yes; No; Not Applicable</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>2020-12-10</td>
        <td>qtswn9lMSXN</td>
        <td>Yes; No</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>2020-12-10</td>
        <td>qu5LpxbpHUa</td>
        <td>Negative; Scanty; +; ++; +++; Not done</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>2021-01-14</td>
        <td>rB88xT5ggFg</td>
        <td>MTB; NTM; No growth; Contaminated</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>2020-12-10</td>
        <td>Vh9kmO4yiKE</td>
        <td>High; Medium; Low; Very low; Trace; Unknown</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>2021-01-12</td>
        <td>ynHtyLDVeJO</td>
        <td>Afghanistan; Aland Islands; Albania; Algeria; American Samoa; Andorra; Angola; Anguilla; Antarctica; Antigua and Barbuda; Argentina; Armenia; Aruba; Australia; Austria; Azerbaijan; Bahamas; Bahrain; Bangladesh; Barbados; another 229 options not shown.</td>
      </tr>
    </table>
    <h2 id="options">Options</h2>
    <table>
      <tr>
        <th>Option Set Name</th>
        <th>Name</th>
        <th>Code</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Romania</td>
        <td>RO</td>
        <td>2021-01-12</td>
        <td>a5ayhZAtUe4</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Speciation Results</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-12-10</td>
        <td>AADFw8OdflX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tuvalu</td>
        <td>TV</td>
        <td>2021-01-12</td>
        <td>aGozKfvhGv6</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Detected</td>
        <td>DETECTED</td>
        <td>2021-01-14</td>
        <td>aIKhwpm3xjg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Brunei Darussalam</td>
        <td>BN</td>
        <td>2021-01-12</td>
        <td>AlKNJVD0Bqv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Algeria</td>
        <td>DZ</td>
        <td>2021-01-12</td>
        <td>ALoq1vKJCDr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Honduras</td>
        <td>HN</td>
        <td>2021-01-12</td>
        <td>ALX1BnV0GrW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sao Tome and Principe</td>
        <td>ST</td>
        <td>2021-01-12</td>
        <td>AMFu6DFAqll</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guadeloupe</td>
        <td>GP</td>
        <td>2021-01-12</td>
        <td>AneyNa28ceQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>India</td>
        <td>IN</td>
        <td>2021-01-12</td>
        <td>AObPqV4cHPb</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Estonia</td>
        <td>EE</td>
        <td>2021-01-12</td>
        <td>aOX23O03bBw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malawi</td>
        <td>MW</td>
        <td>2021-01-12</td>
        <td>ApCSe2JdIUw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Andorra</td>
        <td>AD</td>
        <td>2021-01-12</td>
        <td>aslBaQPVe9V</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Female</td>
        <td>FEMALE</td>
        <td>2021-02-05</td>
        <td>AZK4rjJCss5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sweden</td>
        <td>SE</td>
        <td>2021-01-12</td>
        <td>ban72xOWClE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Central African Republic</td>
        <td>CF</td>
        <td>2021-01-12</td>
        <td>bANs6w1wFgV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iran (Islamic Republic of)</td>
        <td>IR</td>
        <td>2021-01-12</td>
        <td>bEj6P1jqHje</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kiribati</td>
        <td>KI</td>
        <td>2021-01-12</td>
        <td>BFMEIXmaqFE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Sudan</td>
        <td>SS</td>
        <td>2021-01-12</td>
        <td>bhfjgX8aEJQ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>Very low</td>
        <td>VERY_LOW</td>
        <td>2020-10-13</td>
        <td>BKQCd25FwAG</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Indeterminate</td>
        <td>INDETERMINATE</td>
        <td>2021-02-05</td>
        <td>bOnWRnVw30P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Marshall Islands</td>
        <td>MH</td>
        <td>2021-01-12</td>
        <td>BpqJwhPqI9O</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Chile</td>
        <td>CL</td>
        <td>2021-01-12</td>
        <td>bQX37dUQTAr</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>Other</td>
        <td>OTHER</td>
        <td>2021-01-12</td>
        <td>bxKZffLCvEp</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>Ethanol</td>
        <td>ETHANOL</td>
        <td>2020-12-10</td>
        <td>BZCqdbW974l</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malta</td>
        <td>MT</td>
        <td>2021-01-12</td>
        <td>C2Ws5NctBqi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Venezuela (Bolivarian Republic of)</td>
        <td>VE</td>
        <td>2021-01-12</td>
        <td>C3Mf3a5OJa3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Curacao</td>
        <td>CW</td>
        <td>2021-01-12</td>
        <td>C5DXQidiMMc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bahrain</td>
        <td>BH</td>
        <td>2021-01-12</td>
        <td>cc1JEMv0suu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cyprus</td>
        <td>CY</td>
        <td>2021-01-12</td>
        <td>ccs1kikyZS3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Helena, Ascension and Tristan da Cunha</td>
        <td>SH</td>
        <td>2021-01-12</td>
        <td>CCzBKhjSPFo</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>El Salvador</td>
        <td>SV</td>
        <td>2021-01-12</td>
        <td>CDBeT1lT7n2</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Indeterminate (i.e. mutation unknown / not graded)</td>
        <td>INDETERMINATE</td>
        <td>2020-12-10</td>
        <td>cdwZvx6AcLV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Dominican Republic</td>
        <td>DO</td>
        <td>2021-01-12</td>
        <td>CedH1TzSPgO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bulgaria</td>
        <td>BG</td>
        <td>2021-01-12</td>
        <td>cGLoDkT864j</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Burundi</td>
        <td>BI</td>
        <td>2021-01-12</td>
        <td>CIYwznedTto</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Latvia</td>
        <td>LV</td>
        <td>2021-01-12</td>
        <td>CkE4sCvC7zj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Viet Nam</td>
        <td>VN</td>
        <td>2021-01-12</td>
        <td>CndbUcexjyJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Aland Islands</td>
        <td>AX</td>
        <td>2021-01-12</td>
        <td>CNnT7FC710W</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>China</td>
        <td>CN</td>
        <td>2021-01-12</td>
        <td>CQR9IijKrgo</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Indeterminate</td>
        <td>INDETERMINATE</td>
        <td>2021-02-05</td>
        <td>cqyKiKWzg1m</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2021-01-12</td>
        <td>CvivP1rh4ii</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Falkland Islands (Malvinas)</td>
        <td>FK</td>
        <td>2021-01-12</td>
        <td>CWhuePZuC9y</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Speciation Results</td>
        <td>MTBc</td>
        <td>MTBC</td>
        <td>2020-12-10</td>
        <td>cXeTwncrs81</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Germany</td>
        <td>DE</td>
        <td>2021-01-12</td>
        <td>CxKFBwhGuJr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Macedonia (the former Yugoslav Republic of)</td>
        <td>MK</td>
        <td>2021-01-12</td>
        <td>cxvpqSjkTjP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Congo</td>
        <td>CG</td>
        <td>2021-01-12</td>
        <td>Cy4TaW1hskg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>San Marino</td>
        <td>SM</td>
        <td>2021-01-12</td>
        <td>CysWbM6JFgj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Armenia</td>
        <td>AM</td>
        <td>2021-01-12</td>
        <td>CzdkfAxkAqe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uruguay</td>
        <td>UY</td>
        <td>2021-01-12</td>
        <td>CzJoxdewhsm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Reunion</td>
        <td>RE</td>
        <td>2021-01-12</td>
        <td>D9h2axpYFx9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cuba</td>
        <td>CU</td>
        <td>2021-01-12</td>
        <td>DEO4vDvhNEv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Greenland</td>
        <td>GL</td>
        <td>2021-01-12</td>
        <td>dMRNgoCtogj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belarus</td>
        <td>BY</td>
        <td>2021-01-12</td>
        <td>dUEKKaPFcVU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Colombia</td>
        <td>CO</td>
        <td>2021-01-12</td>
        <td>e4CswJZAFBR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Namibia</td>
        <td>NA</td>
        <td>2021-01-12</td>
        <td>e4HCJJlYOQP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ukraine</td>
        <td>UA</td>
        <td>2021-01-12</td>
        <td>E68TvHpnyp5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Moldova (Republic of)</td>
        <td>MD</td>
        <td>2021-01-12</td>
        <td>EABP62Ce29b</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Isle of Man</td>
        <td>IM</td>
        <td>2021-01-12</td>
        <td>ecANXpkkcPT</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>PrimeStore</td>
        <td>PRIMESTORE</td>
        <td>2020-12-10</td>
        <td>eefJopL3w3t</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2021-02-05</td>
        <td>eeiCaPcf3ZX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Hungary</td>
        <td>HU</td>
        <td>2021-01-12</td>
        <td>eGQJGkiLamm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Pakistan</td>
        <td>PK</td>
        <td>2021-01-12</td>
        <td>eHKdzDVgEuj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Myanmar</td>
        <td>MM</td>
        <td>2021-01-12</td>
        <td>ElBqHdoLnsc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guam</td>
        <td>GU</td>
        <td>2021-01-12</td>
        <td>ELm3SnuBHJZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sudan</td>
        <td>SD</td>
        <td>2021-01-12</td>
        <td>ELZXJ7i1DKL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gambia</td>
        <td>GM</td>
        <td>2021-01-12</td>
        <td>EQULu0IwQNE</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Treatment completed</td>
        <td>COMPLETED</td>
        <td>2020-12-04</td>
        <td>eRxCMA3E65a</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jamaica</td>
        <td>JM</td>
        <td>2021-01-12</td>
        <td>etZCdyFxz4w</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Speciation Results</td>
        <td>Contamination</td>
        <td>CONTAMINATION</td>
        <td>2020-12-10</td>
        <td>EzNcSEhsU1n</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>+++</td>
        <td>+++</td>
        <td>2020-12-10</td>
        <td>f0QayRDQJAw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Benin</td>
        <td>BJ</td>
        <td>2021-01-12</td>
        <td>fEV7BkjJi8V</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>New Caledonia</td>
        <td>NC</td>
        <td>2021-01-12</td>
        <td>fg3tUp5fFH1</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turkey</td>
        <td>TR</td>
        <td>2021-01-12</td>
        <td>fmGjlRnf0AW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Holy See</td>
        <td>VA</td>
        <td>2021-01-12</td>
        <td>FmIGl5AnbxN</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>Not done</td>
        <td>NOT_DONE</td>
        <td>2020-12-10</td>
        <td>fP6dG3rRLIW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Finland</td>
        <td>FI</td>
        <td>2021-01-12</td>
        <td>fQzvkEY9chs</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>Medium</td>
        <td>MEDIUM</td>
        <td>2020-10-13</td>
        <td>FwWvCvfkaEp</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Azerbaijan</td>
        <td>AZ</td>
        <td>2021-01-12</td>
        <td>FXk1MDI7CEJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Korea (Republic of)</td>
        <td>KR</td>
        <td>2021-01-12</td>
        <td>G9rNnfnVNcB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Botswana</td>
        <td>BW</td>
        <td>2021-01-12</td>
        <td>ga22tvzYHEZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Grenada</td>
        <td>GD</td>
        <td>2021-01-12</td>
        <td>gDARdk8cZ3H</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bahamas</td>
        <td>BS</td>
        <td>2021-01-12</td>
        <td>GGWWOucyQ5L</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Rwanda</td>
        <td>RW</td>
        <td>2021-01-12</td>
        <td>gSPpYw9P7YO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Japan</td>
        <td>JP</td>
        <td>2021-01-12</td>
        <td>H65niFKFuSs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Swaziland</td>
        <td>SZ</td>
        <td>2021-01-12</td>
        <td>HafX2zWjutb</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Speciation Results</td>
        <td>Failed</td>
        <td>FAILED</td>
        <td>2021-01-12</td>
        <td>HAHhOpw9qIc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tanzania, United Republic of</td>
        <td>TZ</td>
        <td>2021-01-12</td>
        <td>hB9kKEo5Jav</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Western Sahara</td>
        <td>EH</td>
        <td>2021-01-12</td>
        <td>hbiFi85xO2g</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gabon</td>
        <td>GA</td>
        <td>2021-01-12</td>
        <td>hF9y363enrH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Pierre and Miquelon</td>
        <td>PM</td>
        <td>2021-01-12</td>
        <td>hIGURTVsclf</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Togo</td>
        <td>TG</td>
        <td>2021-01-12</td>
        <td>HOiHQKzyA2h</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mauritania</td>
        <td>MR</td>
        <td>2021-01-12</td>
        <td>HScqQPe1X9u</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Peru</td>
        <td>PE</td>
        <td>2021-01-12</td>
        <td>hUQDnRc6BKw</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Error</td>
        <td>ERROR</td>
        <td>2020-12-10</td>
        <td>Hv5WIheOqCR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Korea (Democratic People's Republic of)</td>
        <td>KP</td>
        <td>2021-01-12</td>
        <td>i0Dl3gB8WuY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guinea-Bissau</td>
        <td>GW</td>
        <td>2021-01-12</td>
        <td>I8A7Q4zi1YI</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Georgia</td>
        <td>GE</td>
        <td>2021-01-12</td>
        <td>I9v1TBhT3OV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Niue</td>
        <td>NU</td>
        <td>2021-01-12</td>
        <td>ibFgvQscr1i</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Suriname</td>
        <td>SR</td>
        <td>2021-01-12</td>
        <td>IfwaYvRaIhp</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>Sputum samples or sediments</td>
        <td>SPUTUM_SAMPLES_OR_SEDIMENTS</td>
        <td>2021-01-14</td>
        <td>io6qvQDAP8r</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jordan</td>
        <td>JO</td>
        <td>2021-01-12</td>
        <td>IqyWsh1pbYf</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>No growth</td>
        <td>NO_GROWTH</td>
        <td>2021-02-05</td>
        <td>iRIdWqmsuhn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cote d'Ivoire</td>
        <td>CI</td>
        <td>2021-01-12</td>
        <td>iwk6djvOBNV</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2021-02-05</td>
        <td>Ix8MPUuGZXD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Macao</td>
        <td>MO</td>
        <td>2021-01-12</td>
        <td>IyBPcxO7hfB</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2021-01-12</td>
        <td>IYKMiif5Uno</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>High</td>
        <td>HIGH</td>
        <td>2020-12-10</td>
        <td>j2cnORcpi4l</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB detected (Rifampicin resistant)</td>
        <td>MTB_DETECTED_RIFAMPICIN_RESISTANT</td>
        <td>2020-12-10</td>
        <td>Jbx4393qLtO</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2021-01-12</td>
        <td>jHN7y8U459f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Slovenia</td>
        <td>SI</td>
        <td>2021-01-12</td>
        <td>Jl2tnw6dutF</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Taiwan, Province of China</td>
        <td>TW</td>
        <td>2021-01-12</td>
        <td>jLIOTZIi0Ou</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Norfolk Island</td>
        <td>NF</td>
        <td>2021-01-12</td>
        <td>jmZqHjwAKxJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Norway</td>
        <td>NO</td>
        <td>2021-01-12</td>
        <td>JpY27WXUqOI</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mayotte</td>
        <td>YT</td>
        <td>2021-01-12</td>
        <td>jQ3mYwytyZn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cameroon</td>
        <td>CM</td>
        <td>2021-01-12</td>
        <td>JqPKssESKSC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>British Indian Ocean Territory</td>
        <td>IO</td>
        <td>2021-01-12</td>
        <td>JUY113J4COL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United States Minor Outlying Islands</td>
        <td>UM</td>
        <td>2021-01-12</td>
        <td>JwhF38ZDa7Y</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kazakhstan</td>
        <td>KZ</td>
        <td>2021-01-12</td>
        <td>JWIEjkUmsWH</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2021-01-22</td>
        <td>jwk0lGLsonq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jersey</td>
        <td>JE</td>
        <td>2021-01-12</td>
        <td>JwslMKjECF2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Somalia</td>
        <td>SO</td>
        <td>2021-01-12</td>
        <td>JYfvnvIzM84</td>
      </tr>
      <tr>
        <td>TB DRS Treatment Regimen</td>
        <td>Drug-susceptible regimen (new)</td>
        <td>DS_REG_NEW</td>
        <td>2020-12-04</td>
        <td>K568S90VzOF</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>++</td>
        <td>++</td>
        <td>2020-12-10</td>
        <td>K9PoNq9YiJw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bouvet Island</td>
        <td>BV</td>
        <td>2021-01-12</td>
        <td>k9qiH4Z3K6m</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Madagascar</td>
        <td>MG</td>
        <td>2021-01-12</td>
        <td>kaf9448wuv0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Slovakia</td>
        <td>SK</td>
        <td>2021-01-12</td>
        <td>kdX0FFam8Vz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Northern Mariana Islands</td>
        <td>MP</td>
        <td>2021-01-12</td>
        <td>KGoEICL7PmU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sint Maarten (Dutch part)</td>
        <td>SX</td>
        <td>2021-01-12</td>
        <td>Kjon60bpcC4</td>
      </tr>
      <tr>
        <td>TB DRS Treatment Regimen</td>
        <td>Drug-susceptible regimen (previously treated)</td>
        <td>DS_REG_PREV</td>
        <td>2020-12-04</td>
        <td>kM40CT6fpKQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Svalbard and Jan Mayen</td>
        <td>SJ</td>
        <td>2021-01-12</td>
        <td>kNow7wcQT6z</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Equatorial Guinea</td>
        <td>GQ</td>
        <td>2021-01-12</td>
        <td>KNU7Tm8S245</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Indonesia</td>
        <td>ID</td>
        <td>2021-01-12</td>
        <td>kPQes5oG21J</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Lost to follow-up</td>
        <td>LOST_TO_FOLLOW_UP</td>
        <td>2021-01-14</td>
        <td>KRDPhShyFOe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malaysia</td>
        <td>MY</td>
        <td>2021-01-12</td>
        <td>KtR12m8FoT0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Vincent and the Grenadines</td>
        <td>VC</td>
        <td>2021-01-12</td>
        <td>L1FmwJC0u3z</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guernsey</td>
        <td>GG</td>
        <td>2021-01-12</td>
        <td>l69MO3y6LuS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cambodia</td>
        <td>KH</td>
        <td>2021-01-12</td>
        <td>l8WR0m3GGuB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>New Zealand</td>
        <td>NZ</td>
        <td>2021-01-12</td>
        <td>lBZHFe8qxEL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Montenegro</td>
        <td>ME</td>
        <td>2021-01-12</td>
        <td>lCww3l79Wem</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Liberia</td>
        <td>LR</td>
        <td>2021-01-12</td>
        <td>LfjyJpiu8dL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Thailand</td>
        <td>TH</td>
        <td>2021-01-12</td>
        <td>lGIM5L1ldVZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Yemen</td>
        <td>YE</td>
        <td>2021-01-12</td>
        <td>lJBsaRbZLZP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kyrgyzstan</td>
        <td>KG</td>
        <td>2021-01-12</td>
        <td>LjRX17TMcTX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Anguilla</td>
        <td>AI</td>
        <td>2021-01-12</td>
        <td>LMzYJEbDEN6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Singapore</td>
        <td>SG</td>
        <td>2021-01-12</td>
        <td>loTOnrxGmCv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Aruba</td>
        <td>AW</td>
        <td>2021-01-12</td>
        <td>LoTxSO186BO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Comoros</td>
        <td>KM</td>
        <td>2021-01-12</td>
        <td>LRjLr9oMe1M</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nepal</td>
        <td>NP</td>
        <td>2021-01-12</td>
        <td>LRsQdDERp1f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Barthalemy</td>
        <td>BL</td>
        <td>2021-01-12</td>
        <td>lufRQXPgcJ8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Syrian Arab Republic</td>
        <td>SY</td>
        <td>2021-01-12</td>
        <td>LuMJaVKadYM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Panama</td>
        <td>PA</td>
        <td>2021-01-12</td>
        <td>Lyu0GDGZLU3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Luxembourg</td>
        <td>LU</td>
        <td>2021-01-12</td>
        <td>M2XM0PR40oH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Christmas Island</td>
        <td>CX</td>
        <td>2021-01-12</td>
        <td>m9vCfHK0sLC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Morocco</td>
        <td>MA</td>
        <td>2021-01-12</td>
        <td>MBVq67Tm1wK</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kuwait</td>
        <td>KW</td>
        <td>2021-01-12</td>
        <td>mCnaSMEODSz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belize</td>
        <td>BZ</td>
        <td>2021-01-12</td>
        <td>MdSOAa4C4gW</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2021-01-22</td>
        <td>MhctAiVMO5v</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ecuador</td>
        <td>EC</td>
        <td>2021-01-12</td>
        <td>mJexWvdoaXE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Southern Territories</td>
        <td>TF</td>
        <td>2021-01-12</td>
        <td>MKmqLvOYWos</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Positive</td>
        <td>POSITIVE</td>
        <td>2021-01-12</td>
        <td>Mn39beDtXNS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Dominica</td>
        <td>DM</td>
        <td>2021-01-12</td>
        <td>MpwuGzXBpAk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Antarctica</td>
        <td>AQ</td>
        <td>2021-01-12</td>
        <td>mQ5FOz8JXKs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Poland</td>
        <td>PL</td>
        <td>2021-01-12</td>
        <td>mTmjaDWUfDG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ghana</td>
        <td>GH</td>
        <td>2021-01-12</td>
        <td>N9bYrawJaqR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Micronesia (Federated States of)</td>
        <td>FM</td>
        <td>2021-01-12</td>
        <td>nDTKZYmGEvT</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB detected (Rifampicin indeterminate)</td>
        <td>MTB_DETECTED_RIF_INDETERMINATE</td>
        <td>2020-12-10</td>
        <td>nIKou981NQB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Portugal</td>
        <td>PT</td>
        <td>2021-01-12</td>
        <td>NlVuvr5WbKy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mali</td>
        <td>ML</td>
        <td>2021-01-12</td>
        <td>nOMNxq2fHGq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Philippines</td>
        <td>PH</td>
        <td>2021-01-12</td>
        <td>nTQRDVcTHr0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uganda</td>
        <td>UG</td>
        <td>2021-01-12</td>
        <td>NV1MNzAfPWE</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2021-01-22</td>
        <td>O9zjp4LJUeu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Heard Island and McDonald Islands</td>
        <td>HM</td>
        <td>2021-01-12</td>
        <td>OC0K30ETDLD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guatemala</td>
        <td>GT</td>
        <td>2021-01-12</td>
        <td>Oh3CJhGeaoi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Burkina Faso</td>
        <td>BF</td>
        <td>2021-01-12</td>
        <td>OIXRi2caf6J</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Pitcairn</td>
        <td>PN</td>
        <td>2021-01-12</td>
        <td>oMLQaRXOs1B</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Australia</td>
        <td>AU</td>
        <td>2021-01-12</td>
        <td>omWzNDmT2t7</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Cured</td>
        <td>CURED</td>
        <td>2021-01-12</td>
        <td>onqAZ9bio2t</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Africa</td>
        <td>ZA</td>
        <td>2021-01-12</td>
        <td>OozIOFXlUQB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Seychelles</td>
        <td>SC</td>
        <td>2021-01-12</td>
        <td>Oprr3by24Zt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Guiana</td>
        <td>GF</td>
        <td>2021-01-12</td>
        <td>otDBqUSWuzE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>American Samoa</td>
        <td>AS</td>
        <td>2021-01-12</td>
        <td>OvCy05DV6kt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Papua New Guinea</td>
        <td>PG</td>
        <td>2021-01-12</td>
        <td>ovWqm6wr1dP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mozambique</td>
        <td>MZ</td>
        <td>2021-01-12</td>
        <td>OvzdfV1qrvP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Wallis and Futuna</td>
        <td>WF</td>
        <td>2021-01-12</td>
        <td>oZPItrH57Zf</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>No result</td>
        <td>NO_RESULT</td>
        <td>2021-01-14</td>
        <td>ozqzmmfyvu8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Libya</td>
        <td>LY</td>
        <td>2021-01-12</td>
        <td>p0vsNlHuo7N</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2021-02-05</td>
        <td>p3SXa0Go6cJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saudi Arabia</td>
        <td>SA</td>
        <td>2021-01-12</td>
        <td>p8Tgra7YJ7h</td>
      </tr>
      <tr>
        <td>TB DRS Treatment Regimen</td>
        <td>Drug-resistant regimen (new)</td>
        <td>DR_REG_NEW</td>
        <td>2020-12-04</td>
        <td>pB9Xbeotzhx</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>France</td>
        <td>FR</td>
        <td>2021-01-12</td>
        <td>pBNkmU3hDoT</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Not evaluated</td>
        <td>NOT_EVALUATED</td>
        <td>2021-01-12</td>
        <td>PFLWg0jJAPV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lesotho</td>
        <td>LS</td>
        <td>2021-01-12</td>
        <td>PFq4nWHt0fM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cabo Verde</td>
        <td>CV</td>
        <td>2021-01-12</td>
        <td>phN4setkIfq</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>No</td>
        <td>NO</td>
        <td>2021-02-05</td>
        <td>PLlPgcfbL1D</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Djibouti</td>
        <td>DJ</td>
        <td>2021-01-12</td>
        <td>PMSl473rekw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cayman Islands</td>
        <td>KY</td>
        <td>2021-01-12</td>
        <td>pQhtDfYHXlQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Palestine, State of</td>
        <td>PS</td>
        <td>2021-01-12</td>
        <td>Publ7A7E6r3</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>Not Applicable</td>
        <td>NOT_APPLICABLE</td>
        <td>2021-01-28</td>
        <td>pv1WdxdAZl8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Montserrat</td>
        <td>MS</td>
        <td>2021-01-12</td>
        <td>q36uKrRjq1P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United Arab Emirates</td>
        <td>AE</td>
        <td>2021-01-12</td>
        <td>qCmj8zWn2RQ</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2021-01-12</td>
        <td>qEd2VMWfhan</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Italy</td>
        <td>IT</td>
        <td>2021-01-12</td>
        <td>QIjTIxTedos</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sri Lanka</td>
        <td>LK</td>
        <td>2021-01-12</td>
        <td>qpv7jbqwNTN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Monaco</td>
        <td>MC</td>
        <td>2021-01-12</td>
        <td>QT9Erxe7UaX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Serbia</td>
        <td>RS</td>
        <td>2021-01-12</td>
        <td>QtjohlzA8cl</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Maldives</td>
        <td>MV</td>
        <td>2021-01-12</td>
        <td>Qtp6HW63yqV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Greece</td>
        <td>GR</td>
        <td>2021-01-12</td>
        <td>QyJHXS44Xj9</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2021-01-12</td>
        <td>QYtc2i3L8Jd</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Zimbabwe</td>
        <td>ZW</td>
        <td>2021-01-12</td>
        <td>r15gweUYYrk</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2021-01-22</td>
        <td>R3xLm0LElMI</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cocos (Keeling) Islands</td>
        <td>CC</td>
        <td>2021-01-12</td>
        <td>Rb9W87URnVe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Chad</td>
        <td>TD</td>
        <td>2021-01-12</td>
        <td>rBktLnj3vUY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nauru</td>
        <td>NR</td>
        <td>2021-01-12</td>
        <td>rbvEOlaNkUU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gibraltar</td>
        <td>GI</td>
        <td>2021-01-12</td>
        <td>riIXFPTUnZX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Martin (French part)</td>
        <td>MF</td>
        <td>2021-01-12</td>
        <td>rJTXccXhtTG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Egypt</td>
        <td>EG</td>
        <td>2021-01-12</td>
        <td>RkxuXQTQjxk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mauritius</td>
        <td>MU</td>
        <td>2021-01-12</td>
        <td>RmjKEjs388f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bhutan</td>
        <td>BT</td>
        <td>2021-01-12</td>
        <td>RNUEujTD4AN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tokelau</td>
        <td>TK</td>
        <td>2021-01-12</td>
        <td>roEWVrnX17w</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Angola</td>
        <td>AO</td>
        <td>2021-01-12</td>
        <td>rpzJ5jGkUAn</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2021-02-05</td>
        <td>RrdcLAuvPke</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United States of America</td>
        <td>US</td>
        <td>2021-01-12</td>
        <td>RvhGvhkGceD</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Invalid</td>
        <td>INVALID</td>
        <td>2021-02-05</td>
        <td>rw8mrcHxfHg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cook Islands</td>
        <td>CK</td>
        <td>2021-01-12</td>
        <td>Rx05JdBEHIW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sierra Leone</td>
        <td>SL</td>
        <td>2021-01-12</td>
        <td>rXsByduwzcw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Hong Kong</td>
        <td>HK</td>
        <td>2021-01-12</td>
        <td>S3Dt4ozhM8X</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Treatment failed</td>
        <td>FAILED</td>
        <td>2020-12-04</td>
        <td>S4bXo4JsAbA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Czech Republic</td>
        <td>CZ</td>
        <td>2021-01-12</td>
        <td>Scdk35fgY12</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>No</td>
        <td>NO</td>
        <td>2021-01-12</td>
        <td>sEqMay8BGdJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Virgin Islands (U.S.)</td>
        <td>VI</td>
        <td>2021-01-12</td>
        <td>sgvVI1jilCg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mexico</td>
        <td>MX</td>
        <td>2021-01-12</td>
        <td>sK6lzdZiwIg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lao People's Democratic Republic</td>
        <td>LA</td>
        <td>2021-01-12</td>
        <td>SN9NeGsvfmM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Senegal</td>
        <td>SN</td>
        <td>2021-01-12</td>
        <td>sPFJiL1BLTy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Solomon Islands</td>
        <td>SB</td>
        <td>2021-01-12</td>
        <td>sQNVDVNINvY</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>Error</td>
        <td>ERROR</td>
        <td>2020-08-04</td>
        <td>sSxqp8mUH3o</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lithuania</td>
        <td>LT</td>
        <td>2021-01-12</td>
        <td>SXD2EhrNaQu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Spain</td>
        <td>ES</td>
        <td>2021-01-12</td>
        <td>SXeG3KaIkU8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bangladesh</td>
        <td>BD</td>
        <td>2021-01-12</td>
        <td>t0fFxYw3Cg4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guinea</td>
        <td>GN</td>
        <td>2021-01-12</td>
        <td>T0gujEdp3Z6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Denmark</td>
        <td>DK</td>
        <td>2021-01-12</td>
        <td>t0mq3u8SNgz</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>Low</td>
        <td>LOW</td>
        <td>2021-01-28</td>
        <td>TFPLoEDg3p4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guyana</td>
        <td>GY</td>
        <td>2021-01-12</td>
        <td>TfyHeFLDOKu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lebanon</td>
        <td>LB</td>
        <td>2021-01-12</td>
        <td>THKtWeVTuBk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Puerto Rico</td>
        <td>PR</td>
        <td>2021-01-12</td>
        <td>ThLyMbT1IvD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Polynesia</td>
        <td>PF</td>
        <td>2021-01-12</td>
        <td>THPEMRSnC4G</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Speciation Results</td>
        <td>Mixed MTBc and Other</td>
        <td>MIXED_MTBC_AND_OTHER</td>
        <td>2020-12-10</td>
        <td>tI2yNUx4RML</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ireland</td>
        <td>IE</td>
        <td>2021-01-12</td>
        <td>tiwJrxfBoHT</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2021-02-05</td>
        <td>TKD1XJ4ZhMO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Croatia</td>
        <td>HR</td>
        <td>2021-01-12</td>
        <td>tLn4hW3TbNZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Antigua and Barbuda</td>
        <td>AG</td>
        <td>2021-01-12</td>
        <td>TRETd1l7n1N</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Timor-Leste</td>
        <td>TL</td>
        <td>2021-01-12</td>
        <td>txfMqMjfmGK</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>Invalid</td>
        <td>INVALID</td>
        <td>2021-01-12</td>
        <td>U9s3LZ1Rp6E</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Kitts and Nevis</td>
        <td>KN</td>
        <td>2021-01-12</td>
        <td>uJH3wMNmMNO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kenya</td>
        <td>KE</td>
        <td>2021-01-12</td>
        <td>UJppzPKIQRv</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>Not done</td>
        <td>NOT_DONE</td>
        <td>2020-12-10</td>
        <td>uJXGqaQsBQZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Barbados</td>
        <td>BB</td>
        <td>2021-01-12</td>
        <td>uM1WgdIueNA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mongolia</td>
        <td>MN</td>
        <td>2021-01-12</td>
        <td>UmW7wmw0AX9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tunisia</td>
        <td>TN</td>
        <td>2021-01-12</td>
        <td>uNt8kKM8azp</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Faroe Islands</td>
        <td>FO</td>
        <td>2021-01-12</td>
        <td>upfjuKBGHq9</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF quantitative result</td>
        <td>Trace</td>
        <td>TRACE</td>
        <td>2020-10-13</td>
        <td>URfjy2nT6wH</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Male</td>
        <td>MALE</td>
        <td>2021-01-12</td>
        <td>UrUdMteQzlT</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>MTB</td>
        <td>MTB</td>
        <td>2020-12-10</td>
        <td>UsugTEaeBhi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Paraguay</td>
        <td>PY</td>
        <td>2021-01-12</td>
        <td>UvnjescFIbU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iraq</td>
        <td>IQ</td>
        <td>2021-01-12</td>
        <td>UXyOlL9FJ5o</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Niger</td>
        <td>NE</td>
        <td>2021-01-12</td>
        <td>UzC7hScynz0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Eritrea</td>
        <td>ER</td>
        <td>2021-01-12</td>
        <td>v16FQ3xwnGN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Martinique</td>
        <td>MQ</td>
        <td>2021-01-12</td>
        <td>V1nDCD6QvPs</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>No</td>
        <td>NO</td>
        <td>2021-01-12</td>
        <td>vak9GKjzzAP</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>No Interpretable Result (i.e. insufficient quality)</td>
        <td>NO_INTERPRETABLE_RESULT</td>
        <td>2020-12-10</td>
        <td>vaxQgTZQXpM</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>None</td>
        <td>NONE</td>
        <td>2021-01-28</td>
        <td>vEL863qZ6HA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Virgin Islands (British)</td>
        <td>VG</td>
        <td>2021-01-12</td>
        <td>VEulszgYUL2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tonga</td>
        <td>TO</td>
        <td>2021-01-12</td>
        <td>vjJWFh1j9U5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Georgia and the South Sandwich Islands</td>
        <td>GS</td>
        <td>2021-01-12</td>
        <td>vMAK8GtCXzE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Congo (Democratic Republic of the)</td>
        <td>CD</td>
        <td>2021-01-12</td>
        <td>VnmVMbf4mwL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turkmenistan</td>
        <td>TM</td>
        <td>2021-01-12</td>
        <td>vPk3xrZvimA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Israel</td>
        <td>IL</td>
        <td>2021-01-12</td>
        <td>VQkdjFxCLNH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bonaire, Sint Eustatius and Saba</td>
        <td>BQ</td>
        <td>2021-01-12</td>
        <td>vuiZtzbuwWx</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iceland</td>
        <td>IS</td>
        <td>2021-01-12</td>
        <td>vzzPNV6Wu0J</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Samoa</td>
        <td>WS</td>
        <td>2021-01-12</td>
        <td>w0S8ngASwmq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ethiopia</td>
        <td>ET</td>
        <td>2021-01-12</td>
        <td>W4KroB1nw6P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Costa Rica</td>
        <td>CR</td>
        <td>2021-01-12</td>
        <td>WBvTizbhaXP</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2021-01-12</td>
        <td>WhaoVoBAFxG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bolivia (Plurinational State of)</td>
        <td>BO</td>
        <td>2021-01-12</td>
        <td>WIleZf4Cua4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Zambia</td>
        <td>ZM</td>
        <td>2021-01-12</td>
        <td>WPR1XicphAd</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uzbekistan</td>
        <td>UZ</td>
        <td>2021-01-12</td>
        <td>WrnwBUl0Vzt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Albania</td>
        <td>AL</td>
        <td>2021-01-12</td>
        <td>wuS7cVSEiYA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Fiji</td>
        <td>FJ</td>
        <td>2021-01-12</td>
        <td>wVl5DoJmza2</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB not detected</td>
        <td>MTB_NOT_DETECTED</td>
        <td>2020-12-10</td>
        <td>wxaK4PQwtar</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Lucia</td>
        <td>LC</td>
        <td>2021-01-12</td>
        <td>x4Ohep6Q85T</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Russian Federation</td>
        <td>RU</td>
        <td>2021-01-12</td>
        <td>xF48L1VlFrZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turks and Caicos Islands</td>
        <td>TC</td>
        <td>2021-01-12</td>
        <td>xIvocxUNJvn</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB detected (Rifampicin susceptible)</td>
        <td>MTB_DETECTED_RIFAMPICIN_SUSCEPTIBLE</td>
        <td>2020-12-10</td>
        <td>xq1DHmnRamj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Liechtenstein</td>
        <td>LI</td>
        <td>2021-01-12</td>
        <td>XQZko5dUFGU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nigeria</td>
        <td>NG</td>
        <td>2021-01-12</td>
        <td>xsNVICc3jPD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Palau</td>
        <td>PW</td>
        <td>2021-01-12</td>
        <td>xuUrPK5b7MP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Argentina</td>
        <td>AR</td>
        <td>2021-01-12</td>
        <td>xvYNdt7dLiM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nicaragua</td>
        <td>NI</td>
        <td>2021-01-12</td>
        <td>Y2ze1UBngud</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>CPC</td>
        <td>CPC</td>
        <td>2020-12-10</td>
        <td>Y85Yik3kfq6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bosnia and Herzegovina</td>
        <td>BA</td>
        <td>2021-01-12</td>
        <td>Yf0Gb9nZiQ1</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Not detected</td>
        <td>NOT_DETECTED</td>
        <td>2021-01-22</td>
        <td>YMFMcGchVjk</td>
      </tr>
      <tr>
        <td>TB DRS Treatment Regimen</td>
        <td>Drug-resistant regimen (previously treated)</td>
        <td>DR_REG_PREV</td>
        <td>2020-12-04</td>
        <td>YON3JS2s0pM</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-12-10</td>
        <td>YoZDgCMUpJy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Vanuatu</td>
        <td>VU</td>
        <td>2021-01-12</td>
        <td>yqQ0IiG9maE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Oman</td>
        <td>OM</td>
        <td>2021-01-12</td>
        <td>yxbHuzqF6VS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tajikistan</td>
        <td>TJ</td>
        <td>2021-01-12</td>
        <td>yxvBpzHn9VN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Afghanistan</td>
        <td>AF</td>
        <td>2021-01-12</td>
        <td>yyeQNBfmO7g</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>+</td>
        <td>+</td>
        <td>2020-12-10</td>
        <td>z6UTT4AESR8</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>MTB culture isolates</td>
        <td>MTB_CULTURE_ISOLATES</td>
        <td>2021-01-14</td>
        <td>zAH62QSxRYh</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Switzerland</td>
        <td>CH</td>
        <td>2021-01-12</td>
        <td>ZcaE9JG9xrr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bermuda</td>
        <td>BM</td>
        <td>2021-01-12</td>
        <td>zITeQ1j7Jmz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Trinidad and Tobago</td>
        <td>TT</td>
        <td>2021-01-12</td>
        <td>zJCV30f9Pix</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>No result</td>
        <td>NO_RESULT</td>
        <td>2021-01-14</td>
        <td>znxRpLrCUNj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United Kingdom of Great Britain and Northern Ireland</td>
        <td>GB</td>
        <td>2021-01-12</td>
        <td>ZOGqtsOOfdP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Canada</td>
        <td>CA</td>
        <td>2021-01-12</td>
        <td>zonuQ6g4FFh</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Qatar</td>
        <td>QA</td>
        <td>2021-01-12</td>
        <td>zooDgQrnVkm</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2021-01-12</td>
        <td>zPVS0EAEwia</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Brazil</td>
        <td>BR</td>
        <td>2021-01-12</td>
        <td>ZqOOqkOV8Zm</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>Scanty</td>
        <td>SCANTY</td>
        <td>2021-01-22</td>
        <td>ZS5tTttku2i</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belgium</td>
        <td>BE</td>
        <td>2021-01-12</td>
        <td>zsS0Xx2iUV6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Netherlands</td>
        <td>NL</td>
        <td>2021-01-12</td>
        <td>ztgG5fQPur9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Austria</td>
        <td>AT</td>
        <td>2021-01-12</td>
        <td>zTtjy8I0bcu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Haiti</td>
        <td>HT</td>
        <td>2021-01-12</td>
        <td>ZyGPejjzvGD</td>
      </tr>
    </table>
    <h2 id="indicatorGroups">Indicator Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td></td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td></td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td></td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td></td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td></td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
    </table>
    <h3>Indicator Groups - Indicators</h3>
    <table>
      <tr>
        <th>Indicator Group</th>
        <th>Indicator</th>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Patients with Xpert MTB/RIF Ultra test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: LPA (Fq/2LI): <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>DRS: Patients with LPA (Fq/2LI) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture (solid media) at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture (solid media): <= 3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA (Fq/2LI): <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>DRS: Patients with LPA (Fq/2LI) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>DRS: Patients with Xpert MTB/RIF test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: Patients with LPA (Rif/Inh) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td>DRS: LPA (Rif/Inh): <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture (liquid media) at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture (liquid media): <= 6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Average number of days from sample collection to sample arrival at NRL</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with initial DST (liquid media) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with LPA (Rif/Inh) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Sample Rejection/Loss Rate (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with subsequent DST in (solid media) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with subsequent DST (liquid media) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with initial DST (solid media) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with culture (solid media) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Samples turn-around time: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with culture (liquid media) test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with microscopy test (%)</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td>DRS: Patients with LPA (Fq/2LI) test (%)</td>
      </tr>
    </table>
    <h2 id="indicators">Indicators</h2>
    <table>
      <tr>
        <th>UID</th>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Numerator</th>
        <th>Denominator</th>
        <th>Type</th>
        <th>Last updated</th>
        <th>Indicator group UID</th>
      </tr>
      <tr>
        <td>a8setUueamz</td>
        <td>DRS: Samples turn-around time: <=3 days (%)</td>
        <td>Turn-around time: <=3d (%)</td>
        <td></td>
        <td>Turn-around time: <=3 days - percentage of samples</td>
        <td>Turn-around time: <=3 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>AcHQyohvydu</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture (liquid media) at NRL</td>
        <td>Culture LM: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to culture inoculation in liquid media at NRL</td>
        <td>Average number of days from sample collection to culture inoculation in liquid media at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>ae0oVqByDr1</td>
        <td>DRS: Xpert MTB/RIF: <=4 days (%)</td>
        <td>Xpert MTB/RIF: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=4 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>aeK9KTMrpI1</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
        <td>Xpert MTB/RIF: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>am5DJHSAzK3</td>
        <td>DRS: Average number of days from sample collection to sample arrival at NRL</td>
        <td>Days between collection and arrival (mean)</td>
        <td></td>
        <td>Average number of days from sample collection to sample arrival at NRL</td>
        <td>Average number of days from sample collection to sample arrival at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>aS7bteRrJDZ</td>
        <td>DRS: Xpert MTB/RIF: <=3 days (%)</td>
        <td>Xpert MTB/RIF: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=3 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>bffHR88vA98</td>
        <td>DRS: Xpert MTB/RIF Ultra: 0 days (%)</td>
        <td>Xpert MTB/RIF Ultra: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: 0 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>Bn67IWVrBHi</td>
        <td>DRS: Culture (solid media): <= 4 days (%)</td>
        <td>Culture SM: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 4 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>bSWNVWcyzwB</td>
        <td>DRS: Patients with initial DST (liquid media) test (%)</td>
        <td>Initial DST LM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for initial DST LM out of all enrolled patients</td>
        <td>Patients with inoculation date for initial DST LM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>cBQZ41II5Gc</td>
        <td>DRS: LPA (Fq/2LI): <=5 days (%)</td>
        <td>LPA FQ/2LI: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=5 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>cCwNBsU06Ws</td>
        <td>DRS: Culture (solid media): <= 10+ days (%)</td>
        <td>Culture SM: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Culture SM: <= 10+ days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>cjzSGuUsFi7</td>
        <td>DRS: Culture (solid media): <= 1 day (%)</td>
        <td>Culture SM: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less day turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 1 day</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Cuny2qjvQH8</td>
        <td>DRS: Culture (solid media): <= 9 days (%)</td>
        <td>Culture SM: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 9 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>d7FmPC0FAyO</td>
        <td>DRS: Culture (liquid media): <= 5 days (%)</td>
        <td>Culture LM: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 5 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>dbWMLoaoRXt</td>
        <td>DRS: Culture (solid media): <= 6 days (%)</td>
        <td>Culture SM: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 6 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>DOa8x2MeB7x</td>
        <td>DRS: LPA (Rif/Inh): <=8 days (%)</td>
        <td>LPA RIF/INH: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=8 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>dP9fGLr2xEJ</td>
        <td>DRS: Samples turn-around time: <=2 days (%)</td>
        <td>Turn-around time: <=2d (%)</td>
        <td></td>
        <td>Turn-around time: <=2 days - percentage of samples</td>
        <td>Turn-around time: <=2 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>EJkYRjUldf6</td>
        <td>DRS: Culture (liquid media): <= 7 days (%)</td>
        <td>Culture LM: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 7 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>eoGyZLFAHdV</td>
        <td>DRS: Xpert MTB/RIF: <=10+ days (%)</td>
        <td>Xpert MTB/RIF: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Xpert MTB/RIF: <=10+ days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>eQ99BPBeFto</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
        <td>Xpert MTB/RIF Ultra: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>ESwnQHRtDaJ</td>
        <td>DRS: LPA (Rif/Inh): <=4 days (%)</td>
        <td>LPA RIF/INH: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=4 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>EZbmivyB7nr</td>
        <td>DRS: Xpert MTB/RIF: <=6 days (%)</td>
        <td>Xpert MTB/RIF: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=6 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>f31IE1B3CKi</td>
        <td>DRS: LPA (Rif/Inh): <=3 days (%)</td>
        <td>LPA RIF/INH: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=3 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>fa9SQjryhX3</td>
        <td>DRS: Samples turn-around time: 0 days (%)</td>
        <td>Turn-around time: 0d (%)</td>
        <td></td>
        <td>Turn-around time: 0 days - percentage of samples</td>
        <td>Turn-around time: 0 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>FcQisyQ92Zg</td>
        <td>DRS: LPA (Rif/Inh): <=6 days (%)</td>
        <td>LPA RIF/INH: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=6 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>fE4zG1Hl59F</td>
        <td>DRS: Culture (solid media): <= 10 days (%)</td>
        <td>Culture SM: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 10 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>FFQdb5RH6iS</td>
        <td>DRS: Culture (solid media): <= 8 days (%)</td>
        <td>Culture SM: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 8 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>fH5JqlzYk2i</td>
        <td>DRS: LPA (Fq/2LI): <=9 days (%)</td>
        <td>LPA FQ/2LI: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=9 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>FJA1FIsRWdV</td>
        <td>DRS: LPA (Fq/2LI): <=10+ days (%)</td>
        <td>LPA FQ/2LI: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>LPA (Fq/2LI): <=10+ days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Fknk2pZQ6Tv</td>
        <td>DRS: Samples turn-around time: <=10+ days (%)</td>
        <td>Turn-around time: <=10d+ (%)</td>
        <td></td>
        <td>Turn-around time: <=10+ days - percentage of samples</td>
        <td>Turn-around time: <=10+ days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>flPa9otyXxL</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=2 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=2 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>Fo2Cl7X69Tq</td>
        <td>DRS: LPA (Fq/2LI): <=2 days (%)</td>
        <td>LPA FQ/2LI: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=2 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>g2mOHLxN0tZ</td>
        <td>DRS: Patients with LPA (Rif/Inh) test (%)</td>
        <td>LPA RIF/INH: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for LPA (Rif/Inh) out of all enrolled patients</td>
        <td>Patients with result for LPA (Rif/Inh)</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE, zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>GGY0RHKlpM3</td>
        <td>DRS: Culture (liquid media): 0 days (%)</td>
        <td>Culture LM: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: 0 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>gnv4CbHeRJD</td>
        <td>DRS: Xpert MTB/RIF: <=5 days (%)</td>
        <td>Xpert MTB/RIF: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=5 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>GS5pE9D9xkM</td>
        <td>DRS: Sample Rejection/Loss Rate (%)</td>
        <td>Sample rejection/loss rate (%)</td>
        <td></td>
        <td>Percentage of samples rejected on arrival out of all collected samples</td>
        <td>Samples rejected on arrival</td>
        <td>Sample processing events, total</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>gYtgemihOJi</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=9 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=9 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>H0Y0qVB8UQQ</td>
        <td>DRS: Samples turn-around time: <=10 days (%)</td>
        <td>Turn-around time: <=10d (%)</td>
        <td></td>
        <td>Turn-around time: <=10 days - percentage of samples</td>
        <td>Turn-around time: <=10 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>H9MaiWTz15Q</td>
        <td>DRS: Culture (solid media): <= 7 days (%)</td>
        <td>Culture SM: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 7 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>hAMicIaBmAM</td>
        <td>DRS: Culture (liquid media): <= 2 days (%)</td>
        <td>Culture LM: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 2 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>HdMIlgBYze3</td>
        <td>DRS: Samples turn-around time: <=4 days (%)</td>
        <td>Turn-around time: <=4d (%)</td>
        <td></td>
        <td>Turn-around time: <=4 days - percentage of samples</td>
        <td>Turn-around time: <=4 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>HERepQ0qswD</td>
        <td>DRS: Xpert MTB/RIF: 0 days (%)</td>
        <td>Xpert MTB/RIF: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: 0 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>HH7cj34RWyK</td>
        <td>DRS: LPA (Rif/Inh): <=1 day (%)</td>
        <td>LPA RIF/INH: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=1 day</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>HqR09RvwsJN</td>
        <td>DRS: Patients with subsequent DST in (solid media) test (%)</td>
        <td>Subsequent DST SM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for subsequent DST SM out of all enrolled patients</td>
        <td>Patients with inoculation date for subsequent DST SM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>i1LZPAYNwAt</td>
        <td>DRS: Culture (liquid media): <= 10 days (%)</td>
        <td>Culture LM: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 10 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>i3UxIqflvlW</td>
        <td>DRS: Xpert MTB/RIF: <=10 days (%)</td>
        <td>Xpert MTB/RIF: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=10 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>iSMLdHROvWH</td>
        <td>DRS: Patients with subsequent DST (liquid media) test (%)</td>
        <td>Subsequent DST LM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for subsequent DST LM out of all enrolled patients</td>
        <td>Patients with inoculation date for subsequent DST LM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>j3HE4i1K8UX</td>
        <td>DRS: Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
        <td>LPA FQ/2LI: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
        <td>Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>JBUxyk3lCQ3</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=1 day (%)</td>
        <td>Xpert MTB/RIF Ultra: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=1 day</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>JDVx65Xz6XT</td>
        <td>DRS: Samples turn-around time: <=8 days (%)</td>
        <td>Turn-around time: <=8d (%)</td>
        <td></td>
        <td>Turn-around time: <=8 days - percentage of samples</td>
        <td>Turn-around time: <=8 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>JnEvbkg7hv2</td>
        <td>DRS: LPA (Rif/Inh): <=2 days (%)</td>
        <td>LPA RIF/INH: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=2 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>jp238ubVDNg</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=10 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>jv8wEnsQwUX</td>
        <td>DRS: Samples turn-around time: <=6 days (%)</td>
        <td>Turn-around time: <=6d (%)</td>
        <td></td>
        <td>Turn-around time: <=6 days - percentage of samples</td>
        <td>Turn-around time: <=6 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>LeRvQjCZlmn</td>
        <td>DRS: Samples turn-around time: <=1 day (%)</td>
        <td>Turn-around time: <=1d (%)</td>
        <td></td>
        <td>Turn-around time: <=1 day - percentage of samples</td>
        <td>Turn-around time: <=1 day</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>lFgVlJ9ofDP</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=4 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=4 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>M5rzpqToNVY</td>
        <td>DRS: LPA (Rif/Inh): <=10 days (%)</td>
        <td>LPA RIF/INH: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=10 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>M9PODPpbKal</td>
        <td>DRS: LPA (Rif/Inh): <=7 days (%)</td>
        <td>LPA RIF/INH: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=7 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>Ma6eNUhAnlN</td>
        <td>DRS: Culture (liquid media): <= 4 days (%)</td>
        <td>Culture LM: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 4 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>MeMSwX9uZZp</td>
        <td>DRS: LPA (Rif/Inh): 0 days (%)</td>
        <td>LPA RIF/INH: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): 0 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>MfuvDUrnP6f</td>
        <td>DRS: Culture (liquid media): <= 10+ days (%)</td>
        <td>Culture LM: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Culture LM: <= 10+ days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>MlSNx9HU7TI</td>
        <td>DRS: Xpert MTB/RIF: <=7 days (%)</td>
        <td>Xpert MTB/RIF: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=7 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>mzWxxsEh9og</td>
        <td>DRS: Culture (solid media): <= 5 days (%)</td>
        <td>Culture SM: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 5 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>NhSYNUMNjNs</td>
        <td>DRS: Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
        <td>LPA RIF/INH: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
        <td>Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>nkI1EXXVx6q</td>
        <td>DRS: Xpert MTB/RIF: <=8 days (%)</td>
        <td>Xpert MTB/RIF: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=8 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>NTq2m5syKdO</td>
        <td>DRS: LPA (Fq/2LI): <=7 days (%)</td>
        <td>LPA FQ/2LI: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=7 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>OdJf8tmZ1mj</td>
        <td>DRS: Samples turn-around time: <=7 days (%)</td>
        <td>Turn-around time: <=7d (%)</td>
        <td></td>
        <td>Turn-around time: <=7 days - percentage of samples</td>
        <td>Turn-around time: <=7 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>on52l0lUpel</td>
        <td>DRS: Culture (liquid media): <= 3 days (%)</td>
        <td>Culture LM: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 3 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>pPGxe6kKZlv</td>
        <td>DRS: LPA (Fq/2LI): <=8 days (%)</td>
        <td>LPA FQ/2LI: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=8 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>qhYQV5iWnkt</td>
        <td>DRS: LPA (Fq/2LI): <=6 days (%)</td>
        <td>LPA FQ/2LI: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=6 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2021-02-05</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>qq3lX3j1NZ3</td>
        <td>DRS: LPA (Rif/Inh): <=5 days (%)</td>
        <td>LPA RIF/INH: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=5 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>Qqt73P9tc9Z</td>
        <td>DRS: Xpert MTB/RIF: <=2 days (%)</td>
        <td>Xpert MTB/RIF: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=2 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>qZAPndnoZsD</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture (solid media) at NRL</td>
        <td>Culture SM: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to culture inoculation in solid media at NRL</td>
        <td>Average number of days from sample collection to culture inoculation in solid media at NRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2021-01-14</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>QzGsx5yW3K0</td>
        <td>DRS: Culture (solid media): <= 2 days (%)</td>
        <td>Culture SM: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 2 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>r1bYQSkX7S0</td>
        <td>DRS: Patients with Xpert MTB/RIF Ultra test (%)</td>
        <td>Xpert MTB/RIF Ultra:: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for Xpert MTB/RIF Ultra out of all enrolled patients</td>
        <td>Patients with result for Xpert MTB/RIF Ultra</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>rNnAvLcQaDH</td>
        <td>DRS: Patients with initial DST (solid media) test (%)</td>
        <td>Initial DST SM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for initial DST SM out of all enrolled patients</td>
        <td>Patients with inoculation date for initial DST SM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>rWU3OG0Hoes</td>
        <td>DRS: Culture (solid media): 0 days (%)</td>
        <td>Culture SM: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: 0 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>s0N0628XJk4</td>
        <td>DRS: Culture (liquid media): <= 1 day (%)</td>
        <td>Culture LM: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 1 day</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>SLEcCUelmh4</td>
        <td>DRS: LPA (Rif/Inh): <=9 days (%)</td>
        <td>LPA RIF/INH: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Rif/Inh): <=9 days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>SP6CAQHWVAE</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=6 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=6 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>sU03j4s9XdO</td>
        <td>DRS: Samples turn-around time: <=5 days (%)</td>
        <td>Turn-around time: <=5d (%)</td>
        <td></td>
        <td>Turn-around time: <=5 days - percentage of samples</td>
        <td>Turn-around time: <=5 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>SzaccE231ip</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10+ days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Xpert MTB/RIF Ultra: <=10+ days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>taM6ep0BP6M</td>
        <td>DRS: Patients with culture (solid media) test (%)</td>
        <td>Culture SM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for culture SM out of all enrolled patients</td>
        <td>Patients with inoculation date for culture SM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>TMEDhCBGZ1y</td>
        <td>DRS: Culture (solid media): <= 3 days (%)</td>
        <td>Culture SM: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 3 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Trcb8xHsjt6</td>
        <td>DRS: Samples turn-around time: <=9 days (%)</td>
        <td>Turn-around time: <=9d (%)</td>
        <td></td>
        <td>Turn-around time: <=9 days - percentage of samples</td>
        <td>Turn-around time: <=9 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>Tye8znCo2XQ</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=3 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=3 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>TZWk9KMI4ZG</td>
        <td>DRS: LPA (Fq/2LI): 0 days (%)</td>
        <td>LPA FQ/2LI: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): 0 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>U1hmoiM7tGC</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=5 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=5 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>u8tyaQI2gZv</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=7 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=7 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>UKG5rYhLzB9</td>
        <td>DRS: Xpert MTB/RIF: <=9 days (%)</td>
        <td>Xpert MTB/RIF: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=9 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>vAxhDAwCETT</td>
        <td>DRS: LPA (Rif/Inh): <=10+ days (%)</td>
        <td>LPA RIF/INH: <=10d+ (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>LPA (Rif/Inh): <=10+ days</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>VcyNL2HV7bm</td>
        <td>DRS: Culture (liquid media): <= 9 days (%)</td>
        <td>Culture LM: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 9 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>VPCubNFuzbt</td>
        <td>DRS: LPA (Fq/2LI): <=1 day (%)</td>
        <td>LPA FQ/2LI: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=1 day</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Vt3ZRTycjeI</td>
        <td>DRS: Patients with culture (liquid media) test (%)</td>
        <td>Culture LM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for culture LM out of all enrolled patients</td>
        <td>Patients with inoculation date for culture LM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>wjoodsLQE59</td>
        <td>DRS: LPA (Fq/2LI): <=3 days (%)</td>
        <td>LPA FQ/2LI: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=3 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Wxp1B8XNZzr</td>
        <td>DRS: Xpert MTB/RIF: <=1 day (%)</td>
        <td>Xpert MTB/RIF: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=1 day</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>x4A5M9cr9oq</td>
        <td>DRS: LPA (Fq/2LI): <=4 days (%)</td>
        <td>LPA FQ/2LI: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=4 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>X6dO8wrnZGb</td>
        <td>DRS: Patients with microscopy test (%)</td>
        <td>Microscopy: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for microscopy out of all enrolled patients</td>
        <td>Patients with result for microscopy</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>xAA3QjOSO6O</td>
        <td>DRS: Patients with Xpert MTB/RIF test (%)</td>
        <td>Xpert MTB/RIF: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for Xpert MTB/RIF out of all enrolled patients</td>
        <td>Patients with result for Xpert MTB/RIF</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>xdmAAbHAvnI</td>
        <td>DRS: LPA (Fq/2LI): <=10 days (%)</td>
        <td>LPA FQ/2LI: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA (Fq/2LI): <=10 days</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>xeDY5Q0nchY</td>
        <td>DRS: Culture (liquid media): <= 8 days (%)</td>
        <td>Culture LM: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 8 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>XOtwbmogZ0G</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=8 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=8 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>YGEum9Spb2s</td>
        <td>DRS: Patients with LPA (Fq/2LI) test (%)</td>
        <td>LPA FQ/2LI: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for LPA (Fq/2LI) out of all enrolled patients</td>
        <td>Patients with result for LPA (Fq/2LI)</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U, zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>zvUK5ny3PP1</td>
        <td>DRS: Culture (liquid media): <= 6 days (%)</td>
        <td>Culture LM: <=6d %)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 6 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-12-10</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
    </table>
    <h2 id="indicatorTypes">Indicator types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Factor</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Numerator only (number)</td>
        <td>1</td>
        <td>2021-01-12</td>
        <td>CqNPn5KzksS</td>
      </tr>
      <tr>
        <td>Percentage</td>
        <td>100</td>
        <td>2021-01-12</td>
        <td>e1jRVY5Mcq0</td>
      </tr>
    </table>
    <h2 id="programIndicatorGroups">Program Indicator Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td></td>
        <td>2020-12-10</td>
        <td>BXnv12U5Jy3</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>2020-12-10</td>
        <td>eri8M3D4v6s</td>
      </tr>
      <tr>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td></td>
        <td>2020-12-10</td>
        <td>FiNCOjpEv2I</td>
      </tr>
      <tr>
        <td>TB DRS: LPA RIF/INH</td>
        <td></td>
        <td>2020-12-10</td>
        <td>INbRAyCAOc4</td>
      </tr>
      <tr>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>2020-12-10</td>
        <td>k9lwqiHfz2b</td>
      </tr>
      <tr>
        <td>TB DRS: General</td>
        <td></td>
        <td>2020-12-10</td>
        <td>kmqHGVM4yxV</td>
      </tr>
      <tr>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>2020-12-10</td>
        <td>Mvn7IXcHFo0</td>
      </tr>
      <tr>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td></td>
        <td>2020-12-10</td>
        <td>nSgYWeRLjRp</td>
      </tr>
      <tr>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td></td>
        <td>2020-12-10</td>
        <td>oBqt1YD4p9j</td>
      </tr>
      <tr>
        <td>TB DRS: Microscopy</td>
        <td></td>
        <td>2020-12-10</td>
        <td>os6mytOHLuy</td>
      </tr>
      <tr>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td></td>
        <td>2020-12-10</td>
        <td>qPEvRoiKifn</td>
      </tr>
      <tr>
        <td>TB DRS: LPA FQ/2LI</td>
        <td></td>
        <td>2020-12-10</td>
        <td>QTlcFCQucx2</td>
      </tr>
    </table>
    <h3>Program Indicator Groups - Program Indicators</h3>
    <table>
      <tr>
        <th>Prog.Ind. UID</th>
        <th>Program Indicator Group</th>
        <th>Program Indicator</th>
        <th>Program Indicator UID</th>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - error</td>
        <td>CBzjrquAv7v</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - MTB not detected</td>
        <td>CWCpPgb2Y2r</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - Rif susceptible</td>
        <td>FEiqi1Eorpi</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Samples with Xpert MTB/RIF test result</td>
        <td>GCs58vwZsyf</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 6 days</td>
        <td>GGmlMcmL9hd</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Patients with Xpert MTB/RIF test result</td>
        <td>gnSeNJoGz9T</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - invalid</td>
        <td>GxBSEkFVnml</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 1 day</td>
        <td>in2GZS5lUD5</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Patients with error, invalid or no result for Xpert MTB/RIF</td>
        <td>JIZ6X5rD7OK</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: previously treated patients - Rif susceptible</td>
        <td>l8EQ2Kz8HMy</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - Rif resistant</td>
        <td>MJNbrK0Q80m</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - MTB not detected</td>
        <td>n31mFHYciKv</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - Rif indeterminate </td>
        <td>ncciXS4015B</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>nhi2Mi5MXVW</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: previously treated patients - Rif resistant</td>
        <td>NZul7fh2R8B</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Days from sample collection to date of Xpert MTB/RIF test</td>
        <td>O81jVgPRPJZ</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: new patients - Rif susceptible</td>
        <td>oOTpUbHvOxn</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 8 days</td>
        <td>OVysV7KptVe</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 10 days</td>
        <td>PdeRbkFtsIC</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - MTB, Rif indeterminate</td>
        <td>PDSh98oi6iG</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 5 days</td>
        <td>PvKoYkm2MCX</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: new patients - Rif indeterminate</td>
        <td>QvrvOrqNR9s</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: previously treated patients - Rif indeterminate</td>
        <td>S8lSfngoxu7</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 4 days</td>
        <td>TUguO2Ynxex</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Patients with interpretable Xpert MTB/RIF result</td>
        <td>VBrNPAkO9f1</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 3 days</td>
        <td>wHvQW41KS4c</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: new patients - Rif resistant</td>
        <td>Wq80cCyFEPj</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 9 days</td>
        <td>XqOkeUv3qn6</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 2 days</td>
        <td>Y9ecVYqq2wF</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 10+ days</td>
        <td>YLgDcklInvQ</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - no result</td>
        <td>ymjPwXARDTy</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - Rif resistant</td>
        <td>YrnVXhFyLCd</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - Rif susceptible</td>
        <td>YsIIurLgmPo</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 0 days</td>
        <td>yw1VqE1IjSk</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 7 days</td>
        <td>ZcZOvviknKv</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - MTB</td>
        <td>ZWyfaOl5ga7</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 1 day</td>
        <td>apEsA0h0WnR</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): new patients - NTM</td>
        <td>Bl0VfF5WWxe</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Days from sample collection to culture inoculation (liquid media)</td>
        <td>BwTuzAmHJY2</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): samples - MTB</td>
        <td>CgDIb7hgosn</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 9 days</td>
        <td>CtUD7DpDhUt</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 2 days</td>
        <td>cyOnOSTFAny</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): new patients - contaminated</td>
        <td>elHXs7QIHeg</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): patients - no growth</td>
        <td>emvCVU7nSyP</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): previously treated patients - MTB</td>
        <td>fq4aooEypot</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): patients - MTB</td>
        <td>hDf5GZVCh6b</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): samples - contaminated</td>
        <td>IV7jORMyeU0</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 5 days</td>
        <td>JH0XVP5TaUz</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): patients - NTM</td>
        <td>K0Ni8uEHLXY</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 10 days</td>
        <td>l0oQQUpCe0t</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 7 days</td>
        <td>LKgEs168uwz</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Samples with culture result(liquid media)</td>
        <td>lx4tkD2nyiv</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Patients with culture result (liquid media)</td>
        <td>Nwoz37ThBzC</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 3 days</td>
        <td>oE4qleMRIsc</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): samples - No growth</td>
        <td>pTDVLacJUAm</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Patients with culture inoculation date (liquid media)</td>
        <td>R1AWAmtWXNh</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): previously treated patients - no growth</td>
        <td>R3JPrdIcmjs</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 8 days</td>
        <td>RV2PlhWoox8</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): previously treated patients - contaminated</td>
        <td>sRaCkGSjiLt</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 6 days</td>
        <td>STuGYEEZ6o5</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): new patients - MTB</td>
        <td>t3qthExhQKL</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): patients - contaminated</td>
        <td>tIgRROcdrWC</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Samples with culture inoculation date (liquid media)</td>
        <td>vkspdWX0mzd</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 10+ days</td>
        <td>WJwWEO1wLoD</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): new patients - no growth</td>
        <td>wQisEHlG43c</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): previously treated patients - NTM</td>
        <td>WTblEFaKYPi</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): samples - NTM</td>
        <td>xFN86BRI9Z6</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 4 days</td>
        <td>YhbI5N1k81G</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Started culture (liquid media) tests</td>
        <td>yqSM0imyakl</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture (liquid media): 0 days</td>
        <td>ZM7UpCaGTY1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Rif resistant</td>
        <td>B5d9eKm8nRR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Pza resistant</td>
        <td>bbvugBgfLh0</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Dlm resistant</td>
        <td>belqKaig0KY</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Bdq contaminated/indeterminate</td>
        <td>bIHg1wvFPuX</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Amk contaminated</td>
        <td>bNdyJEAQZYH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CB) resistant</td>
        <td>BTG0cxe1miz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Lfx susceptible</td>
        <td>btPg6w5CrOs</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Emb susceptible</td>
        <td>BXayDcGzAQ5</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Inh (CB) resistant</td>
        <td>bxVekLXvoG6</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Dlm contaminated/indeterminate</td>
        <td>BZapNkxbmGh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Bdq contaminated</td>
        <td>bZiq1qPRaJM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Mfx (CB) susceptible</td>
        <td>c0Z8dcZwA9o</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Bdq resistant</td>
        <td>c9iFIVVuVMD</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Rif susceptible</td>
        <td>ccIrRzBwp6v</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Lzd contaminated/indeterminate</td>
        <td>CCqP9jWQpAH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Dlm resistant</td>
        <td>ckCldwmEQAl</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Mfx (CC) resistant</td>
        <td>CR1sEF01MvB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Amk resistant</td>
        <td>D4I7CFxNoxO</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Dlm susceptible</td>
        <td>d4K0yZYr5sf</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Dlm indeterminate</td>
        <td>d5VDVBgpNff</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Cfz contaminated</td>
        <td>D9GN83zB1tB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lfx indeterminate</td>
        <td>dCXS1Srtvzz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>dflTpUL9TOd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Inh (CC) resistant</td>
        <td>dh2mOeE0ieM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CC) susceptible</td>
        <td>dNbYkrR3zua</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lzd indeterminate</td>
        <td>doQ3NVOHYPH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CC) indeterminate</td>
        <td>DQ6TpILpwGm</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Pza susceptible</td>
        <td>DQiw76Xw1r4</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Bdq susceptible</td>
        <td>DTPsQiXmWTp</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>DXmiExPcVmJ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Mfx (CB) susceptible</td>
        <td>EAwBFKFUQcM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>elpk5h0qKHQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Lzd resistant</td>
        <td>eLzDUToUdCS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Lzd susceptible</td>
        <td>eohX6MLy3Pz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>epZELbYw3Dp</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Cfz resistant</td>
        <td>eZ7eIDHaYnM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Rif contaminated/indeterminate</td>
        <td>f7CKyOdJg01</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>F9aDDuk2zH7</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Inh (CB) resistant</td>
        <td>fcxcyNcQjzi</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CC) resistant</td>
        <td>FFBHhpROVU4</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Lzd contaminated/indeterminate</td>
        <td>ffqUD3Dxlfs</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Bdq susceptible</td>
        <td>FI5yCrIHoow</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Mfx (CC) susceptible</td>
        <td>fkSqKvpD6PA</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Amk resistant</td>
        <td>FNvQMKWecPh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Mfx (CC) resistant</td>
        <td>fOxfV0W9xb1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Inh (CB) susceptible</td>
        <td>G5dwFp4FeUI</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Cfz indeterminate</td>
        <td>GCHhMllhJcW</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>GGmrn3hUfJ1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Bdq resistant</td>
        <td>GTJ6K25PdVV</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Bdq indeterminate</td>
        <td>GYiY3HvV1Gy</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Dlm susceptible</td>
        <td>HdRTHmCBN5P</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Emb resistant</td>
        <td>hzrdf9T71sf</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CC) contaminated</td>
        <td>IAyxc41e5Yy</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CB) susceptible</td>
        <td>ijcH0gNXBx9</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Dlm resistant</td>
        <td>iKfKE7FhH9H</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Emb contaminated/indeterminate</td>
        <td>IMmK1P6fBva</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Emb contaminated</td>
        <td>IQbtsnDkfAq</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Bdq resistant</td>
        <td>J3ahtr4IVZn</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Pza resistant</td>
        <td>j3vGe1RQoJ3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Inh (CC) resistant</td>
        <td>JBxsvdKtcZI</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>jgpxNB7lUtw</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Lzd susceptible</td>
        <td>jihuemWnruh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Bdq susceptible</td>
        <td>jR50rSWqk0y</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CB) indeterminate</td>
        <td>jxvva3VcMqQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Bdq susceptible</td>
        <td>jZODNlINPVG</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>k6SBsqcv8Pw</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Cfz susceptible</td>
        <td>KbOntu5fKTV</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Pza contaminated/indeterminate</td>
        <td>KJe6BdMVXF3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CB) susceptible</td>
        <td>kn7mJ4XH40C</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Dlm susceptible</td>
        <td>kqrwj0JOJon</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CC) resistant</td>
        <td>l9WK4N0BUzx</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Lfx contaminated/indeterminate</td>
        <td>LAsyN6saoOd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Amk susceptible</td>
        <td>lvGGYtdHr0u</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Inh (CB) resistant</td>
        <td>lxX3YYtafD4</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Emb susceptible</td>
        <td>lyaTr1HCOH2</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CC) contaminated</td>
        <td>Me0P8Hywg5V</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lzd contaminated</td>
        <td>mQmX7NJ2iWr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>mU0CgKC2iWM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Pza susceptible</td>
        <td>MVspOs3ajZ8</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Inh (CC) resistant</td>
        <td>mZ25KRwF5Gy</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Rif indeterminate</td>
        <td>NadcebWfg1z</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Pza resistant</td>
        <td>nbNPEdgcXHR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Pza susceptible</td>
        <td>NJDQNJw2tGD</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Rif contaminated</td>
        <td>NQXMN2Td6gk</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>NXVfkJA7wg5</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Rif resistant</td>
        <td>NyzaBaIm5jS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Lfx susceptible</td>
        <td>nzj3O4baUVb</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CB) contaminated</td>
        <td>oaIfTkuTRsC</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Emb susceptible</td>
        <td>OlecwgQa57o</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>Olrvc8Jhijd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Cfz resistant</td>
        <td>ou4WNqCxMuu</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Bdq resistant</td>
        <td>Pc6xpNNg7LE</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Pza resistant</td>
        <td>pEpZ5PTUhJz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Pf9TOtsHmci</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Amk susceptible</td>
        <td>pfmjHNJ9x6R</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Amk susceptible</td>
        <td>phffikkxLSj</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Pi8ayoXTRKO</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Emb contaminated/indeterminate</td>
        <td>pkgY5FqeFjb</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Rif resistant</td>
        <td>PL2mZFknpzr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Lzd susceptible</td>
        <td>plvxpzzpVzo</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Pza indeterminate</td>
        <td>pqKUQg6IVks</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Cfz susceptible</td>
        <td>Pr1eRaFDtRG</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Cfz contaminated/indeterminate</td>
        <td>pvcjXzf476j</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Dlm resistant</td>
        <td>QEcUcHVFJho</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Rif susceptible</td>
        <td>QGjAcTm4uv2</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>QgZ5U6ocKbS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Pza contaminated/indeterminate</td>
        <td>qtJLBYBxHXE</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Cfz susceptible</td>
        <td>qUcV1AsyrjM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Patients with result for initial DST (liquid media)</td>
        <td>QXiAL03hJjW</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Lzd resistant</td>
        <td>rb5UEJsvHMs</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Emb indeterminate</td>
        <td>Rfz2wpp9wsI</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lzd susceptible</td>
        <td>RK2d2KxY2ln</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Bdq contaminated/indeterminate</td>
        <td>RLMAFAjdM1P</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Amk susceptible</td>
        <td>RsElKBSc1kB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>s4ojXwTRVMB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>sGLpHvkrJl0</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CB) resistant</td>
        <td>SGT2z6fisYd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Amk resistant</td>
        <td>smBK9aQLZVt</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Lfx resistant</td>
        <td>Sn1Y3lTblQ2</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>snExB8w3Gcm</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CB) contaminated</td>
        <td>su6weiXSIti</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Cfz susceptible</td>
        <td>svpfoQw6O39</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lfx contaminated</td>
        <td>tA5pYtchuWU</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Rif contaminated/indeterminate</td>
        <td>TeRX9Z45EzR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Emb resistant</td>
        <td>tlmQ6gisAGh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Dlm susceptible</td>
        <td>tois9I4EkY3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Lfx contaminated/indeterminate</td>
        <td>TORYgaK1YUF</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CB) indeterminate</td>
        <td>TOU4KSWSS1b</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Inh (CB) susceptible</td>
        <td>TTy1mozDhty</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CC) indeterminate</td>
        <td>tuy3A2HETxn</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Cfz resistant</td>
        <td>U0KbG9khPd5</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Cfz resistant</td>
        <td>U4YZsFclJlk</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Lzd resistant</td>
        <td>Uchb5CJcAOn</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CC) susceptible</td>
        <td>uM6AKPkeUwQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Samples with result for initial DST (liquid media)</td>
        <td>VCucFY6roOu</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Rif resistant</td>
        <td>VIgX0suMyw3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Mfx (CC) resistant</td>
        <td>vIvpAQtmuvr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lfx susceptible</td>
        <td>vjf4N8MCOV3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>vnRU4p2WNZH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>VvwaGW8ihTk</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Cfz contaminated/indeterminate</td>
        <td>W8slaPHit8G</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Emb resistant</td>
        <td>waI6zGdAC0L</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Lfx susceptible</td>
        <td>WAOO1PP801X</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Amk resistant</td>
        <td>Wb7mB8gZmxS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Amk indeterminate</td>
        <td>weuEp8gEYiA</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Emb susceptible</td>
        <td>Wh5ltuI2RdR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>WQ2ZlVJAL1d</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Mfx (CC) susceptible</td>
        <td>wSl9gzxcHBr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Lfx resistant</td>
        <td>xCg1UJXJ5Yc</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Inh (CC) susceptible</td>
        <td>XhNxSlnrws1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Mfx (CB) resistant</td>
        <td>xLut6liwpel</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Inh (CB) susceptible</td>
        <td>xmRYHCLPMTe</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Emb resistant</td>
        <td>xMXHVJ3TGdP</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Samples with inoculation date for initial DST (liquid media)</td>
        <td>xRHkullgtDD</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Patients with inoculation date for initial DST (liquid media)</td>
        <td>xrpPtTU0Zkc</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>xvIpBKT8S5R</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Pza contaminated</td>
        <td>yFUJCbawmOX</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Amk contaminated/indeterminate</td>
        <td>yi5Rehcel7M</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Dlm contaminated/indeterminate</td>
        <td>yLH2B6wc2uR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Inh (CB) resistant</td>
        <td>YOEdyHoPgPV</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Dlm contaminated</td>
        <td>YWOxEKIW5KB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Z4MdCZDK7cg</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>zB5B6o1lCXQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lzd resistant</td>
        <td>ZBWtuPoGXl6</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Amk contaminated/indeterminate</td>
        <td>ZCuphHumZGJ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Lfx resistant</td>
        <td>zD5P8ROnJci</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Rif susceptible</td>
        <td>zd6SD8bbBl3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Mfx (CB) resistant</td>
        <td>zgKh2FOhkSv</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Pza susceptible</td>
        <td>zIkLhe4NJc1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): new patients - Inh (CC) susceptible</td>
        <td>ZlyejogmAYG</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Rif susceptible</td>
        <td>zsxVBbRRx6D</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): samples - Lfx resistant</td>
        <td>ZUax8mb3Fht</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS: Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST (liquid media): patients - Inh (CC) susceptible</td>
        <td>ZY5fuX5XP7P</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - Inh indeterminate</td>
        <td>aRT2098p8t3</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>Samples with LPA (Rif/Inh) test result</td>
        <td>bE3YcdNxA3g</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>Patients with invalid result for LPA (Rif/Inh)</td>
        <td>bUSPnAIXlHM</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 2 days</td>
        <td>c2pvFmOjpxD</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - Rif susceptible</td>
        <td>CHMTFoEGDYW</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): previously treated patients - Inh indeterminate</td>
        <td>coaXGRyCvbg</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 9 days</td>
        <td>Dh7a17admqQ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 5 days</td>
        <td>dIx2cpCkvtj</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): new patients - Inh susceptible</td>
        <td>eqA9DYBlpOk</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>Processed LPA (Rif/Inh) samples</td>
        <td>henuXSapu7A</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): new patients - Rif susceptible</td>
        <td>hfYRwQKgaXt</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): previously treated patients - Rif indeterminate</td>
        <td>iK1pi7QPSVA</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 10+ days</td>
        <td>Ik9eYxKo6pQ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Inh resistant</td>
        <td>IQERFALbvVz</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Rif susceptible</td>
        <td>jnBglStivhT</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 1 day</td>
        <td>JXTklB80mSZ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>Days from sample collection to date of LPA (Rif/Inh) test</td>
        <td>LaSMRgk7CXT</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Inh susceptible</td>
        <td>lmfraes6AwW</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): previously treated patients - Inh susceptible</td>
        <td>lMxeHgDnnYU</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Inh indeterminate</td>
        <td>lNfI3Vav9ya</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): previously treated patients - Inh resistant</td>
        <td>m9N36IcoG1l</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>Patients with LPA (Rif/Inh) test result</td>
        <td>MJ93HUyctIa</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Rif indeterminate</td>
        <td>MmgqczjBy4x</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - Inh susceptible</td>
        <td>mXnpYGKvJOJ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 6 days</td>
        <td>NOwoUDobC82</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - Inh resistant</td>
        <td>pDr45R9KiqB</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - MTB</td>
        <td>pytuZVI0ukZ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 4 days</td>
        <td>pYWJoY1zICY</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): new patients - Rif resistant</td>
        <td>qAaqiEtHFgB</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - MTB</td>
        <td>qgRHOse57eS</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - MTB not detected</td>
        <td>r1f4FeokEfS</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 7 days</td>
        <td>s2MFQfmgwDR</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): new patients - Inh resistant</td>
        <td>sHgmMnlbGOd</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): new patients - Inh indeterminate</td>
        <td>SMQaa2FME9m</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - Rif resistant</td>
        <td>spav9vMokn2</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - Rif indeterminate</td>
        <td>sPBdvSLlJZY</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 10 days</td>
        <td>u7o1DWalCtg</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 3 days</td>
        <td>uNBJmNEtRBF</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Invalid</td>
        <td>VsbiIWP2J2F</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 8 days</td>
        <td>w3AZnT9pW4i</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): 0 days</td>
        <td>WcDv2gi6Pek</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): previously treated patients - Rif resistant</td>
        <td>XoQx6SJPRTV</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): previously treated patients - Rif susceptible</td>
        <td>y0yp20p5Pfr</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): patients - MTB not detected</td>
        <td>Ym7g5TyBlyV</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): samples - Rif resistant</td>
        <td>yNQDN6Y7RRv</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS: LPA RIF/INH</td>
        <td>LPA (Rif/Inh): new patients - Rif indeterminate</td>
        <td>yw5erBUqN3l</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - invalid</td>
        <td>bZYLsyngaPn</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 5 days</td>
        <td>Ccxbjmjx4DF</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 1 day</td>
        <td>CkH4cl9Ip25</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - no result</td>
        <td>cKlPzK4efeq</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Days from sample collection to date of Xpert MTB/RIF Ultra test</td>
        <td>DVMln9sMq2c</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - Rif indeterminate </td>
        <td>e33nRsNWbUl</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 0 days</td>
        <td>EbYQHywJJT7</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 9 days</td>
        <td>F790gdBXKhI</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Patients with Xpert MTB/RIF Ultra test result</td>
        <td>fpV3tkYm9rn</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: previously treated patients - Rif indeterminate</td>
        <td>gZCthbeejQI</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: new patients - Rif indeterminate</td>
        <td>Hbaf9zZw15P</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - MTB, Rif indeterminate</td>
        <td>hHniKx89xJK</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Patients with error, invalid or no result for Xpert MTB/RIF Ultra</td>
        <td>HTBvmWX11N2</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: new patients - RS</td>
        <td>IIRJBuBrOTJ</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 7 days</td>
        <td>jvvRyJ0orNz</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 4 days</td>
        <td>Kk7fwdFUnYo</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RS</td>
        <td>LRW1AeEUfTs</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 10 days</td>
        <td>LuoF6aB4C7j</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 6 days</td>
        <td>NkcFiEE3PpA</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Patients with interpretable Xpert MTB/RIF Ultra result</td>
        <td>nNXqEhYPq12</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 2 days</td>
        <td>NqXeQze1Q7b</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 8 days</td>
        <td>NVZjjPEo2QI</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 10+ days</td>
        <td>NyyAfu95mCo</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - MTB not detected</td>
        <td>Poolb0bKeix</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RR</td>
        <td>pzTm4eHbXdp</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - Rif resistant</td>
        <td>qQlS4yw9RaV</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - MTB not detected</td>
        <td>QSa605mN246</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Samples with Xpert MTB/RIF Ultra test result</td>
        <td>rkXSq0Sf1Lc</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - Rif susceptible</td>
        <td>SH0iOmEe0AR</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - MTB</td>
        <td>SJIgoySQSL9</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 3 days</td>
        <td>tqXqhNzjbLK</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - error</td>
        <td>v4o5oChYOcF</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: new patients - RR</td>
        <td>XBM747hHcXa</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Ydf2CAJR8of</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - RR</td>
        <td>ykeijqKZSTD</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - RS</td>
        <td>ZLg4V9cAXmw</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Missing data: age</td>
        <td>AIhr0Sqq0Nl</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Patients with negative HIV status</td>
        <td>dOXNXZWb32d</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Patients with positive HIV status</td>
        <td>FGsZGC28X8R</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Enrolled patients</td>
        <td>gTPmPsKLwdR</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Samples rejected on arrival</td>
        <td>hZP8QqW2Hgr</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Missing data: TB treatment history</td>
        <td>Ir4RiYE3Nke</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Previously treated patients (cumulative)</td>
        <td>J9VPfek4eYG</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Patients with unknown HIV status</td>
        <td>jhm47tAnQV8</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Patients with unknown treatment history (cumulative)</td>
        <td>nDbv7VbejeH</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Sample collection and arrival events</td>
        <td>P9K7xj7hHgZ</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>New patients (cumulative)</td>
        <td>PK5i0N7y7Ja</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Enrolled patients (cumulative)</td>
        <td>qd9PbhmNYnR</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Missing data: patients with no registered age, gender, HIV test result, or TB treatment history</td>
        <td>qGLJdB5Qg2I</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Missing data: sex</td>
        <td>vXwdB7fhkW5</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Missing data: HIV test result</td>
        <td>XOE7Mzfedq4</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Sample processing events, total</td>
        <td>Z0pHyvWCUNG</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Days from all lab sample collection to arrival, sum</td>
        <td>ZeEskzvKb72</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS: General</td>
        <td>Patients with 1+ test started, cumulative</td>
        <td>zIR9P1JOf0P</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Emb resistant</td>
        <td>AAaf1N6q9Kc</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lzd contaminated</td>
        <td>ADNg2qsAAcK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) contaminated</td>
        <td>Ae5XHffdlOT</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Emb susceptible</td>
        <td>ahmEPvvLdlB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Cfz susceptible</td>
        <td>AhU8qnVRvyB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CC) indeterminate</td>
        <td>Aiy6br5cVtS</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CC) contaminated</td>
        <td>aLoApEYPHN8</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Rif resistant</td>
        <td>aQYGSuGN2yc</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Pza indeterminate</td>
        <td>ASk2lczUEoC</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CC) resistant</td>
        <td>ATlmsxFz21i</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lfx susceptible</td>
        <td>AxJiEHXPR4O</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Samples with inoculation date for subsequent DST (liquid media)</td>
        <td>BAx8oO7z3BL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Cfz resistant</td>
        <td>Bd06WGYcdgI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Amk contaminated/indeterminate</td>
        <td>bg6znd2CWYH</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CB) susceptible</td>
        <td>BifclMTmRC8</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Bdq contaminated/indeterminate</td>
        <td>bPWnbBZ4zc1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Amk contaminated/indeterminate</td>
        <td>bSe8cLu9vaB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CB) susceptible</td>
        <td>bxokCBL7Fa6</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Dlm resistant</td>
        <td>bYO87TQdvrx</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Rif contaminated/indeterminate</td>
        <td>cD6yomdezwR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Amk contaminated</td>
        <td>D1txAWeoz5n</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Bdq contaminated</td>
        <td>D2XDPZzaKjH</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) resistant</td>
        <td>D74MdAoARVD</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>dBGD2K40yW9</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lfx resistant</td>
        <td>djuou80be4X</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) resistant</td>
        <td>dkKIGNb3BPe</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Cfz indeterminate</td>
        <td>dvBHjZYq37O</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) indeterminate</td>
        <td>eCIxImB6qsO</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Rif contaminated</td>
        <td>ecuAlCQqOV0</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CC) susceptible</td>
        <td>eId8rqyJur9</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Mfx (CC) susceptible</td>
        <td>enpdoV1nHk0</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CC) susceptible</td>
        <td>EPdS0YCH90B</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Bdq susceptible</td>
        <td>EpspNpkl2xy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Bdq susceptible</td>
        <td>erA6BTudlqi</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Rif resistant</td>
        <td>eSVL9Sr7zpp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>F7BmHiwjier</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Lfx susceptible</td>
        <td>Fgoss6VRywe</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Rif susceptible</td>
        <td>fmtrEnAYaRK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Bdq resistant</td>
        <td>FNYTBE2wcLm</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Bdq contaminated/indeterminate</td>
        <td>frJyeMsmKYo</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Dlm resistant</td>
        <td>fUdI3Clnew1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Rif resistant</td>
        <td>fYERuvsUVki</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Mfx (CC) resistant</td>
        <td>fyw7CVbbp5r</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Cfz contaminated</td>
        <td>g9Sp1K9EgQZ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Amk resistant</td>
        <td>gCQxWn0enit</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lzd resistant</td>
        <td>GGor2BR1Yq1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>GPMaGbyEjG4</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CC) resistant</td>
        <td>htk2PaBn9n6</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Cfz susceptible</td>
        <td>HTYSiumflrW</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) susceptible</td>
        <td>HuH9Wbdba4q</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Pza susceptible</td>
        <td>hvqTrO9xqPC</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Emb resistant</td>
        <td>HXeaRn0AaLL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Bdq susceptible</td>
        <td>hZn5S7DWqzF</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CC) contaminated</td>
        <td>HZQG39GLjUK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Patients with result for subsequent DST (liquid media)</td>
        <td>I4aotZJ6il4</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>IOIQueZoXmk</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Inh (CB) resistant</td>
        <td>IpbcHr0Sl5m</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Rif susceptible</td>
        <td>IZmFYcpgXBt</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CB) contaminated</td>
        <td>j3G2AoTFI9u</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Lfx susceptible</td>
        <td>Je3u7mBTONj</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>jFmQ13LrhXY</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Inh (CB) susceptible</td>
        <td>jIlJF6otQaS</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Lfx resistant</td>
        <td>JuE3ZTRER0P</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Mfx (CB) susceptible</td>
        <td>JxdzwSOjm8A</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>k1YfISnKxoF</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>KBbgHraFGGs</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Cfz contaminated/indeterminate</td>
        <td>kBPPbfaHHLL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Pza susceptible</td>
        <td>kDH4tyBM6FG</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Lfx resistant</td>
        <td>kghHkgNoh1r</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Cfz susceptible</td>
        <td>KXylN7DLOAI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Dlm contaminated/indeterminate</td>
        <td>l2og8x5vEYa</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Emb resistant</td>
        <td>l9hGqsUThxS</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Lzd resistant</td>
        <td>Lc5HjAi5vyL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lfx contaminated</td>
        <td>lopaZTLHpyB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>LX5Y5X1ijjJ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Emb contaminated/indeterminate</td>
        <td>maRlEPKLrit</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Lfx susceptible</td>
        <td>mI5CLdPFdly</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Emb contaminated/indeterminate</td>
        <td>MkaxSDtr5lN</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Bdq resistant</td>
        <td>MkpDzk0VVOn</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Ml5TUmEp9co</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Pza contaminated</td>
        <td>MnhS9zbQTuz</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Rif indeterminate</td>
        <td>MNQ2cVPKts0</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Mfx (CB) resistant</td>
        <td>MRE4oCbTgdp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Lzd resistant</td>
        <td>mS4y1f2N2qr</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Cfz contaminated/indeterminate</td>
        <td>mUmuZc4YfoA</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Amk susceptible</td>
        <td>MwMGpZDEsVq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Amk resistant</td>
        <td>mWVJ6NngcOg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CC) resistant</td>
        <td>N8T2Ka08phP</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Lzd susceptible</td>
        <td>NeWHeUHbtLY</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) indeterminate</td>
        <td>nl8UjHDuOJp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Emb susceptible</td>
        <td>ntgkubZBIVR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Mfx (CC) susceptible</td>
        <td>o2vVY3Tou4b</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Amk resistant</td>
        <td>o5VfgMGlYLo</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CB) resistant</td>
        <td>O6It7XLWzij</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Dlm resistant</td>
        <td>OebNebICI0h</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Bdq susceptible</td>
        <td>oftX0vZAM9r</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Emb contaminated</td>
        <td>onZWy5SCjZ5</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Inh (CC) resistant</td>
        <td>oqv395bpDv1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Lzd contaminated/indeterminate</td>
        <td>PgBqxJAbupy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Dlm susceptible</td>
        <td>phorDunwGXo</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>PJZO3meSj8D</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Patients with inoculation date for subsequent DST (liquid media)</td>
        <td>PldVWpl9xeq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Pza contaminated/indeterminate</td>
        <td>pLUGwLLLQMF</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Lfx contaminated/indeterminate</td>
        <td>pMGwv0JLXEt</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Lzd susceptible</td>
        <td>PtpSwoTHmcG</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Pza contaminated/indeterminate</td>
        <td>PUMHNoEubMR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Inh (CB) resistant</td>
        <td>pXysNcjM76l</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>QjC1EgtnJAD</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Mfx (CC) resistant</td>
        <td>QmGU5r5l9Ab</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>qoEyqH4wwwm</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>QxlIXjaP09h</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Cfz susceptible</td>
        <td>REb86WxR7NW</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Dlm - contaminated</td>
        <td>rWJyTJVZl5s</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>RZPj0Wrcnxn</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Pza susceptible</td>
        <td>S33osVSK7bu</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Mfx (CB) susceptible</td>
        <td>SftNGftUtHI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>sg927BRQATg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Dlm indeterminate</td>
        <td>sJxBmDVVRFI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Inh (CB) susceptible</td>
        <td>SNTw9Vpw8qb</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>ss7bHfxhLrq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lzd susceptible</td>
        <td>stEHUWnoMq5</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Lfx contaminated/indeterminate</td>
        <td>Tcq1ZiYT7Yq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Dlm susceptible</td>
        <td>Tegm0xLM4rn</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Dlm susceptible</td>
        <td>titK1r1BOlH</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Pza resistant</td>
        <td>tJa81zjWUkG</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Amk resistant</td>
        <td>TXzYZ5NUzGE</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lfx indeterminate</td>
        <td>U5WRXT9rtyA</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Amk susceptible</td>
        <td>UBxYSphJOOI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Emb susceptible</td>
        <td>UnMZYDDbWef</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>uSojnfuocie</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>uvQVPvXOXSK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Uy0fdbBkqgV</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Cfz resistant</td>
        <td>V0x2p9VH7D8</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Pza susceptible</td>
        <td>V4GWEENoVdy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Amk susceptible</td>
        <td>veREteT6hlg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Pza resistant</td>
        <td>VkB0mC22R4E</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Dlm susceptible</td>
        <td>VPiRrxWIeAu</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Amk susceptible</td>
        <td>VrkQDJXIDDP</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CB) resistant</td>
        <td>vSMBlVfDmft</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Mfx (CB) resistant</td>
        <td>vYwZAP4yu5U</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Amk indeterminate</td>
        <td>WdtDDovKwwJ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Lzd susceptible</td>
        <td>wfYOu1lx6Qa</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Lfx resistant</td>
        <td>WiIoqdGvg1M</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Emb resistant</td>
        <td>wqHfPAv7vWy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Samples with result for subsequent DST (liquid media)</td>
        <td>wsLnXY7LDlA</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Lzd indeterminate</td>
        <td>WzSjzok3JLp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Rif susceptible</td>
        <td>x0BuFyVqp5G</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Inh (CC) resistant</td>
        <td>x2pAZdpQDUD</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Rif resistant</td>
        <td>xEEDBnzahPe</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>XGMW0GtBuNg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Bdq resistant</td>
        <td>xMEWouqClFf</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Rif susceptible</td>
        <td>xPHG0IoL3gy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Bdq resistant</td>
        <td>XqdaRwwmYFx</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Mfx (CB) susceptible</td>
        <td>xQzcgF6mGZd</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Rif contaminated/indeterminate</td>
        <td>xRxkG7NLgxN</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Dlm resistant</td>
        <td>XtISOg6IH58</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Inh (CC) susceptible</td>
        <td>Xvi6xboD8rO</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Lzd resistant</td>
        <td>xWTCtUoYESr</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Bdq indeterminate</td>
        <td>Y3IoUjmY7AN</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Pza resistant</td>
        <td>yEIeCX7IwVi</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>YgU4PmqMkzP</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Pza resistant</td>
        <td>YhxAkBpMTmd</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Dlm contaminated/indeterminate</td>
        <td>YRkeyxS2xir</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Mfx (CB) resistant</td>
        <td>YTfcpgyo1OW</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Lzd contaminated/indeterminate</td>
        <td>zBFap1a5xsV</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Emb indeterminate</td>
        <td>zdHSqAwHF7w</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>zdJzjF1oAzR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>ZEWoHGVMJHT</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): previously treated patients - Cfz resistant</td>
        <td>ZONe9AdoHYE</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Cfz resistant</td>
        <td>zp3uN4hpm22</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): patients - Inh (CC) susceptible</td>
        <td>zq6n2KdR9yQ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): samples - Inh (CB) indeterminate</td>
        <td>ZQk5pK5QPhu</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST (liquid media): new patients - Emb susceptible</td>
        <td>Zvwpbgxmp94</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Inh (CC) susceptible</td>
        <td>A4tOZ6DtOz6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Dlm resistant</td>
        <td>A9gJNpnubW6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>abdl4RkyzwL</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Bdq resistant</td>
        <td>adnY7HmKOSi</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Rif contaminated</td>
        <td>AnE9y3CTG55</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Dlm susceptible</td>
        <td>AoNRpuKHFIA</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CC) resistant</td>
        <td>ap5DhakUaof</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Mfx (CB) susceptible</td>
        <td>APrBMG15JPD</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Inh (CC) susceptible</td>
        <td>aqiSmfOO1Y8</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Cfz contaminated/indeterminate</td>
        <td>AUZxWKFQOIK</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>aW1dvUXmJzF</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Lzd resistant</td>
        <td>b5ipTVVUxgZ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CB) resistant</td>
        <td>B9veWJCIhm3</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Lzd susceptible</td>
        <td>BDa3bpSHQfR</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Lzd susceptible</td>
        <td>booODOHpIFb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Mfx (CB) susceptible</td>
        <td>bPfqNC7BOgJ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Amk contaminated/indeterminate</td>
        <td>BQ8ftQEraa4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CC) indeterminate</td>
        <td>bYFSgzsh4y2</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>BzfUTfps4gS</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Mfx (CB) resistant</td>
        <td>c7A83DBkpom</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Pza resistant</td>
        <td>cVY0RGqdI69</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Lzd contaminated/indeterminate</td>
        <td>cYQnmEGAuSH</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Rif susceptible</td>
        <td>dEk1wwgfnnD</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Dlm indeterminate</td>
        <td>dlC6LusCW5i</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Lzd susceptible</td>
        <td>dZ0rHB1EkHD</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Pza susceptible</td>
        <td>e9RjhGOu3Fz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Inh (CB) susceptible</td>
        <td>EELFTduH3M9</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Rif contaminated/indeterminate</td>
        <td>EEQ0GjzL3Xl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lfx indeterminate</td>
        <td>EfhWg7dKNsv</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Pza contaminated/indeterminate</td>
        <td>eHQizAJZuXK</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Rif resistant</td>
        <td>EICJmQVZa2a</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Patients with inoculation date for subsequent DST (solid media)</td>
        <td>EtO96EwY8GU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Pza resistant</td>
        <td>EvcKhBk9htx</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Dlm contaminated</td>
        <td>f8OaQON8Jug</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Dlm susceptible</td>
        <td>FMvbZg2LHhV</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Amk susceptible</td>
        <td>FNMPwjQNg4U</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Amk resistant</td>
        <td>FRGmGDJHpkM</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Cfz susceptible</td>
        <td>fxAlrUlm1GU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Rif susceptible</td>
        <td>g3oYfS8eQAq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Amk susceptible</td>
        <td>Gc2umtqZ1lY</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CB) susceptible</td>
        <td>GCpLmFiy28k</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Inh (CC) resistant</td>
        <td>GDUhrJPqy6w</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Bdq resistant</td>
        <td>gHTL2er7krj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Bdq indeterminate</td>
        <td>GLSkgEz1sfT</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Emb resistant</td>
        <td>gnJSzbNuMYw</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>GStm6UzOQdq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Mfx (CC) susceptible</td>
        <td>gvvZUXARGg0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Emb contaminated</td>
        <td>H0uraA1hI5d</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Amk indeterminate</td>
        <td>H185R6OCh9r</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Emb resistant</td>
        <td>h8kBZ3K0T2d</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>hcnG8PMuECt</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Cfz resistant</td>
        <td>hhcHMksqM3z</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CC) susceptible</td>
        <td>HkdrJSar6If</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lzd resistant</td>
        <td>HLrMymgpoqI</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>hLYwIBpo278</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lzd indeterminate</td>
        <td>HqO6R44DBqY</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lfx resistant</td>
        <td>HxB1sbrTKkv</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CB) resistant</td>
        <td>IPCjhHOQMWl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>IWSzulLtcRU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Pza contaminated</td>
        <td>j1utfSEDGOO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Cfz resistant</td>
        <td>J230BlAaQlK</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Lzd resistant</td>
        <td>J3wjJEF8aq0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Pza contaminated/indeterminate</td>
        <td>j89ph75ZaX8</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Emb susceptible</td>
        <td>JCJ6UNRWuJi</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>jcm5Bo8ve5A</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>JDINMJYfpt8</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CB) indeterminate</td>
        <td>jKYooU49mG4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CC) resistant</td>
        <td>JqBF765vRaI</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>JsAylXp8loj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Rif susceptible</td>
        <td>jyLq8xUOZne</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>K3RhiJId07S</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CB) resistant</td>
        <td>kGnLALoufUa</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Pza susceptible</td>
        <td>Kl1ONdPznGh</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>kLiVVkPNcEG</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lzd susceptible</td>
        <td>KNZKCM67NGi</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Rif resistant</td>
        <td>KW0n6JUuqVn</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Inh (CB) resistant</td>
        <td>lfHTvcRzmXT</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Bdq susceptible</td>
        <td>LhJkKbrTOOS</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CC) resistant</td>
        <td>LOLIwqxd2wm</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Amk contaminated</td>
        <td>LROUBwdzaVw</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Mfx (CC) resistant</td>
        <td>M2IinLZavHj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Lzd contaminated/indeterminate</td>
        <td>m5nShXZwfvl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>M74bikagdCn</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>M7Z1bApwb6J</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Bdq contaminated/indeterminate</td>
        <td>MAfGE8h9nR5</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>MGHQjfJcv8i</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Amk susceptible</td>
        <td>MlKowimCL4m</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Pza indeterminate</td>
        <td>mqf825wSgBW</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Bdq resistant</td>
        <td>MQz9ho7oTxM</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Pza susceptible</td>
        <td>MX0ZgqJRARO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>nAG3hPJLNRZ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Inh (CC) resistant</td>
        <td>nFdMqXBCHgs</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Lfx susceptible</td>
        <td>NfZJb3KTVAO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Samples with result for subsequent DST (solid media)</td>
        <td>NiZZuTnJcqI</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Rif resistant</td>
        <td>NLogSNyPLrG</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>nNgTAOUHVVf</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Bdq contaminated/indeterminate</td>
        <td>nvL2apj8ESp</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lfx susceptible</td>
        <td>nVXSEczhAvM</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Bdq susceptible</td>
        <td>NYBeJuBeqD6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Dlm susceptible</td>
        <td>NzGW6C58GkF</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Pza resistant</td>
        <td>O9hhMPIUYZO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Dlm resistant</td>
        <td>oeZepiNfmKj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lzd contaminated</td>
        <td>OLR2G7P2KLX</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Cfz contaminated/indeterminate</td>
        <td>OQeEjNs3Ho9</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CC) contaminated</td>
        <td>oUz32KzStH0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Rif indeterminate</td>
        <td>oz7eO5DDvNa</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>pDF9ROzD1cb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Dlm susceptible</td>
        <td>PPl4KMHIJT3</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CC) resistant</td>
        <td>PpTb1ERfg3Q</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Amk resistant</td>
        <td>pwDBHevJNrL</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Emb susceptible</td>
        <td>q76HsI6ClCd</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Cfz susceptible</td>
        <td>q9KghOGpcdq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Cfz indeterminate</td>
        <td>QLdY9WHtJDz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Cfz resistant</td>
        <td>qxFMe08GfWQ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Dlm contaminated/indeterminate</td>
        <td>RBicbarJPl4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Lfx contaminated/indeterminate</td>
        <td>rcICF38L7mE</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Rif contaminated/indeterminate</td>
        <td>RCuCuQq8EVw</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CC) susceptible</td>
        <td>rMKJMrIdwxU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>rocQB4VEATy</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Amk resistant</td>
        <td>rShSocJ14lJ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Amk susceptible</td>
        <td>ruLVyeypubb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Lfx resistant</td>
        <td>s8ca1kbNVCy</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Bdq susceptible</td>
        <td>SARbVYz3ovb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CB) susceptible</td>
        <td>SbfRyAQCsp4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CC) contaminated</td>
        <td>SkrMaOzuaOx</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>srZG8NDtJ3h</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Bdq susceptible</td>
        <td>SwmPVQY2FJ3</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Amk resistant</td>
        <td>sYiVV33usyC</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Inh (CB) resistant</td>
        <td>SzYSBtaPujQ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Mfx (CC) susceptible</td>
        <td>T1D14wQc6Pe</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CB) contaminated</td>
        <td>TAJrVlUWA15</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Mfx (CB) resistant</td>
        <td>TePspFbeIA5</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Inh (CB) susceptible</td>
        <td>TkKU87tvUfC</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Cfz resistant</td>
        <td>U61I4srgNTl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CB) contaminated</td>
        <td>Ugg2hcmNkv1</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Dlm resistant</td>
        <td>uHVdQW61TK6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Emb contaminated/indeterminate</td>
        <td>uOiAgPqfSca</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Inh (CC) indeterminate</td>
        <td>Ur2unOu0ABe</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Emb susceptible</td>
        <td>UuJnpUZEIMt</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Patients with result for subsequent DST (solid media)</td>
        <td>uXexeo22Whu</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Lfx resistant</td>
        <td>UzmVwVcCDsP</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Dlm resistant</td>
        <td>V36JWd4DEwS</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>V8h0smTVb4r</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Lfx susceptible</td>
        <td>vJljhgD71Ny</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>VTQkjI3hSkm</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Pza resistant</td>
        <td>vWmY0yvNVfc</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Bdq contaminated</td>
        <td>VxJFIFNjhb4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Emb indeterminate</td>
        <td>W0OTsurXcBq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Mfx (CC) resistant</td>
        <td>W3jcBVNTObT</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Lfx contaminated</td>
        <td>w4Oc9nvJwmg</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Lfx contaminated/indeterminate</td>
        <td>WaQFRJ0X8xv</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Lzd resistant</td>
        <td>WjpPcWta7Gz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Samples with inoculation date for subsequent DST (solid media)</td>
        <td>wxKzVyo48o2</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Lfx resistant</td>
        <td>Wyv5aIEB1Gl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Dlm contaminated/indeterminate</td>
        <td>XdE897XapaW</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CC) susceptible</td>
        <td>xDI1TZpYM8S</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>XjFQ4NnAU7N</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Bdq resistant</td>
        <td>xLxjI8jmbas</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Cfz susceptible</td>
        <td>XRPgDH3Z3Fq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Inh (CB) susceptible</td>
        <td>YADgwHM5hbx</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CB) indeterminate</td>
        <td>yb8FgBYSj32</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Pza susceptible</td>
        <td>YCmTdM8P0s0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Mfx (CB) resistant</td>
        <td>YGAd7tN7N6e</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Cfz susceptible</td>
        <td>yIGqQACwPj5</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Rif resistant</td>
        <td>ylIA0CiL0uz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Amk contaminated/indeterminate</td>
        <td>ymG3jrd4Aba</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Emb susceptible</td>
        <td>YOjNYg1yUIh</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): previously treated patients - Emb resistant</td>
        <td>YqnFKRIK0VQ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): samples - Cfz contaminated</td>
        <td>YVm2y4ROVLo</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Emb contaminated/indeterminate</td>
        <td>YytrJOimdR2</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Lfx susceptible</td>
        <td>ZiA5jXTrmaY</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): patients - Emb resistant</td>
        <td>ZiVkPofyVfW</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST (solid media): new patients - Rif susceptible</td>
        <td>ZZoPud9wM6I</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): previously treated patients - contaminated</td>
        <td>aLyPlwg2jot</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): patients - contaminated</td>
        <td>BRoeNFPYHhT</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Started culture (solid media) tests</td>
        <td>bXTRrrObrqh</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Patients with culture inoculation date (solid media)</td>
        <td>c5whDMhSvRT</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Days from sample collection to culture inoculation (solid media)</td>
        <td>dGKwqxO3eKj</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 0 days</td>
        <td>EqAuIAkWriW</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Samples with culture inoculation date (solid media)</td>
        <td>eSmBD2Ihlyp</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): patients - MTB</td>
        <td>EU2sU2GqFEJ</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 7 days</td>
        <td>fFuaaoUS5fC</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 8 days</td>
        <td>FrIJvXbBKJ9</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 10+ days</td>
        <td>h3ZPbULlyUP</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Patients with culture result (solid media)</td>
        <td>HRT8j3uimEB</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): new patients - contaminated</td>
        <td>HT5df1hXx46</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 4 days</td>
        <td>hyoQv9Zr56m</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 6 days</td>
        <td>JCsNAS3pqZZ</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): patients - no growth</td>
        <td>JxcokEnr3xj</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 5 days</td>
        <td>kgPgADkI9De</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): previously treated patients - NTM</td>
        <td>l3xgbTao9qK</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 10 days</td>
        <td>Lje8dx9lWYQ</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Samples with culture result (solid media)</td>
        <td>lZ1tOjYHm2t</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 2 days</td>
        <td>mNIzirHVwvO</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): new patients - NTM</td>
        <td>MuqppHWlVvW</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): samples - NTM</td>
        <td>NuvmZiORoOd</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): samples - no growth</td>
        <td>oXa3DtiSYe0</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 1 day</td>
        <td>Rlbs4UiZydq</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): samples - contaminated</td>
        <td>RX5YwuS9RbM</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): patients - NTM</td>
        <td>snFxSirfErx</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): previously treated patients - MTB</td>
        <td>UrPUE2i8GAU</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 9 days</td>
        <td>utTgYdaTGrb</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): previously treated patients - no growth</td>
        <td>vlhg0jTKrsH</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): 3 days</td>
        <td>x9RZw5fD8fa</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): new patients - MTB</td>
        <td>xDByzKWh8B5</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): new patients - no growth</td>
        <td>XZiRvxDYZTg</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS: Culture in solid media (e.g. LJ)</td>
        <td>Culture (solid media): samples - MTB</td>
        <td>ZPXThwLCqnd</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Microscopy: previously treated patients - negative</td>
        <td>by5T3Wqf1Yx</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Microscopy: patients - positive</td>
        <td>G3yAX5ER7E3</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Microscopy: patients - negative</td>
        <td>HDPycwY4BhS</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Microscopy: new patients - positive</td>
        <td>HxgMmSOXRO9</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Samples with microscopy result</td>
        <td>rV8cfZVEqZK</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Microscopy: previously treated patients - positive</td>
        <td>RZEpC4Mmmsp</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Microscopy: new patients - negative</td>
        <td>YkUfHLCaQMC</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS: Microscopy</td>
        <td>Patients with microscopy result</td>
        <td>ZxM3pubMWLI</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Pza contaminated/indeterminate</td>
        <td>A6hImpJUCnp</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Mfx (CB) susceptible</td>
        <td>aEQVSqDQ91m</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CC) indeterminate</td>
        <td>AJ626bsdSe7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lfx contaminated</td>
        <td>ATMaMtQexcy</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CC) resistant</td>
        <td>AZuK40TqYeX</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Bdq contaminated/indeterminate</td>
        <td>BaMzkG7QFr3</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Emb resistant</td>
        <td>BBfev9dl9RM</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Mfx (CC) susceptible</td>
        <td>bibTiiTflBW</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Inh (CC) contaminated/indeterminate</td>
        <td>bLhO4Hh4j7O</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Amk resistant</td>
        <td>C2bwEfFwiBX</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Cfz susceptible</td>
        <td>c2PFlkVS4Zz</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Samples with inoculation date for initial DST (solid media)</td>
        <td>cJ9JXbZ0itN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Bdq contaminated</td>
        <td>cKpRfFeeqeK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Inh (CC) contaminated/indeterminate</td>
        <td>cOFUIqdayX1</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Emb contaminated/indeterminate</td>
        <td>cyJiS3rV7KV</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Cfz contaminated/indeterminate</td>
        <td>d2CN7zcwQq2</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Emb resistant</td>
        <td>d5iwto9PKqu</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Dlm resistant</td>
        <td>DesYHcLzFQQ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Inh (CC) susceptible</td>
        <td>dhS0qZCbUgr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Mfx (CB) contaminated/indeterminate</td>
        <td>DmK5rIflVja</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Lfx resistant</td>
        <td>dU8neclU24g</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Bdq susceptible</td>
        <td>dZZHJma1Kge</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Amk contaminated/indeterminate</td>
        <td>e0cJcbD47aQ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Rif susceptible</td>
        <td>e0gi9i7AftL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CB) susceptible</td>
        <td>E4zdpgEfh2D</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Lzd susceptible</td>
        <td>EGNwXUQWIKb</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Mfx (CB) resistant</td>
        <td>EhnADaDfnTB</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Lzd contaminated/indeterminate</td>
        <td>ePD0F8obRs8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Emb contaminated/indeterminate</td>
        <td>EtQJDbQppQI</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Pza resistant</td>
        <td>EUoIM0Gbjcq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Dlm resistant</td>
        <td>Ew0ZLYwvP0N</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Lfx resistant</td>
        <td>exwSqqUbu1i</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Amk indeterminate</td>
        <td>f5iJzjQNKc0</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Cfz resistant</td>
        <td>F8DmuEmfrYR</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Inh (CB) resistant</td>
        <td>FaO1ALEZbWD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Inh (CB) resistant</td>
        <td>fEZeFn8VTpk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Mfx (CC) contaminated/indeterminate</td>
        <td>FHU4eNjE5FD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Pza contaminated/indeterminate</td>
        <td>fIbds4Nfw1i</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CB) contaminated</td>
        <td>fITjLSEGjiq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Inh (CB) susceptible</td>
        <td>fkva9qgQzv1</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Lzd resistant</td>
        <td>fpXisLGhJfK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Amk resistant</td>
        <td>FzvIunVITV7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Cfz susceptible</td>
        <td>g8HOqnoSNJ9</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CB) contaminated</td>
        <td>glxNdJrAU4x</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lfx indeterminate</td>
        <td>gpcKhKQvKWR</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Pza indeterminate</td>
        <td>GUWNoDKwVeB</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Inh (CB) susceptible</td>
        <td>gwJnPsEhIvZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Emb contaminated/indeterminate</td>
        <td>gYdixn3rVl7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Mfx (CC) susceptible</td>
        <td>H3TqQeEo9MY</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Emb susceptible</td>
        <td>h4iCiDYGYwR</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Bdq resistant</td>
        <td>H8hAkVy6cc6</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Inh (CB) contaminated/indeterminate</td>
        <td>H9pBIDDmvRF</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Bdq susceptible</td>
        <td>Hb3NQ6s8obq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Amk contaminated/indeterminate</td>
        <td>HJ7yxI5uok5</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Amk susceptible</td>
        <td>hL4mwtjHRFZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lfx resistant</td>
        <td>HNLM0vPGidN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CC) contaminated</td>
        <td>i14osWxv3vs</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CB) indeterminate</td>
        <td>I64mYichCJ7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Emb susceptible</td>
        <td>i7BNLtz6jEk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Mfx (CB) contaminated/indeterminate</td>
        <td>ibm1blKTuPA</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Inh (CC) resistant</td>
        <td>ic0VoKRJi8V</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Mfx (CB) susceptible</td>
        <td>iNHCjhXr71r</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Lfx susceptible</td>
        <td>JBEHF7dwqbE</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Rif resistant</td>
        <td>jEFlq5DrhmK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Mfx (CC) resistant</td>
        <td>jGOj77I7ivr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Inh (CB) resistant</td>
        <td>jmASgzacESm</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Bdq resistant</td>
        <td>JMJzISQzRK2</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Inh (CB) contaminated/indeterminate</td>
        <td>JzIoXaU5gc7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lzd resistant</td>
        <td>K0pjdy1M4eD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Bdq indeterminate</td>
        <td>k1b1mUVqTvK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Emb resistant</td>
        <td>K59BIxT2i6P</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Dlm contaminated/indeterminate</td>
        <td>KDMYnCVSgTk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Inh (CB) susceptible</td>
        <td>KeCuEyh87Ga</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Emb resistant</td>
        <td>KiRnQZDm9hc</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CB) indeterminate</td>
        <td>kRJlr5MFMSh</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Inh (CB) contaminated/indeterminate</td>
        <td>KVMYPcUq22W</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Cfz contaminated/indeterminate</td>
        <td>L26pzli6SQ3</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CC) contaminated</td>
        <td>L2Sv0Lmeke5</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Amk contaminated</td>
        <td>l76u70Y8RNm</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Rif resistant</td>
        <td>lAFXVyIOz59</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lzd contaminated</td>
        <td>lQnrHEMWAee</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Lzd susceptible</td>
        <td>ltuLoYVJ4yN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CC) susceptible</td>
        <td>luMcMB4YiL9</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Bdq susceptible</td>
        <td>lWEOXjxUbwf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Lfx resistant</td>
        <td>lwr3AChFg30</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CC) resistant</td>
        <td>m6bgoNYcG12</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Inh (CC) resistant</td>
        <td>m8N1dCCrsaT</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Amk susceptible</td>
        <td>M9mlpuwMiJ8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Inh (CC) susceptible</td>
        <td>mBK3lYq8HO8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Mfx (CB) susceptible</td>
        <td>mdIjVH1NUaF</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Pza susceptible</td>
        <td>mgyXxutltWj</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Emb susceptible</td>
        <td>MIDce43XVMU</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Rif contaminated/indeterminate</td>
        <td>MT7aEWVXFBf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Patients with inoculation date for initial DST (solid media)</td>
        <td>MTU6QAz2cpX</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Lfx contaminated/indeterminate</td>
        <td>N7o1Xqjimlj</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Rif resistant</td>
        <td>nea65dZOQfp</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Lfx contaminated/indeterminate</td>
        <td>npECBAtnX10</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Amk susceptible</td>
        <td>nQp5mF3EWSv</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Dlm contaminated/indeterminate</td>
        <td>NQyWPTJyzhL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Dlm indeterminate</td>
        <td>O07GF4PWILB</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Bdq contaminated/indeterminate</td>
        <td>o0r6wVvQT1H</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Bdq resistant</td>
        <td>O6sByxTUSCg</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Lfx contaminated/indeterminate</td>
        <td>OSIs8OpyxVO</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Cfz resistant</td>
        <td>oyDpKH5EAxE</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Inh (CC) resistant</td>
        <td>P1wRsnQDSoO</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Cfz resistant</td>
        <td>pg04Amkdg8w</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Inh (CC) contaminated/indeterminate</td>
        <td>PHv62Yu06oi</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Emb susceptible</td>
        <td>pnT5LoEQyzr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Lzd contaminated/indeterminate</td>
        <td>QBlVFZk3DBu</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Rif indeterminate</td>
        <td>QBTDDGn35IH</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Mfx (CC) contaminated/indeterminate</td>
        <td>qhTaRzXxdgE</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Lfx susceptible</td>
        <td>QLOD6SMC2A0</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Mfx (CC) resistant</td>
        <td>qogSzR2VXkK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Samples with result for initial DST (solid media)</td>
        <td>QPGYhthplln</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Lzd susceptible</td>
        <td>r35T9E2eN0J</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Cfz susceptible</td>
        <td>rAIsq8tQ0rL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lzd susceptible</td>
        <td>RBKOeLO8kFs</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Rif resistant</td>
        <td>RFUHj0EVvIW</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Amk susceptible</td>
        <td>rq7eOFDLmQK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Mfx (CB) resistant</td>
        <td>rQXzjEVe3c2</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CB) susceptible</td>
        <td>RTLLeqWAffq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Dlm contaminated</td>
        <td>rUvdF2y3yQV</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Pza susceptible</td>
        <td>RyF9HEzgBBn</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Cfz resistant</td>
        <td>s560uws0IhG</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Rif susceptible</td>
        <td>sh8xXpr7SOC</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Pza contaminated</td>
        <td>Smx6TYW3634</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Dlm contaminated/indeterminate</td>
        <td>sqp1Bv70e3U</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CB) resistant</td>
        <td>t2EcSOcA09t</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Cfz susceptible</td>
        <td>tDKHvNwKNRL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Dlm susceptible</td>
        <td>thTqoznl0K7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CC) indeterminate</td>
        <td>ToEpkaCnJuf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Inh (CC) susceptible</td>
        <td>TSS4Ymmu0qa</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Dlm resistant</td>
        <td>ttyarOal7wI</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Dlm susceptible</td>
        <td>tuFTLk3Q0ss</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Mfx (CC) susceptible</td>
        <td>U4mKeK8i4Hk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Rif susceptible</td>
        <td>UfEFCBuifbO</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Rif contaminated/indeterminate</td>
        <td>ulABEq4nBsW</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lzd indeterminate</td>
        <td>VFwlYCRpKT8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Rif contaminated</td>
        <td>VIGJElSLwE6</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Cfz indeterminate</td>
        <td>vMpjSJHqaNa</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Mfx (CB) resistant</td>
        <td>vpFUsKTHw7C</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Cfz contaminated/indeterminate</td>
        <td>vPjEMOUrOiA</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Amk resistant</td>
        <td>VsaE6AEggjD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Mfx (CC) resistant</td>
        <td>VxTMToeTQsg</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Mfx (CC) susceptible</td>
        <td>vxy56EFkTrH</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Emb indeterminate</td>
        <td>w2AaUjwDGui</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Amk contaminated/indeterminate</td>
        <td>wjQ7CrAeA6p</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Rif contaminated/indeterminate</td>
        <td>WLH2VJO0PkN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Dlm susceptible</td>
        <td>wMrYlXritKK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Pza contaminated/indeterminate</td>
        <td>wnmc8YIahud</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Rif susceptible</td>
        <td>Won3WS3jgBz</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Bdq contaminated/indeterminate</td>
        <td>WwLq06C7iTC</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Lfx susceptible</td>
        <td>WYIKQdnWj8v</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Lzd contaminated/indeterminate</td>
        <td>X1OWCAaNwhw</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Mfx (CB) contaminated/indeterminate</td>
        <td>XbDlCbLLMWa</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Cfz contaminated</td>
        <td>XCJmxcszJ4E</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Pza susceptible</td>
        <td>xHZKn549ZRN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Pza resistant</td>
        <td>XJom38gElVN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Dlm susceptible</td>
        <td>xjqlj9qGNwf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Pza susceptible</td>
        <td>XQluYa6a41F</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Emb contaminated</td>
        <td>YeU707qWYqZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Amk resistant</td>
        <td>yj67gy58tvc</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Inh (CB) resistant</td>
        <td>yw1mFlZWAMP</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Dlm resistant</td>
        <td>ywEgFe3CmDN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Lfx susceptible</td>
        <td>Z28tLWyehWi</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Lzd resistant</td>
        <td>z4w7a7VHWsr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): new patients - Bdq resistant</td>
        <td>ZhWUJgUGMzD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Bdq susceptible</td>
        <td>Zie6OAMjczP</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Patients with result for initial DST (solid media)</td>
        <td>ZMo9mf0LfWt</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): samples - Pza resistant</td>
        <td>zN38C55xHYZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Mfx (CC) contaminated/indeterminate</td>
        <td>Ztm42od2b6y</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): previously treated patients - Lzd resistant</td>
        <td>zwG40huDp6Q</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS: Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST (solid media): patients - Pza resistant</td>
        <td>ZWGzbjgAKMS</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Kan resistant</td>
        <td>afmIU4uXULr</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>Samples with LPA (Fq/2LI) test result</td>
        <td>BP1h0h5Fcsc</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Amk/Cap resistant</td>
        <td>BpRbOc95EiZ</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Amk/Cap indeterminate</td>
        <td>cjamO4QmiQl</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>Patients with invalid result for LPA (Fq/2LI)</td>
        <td>cMcje1sf4Pn</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Amk/Cap indeterminate</td>
        <td>CVHpNLwyPw9</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Kan indeterminate</td>
        <td>dFWU6kNKodU</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 6 days</td>
        <td>eMQxOQjYOAk</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Kan susceptible</td>
        <td>EXziKxYBfcC</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Kan susceptible</td>
        <td>FBfIl9ERVVt</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Emb resistant</td>
        <td>fE6l4xcNtLq</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Kan indeterminate</td>
        <td>FeaSAdlKno2</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Kan susceptible</td>
        <td>fI46ToIG10v</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Emb resistant</td>
        <td>FLYNb9akyHF</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Emb indeterminate</td>
        <td>GAPMlTbDkXb</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 10+ days</td>
        <td>GLQZXhtNL52</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Amk/Cap resistant</td>
        <td>gSD4sqSzgGL</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 4 days</td>
        <td>H8hl6NVdcGi</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Emb indeterminate</td>
        <td>HfuHrxdatgU</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 5 days</td>
        <td>HicWDsLR7Nj</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Amk/Cap susceptible</td>
        <td>HkAV7ShttEV</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>Days from sample collection to date of LPA (Fq/2LI) test</td>
        <td>ibSDbrIrEph</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Amk/Cap susceptible</td>
        <td>IkHjK7xP7Xf</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Emb susceptible</td>
        <td>jRlXrgXU6gg</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Fq indeterminate</td>
        <td>jZM5koLMnTL</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Kan resistant</td>
        <td>k3dVli6pjex</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 8 days</td>
        <td>KaGNXiu65VF</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Fq resistant</td>
        <td>KDdD36jnouX</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Fq resistant</td>
        <td>lHv7SkxUIi0</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - MTB</td>
        <td>M65WBBPkgIF</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Fq susceptible</td>
        <td>mg6xbOMevpk</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 1 day</td>
        <td>mmAog6SHRqH</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Fq indeterminate</td>
        <td>mSoVmSlOATC</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Amk/Cap indeterminate</td>
        <td>mx7q7B3ZSpH</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Fq susceptible</td>
        <td>n6Rrth8edSM</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Fq susceptible</td>
        <td>NbEBOhJFhBx</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Fq resistant</td>
        <td>nVrp5WyTpvb</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Fq indeterminate</td>
        <td>NWJoPKtoVSu</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Emb indeterminate</td>
        <td>nYuAYvmgfbs</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Kan indeterminate</td>
        <td>oLyx8mPsMUU</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Kan resistant</td>
        <td>OxtZda8ABPq</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Amk/Cap resistant</td>
        <td>P8GK4wGFFTE</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Kan susceptible</td>
        <td>PCemW9SgW7M</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Emb resistant</td>
        <td>pcyI2L4i2bS</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 0 days</td>
        <td>PD1r3kjNsEZ</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - MTB</td>
        <td>q6rKTcc0b4G</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 7 days</td>
        <td>QarDtlid8zk</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Emb resistant</td>
        <td>Qfhf25Oce5X</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 2 days</td>
        <td>rnxWrZanCtV</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 3 days</td>
        <td>rSrlFohRGM1</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>Processed LPA (Fq/2LI) samples</td>
        <td>rxuYRTJZ2ej</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Fq susceptible</td>
        <td>s9gdW5R4nj1</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Emb susceptible</td>
        <td>SjJygt0PwVc</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Kan resistant</td>
        <td>SKYQM109VlR</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Emb susceptible</td>
        <td>SmerIApsjMN</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Fq indeterminate</td>
        <td>tiuKqMsWxrw</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Invalid</td>
        <td>tja5fRSuTBE</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 10 days</td>
        <td>tYLvtd2eq1T</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Emb indeterminate</td>
        <td>u8hqJ0vFyDx</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): 9 days</td>
        <td>uu0066KEVEY</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - Amk/Cap resistant</td>
        <td>uvyU5oBD2oz</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): patients - MTB not detected</td>
        <td>VCfBUEMSE8h</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - MTB not detected</td>
        <td>VVv5IQaPrdI</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Amk/Cap indeterminate</td>
        <td>W2V43bhnDpW</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): previously treated patients - Amk/Cap susceptible</td>
        <td>XmzqEJb0w79</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): samples - Emb susceptible</td>
        <td>XNFmjjFC52a</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>Patients with LPA (Fq/2LI) test result</td>
        <td>Yb4I8XsLvAC</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Amk/Cap susceptible</td>
        <td>yXTY7DS9wuu</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Kan indeterminate</td>
        <td>Z0nNQL81cpK</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS: LPA FQ/2LI</td>
        <td>LPA (Fq/2LI): new patients - Fq resistant</td>
        <td>zo63zcpBZCV</td>
      </tr>
    </table>
    <h2 id="dashboards">Dashboards</h2>
    <h3>DRS - 14. LPA (Fq/2LI)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 14. LPA (Fq/2LI)</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>T2oy9FbAh2G</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>II20o7gabiz</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by LPA FQ/2LI (last year, current year)</td>
        <td>dJJR521i5Ny</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>iG4dAT1HEWJ</td>
        <td>visualizations</td>
        <td>Emb - previously treated patients</td>
        <td>WleZBVgnck1</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>FXzZHPzkCKt</td>
        <td>visualizations</td>
        <td>Emb - new patients</td>
        <td>Tg9c9OOyHUA</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>ohQ5OpmpMIR</td>
        <td>visualizations</td>
        <td>Amk/Cap - previously treated patients</td>
        <td>eLRLojeu8HS</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>G5KYplbOkBV</td>
        <td>visualizations</td>
        <td>Amk/Cap - new patients</td>
        <td>tYe9YP1qKPk</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>C4OVijAvxbh</td>
        <td>visualizations</td>
        <td>Kan - previously treated patients</td>
        <td>QSaiufzyDH5</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>QEeBotUbOrT</td>
        <td>visualizations</td>
        <td>Kan - new patients</td>
        <td>OTbxQwzYrvp</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>vMjeNWMrRj4</td>
        <td>visualizations</td>
        <td>Fq - previously treated patients</td>
        <td>t2v1GLQtNJi</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>UhrAlpevEYj</td>
        <td>visualizations</td>
        <td>Fq - new patients</td>
        <td>APy4Nj7NQyZ</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>LEUdKDr5L1a</td>
        <td>visualizations</td>
        <td>Resistance to Emb</td>
        <td>wbCo0X3fQ1y</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>lhVtzsnOKDu</td>
        <td>visualizations</td>
        <td>Resistance to Amk/Cap</td>
        <td>L0TjWt6rLHR</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>dQScB8Kubd8</td>
        <td>visualizations</td>
        <td>Resistance to Kan</td>
        <td>jblE8HDlXDu</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>beD8lhuXasY</td>
        <td>visualizations</td>
        <td>Resistance to Fq</td>
        <td>Fveg5VlieyT</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>Oq75BjEITeq</td>
        <td>visualizations</td>
        <td>Patients with invalid result</td>
        <td>WyTPZxftu7d</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>T9baH5KLoyq</td>
        <td>visualizations</td>
        <td>Patients with MTB not detected</td>
        <td>ofQ3ydLlzZv</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>kFUtsdrzsEV</td>
        <td>visualizations</td>
        <td>Patients with MTB detected</td>
        <td>duT1kf7EKBi</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>wI72DkfV2hw</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>MrsCuA5bWuM</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>xpG4UnOdVui</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Ioc0x6eB2X3</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>TDkTIgZEDTX</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>JVGQKzRmsLR</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>EKoW2CwLgyM</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>zbDy43okPhi</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>tYHTNuQEeHF</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>JyB98dI9pLb</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>nR4BBVBeTZ7</td>
        <td>visualizations</td>
        <td>Samples tested by LPA (Fq/2LI)</td>
        <td>pdnlk3Ylels</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>VQXUgyRIYLC</td>
        <td>visualizations</td>
        <td>Turn-around time - (Cumulative %)</td>
        <td>WnIX7p7FXON</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>ZyuEkUrTrCc</td>
        <td>visualizations</td>
        <td>Days from sample collection to sample test date at NRL</td>
        <td>SlWAad5qjj3</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>RBNfEOS5n1h</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
        <td>Wr331kmgTw7</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>AfwsBpg4EHN</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>qsLuyHyw1bH</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>D00s3xjiw09</td>
        <td>visualizations</td>
        <td>Resistance to Emb (samples)</td>
        <td>vcdjShNlN3a</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>KwTMGMSw5zJ</td>
        <td>visualizations</td>
        <td>Resistance to Amk/Cap (samples)</td>
        <td>iDJ2W28QtBL</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>leIoVrq7UJ6</td>
        <td>visualizations</td>
        <td>Resistance to Kan (samples)</td>
        <td>GEsGnZmOf5t</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>hja6zsSoVpW</td>
        <td>visualizations</td>
        <td>MTB detection (samples)</td>
        <td>AhEFMN6HGdZ</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>SWekIBtNWd7</td>
        <td>visualizations</td>
        <td>Resistance to Fq (samples)</td>
        <td>zjd8BGC5Wdw</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
      <tr>
        <td>ieNOfHx6BBR</td>
        <td>visualizations</td>
        <td>Patients tested by LPA (Fq/2LI)</td>
        <td>DHCKh8c4pUr</td>
        <td>2020-12-10</td>
        <td>doSkehy2fIQ</td>
      </tr>
    </table>
    <h3>DRS - 08. Culture in liquid media (e.g. MGIT)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 08. Culture in liquid media (e.g. MGIT)</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td> </td>
        <td>Resource (shortcuts)</td>
        <td> </td>
        <td>Vvmhp7AbTt3</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>KH9PdDr0Q0w</td>
        <td>visualizations</td>
        <td>Previously treated patients with result for culture (liquid media)</td>
        <td>snv3a90vgGG</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>IiJ9tpLTQvI</td>
        <td>visualizations</td>
        <td>New patients with culture result (liquid media)</td>
        <td>fmifHxZEVm9</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>jWsixkLlTt7</td>
        <td>visualizations</td>
        <td>Patients with culture result (liquid media)</td>
        <td>fZLS1evUwS6</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>O2mbE0WwCy1</td>
        <td>visualizations</td>
        <td>Samples with culture inoculation date (liquid media)</td>
        <td>ag8XyqUhP3f</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>BxAWMPuWO2G</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>WCgUqzebv1v</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>RpEvHouF06q</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>ALB7tO5zaRX</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>QlqhxnKkycE</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by culture LM (last year, current year)</td>
        <td>rOLfYmGNkR2</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>YhGGmmi0wnU</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>YBAS6rqyoSK</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>IB8sy1NGl0E</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>yvpMX7ZOZ1J</td>
        <td>visualizations</td>
        <td>Samples with culture result (liquid media)</td>
        <td>UpFcheZwQkh</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>ysMzvrIYK79</td>
        <td>visualizations</td>
        <td>Patients with culture result (liquid media)</td>
        <td>QMvXKqRO0L9</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>WLZkoGeG2ZS</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>G3WcSC5OfCD</td>
        <td>visualizations</td>
        <td>Turn-around time - Culture in liquid media (Cumulative %)</td>
        <td>FImilCAON41</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>jcxG1GQfZoh</td>
        <td>visualizations</td>
        <td>Days from sample collection to inoculation date</td>
        <td>SthzIkoV6oc</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>xdOEArjEa8e</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to culture inoculation at NRL (liquid media)</td>
        <td>Axp4LSIVUsb</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>lrUstKnOq8h</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>P0cKIuG966C</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>jPqtZEibOnx</td>
        <td>visualizations</td>
        <td>Results for culture in liquid media (samples)</td>
        <td>l3ro4FgPQGP</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
      <tr>
        <td>X6uSXh7tE1z</td>
        <td>visualizations</td>
        <td>Patients with culture inoculation date (liquid media)</td>
        <td>aWI1f04bCYJ</td>
        <td>2020-12-10</td>
        <td>ED7gSSvpUCi</td>
      </tr>
    </table>
    <h3>DRS - 04. Microscopy</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 04. Microscopy</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>ifRCDomK7iD</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>yzcKCyDo2Iu</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>lnLMfy27UZA</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td>bpTrN5QtYBf</td>
        <td>visualizations</td>
        <td>Samples with microscopy result</td>
        <td>WimV4cg7Tpl</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>zL7nytJNufM</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td>HhEwiZxXl81</td>
        <td>visualizations</td>
        <td>New patients with microscopy result</td>
        <td>a6hC6Cw6NxW</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td>Ej8MbUOoVEE</td>
        <td>visualizations</td>
        <td>Previously treated patients with result for microscopy</td>
        <td>hqx5H9tIeXu</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>NbUBzjE7iDY</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td>iFEsGz7MUiU</td>
        <td>visualizations</td>
        <td>Patients with microscopy result</td>
        <td>nTHWU8yaSag</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
      <tr>
        <td>eGImCpP8rA4</td>
        <td>visualizations</td>
        <td>Patients with microscopy result</td>
        <td>goKWfJmKEU3</td>
        <td>2020-12-10</td>
        <td>Ij4blZ91I9g</td>
      </tr>
    </table>
    <h3>DRS - 07. Culture in solid media (e.g. LJ)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 07. Culture in solid media (e.g. LJ)</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td> </td>
        <td>Resource (shortcuts)</td>
        <td> </td>
        <td>LDU6gFbtYeX</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>uQWxOo4eWRf</td>
        <td>visualizations</td>
        <td>Patients with culture result (solid media)</td>
        <td>etxcv1ac8Z0</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>jEcL61jz154</td>
        <td>visualizations</td>
        <td>Previously treated patients with result for culture (solid media)</td>
        <td>VP8ERqGNV5E</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>l5GNHYa9Nsd</td>
        <td>visualizations</td>
        <td>New patients with culture result (solid media)</td>
        <td>NKNTG2CbrYL</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>QPmidkANRk0</td>
        <td>visualizations</td>
        <td>Samples with culture inoculation date (solid media)</td>
        <td>lcRgwILv0S2</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>X46dcSAOlmQ</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>EWdLIFuw05d</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>hGJJaRv6WVa</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>FpPaG9QGITz</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>L1yRKfA5gUk</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>jTJdYcjkYtO</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by culture SM (last year, current year)</td>
        <td>pah5wzxo0NC</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>GXJOEXvO9PU</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>VszEXH7ZyCx</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>leHYVTzL7P1</td>
        <td>visualizations</td>
        <td>Samples with culture result (solid media)</td>
        <td>nMg0aQfxJsa</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>lstK4dpi7QV</td>
        <td>visualizations</td>
        <td>Patients with culture result (solid media)</td>
        <td>RMF2u0hS5p2</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>pA2YnScQQO3</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>AcaciZ4oGgL</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>p0YvQlUzZhp</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>VTxJ4FqPiZ1</td>
        <td>visualizations</td>
        <td>Turn-around time - Culture in solid media (Cumulative %)</td>
        <td>CJ1gChVjGhG</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>mvBsrx7Ouv6</td>
        <td>visualizations</td>
        <td>Days from sample collection to inoculation date</td>
        <td>ov6hROXxodH</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>ZmrvMWkhiqL</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to culture inoculation at NRL (solid media)</td>
        <td>CBvVLp8UY59</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>aFFpc0n6lgn</td>
        <td>visualizations</td>
        <td>Results for culture in solid media (samples)</td>
        <td>y6gWKrfVnZk</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
      <tr>
        <td>pWqecnDABin</td>
        <td>visualizations</td>
        <td>Patients with culture inoculation date (solid media)</td>
        <td>Ar7R1MmD2VV</td>
        <td>2020-12-10</td>
        <td>laafg7bB6g5</td>
      </tr>
    </table>
    <h3>DRS - 10. Initial DST in liquid media (e.g. MGIT)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 10. Initial DST in liquid media (e.g. MGIT)</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td>dqi5lGsIoD8</td>
        <td>visualizations</td>
        <td>Samples with initial DST inoculation date (liquid media)</td>
        <td>sPdvRYFXFXl</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>WHzX7ziCEtJ</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>M52w6tE1m80</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by Initial DST LM (last year, current year)</td>
        <td>cNuNqCXmIso</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>UsdQHSjPtWX</td>
        <td>visualizations</td>
        <td>Dlm - previously treated patients</td>
        <td>Dz6U8AiERmR</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>dqLeOPey91y</td>
        <td>visualizations</td>
        <td>Rif - previously treated patients</td>
        <td>SJrvK0Of0dy</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>I627wRgZ4QT</td>
        <td>visualizations</td>
        <td>Inh (CC) - previously treated patients</td>
        <td>CSSPF5ckU8a</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>DLS3Be5bz8Q</td>
        <td>visualizations</td>
        <td>Inh (CB) - previously treated patients</td>
        <td>s0yEwc33ppn</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>fs5HhajBUL0</td>
        <td>visualizations</td>
        <td>Pza - previously treated patients</td>
        <td>luA5RjU6gmv</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>cKz5lKn3xGh</td>
        <td>visualizations</td>
        <td>Emb - previously treated patients</td>
        <td>NVUvf0ZMFxC</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>xbdjjxp44oH</td>
        <td>visualizations</td>
        <td>Lfx - previously treated patients</td>
        <td>ep66K0grvTT</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>LjWbJG0O38q</td>
        <td>visualizations</td>
        <td>Mfx (CC) - previously treated patients</td>
        <td>yhbSwKEqse8</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>mqlNxC7wSrV</td>
        <td>visualizations</td>
        <td>Mfx (CB) - previously treated patients</td>
        <td>wnpDkRqQYDX</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>p9eupZPh9gE</td>
        <td>visualizations</td>
        <td>Amk - previously treated patients</td>
        <td>jdRSp3rPNU0</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>Mngd8Vigd4Y</td>
        <td>visualizations</td>
        <td>Bdq - previously treated patients</td>
        <td>fex6TGKfIma</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>n62AD2ww4K3</td>
        <td>visualizations</td>
        <td>Lzd - previously treated patients</td>
        <td>Sl3GVxC10Y4</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>onUkoC997zo</td>
        <td>visualizations</td>
        <td>Cfz - previously treated patients</td>
        <td>YhDW1U0gx36</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>pTumYaD0P0Q</td>
        <td>visualizations</td>
        <td>Cfz - new patients</td>
        <td>hdAiaYtBImH</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>EcHsKYrhXnH</td>
        <td>visualizations</td>
        <td>Lzd - new patients</td>
        <td>ShyLBvHI5zO</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>qG2g3ZdTHU9</td>
        <td>visualizations</td>
        <td>Dlm - new patients</td>
        <td>ybWksc4vmsh</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>JxfNDGLZihK</td>
        <td>visualizations</td>
        <td>Bdq - new patients</td>
        <td>FE7QLgDgIQD</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>UAJZ6hfu31F</td>
        <td>visualizations</td>
        <td>Amk - new patients</td>
        <td>hNEfsvcyPWX</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>zOGy7fTKh2O</td>
        <td>visualizations</td>
        <td>Mfx (CB) - new patients</td>
        <td>Ip7LSyt69kx</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>O3HBBg5zrQ4</td>
        <td>visualizations</td>
        <td>Mfx (CC) - new patients</td>
        <td>hHs8Zgj9u2E</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>tXgkoP5dIbJ</td>
        <td>visualizations</td>
        <td>Lfx - new patients</td>
        <td>wKQQruWvT1f</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>aHI7LkZopPe</td>
        <td>visualizations</td>
        <td>Emb - new patients</td>
        <td>HtBN2wYwJ4X</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>A4hzokLF4Js</td>
        <td>visualizations</td>
        <td>Pza - new patients</td>
        <td>oLfPiqsiHgW</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>SV4CPwttA3l</td>
        <td>visualizations</td>
        <td>Inh (CB) - new patients</td>
        <td>PXyInyc2uB2</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>LcSUiJ4egVu</td>
        <td>visualizations</td>
        <td>Inh (CC) - new patients</td>
        <td>DAGMIGoAov5</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>cFJqrZQKHgF</td>
        <td>visualizations</td>
        <td>Rif - new patients</td>
        <td>yKJ7YlU45oA</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>SHlHySH71S2</td>
        <td>visualizations</td>
        <td>Resistance to Rif</td>
        <td>ADCMQppZEwy</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>IeSFBNrXClS</td>
        <td>visualizations</td>
        <td>Resistance to Pza</td>
        <td>grdOjjCXass</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>wv296E9UrGG</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC)</td>
        <td>MdpHOaAKuS6</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>jpfLJ32aeGt</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB)</td>
        <td>B78TqfArtmR</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>wl9jNg38cz7</td>
        <td>visualizations</td>
        <td>Resistance to Lzd</td>
        <td>HjAQFnAIEub</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>TSDVmBvIneN</td>
        <td>visualizations</td>
        <td>Resistance to Lfx</td>
        <td>BpbY18TmrF2</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>Hc9jtStLefh</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC)</td>
        <td>I436ZcLU5uB</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>PW0Z2EweAsF</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB)</td>
        <td>gbA0WfyMHYQ</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>WTPysmCBftB</td>
        <td>visualizations</td>
        <td>Resistance to Emb</td>
        <td>OOw9UiQbHYM</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>BA09TUcaRPc</td>
        <td>visualizations</td>
        <td>Resistance to Dlm</td>
        <td>vCA04hkwkgS</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>FTyV3ikFRTc</td>
        <td>visualizations</td>
        <td>Resistance to Cfz</td>
        <td>U6gPoOdV6fw</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>oamkDbKVY7J</td>
        <td>visualizations</td>
        <td>Resistance to Bdq</td>
        <td>a1TCWrhRIXx</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>T0iBCI69Km2</td>
        <td>visualizations</td>
        <td>Resistance to Amk</td>
        <td>YhgbASe0eJW</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>sdeMaAoOGO7</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>aeMK8cyHYjQ</td>
        <td>visualizations</td>
        <td>Resistance to Bdq (samples)</td>
        <td>MkrxJ2RvupS</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>p8IqxLz6yIv</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>CxoUDRjCP66</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>hDC9DVfS9Uc</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>twze4MECtSE</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>i8YbPnPRxFH</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>BhDtzX4p4Dc</td>
        <td>visualizations</td>
        <td>Samples with initial DST result (liquid media)</td>
        <td>IQX2kHMoQr0</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>Zq5jhE1lASV</td>
        <td>visualizations</td>
        <td>Patients with initial DST result (liquid media)</td>
        <td>Ug7PED5wix8</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>KJjXSkoWjMs</td>
        <td>visualizations</td>
        <td>Resistance to Dlm (samples)</td>
        <td>irSq1B6Umws</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>e7LQhueHCdC</td>
        <td>visualizations</td>
        <td>Resistance to Cfz (samples)</td>
        <td>Ghhz6ITY48E</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>NuQW3zdrLf2</td>
        <td>visualizations</td>
        <td>Resistance to Lzd (samples)</td>
        <td>FSYGux9gEqL</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>O8gN0OzPTxz</td>
        <td>visualizations</td>
        <td>Resistance to Amk (samples)</td>
        <td>EnoLkmB5VmS</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>fHv6yNQ1wR4</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>noq0TqBvSSX</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>ipzFvaEa97c</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>rbmKFjT85GX</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>Zte7iUlyo6a</td>
        <td>visualizations</td>
        <td>Resistance to Lfx (samples)</td>
        <td>QQHEPSm6eKi</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>Jje0NRe1NbT</td>
        <td>visualizations</td>
        <td>Resistance to Emb (samples)</td>
        <td>IjidYUlGhEb</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>lk33yehvMKx</td>
        <td>visualizations</td>
        <td>Resistance to Pza (samples)</td>
        <td>rje6d4LLtqC</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>cktDmhvOWZa</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>Th2Qzb2yumc</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>foDYQgWarwE</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>HGLeHwyjwnK</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>x4iYtBG0S7r</td>
        <td>visualizations</td>
        <td>Resistance to Rif (samples)</td>
        <td>ZAI4cWgvFc6</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>FBH6Ggi1lnw</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
      <tr>
        <td>oDgNwrOiBVm</td>
        <td>visualizations</td>
        <td>Patients with inoculation date for initial DST (liquid media)</td>
        <td>jtYmf1JsCWH</td>
        <td>2020-12-10</td>
        <td>LHzD9cyEKJD</td>
      </tr>
    </table>
    <h3>DRS - 05. Xpert MTB/RIF</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 05. Xpert MTB/RIF</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td> </td>
        <td>Resource (shortcuts)</td>
        <td> </td>
        <td>MQVurC26nvP</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>jgzPuQ3HIel</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>yCFmhf1WbAu</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>INgQpPhYxtY</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>EkB83FOYDCa</td>
        <td>visualizations</td>
        <td>Patients with MTB not detected</td>
        <td>yCPmGMgZeCE</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>MdnAKUS1j8C</td>
        <td>visualizations</td>
        <td>Patients with MTB detected</td>
        <td>yIGY71iDpKs</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>dd4Hjk0G3Ap</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>BYf7J0Ld4JD</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>mepSgyFIhDg</td>
        <td>visualizations</td>
        <td>Patients with error, invalid or no result</td>
        <td>QY9FAVsczjb</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>pJXuBVBPcbo</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>u3Q5k5dUo8N</td>
        <td>visualizations</td>
        <td>Previously treated patients with MTB detected</td>
        <td>At2eyo7fGLS</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>o6bLNVpJ0cn</td>
        <td>visualizations</td>
        <td>New patients with MTB detected</td>
        <td>gxBACxQmdMF</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>kl0b4pjBMLc</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>LIyNdPKp62v</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>fwBQKBqu6Ns</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by Xpert MTB/RIF (last year, current year)</td>
        <td>Ovxfliif4rE</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>eK6jLV0dfCv</td>
        <td>visualizations</td>
        <td>Patients with MTB detected</td>
        <td>PYTLrQ8yPnA</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>CYvdEh2Ktnk</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>ekabm7c2qeY</td>
        <td>visualizations</td>
        <td>Samples tested by Xpert MTB/RIF</td>
        <td>D1rGOeb7pKz</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Q21N2OHCoPq</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Pc8ap3gZNt8</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>exJtTJxFoOQ</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>wUOoMaMdOjY</td>
        <td>visualizations</td>
        <td>Days from sample collection o sample test date at NRL</td>
        <td>MS9VzdhOcdg</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>H2Aiv0M4LNQ</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
        <td>pOVhIg4CyYN</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>hTHJ2wtGxWK</td>
        <td>visualizations</td>
        <td>Turn-around time - (Cumulative %)</td>
        <td>qbMZuCIxeBo</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>jKhHBRO93cq</td>
        <td>visualizations</td>
        <td>Xpert MTB/RIF test results (samples)</td>
        <td>EhBk21uOLGP</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
      <tr>
        <td>lBcNYF3y4y9</td>
        <td>visualizations</td>
        <td>Patients tested by Xpert MTB/RIF</td>
        <td>aHRWEGO4ZAR</td>
        <td>2020-12-10</td>
        <td>OA71FPTT551</td>
      </tr>
    </table>
    <h3>DRS - 12. Subsequent DST in liquid media (e.g. MGIT)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 12. Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td>LbqAqZXje61</td>
        <td>visualizations</td>
        <td>Samples with subsequent DST inoculation date (liquid media)</td>
        <td>pz3MXMk4ZL3</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>alMouhN2JWv</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ZSc8l1iHQXE</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by Subsequent DST LM (last year, current year)</td>
        <td>oNIuIWNMoHO</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>tjT7jrtS1pa</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>ccSCnzj0wWy</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>MKdKVBf20fU</td>
        <td>visualizations</td>
        <td>Rif - previously treated patients</td>
        <td>UZzxay6P7Py</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>VHE1E1MF8mV</td>
        <td>visualizations</td>
        <td>Inh (CC) - previously treated patients</td>
        <td>cdIpic1xOGk</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>url5ZeOYYdo</td>
        <td>visualizations</td>
        <td>Inh (CB) - previously treated patients</td>
        <td>AXgCVP73XMA</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>N6aDWfiF17p</td>
        <td>visualizations</td>
        <td>Pza - previously treated patients</td>
        <td>NngpkXCAPUa</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>S3yDihOC9Lf</td>
        <td>visualizations</td>
        <td>Emb - previously treated patients</td>
        <td>HF7Jhjkd9oK</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>k7Zla8Drzwj</td>
        <td>visualizations</td>
        <td>Lfx - previously treated patients</td>
        <td>eAr5iZQUPI3</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ObmR9NvVeRC</td>
        <td>visualizations</td>
        <td>Mfx (CC) - previously treated patients</td>
        <td>lYASx7O6GKy</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>rnTHBV8dv79</td>
        <td>visualizations</td>
        <td>Mfx (CB) - previously treated patients</td>
        <td>z7AwyDdKEzF</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ymzubLo1nSE</td>
        <td>visualizations</td>
        <td>Amk - previously treated patients</td>
        <td>IGX8cdo5z0t</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Go33kUTQSvz</td>
        <td>visualizations</td>
        <td>Bdq - previously treated patients</td>
        <td>aFEnT8S6WxM</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>xqReKuS85hm</td>
        <td>visualizations</td>
        <td>Dlm - previously treated patients</td>
        <td>iA1poxvfFzA</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>aegNQwFewqY</td>
        <td>visualizations</td>
        <td>Lzd - previously treated patients</td>
        <td>ynVTTBMMiLT</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ycFsgydGYQv</td>
        <td>visualizations</td>
        <td>Cfz - previously treated patients</td>
        <td>UUof5PtTCl3</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>vh6zb8svQtQ</td>
        <td>visualizations</td>
        <td>Rif - new patients</td>
        <td>X6z5OMgQS4P</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>oBw0wU3yO7C</td>
        <td>visualizations</td>
        <td>Inh (CC) - new patients</td>
        <td>dP0YHBx59FL</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>HLv9cxNEo3f</td>
        <td>visualizations</td>
        <td>Inh (CB) - new patients</td>
        <td>gwpu7mUKHFe</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>dr8wLFfEgQa</td>
        <td>visualizations</td>
        <td>Pza - new patients</td>
        <td>jZ1QUREbjA2</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>wvcK3HQicCX</td>
        <td>visualizations</td>
        <td>Emb - new patients</td>
        <td>VpUvlWd7LIA</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>jjc1bLPes8H</td>
        <td>visualizations</td>
        <td>Lfx - new patients</td>
        <td>Mk3GUuLqrRr</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>RExxXicHhxr</td>
        <td>visualizations</td>
        <td>Mfx (CC) - new patients</td>
        <td>wgObXWk45aO</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>vOGNs1ZENKw</td>
        <td>visualizations</td>
        <td>Mfx (CB) - new patients</td>
        <td>B9FhsECwvQG</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>rjLCLnYpA1I</td>
        <td>visualizations</td>
        <td>Bdq - new patients</td>
        <td>cw3TCkhSHLJ</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Fa9Ul35r9pz</td>
        <td>visualizations</td>
        <td>Dlm - new patients</td>
        <td>KmP4RT9Q4Ey</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Of3zi9XgoAu</td>
        <td>visualizations</td>
        <td>Lzd - new patients</td>
        <td>X9iF6UG9hij</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>piaFqrKhT4Q</td>
        <td>visualizations</td>
        <td>Cfz - new patients</td>
        <td>iIepQkGinLT</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>MsRE9GlLWdb</td>
        <td>visualizations</td>
        <td>Resistance to Pza</td>
        <td>WbPXAEA3W7E</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>tvH2WO4uyt1</td>
        <td>visualizations</td>
        <td>Resistance to Rif</td>
        <td>p3qBPUm3Haw</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Dp7puzuYHMm</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC)</td>
        <td>FRDfQHdJOCK</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>u6w3chA0T7H</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB)</td>
        <td>xKIzuD5XUZm</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>lHXvAIIDEdC</td>
        <td>visualizations</td>
        <td>Resistance to Emb</td>
        <td>qqnjEWFqeuz</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Ypto0x4QbZG</td>
        <td>visualizations</td>
        <td>Resistance to Lfx</td>
        <td>TePiQjd0Gdp</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ne9D30vUOQ2</td>
        <td>visualizations</td>
        <td>Amk - new patients</td>
        <td>B9aqMToECRa</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ZgHO5dOyAlw</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC)</td>
        <td>hKCC2ckpUAC</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>XkSbmIgLtVQ</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB)</td>
        <td>pgXhU77k5sI</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>z7aFwudMAAQ</td>
        <td>visualizations</td>
        <td>Resistance to Amk</td>
        <td>igtqTBRpPJO</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>l97UW74mZiK</td>
        <td>visualizations</td>
        <td>Resistance to Bdq</td>
        <td>pnxg19NzvAQ</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>RxK8JDHqUud</td>
        <td>visualizations</td>
        <td>Resistance to Dlm</td>
        <td>Qw8foiMCeAQ</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>FeZw3M57SPl</td>
        <td>visualizations</td>
        <td>Resistance to Lzd</td>
        <td>ElPLxRDw3iM</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>P6vL3w0p01K</td>
        <td>visualizations</td>
        <td>Resistance to Cfz</td>
        <td>PyhS5DC4VYT</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Gwhu5POgYgN</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>mITcv1kmgVx</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>JEqSe2uX0Mw</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>qDINWZckBYH</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>k2tU8E5dEJe</td>
        <td>visualizations</td>
        <td>Samples with subsequent DST result (liquid media)</td>
        <td>MXvsTvw8Vjc</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Tr8iuaXmXEN</td>
        <td>visualizations</td>
        <td>Patients with subsequent DST result (liquid media)</td>
        <td>w7B8F9MRGee</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>MmnpPCsNclV</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>A5wzv2jpGsD</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>kneiEKxrJgp</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>Bke2dS6Saoo</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>NiPJOiYsxiQ</td>
        <td>visualizations</td>
        <td>Resistance to Lzd (samples)</td>
        <td>TM6OWXkceKu</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Fk2TmAyOpag</td>
        <td>visualizations</td>
        <td>Resistance to Lfx (samples)</td>
        <td>UXJUTJ7a09g</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ANXqiUngJqW</td>
        <td>visualizations</td>
        <td>Resistance to Dlm (samples)</td>
        <td>vHWUl0rjwrH</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>gPr0OavnoRo</td>
        <td>visualizations</td>
        <td>Resistance to Cfz (samples)</td>
        <td>LMKvNh9GuQD</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>KxBQWoRCB03</td>
        <td>visualizations</td>
        <td>Resistance to Bdq (samples)</td>
        <td>M1Tbl0c3OU8</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>Ufb3izlpsLk</td>
        <td>visualizations</td>
        <td>Resistance to Amk (samples)</td>
        <td>JpfXq6gmAzV</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>lZ2mFM2ePmS</td>
        <td>visualizations</td>
        <td>Resistance to Emb (samples)</td>
        <td>KyVriunZEEh</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>XgsLr4tC8r0</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>bhUj84f4YQS</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>yIBx6hllNq8</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>FgoyOZhqiGA</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>t3jOHDviiFd</td>
        <td>visualizations</td>
        <td>Resistance to Pza (samples)</td>
        <td>HyIxThBgBUX</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>ijfAvuMpluV</td>
        <td>visualizations</td>
        <td>Resistance to Rif (samples)</td>
        <td>wfzdPsAxAOR</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>pMV5fNTbBRI</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
      <tr>
        <td>FwhCb8WGQ53</td>
        <td>visualizations</td>
        <td>Patients with inoculation date for subsequent DST (liquid media)</td>
        <td>VQDLLZI5LkZ</td>
        <td>2020-12-10</td>
        <td>pr38ZL9hUpY</td>
      </tr>
    </table>
    <h3>DRS - 02. Missing data report</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 02. Missing data report</td>
        <td>2020-10-14</td>
        <td>rH6F0XZqbb8</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>C5y8qMBKwgG</td>
        <td>2020-10-14</td>
        <td>rH6F0XZqbb8</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>x7nmPhiFab9</td>
        <td>2020-10-14</td>
        <td>rH6F0XZqbb8</td>
      </tr>
      <tr>
        <td>s66zrjrEKaa</td>
        <td>Event report</td>
        <td>Missing data line list</td>
        <td>H5p3S5XoRWP</td>
        <td>2020-10-14</td>
        <td>rH6F0XZqbb8</td>
      </tr>
      <tr>
        <td>PazB6GSITwK</td>
        <td>visualizations</td>
        <td>Missing data report</td>
        <td>cMY55xWflIp</td>
        <td>2020-10-14</td>
        <td>rH6F0XZqbb8</td>
      </tr>
    </table>
    <h3>DRS - 03. Sample transport, laboratory processing and test results (general)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 03. Sample transport, laboratory processing and test results (general)</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>xLOttqHIPQr</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td>lH4hJMrZWYs</td>
        <td>visualizations</td>
        <td>Progress in sample processing</td>
        <td>b6ysyaCDMBu</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td>GinRhTtdKnI</td>
        <td>visualizations</td>
        <td>Percentage of samples rejected on arrival at NTRL</td>
        <td>PvPelRrx2E6</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>qNnrEeNzgZP</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>NMv1LyCpCvf</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td>SZfv73nGXHE</td>
        <td>visualizations</td>
        <td>Samples turn-around time (Cumulative %)</td>
        <td>kPkRGuo7gF0</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td>q96JtVS7qYv</td>
        <td>visualizations</td>
        <td>Days from sample collection to sample arrival at NRL</td>
        <td>kNr4v7uhNSi</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>H0PmhOzF3G7</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
      <tr>
        <td>dZOYcMkF3Va</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to sample arrival at NRL</td>
        <td>DxjvUR8oge6</td>
        <td>2020-11-03</td>
        <td>rPssf2LMHNy</td>
      </tr>
    </table>
    <h3>DRS - 11. Subsequent DST in solid media (e.g. LJ)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 11. Subsequent DST in solid media (e.g. LJ)</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td>ObRBFG9XaQZ</td>
        <td>visualizations</td>
        <td>Samples with subsequent DST inoculation date (solid media)</td>
        <td>PUhiUUXnYqZ</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>fzZFvA1FtlC</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>xvyAxvJ0H1k</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by Subsequent DST SM (last year, current year)</td>
        <td>guBtKp7PMKq</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>hQy2JqWsbt0</td>
        <td>visualizations</td>
        <td>Rif - previously treated patients</td>
        <td>iApEXytWjEV</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>ihgJ65J1UMA</td>
        <td>visualizations</td>
        <td>Inh (CC) - previously treated patients</td>
        <td>pjyTYTT1d0l</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>YQ0QlU6Kxvi</td>
        <td>visualizations</td>
        <td>Inh (CB) - previously treated patients</td>
        <td>mFtG5jYLUUX</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>qX7yrDi7mOq</td>
        <td>visualizations</td>
        <td>Pza - previously treated patients</td>
        <td>phsJ2ExzYB0</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>Rc8TYRizjqh</td>
        <td>visualizations</td>
        <td>Emb - previously treated patients</td>
        <td>wavtntqXI07</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>EiCzDOiO8bm</td>
        <td>visualizations</td>
        <td>Lfx - previously treated patients</td>
        <td>NY1fwA2Todw</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>w84CV2ceiJK</td>
        <td>visualizations</td>
        <td>Mfx (CC) - previously treated patients</td>
        <td>sihPp8kHYGn</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>EUr2DpEAQkm</td>
        <td>visualizations</td>
        <td>Mfx (CB) - previously treated patients</td>
        <td>An5eJStKqpd</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>w8Byd7sNBmq</td>
        <td>visualizations</td>
        <td>Amk - previously treated patients</td>
        <td>dca5pqFuIzT</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>ULU6us1uP6h</td>
        <td>visualizations</td>
        <td>Bdq - previously treated patients</td>
        <td>bXixhG4alTj</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>pXn8CZJy39E</td>
        <td>visualizations</td>
        <td>Dlm - previously treated patients</td>
        <td>oxjaibmhE1H</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>n1XPz9fsu3y</td>
        <td>visualizations</td>
        <td>Lzd - previously treated patients</td>
        <td>Flu380j5te0</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>T1Zk1rLyysE</td>
        <td>visualizations</td>
        <td>Cfz - previously treated patients</td>
        <td>CN8oRUbQLdP</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>PLu0C4TeOay</td>
        <td>visualizations</td>
        <td>Rif - new patients</td>
        <td>pAzGJwQaqJD</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>emYVgDuDucX</td>
        <td>visualizations</td>
        <td>Inh (CC) - new patients</td>
        <td>waZ0N8napBS</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>a2zCUUlpWJU</td>
        <td>visualizations</td>
        <td>Inh (CB) - new patients</td>
        <td>OI7QbVYTiHa</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>CLSLUzJdCuq</td>
        <td>visualizations</td>
        <td>Pza - new patients</td>
        <td>nN96WhJBmrz</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>mTyUyUzGra9</td>
        <td>visualizations</td>
        <td>Emb - new patients</td>
        <td>jPtidtslQv2</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>aEw2XfprWsw</td>
        <td>visualizations</td>
        <td>Lfx - new patients</td>
        <td>NcYLTJIy74v</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>F6tAKWre2CZ</td>
        <td>visualizations</td>
        <td>Mfx (CC) - new patients</td>
        <td>bOJEpk8ONku</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>OiobLq9yzLX</td>
        <td>visualizations</td>
        <td>Mfx (CB) - new patients</td>
        <td>HoRZCHU2oDf</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>HhZlsNH320n</td>
        <td>visualizations</td>
        <td>Amk - new patients</td>
        <td>AcOrlonQmKv</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>K6SZfRpy8qY</td>
        <td>visualizations</td>
        <td>Bdq - new patients</td>
        <td>mhqF4xeadgN</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>hec5A4nwmjI</td>
        <td>visualizations</td>
        <td>Dlm - new patients</td>
        <td>ZFiMxTINzvs</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>awSxldaNoqk</td>
        <td>visualizations</td>
        <td>Lzd - new patients</td>
        <td>NcpM8QHHRVn</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>cjHSPSneRnG</td>
        <td>visualizations</td>
        <td>Cfz - new patients</td>
        <td>nexgvcerLmT</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>D25kT4vRlL2</td>
        <td>visualizations</td>
        <td>Resistance to Pza</td>
        <td>HeDkCi3GlKR</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>wOLQDCSW8a6</td>
        <td>visualizations</td>
        <td>Resistance to Rif</td>
        <td>fwGXzNtd3M6</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>PL1gP2my7m4</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC)</td>
        <td>etzeBPIwqWy</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>MazLayAlMZt</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB)</td>
        <td>Wk8oXSMq7ux</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>vFjdo58Zxkr</td>
        <td>visualizations</td>
        <td>Resistance to Emb</td>
        <td>aLFKOk8KN8J</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>fXhF7qU5uEL</td>
        <td>visualizations</td>
        <td>Resistance to Lfx</td>
        <td>oCcWwqoN8JY</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>LKnYqCYbSZK</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC)</td>
        <td>VKtoxDHaHzR</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>UmnCZy3mVnB</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB)</td>
        <td>dyxfpl5KBRk</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>jovCNzeVi4M</td>
        <td>visualizations</td>
        <td>Resistance to Amk</td>
        <td>Qp8wLGkuEmA</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>ZZ0Ox1hIaFo</td>
        <td>visualizations</td>
        <td>Resistance to Bdq</td>
        <td>qWHCGcabRfV</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>R9EJpGiUM9A</td>
        <td>visualizations</td>
        <td>Resistance to Dlm</td>
        <td>b7sjYONR9ZE</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>PHMhhdGBy6u</td>
        <td>visualizations</td>
        <td>Resistance to Lzd</td>
        <td>s0Fp2mTN9RE</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>MEr4EVGlmES</td>
        <td>visualizations</td>
        <td>Resistance to Cfz</td>
        <td>VpQVzDxU3Wr</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>ljx9YjyIrN2</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>O15c4h05JRt</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>eXiZBLEpixl</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>IMHpH0u38Sv</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>JXa59uRehMW</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>IYRukplIKR0</td>
        <td>visualizations</td>
        <td>Samples with subsequent DST result (solid media)</td>
        <td>xYOBvAY7gzE</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>lqjr3ijnXLz</td>
        <td>visualizations</td>
        <td>Patients with subsequent DST result (solid media)</td>
        <td>hJHyHFmQnBf</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>v7UvsEI4rSi</td>
        <td>visualizations</td>
        <td>Resistance to Pza (samples)</td>
        <td>LVZEMOCnh27</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>QThQOSR2R2p</td>
        <td>visualizations</td>
        <td>Resistance to Rif (samples)</td>
        <td>do3Ydvgh0eY</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>EYCtE5oVkqk</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>EL3GQsmuF2e</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>ZwkbWeCIYPF</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>E3e881pu1oK</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>v6oY4jwBcT9</td>
        <td>visualizations</td>
        <td>Resistance to Lzd (samples)</td>
        <td>indHzwC0JjE</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>iM6JWuhj3lg</td>
        <td>visualizations</td>
        <td>Resistance to Lfx (samples)</td>
        <td>F2SthBpA1Ew</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>gJuYzn7d4HM</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>xhaARxWQPwI</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>DorTOrUuHur</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>KOY3e7hDmxg</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>tOfdO3dkP2H</td>
        <td>visualizations</td>
        <td>Resistance to Emb (samples)</td>
        <td>TlKUxl2S0Pw</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>ppxfqkBMbG9</td>
        <td>visualizations</td>
        <td>Resistance to Dlm (samples)</td>
        <td>jJWiOtoh0Bf</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>DNNnNgXXOCU</td>
        <td>visualizations</td>
        <td>Resistance to Cfz (samples)</td>
        <td>w9yIKFYJF83</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>JRGgjWK15U9</td>
        <td>visualizations</td>
        <td>Resistance to Bdq (samples)</td>
        <td>P8QUfzp4z2E</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>A0GUyinxMnM</td>
        <td>visualizations</td>
        <td>Resistance to Amk (samples)</td>
        <td>gVQdaMDmHqZ</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>TJ5Dm6RsvA7</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>I7w9FI4ZFoH</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
      <tr>
        <td>nPTiRJBE9NZ</td>
        <td>visualizations</td>
        <td>Patients with inoculation date for subsequent DST (solid media)</td>
        <td>ri5SLojsii1</td>
        <td>2020-12-10</td>
        <td>SaNv3EGbpNg</td>
      </tr>
    </table>
    <h3>DRS - 01. Enrollment</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 01. Enrollment</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Pm61iWFp7yO</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>F8xgVettUL1</td>
        <td>visualizations</td>
        <td>Enrolled previously treated patients - (last 12 months, current month)</td>
        <td>RQdv5N1Ytcc</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>Hn29FVaLiMV</td>
        <td>visualizations</td>
        <td>Enrolled patients with unknown treatment history - (last 12 months, current month)</td>
        <td>C9XOxpug6Pq</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>xgCWbAaOW1U</td>
        <td>visualizations</td>
        <td>Enrolled new patients - (last 12 months, current month)</td>
        <td>p23oy7g57Is</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>XiC5SRu6xqu</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>haCVHvoqhlX</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>oYJX6cDshdO</td>
        <td>visualizations</td>
        <td>Total enrolled patients (last 12 months, current month)</td>
        <td>pZnv8bzCFDh</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>p31TCQDSQsR</td>
        <td>visualizations</td>
        <td>Enrolled patients with unknown treatment history (cumulative)</td>
        <td>DesPSw9qkmt</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>IQY4krluVlQ</td>
        <td>visualizations</td>
        <td>Emrolled previously treated patients (cumulative)</td>
        <td>YXZWjkKURei</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>kdi7ULxNJzN</td>
        <td>visualizations</td>
        <td>Enrolled new patients (cumulative)</td>
        <td>zhBcO1ZU56K</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>o7j0HGAyOT6</td>
        <td>visualizations</td>
        <td>Total enrolled patients (cumulative)</td>
        <td>xHNB6XwVQeQ</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
      <tr>
        <td>CrxqCiQyhay</td>
        <td>visualizations</td>
        <td>Enrolled patients by facility (cumulative)</td>
        <td>oyMd5MFN9nh</td>
        <td>2020-10-08</td>
        <td>smoCRjXTjwj</td>
      </tr>
    </table>
    <h3>DRS - 06. Xpert MTB/RIF Ultra</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 06. Xpert MTB/RIF Ultra</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td> </td>
        <td>Resource (shortcuts)</td>
        <td> </td>
        <td>olu7viSfeOQ</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Xx8M2ZQSVfo</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>DLepRAhkp8Y</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>cVTY2NPj2tZ</td>
        <td>visualizations</td>
        <td>Patients with MTB not detected</td>
        <td>rIAgXh7oSG4</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>dRkcdEiEstM</td>
        <td>visualizations</td>
        <td>Patients with MTB detected</td>
        <td>mgfTTUk7gte</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>B1YZIwT20ls</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>UZri202hn1u</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>xBpxkfkansE</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>lyx7VgM9hOG</td>
        <td>visualizations</td>
        <td>Patients with error, invalid or no result</td>
        <td>QhRpCx78tTf</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>C4Ij1E5oQMH</td>
        <td>visualizations</td>
        <td>Previously treated patients with MTB detected</td>
        <td>vY7GtnGu0rA</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>Kt4dU1V1dtF</td>
        <td>visualizations</td>
        <td>New patients with MTB detected</td>
        <td>p0m7rSVzZM3</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>XQYkNNvpMW4</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Z0zp13Sd3qH</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>DEwPy7vlGQF</td>
        <td>visualizations</td>
        <td>Patients with MTB detected</td>
        <td>kRJnvncrZWE</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>VFTum2d1lQH</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by Xpert MTB/RIF Ultra (last year, current year)</td>
        <td>RDx0nYzgWep</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>OEUYw3CLgnA</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>iTjxetgKAgv</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>C8eJcXu9maP</td>
        <td>visualizations</td>
        <td>Samples tested by Xpert MTB/RIF Ultra</td>
        <td>PmR7RVUvty5</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>nylalB6gkvq</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>tcBRmTXHNN7</td>
        <td>visualizations</td>
        <td>Turn-around time - Xpert MTB/RIF Ultra (Cumulative %)</td>
        <td>VhcdaiEBUqC</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>EtxzHzvwkin</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
        <td>g4yMtGLFQPy</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>ugHwPgkobfk</td>
        <td>visualizations</td>
        <td>Days from sample collection to sample test date at NRL</td>
        <td>VdYPKlEqjmv</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>SAQlM0eMMD7</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>ni0Z32P6sIf</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>NnWyYGrnQNb</td>
        <td>visualizations</td>
        <td>Patients tested by Xpert MTB/RIF Ultra</td>
        <td>okv31V2mEuw</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
      <tr>
        <td>JrKTgG3HCkb</td>
        <td>visualizations</td>
        <td>Xpert MTB/RIF Ultra test results (samples)</td>
        <td>UEqPRak3l8w</td>
        <td>2020-12-10</td>
        <td>UnZLaVmbZXf</td>
      </tr>
    </table>
    <h3>DRS - 15. Maps</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 15. Maps</td>
        <td>2020-11-03</td>
        <td>WXuWmE5CeEA</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td>u4FxBzXoiml</td>
        <td>Map</td>
        <td>RR-TB patients resistant to Fq (by health facility)</td>
        <td>xOfHJ8ZrsDP</td>
        <td>2020-08-31</td>
        <td>WXuWmE5CeEA</td>
      </tr>
      <tr>
        <td>vgIrIjzONuV</td>
        <td>Map</td>
        <td>Patients with isoniazid resistant and rifampicin susceptible TB (by health facility)</td>
        <td>AMT4CectP4y</td>
        <td>2020-08-31</td>
        <td>WXuWmE5CeEA</td>
      </tr>
      <tr>
        <td>JUbkmvmNxbB</td>
        <td>Map</td>
        <td>RR-TB patients (by health facility)</td>
        <td>SNLlRI6Jlve</td>
        <td>2020-08-31</td>
        <td>WXuWmE5CeEA</td>
      </tr>
    </table>
    <h3>DRS - 09. Initial DST in solid media (e.g. LJ)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 09. Initial DST in solid media (e.g. LJ)</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td>VSWXYPl2ICa</td>
        <td>visualizations</td>
        <td>Samples with initial DST inoculation date (solid media)</td>
        <td>Yj0UeSgxCbQ</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>zJPSRYQq3qp</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>kbjk3qOzIIC</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by Initial DST SM (last year, current year)</td>
        <td>Wks6Mnt5LvB</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>d6PF4Q0GHNv</td>
        <td>visualizations</td>
        <td>Cfz - previously treated patients</td>
        <td>XQ3G4P5j7UD</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>njD1tVTj84X</td>
        <td>visualizations</td>
        <td>Lzd - previously treated patients</td>
        <td>hd7rp2eP8df</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>p496TnooKRY</td>
        <td>visualizations</td>
        <td>Dlm - previously treated patients</td>
        <td>Qlv1PX6wz8U</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>U6Mb41OYPvp</td>
        <td>visualizations</td>
        <td>Bdq - previously treated patients</td>
        <td>IgdjXbEDoIx</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>wCz17K0CRyW</td>
        <td>visualizations</td>
        <td>Mfx (CB) - previously treated patients</td>
        <td>aBbVYDhuhPk</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>xNRAnZIHoiI</td>
        <td>visualizations</td>
        <td>Mfx (CC) - previously treated patients</td>
        <td>oLTX5h3EhvQ</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>ut3DEG03LR0</td>
        <td>visualizations</td>
        <td>Lfx - previously treated patients</td>
        <td>w5W6iE7lBj0</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>YvBd8YtBoYQ</td>
        <td>visualizations</td>
        <td>Emb - previously treated patients</td>
        <td>sI1xThHfUV1</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>agNfRnyoQGj</td>
        <td>visualizations</td>
        <td>Pza - previously treated patients</td>
        <td>yeIBRmVCeSj</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>kr7ctd10yzK</td>
        <td>visualizations</td>
        <td>Inh (CB) - previously treated patients</td>
        <td>PxlOUDOf6GJ</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>Nd7PqCbehde</td>
        <td>visualizations</td>
        <td>Inh (CC) - previously treated patients</td>
        <td>unql3ajg8vM</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>UwArTJbask8</td>
        <td>visualizations</td>
        <td>Rif - previously treated patients</td>
        <td>PDJcY376FIf</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>nDP7wEHhaNJ</td>
        <td>visualizations</td>
        <td>Cfz - new patients</td>
        <td>R8bpLjEPWbi</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>AP405vQUgft</td>
        <td>visualizations</td>
        <td>Lzd - new patients</td>
        <td>fkim08wd0zF</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>WzGH9xTfC88</td>
        <td>visualizations</td>
        <td>Dlm - new patients</td>
        <td>zJV3jkYCblL</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>ldHjkLk3Ubu</td>
        <td>visualizations</td>
        <td>Bdq - new patients</td>
        <td>IbAL1laY0dY</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>klPI9qiBaJ7</td>
        <td>visualizations</td>
        <td>Mfx (CB) - new patients</td>
        <td>U2uQKZE9HG6</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>m7O5hwrq0ce</td>
        <td>visualizations</td>
        <td>Mfx (CC) - new patients</td>
        <td>xO5FWeXK0Xv</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>w3oL3C68nXe</td>
        <td>visualizations</td>
        <td>Lfx - new patients</td>
        <td>GAFf77qVG7Y</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>pgcm0rJkyvE</td>
        <td>visualizations</td>
        <td>Emb - new patients</td>
        <td>rVbSsSzieua</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>c725QhcstZk</td>
        <td>visualizations</td>
        <td>Pza - new patients</td>
        <td>Niok54N4YWa</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>LjSOI8trTcA</td>
        <td>visualizations</td>
        <td>Inh (CB) - new patients</td>
        <td>mKSqInt00PK</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>LPCZqrOtg3V</td>
        <td>visualizations</td>
        <td>Inh (CC) - new patients</td>
        <td>XgMSHWyQ69C</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>M7EpQrJdAkN</td>
        <td>visualizations</td>
        <td>R - new patients</td>
        <td>nQozylYS0pc</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>oz3WkbYtzQR</td>
        <td>visualizations</td>
        <td>Resistance to Pza</td>
        <td>eZPEMnwI4Ed</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>mqOp1uuJddI</td>
        <td>visualizations</td>
        <td>Resistance to Rif</td>
        <td>Hs41xTnV8TP</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>bGicRkyAAhN</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC)</td>
        <td>UiD31pe7c8b</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>hamA3nSqQAP</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB)</td>
        <td>pivpaOjuop8</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>s1MmdQWxnj6</td>
        <td>visualizations</td>
        <td>Resistance to Lzd</td>
        <td>tBfq3SdzOe8</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>IEED1VKCwGg</td>
        <td>visualizations</td>
        <td>Resistance to Lfx</td>
        <td>FzXeNRXQYww</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>ka97kR73CXU</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC)</td>
        <td>UHzK5JN1W4O</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>OYp1AckDY1K</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB)</td>
        <td>FihxitXrS22</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>Ii57jCO0Sxu</td>
        <td>visualizations</td>
        <td>Resistance to Emb</td>
        <td>W4xdUHxQhyg</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>jEEwA8m27lD</td>
        <td>visualizations</td>
        <td>Resistance to Dlm</td>
        <td>rYreASLbhk4</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>ih5yOFFfdr4</td>
        <td>visualizations</td>
        <td>Resistance to Cfz</td>
        <td>zGVRkkiBVcw</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>jTXvHxr70fc</td>
        <td>visualizations</td>
        <td>Resistance to Bdq</td>
        <td>STsYmk2CSt9</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>FOw9BGs2oUH</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>X0FvdB0QlyI</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>mvKSbGUqjJp</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>lFfdJDT8vFy</td>
        <td>visualizations</td>
        <td>Amk - previously treated patients</td>
        <td>yjPTfC4fmJa</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>PGPZTjZtrpp</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>H6mUfTFw6Gb</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>GN3nBnPDqkz</td>
        <td>visualizations</td>
        <td>Resistance to Amk</td>
        <td>lq8TRXWQlYx</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>cONdlUywTjF</td>
        <td>visualizations</td>
        <td>Amk - new patients</td>
        <td>Zu082NkXoqW</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Mhhl7v76rUp</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>D2kNoiaHkd4</td>
        <td>visualizations</td>
        <td>Samples with initial DST result (solid media)</td>
        <td>vMJ7B33gdBa</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>jVz0H7gALIf</td>
        <td>visualizations</td>
        <td>Patients with initial DST result (solid media)</td>
        <td>M7d3HIjE0eM</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>PybhgC4XZTw</td>
        <td>visualizations</td>
        <td>Resistance to Cfz (samples)</td>
        <td>KjQLNYQmygs</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>DWZ9pvuyhSh</td>
        <td>visualizations</td>
        <td>Resistance to Lzd (samples)</td>
        <td>WERBYWFTNRF</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>J8c1wHvzxrg</td>
        <td>visualizations</td>
        <td>Resistance to Dlm (samples)</td>
        <td>n0KbiGu7EeH</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>ffVfSsSbbLp</td>
        <td>visualizations</td>
        <td>Resistance to Bdq (samples)</td>
        <td>F55imnpaEzn</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>n1CL43NMU9h</td>
        <td>visualizations</td>
        <td>Resistance to Amk (samples)</td>
        <td>zhXRT4n3JpE</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>PM9PVJ4yyz4</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>pE25YjIlGYO</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>UkXxLzQCAso</td>
        <td>visualizations</td>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>iE3grdz2qZy</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>JF4IcGSvdKZ</td>
        <td>visualizations</td>
        <td>Resistance to Lfx (samples)</td>
        <td>lQZD3xRQP2q</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>Qy3on973OWc</td>
        <td>visualizations</td>
        <td>Resistance to Emb (samples)</td>
        <td>GRmFRiDxTyG</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>EgwPWAWbbvg</td>
        <td>visualizations</td>
        <td>Resistance to Pza (samples)</td>
        <td>TeYfP0zqpch</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>WwPSvH8d1DL</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>gvzxUchxAhj</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>Hovkta4TlFm</td>
        <td>visualizations</td>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>xKCEEQbaFTg</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>n3WNvo7TMeo</td>
        <td>visualizations</td>
        <td>Resistance to Rif (samples)</td>
        <td>LA5LqJnsib0</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>OEtoiDUm51J</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
      <tr>
        <td>qP0IsmPLpry</td>
        <td>visualizations</td>
        <td>Patients with inoculation date for initial DST (solid media)</td>
        <td>fZyPuhfsRXM</td>
        <td>2020-12-10</td>
        <td>YYwTlkCofR6</td>
      </tr>
    </table>
    <h3>DRS - 13. LPA (Rif/Inh)</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>DRS - 13. LPA (Rif/Inh)</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>CxfkB9m7OWz</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>j5Cp0UMwi6i</td>
        <td>Event report</td>
        <td>Patients with multiple samples tested by LPA RIF/INH (last year, current year)</td>
        <td>pfbIw4w7G9E</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>K1Qsk59UTGh</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>QmbqbAM2drG</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>se2PeR2RKmz</td>
        <td>visualizations</td>
        <td>Inh - previously treated patients</td>
        <td>udwa6HBaxzM</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>BzQsEMb81q4</td>
        <td>visualizations</td>
        <td>Inh - new patients</td>
        <td>pbJOHZianM5</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>pQBYrLdusMi</td>
        <td>visualizations</td>
        <td>Resistance to Inh</td>
        <td>byr3ztedK7l</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>xcY7uEWjLzG</td>
        <td>visualizations</td>
        <td>Rif - new patients</td>
        <td>TBGsaEFLEc1</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>zxN2vfgQ5Ak</td>
        <td>visualizations</td>
        <td>Rif - previously treated patients</td>
        <td>Fo0JFo9upyb</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>EWFm6mZgJAb</td>
        <td>visualizations</td>
        <td>Resistance to Rif</td>
        <td>MrWIU7oZLLn</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>vHBHVrIVAQ6</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>GVrbj9LJLFX</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>XC75VKVgvQ0</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>OnfjQrJmd3y</td>
        <td>visualizations</td>
        <td>Patients with MTB not detected</td>
        <td>wLuKxzz3UbO</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>GcGB0aKvWr7</td>
        <td>visualizations</td>
        <td>Patients with MTB detected</td>
        <td>VPJDV4H03yt</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>nOipLXhGlIX</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>s2oCGrLqRZ3</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>Lqpo13lwI9q</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>xEFSLe7DvPF</td>
        <td>visualizations</td>
        <td>Patients with invalid result</td>
        <td>wRIqMihMSfC</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>naxUYksE2eq</td>
        <td>visualizations</td>
        <td>Samples tested by LPA (Rif/Inh)</td>
        <td>vDaaWhMC6Im</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>cyMO2nixxDQ</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>u9fm8QlHOGJ</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>xm0ENkTvUGM</td>
        <td>visualizations</td>
        <td>Turn-around time - (Cumulative %)</td>
        <td>ktnEUPRZexp</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>wXY4PUTXTmR</td>
        <td>visualizations</td>
        <td>Days from sample collection to sample test date at NRL</td>
        <td>ZYAiKSIgD6g</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>LO8UDFtOX1a</td>
        <td>visualizations</td>
        <td>Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
        <td>OIEAw3DXaBD</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>ZuPQCcebYzh</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>dVZiCKfIWz2</td>
        <td>visualizations</td>
        <td>Resistance to Inh (samples)</td>
        <td>L1DNxfXacWf</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>eo9FInm1M6P</td>
        <td>visualizations</td>
        <td>Resistance to Rif (samples)</td>
        <td>NlpqA3bhRrr</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>bwhBnGNO8Y3</td>
        <td>visualizations</td>
        <td>MTB detection (samples)</td>
        <td>wYB7ko54cXs</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
      <tr>
        <td>f6OIh4puicC</td>
        <td>visualizations</td>
        <td>Patients tested by LPA (Rif/Inh)</td>
        <td>MoKPliuX9QV</td>
        <td>2020-12-10</td>
        <td>YZKPnMw2WRu</td>
      </tr>
    </table>
    <h2 id="visualizations">Visualizations</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Resistance to Amk (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Amk (samples)</td>
        <td>2021-01-28T17:12:24.763</td>
        <td>A0GUyinxMnM</td>
      </tr>
      <tr>
        <td>Inh (CB) - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Inh (CB)</td>
        <td>2020-12-10T19:00:34.434</td>
        <td>a2zCUUlpWJU</td>
      </tr>
      <tr>
        <td>Pza - new patients</td>
        <td>Initial DST (liquid media) - new patients - Pza</td>
        <td>2021-01-28T17:12:24.964</td>
        <td>A4hzokLF4Js</td>
      </tr>
      <tr>
        <td>Lzd - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Lzd</td>
        <td>2020-12-10T19:00:35.195</td>
        <td>aegNQwFewqY</td>
      </tr>
      <tr>
        <td>Resistance to Bdq (samples)</td>
        <td>Initial DST (liquid media) - resistance to Bdq (samples)</td>
        <td>2020-12-10T19:00:35.041</td>
        <td>aeMK8cyHYjQ</td>
      </tr>
      <tr>
        <td>Lfx - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Lfx</td>
        <td>2020-12-10T19:00:34.577</td>
        <td>aEw2XfprWsw</td>
      </tr>
      <tr>
        <td>Results for culture in solid media (samples)</td>
        <td>Results for culture (solid media) (samples)</td>
        <td>2020-12-10T19:00:34.724</td>
        <td>aFFpc0n6lgn</td>
      </tr>
      <tr>
        <td>Pza - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Pza</td>
        <td>2020-12-10T19:00:35.348</td>
        <td>agNfRnyoQGj</td>
      </tr>
      <tr>
        <td>Emb - new patients</td>
        <td>Initial DST (liquid media) - new patients - Emb</td>
        <td>2021-01-28T17:12:28.746</td>
        <td>aHI7LkZopPe</td>
      </tr>
      <tr>
        <td>Resistance to Dlm (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Dlm (samples)</td>
        <td>2021-01-28T17:12:25.168</td>
        <td>ANXqiUngJqW</td>
      </tr>
      <tr>
        <td>Lzd - new patients</td>
        <td>Initial DST (solid media) - new patients - Lzd</td>
        <td>2021-01-28T17:12:25.358</td>
        <td>AP405vQUgft</td>
      </tr>
      <tr>
        <td>Lzd - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Lzd</td>
        <td>2021-01-28T17:12:28.942</td>
        <td>awSxldaNoqk</td>
      </tr>
      <tr>
        <td>Resistance to Dlm</td>
        <td>Initial DST (liquid media) - resistance to Dlm</td>
        <td>2021-01-28T17:12:25.557</td>
        <td>BA09TUcaRPc</td>
      </tr>
      <tr>
        <td>Resistance to Fq</td>
        <td>LPA (Fq/2LI) - resistance to Fq</td>
        <td>2020-12-10T19:00:35.786</td>
        <td>beD8lhuXasY</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC)</td>
        <td>Initial DST (solid media) - resistance to Mfx (CC)</td>
        <td>2020-12-10T19:00:35.643</td>
        <td>bGicRkyAAhN</td>
      </tr>
      <tr>
        <td>Samples with initial DST result (liquid media)</td>
        <td>Samples with initial DST result (liquid media)</td>
        <td>2021-01-28T17:12:25.778</td>
        <td>BhDtzX4p4Dc</td>
      </tr>
      <tr>
        <td>Samples with microscopy result</td>
        <td>Samples with result for microscopy</td>
        <td>2020-12-10T19:00:35.935</td>
        <td>bpTrN5QtYBf</td>
      </tr>
      <tr>
        <td>MTB detection (samples)</td>
        <td>MTB - LPA (Rif/Inh) (samples)</td>
        <td>2020-12-10T19:00:36.082</td>
        <td>bwhBnGNO8Y3</td>
      </tr>
      <tr>
        <td>Inh - new patients</td>
        <td>LPA (Rif/Inh) - new patients - Inh</td>
        <td>2021-01-28T17:12:25.992</td>
        <td>BzQsEMb81q4</td>
      </tr>
      <tr>
        <td>Previously treated patients with MTB detected</td>
        <td>Xpert MTB/RIF Ultra - previously treated patients with MTB detected</td>
        <td>2021-01-28T17:12:26.202</td>
        <td>C4Ij1E5oQMH</td>
      </tr>
      <tr>
        <td>Kan - previously treated patients</td>
        <td>LPA (Fq/2LI) - previously treated patients - Kan</td>
        <td>2021-01-28T17:12:26.401</td>
        <td>C4OVijAvxbh</td>
      </tr>
      <tr>
        <td>Pza - new patients</td>
        <td>Initial DST (solid media) - new patients - Pza</td>
        <td>2021-01-28T17:12:29.136</td>
        <td>c725QhcstZk</td>
      </tr>
      <tr>
        <td>Samples tested by Xpert MTB/RIF Ultra</td>
        <td>Samples with result for Xpert MTB/RIF Ultra</td>
        <td>2021-01-28T17:12:26.602</td>
        <td>C8eJcXu9maP</td>
      </tr>
      <tr>
        <td>Rif - new patients</td>
        <td>Initial DST (liquid media) - new patients - Rif</td>
        <td>2020-12-10T19:00:36.378</td>
        <td>cFJqrZQKHgF</td>
      </tr>
      <tr>
        <td>Cfz - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Cfz</td>
        <td>2020-12-10T19:00:36.982</td>
        <td>cjHSPSneRnG</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>Initial DST (liquid media) - resistance to Inh (CC) (samples)</td>
        <td>2020-12-10T19:00:37.135</td>
        <td>cktDmhvOWZa</td>
      </tr>
      <tr>
        <td>Emb - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Emb</td>
        <td>2020-12-10T19:00:36.522</td>
        <td>cKz5lKn3xGh</td>
      </tr>
      <tr>
        <td>Pza - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Pza</td>
        <td>2021-01-28T17:12:26.813</td>
        <td>CLSLUzJdCuq</td>
      </tr>
      <tr>
        <td>Amk - new patients</td>
        <td>Initial DST (solid media) - new patients - Amk</td>
        <td>2020-12-10T19:00:36.666</td>
        <td>cONdlUywTjF</td>
      </tr>
      <tr>
        <td>Enrolled patients by facility (cumulative)</td>
        <td>DRS - Enrolled patients by facility (cumulative)</td>
        <td>2020-09-15T12:48:57.810</td>
        <td>CrxqCiQyhay</td>
      </tr>
      <tr>
        <td>Patients with MTB not detected</td>
        <td>Xpert MTB/RIF Ultra - Patients with MTB not detected</td>
        <td>2020-12-10T19:00:36.820</td>
        <td>cVTY2NPj2tZ</td>
      </tr>
      <tr>
        <td>Resistance to Emb (samples)</td>
        <td>LPA (Fq/2LI) - resistance to Emb (samples)</td>
        <td>2020-12-10T19:00:13.186</td>
        <td>D00s3xjiw09</td>
      </tr>
      <tr>
        <td>Resistance to Pza</td>
        <td>Subsequent DST (solid media) - resistance to Pza</td>
        <td>2021-01-07T12:09:21.268</td>
        <td>D25kT4vRlL2</td>
      </tr>
      <tr>
        <td>Samples with initial DST result (solid media)</td>
        <td>Samples with initial DST result (solid media)</td>
        <td>2020-12-10T19:00:13.493</td>
        <td>D2kNoiaHkd4</td>
      </tr>
      <tr>
        <td>Cfz - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Cfz</td>
        <td>2020-12-10T19:00:37.289</td>
        <td>d6PF4Q0GHNv</td>
      </tr>
      <tr>
        <td>Patients with MTB detected</td>
        <td>Xpert MTB/RIF Ultra - patients with MTB detected</td>
        <td>2020-12-10T19:00:13.651</td>
        <td>DEwPy7vlGQF</td>
      </tr>
      <tr>
        <td>Inh (CB) - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Inh (CB)</td>
        <td>2021-01-07T12:09:21.620</td>
        <td>DLS3Be5bz8Q</td>
      </tr>
      <tr>
        <td>Resistance to Cfz (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Cfz (samples)</td>
        <td>2021-01-07T12:09:21.783</td>
        <td>DNNnNgXXOCU</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Inh (CB) (samples)</td>
        <td>2021-01-07T12:09:22.133</td>
        <td>DorTOrUuHur</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC)</td>
        <td>Subsequent DST (liquid media) - resistance to Inh (CC)</td>
        <td>2021-01-07T12:09:22.293</td>
        <td>Dp7puzuYHMm</td>
      </tr>
      <tr>
        <td>Samples with initial DST inoculation date (liquid media)</td>
        <td>Samples with initial DST inoculation date (liquid media)</td>
        <td>2020-12-10T19:00:38.180</td>
        <td>dqi5lGsIoD8</td>
      </tr>
      <tr>
        <td>Rif - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Rif</td>
        <td>2020-12-10T19:00:38.036</td>
        <td>dqLeOPey91y</td>
      </tr>
      <tr>
        <td>Resistance to Kan</td>
        <td>LPA (Fq/2LI) - resistance to Kan</td>
        <td>2020-12-10T19:00:37.438</td>
        <td>dQScB8Kubd8</td>
      </tr>
      <tr>
        <td>Pza - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Pza</td>
        <td>2021-01-28T17:12:29.339</td>
        <td>dr8wLFfEgQa</td>
      </tr>
      <tr>
        <td>Patients with MTB detected</td>
        <td>Xpert MTB/RIF Ultra - Patients with MTB detected</td>
        <td>2020-12-10T19:00:37.591</td>
        <td>dRkcdEiEstM</td>
      </tr>
      <tr>
        <td>Resistance to Inh (samples)</td>
        <td>LPA (Rif/Inh) - resistance to Inh (samples)</td>
        <td>2020-12-10T19:00:37.745</td>
        <td>dVZiCKfIWz2</td>
      </tr>
      <tr>
        <td>Resistance to Lzd (samples)</td>
        <td>Initial DST (solid media) - resistance to Lzd (samples)</td>
        <td>2021-01-07T12:09:21.945</td>
        <td>DWZ9pvuyhSh</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to sample arrival at NRL</td>
        <td>Days from sample collection to sample arrival at NRL (mean)</td>
        <td>2021-02-05T15:08:59.834</td>
        <td>dZOYcMkF3Va</td>
      </tr>
      <tr>
        <td>Resistance to Cfz (samples)</td>
        <td>Initial DST (liquid media) - resistance to Cfz (samples)</td>
        <td>2020-12-10T19:00:38.487</td>
        <td>e7LQhueHCdC</td>
      </tr>
      <tr>
        <td>Lzd - new patients</td>
        <td>Initial DST (liquid media) - new patients - Lzd</td>
        <td>2021-01-28T17:12:27.003</td>
        <td>EcHsKYrhXnH</td>
      </tr>
      <tr>
        <td>Patients with microscopy result</td>
        <td>Patients with result for microscopy</td>
        <td>2020-12-10T19:00:38.634</td>
        <td>eGImCpP8rA4</td>
      </tr>
      <tr>
        <td>Resistance to Pza (samples)</td>
        <td>Initial DST (solid media) - resistance to Pza (samples)</td>
        <td>2021-01-07T12:09:23.075</td>
        <td>EgwPWAWbbvg</td>
      </tr>
      <tr>
        <td>Lfx - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Lfx</td>
        <td>2020-12-10T19:00:15.357</td>
        <td>EiCzDOiO8bm</td>
      </tr>
      <tr>
        <td>Previously treated patients with result for microscopy</td>
        <td>Previously treated patients with result for microscopy</td>
        <td>2020-12-10T19:00:15.512</td>
        <td>Ej8MbUOoVEE</td>
      </tr>
      <tr>
        <td>Patients with MTB detected</td>
        <td>Xpert MTB/RIF - patients with MTB detected</td>
        <td>2020-12-10T19:00:38.780</td>
        <td>eK6jLV0dfCv</td>
      </tr>
      <tr>
        <td>Samples tested by Xpert MTB/RIF</td>
        <td>Samples with result for Xpert MTB/RIF</td>
        <td>2020-12-10T19:00:38.925</td>
        <td>ekabm7c2qeY</td>
      </tr>
      <tr>
        <td>Patients with MTB not detected</td>
        <td>Xpert MTB/RIF - patients with MTB not detected</td>
        <td>2020-12-10T19:00:15.677</td>
        <td>EkB83FOYDCa</td>
      </tr>
      <tr>
        <td>Inh (CC) - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Inh (CC)</td>
        <td>2020-12-10T19:00:39.085</td>
        <td>emYVgDuDucX</td>
      </tr>
      <tr>
        <td>Resistance to Rif (samples)</td>
        <td>LPA (Rif/Inh) - resistance to Rif (samples)</td>
        <td>2020-12-10T19:00:39.384</td>
        <td>eo9FInm1M6P</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NRL</td>
        <td>2021-02-05T14:55:29.318</td>
        <td>EtxzHzvwkin</td>
      </tr>
      <tr>
        <td>Mfx (CB) - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Mfx (CB)</td>
        <td>2021-01-07T12:09:22.451</td>
        <td>EUr2DpEAQkm</td>
      </tr>
      <tr>
        <td>Resistance to Rif</td>
        <td>LPA (Rif/Inh) - resistance to Rif</td>
        <td>2021-01-07T12:09:22.604</td>
        <td>EWFm6mZgJAb</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Mfx (CC) (samples)</td>
        <td>2021-01-07T12:09:22.757</td>
        <td>EYCtE5oVkqk</td>
      </tr>
      <tr>
        <td>Patients tested by LPA (Rif/Inh)</td>
        <td>Patients with result for LPA (Rif/Inh)</td>
        <td>2020-12-10T19:00:39.527</td>
        <td>f6OIh4puicC</td>
      </tr>
      <tr>
        <td>Mfx (CC) - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:16.041</td>
        <td>F6tAKWre2CZ</td>
      </tr>
      <tr>
        <td>Enrolled previously treated patients - (last 12 months, current month)</td>
        <td>DRS enrollments - previously treated patients - (last 12 months, current month)</td>
        <td>2020-12-10T19:00:16.211</td>
        <td>F8xgVettUL1</td>
      </tr>
      <tr>
        <td>Dlm - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Dlm</td>
        <td>2020-12-10T19:00:16.678</td>
        <td>Fa9Ul35r9pz</td>
      </tr>
      <tr>
        <td>Resistance to Lzd</td>
        <td>Subsequent DST (liquid media) - resistance to Lzd</td>
        <td>2020-12-10T19:00:16.839</td>
        <td>FeZw3M57SPl</td>
      </tr>
      <tr>
        <td>Resistance to Bdq (samples)</td>
        <td>Initial DST (solid media) - resistance to Bdq (samples)</td>
        <td>2020-12-10T19:00:39.979</td>
        <td>ffVfSsSbbLp</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>Initial DST (liquid media) - resistance to Mfx (CC) (samples)</td>
        <td>2020-12-10T19:00:39.683</td>
        <td>fHv6yNQ1wR4</td>
      </tr>
      <tr>
        <td>Resistance to Lfx (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Lfx (samples)</td>
        <td>2020-12-10T19:00:16.986</td>
        <td>Fk2TmAyOpag</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>Initial DST (liquid media) - resistance to Inh (CB) (samples)</td>
        <td>2020-12-10T19:00:40.142</td>
        <td>foDYQgWarwE</td>
      </tr>
      <tr>
        <td>Pza - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Pza</td>
        <td>2020-12-10T19:00:40.285</td>
        <td>fs5HhajBUL0</td>
      </tr>
      <tr>
        <td>Resistance to Cfz</td>
        <td>Initial DST (liquid media) - resistance to Cfz</td>
        <td>2020-12-10T19:00:16.361</td>
        <td>FTyV3ikFRTc</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for subsequent DST (liquid media)</td>
        <td>Patients with inoculation date for subsequent DST (liquid media)</td>
        <td>2020-12-10T19:00:17.139</td>
        <td>FwhCb8WGQ53</td>
      </tr>
      <tr>
        <td>Resistance to Lfx</td>
        <td>Subsequent DST (solid media) - resistance to Lfx</td>
        <td>2020-12-10T19:00:39.831</td>
        <td>fXhF7qU5uEL</td>
      </tr>
      <tr>
        <td>Emb - new patients</td>
        <td>LPA (Fq/2LI) - new patients - Emb</td>
        <td>2021-01-28T17:12:27.198</td>
        <td>FXzZHPzkCKt</td>
      </tr>
      <tr>
        <td>Turn-around time - Culture in liquid media (Cumulative %)</td>
        <td>Turn-around time - Culture in liquid media (Cumulative %)</td>
        <td>2020-08-13T11:19:32.230</td>
        <td>G3WcSC5OfCD</td>
      </tr>
      <tr>
        <td>Amk/Cap - new patients</td>
        <td>LPA (Fq/2LI) - new patients - Amk/Cap</td>
        <td>2020-12-10T19:00:17.289</td>
        <td>G5KYplbOkBV</td>
      </tr>
      <tr>
        <td>Patients with MTB detected</td>
        <td>LPA (Rif/Inh) - patients with MTB detected</td>
        <td>2020-12-10T19:00:17.613</td>
        <td>GcGB0aKvWr7</td>
      </tr>
      <tr>
        <td>Percentage of samples rejected on arrival at NTRL</td>
        <td>Percentage of samples rejected on arrival at NTRL</td>
        <td>2021-02-05T15:13:30.098</td>
        <td>GinRhTtdKnI</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Inh (CC) (samples)</td>
        <td>2020-12-10T19:00:40.433</td>
        <td>gJuYzn7d4HM</td>
      </tr>
      <tr>
        <td>Resistance to Amk</td>
        <td>Initial DST (solid media) - resistance to Amk</td>
        <td>2020-12-10T19:00:17.465</td>
        <td>GN3nBnPDqkz</td>
      </tr>
      <tr>
        <td>Bdq - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Bdq</td>
        <td>2020-12-10T19:00:17.763</td>
        <td>Go33kUTQSvz</td>
      </tr>
      <tr>
        <td>Resistance to Cfz (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Cfz (samples)</td>
        <td>2020-12-10T19:00:40.583</td>
        <td>gPr0OavnoRo</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NRL</td>
        <td>2021-02-05T14:51:25.955</td>
        <td>H2Aiv0M4LNQ</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB)</td>
        <td>Initial DST (solid media) - resistance to Mfx (CB)</td>
        <td>2020-12-10T19:00:40.878</td>
        <td>hamA3nSqQAP</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC)</td>
        <td>Initial DST (liquid media) - resistance to Inh (CC)</td>
        <td>2020-12-10T19:00:18.228</td>
        <td>Hc9jtStLefh</td>
      </tr>
      <tr>
        <td>Dlm - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Dlm</td>
        <td>2020-12-10T19:00:41.023</td>
        <td>hec5A4nwmjI</td>
      </tr>
      <tr>
        <td>New patients with microscopy result</td>
        <td>New patients with result for microscopy</td>
        <td>2020-12-10T19:00:18.383</td>
        <td>HhEwiZxXl81</td>
      </tr>
      <tr>
        <td>Amk - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Amk</td>
        <td>2020-12-10T19:00:18.530</td>
        <td>HhZlsNH320n</td>
      </tr>
      <tr>
        <td>MTB detection (samples)</td>
        <td>MTB - LPA (Fq/2LI) (samples)</td>
        <td>2020-12-10T19:00:41.167</td>
        <td>hja6zsSoVpW</td>
      </tr>
      <tr>
        <td>Inh (CB) - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Inh (CB)</td>
        <td>2020-12-10T19:00:18.064</td>
        <td>HLv9cxNEo3f</td>
      </tr>
      <tr>
        <td>Enrolled patients with unknown treatment history - (last 12 months, current month)</td>
        <td>DRS enrollments - patients with unknown treatment history - (last 12 months, current month)</td>
        <td>2020-12-10T19:00:18.685</td>
        <td>Hn29FVaLiMV</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>Initial DST (solid media) - resistance to Inh (CC) (samples)</td>
        <td>2020-12-10T19:00:18.837</td>
        <td>Hovkta4TlFm</td>
      </tr>
      <tr>
        <td>Rif - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Rif</td>
        <td>2020-12-10T19:00:40.731</td>
        <td>hQy2JqWsbt0</td>
      </tr>
      <tr>
        <td>Turn-around time - (Cumulative %)</td>
        <td>Turn-around time Xpert MTB/RIF (Cumulative %)</td>
        <td>2020-12-10T19:03:53.038</td>
        <td>hTHJ2wtGxWK</td>
      </tr>
      <tr>
        <td>Inh (CC) - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Inh (CC)</td>
        <td>2020-12-10T19:00:18.990</td>
        <td>I627wRgZ4QT</td>
      </tr>
      <tr>
        <td>Resistance to Lfx</td>
        <td>Initial DST (solid media) - resistance to Lfx</td>
        <td>2020-12-10T19:00:19.141</td>
        <td>IEED1VKCwGg</td>
      </tr>
      <tr>
        <td>Patients tested by LPA (Fq/2LI)</td>
        <td>Patients with result for LPA (Fq/2LI)</td>
        <td>2020-12-10T19:00:41.744</td>
        <td>ieNOfHx6BBR</td>
      </tr>
      <tr>
        <td>Resistance to Pza</td>
        <td>Initial DST (liquid media) - resistance to Pza</td>
        <td>2020-12-10T19:00:19.598</td>
        <td>IeSFBNrXClS</td>
      </tr>
      <tr>
        <td>Patients with microscopy result</td>
        <td>Patients with result for microscopy</td>
        <td>2020-12-10T19:00:41.309</td>
        <td>iFEsGz7MUiU</td>
      </tr>
      <tr>
        <td>Emb - previously treated patients</td>
        <td>LPA (Fq/2LI) - previously treated patients - Emb</td>
        <td>2020-12-10T19:00:41.457</td>
        <td>iG4dAT1HEWJ</td>
      </tr>
      <tr>
        <td>Resistance to Cfz</td>
        <td>Initial DST (solid media) - resistance to Cfz</td>
        <td>2020-12-10T19:00:41.886</td>
        <td>ih5yOFFfdr4</td>
      </tr>
      <tr>
        <td>Inh (CC) - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Inh (CC)</td>
        <td>2020-12-10T19:00:42.027</td>
        <td>ihgJ65J1UMA</td>
      </tr>
      <tr>
        <td>Resistance to Emb</td>
        <td>Initial DST (solid media) - resistance to Emb</td>
        <td>2020-12-10T19:00:19.743</td>
        <td>Ii57jCO0Sxu</td>
      </tr>
      <tr>
        <td>New patients with culture result (liquid media)</td>
        <td>New patients with result for culture (liquid media)</td>
        <td>2020-12-10T19:00:19.897</td>
        <td>IiJ9tpLTQvI</td>
      </tr>
      <tr>
        <td>Resistance to Rif (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Rif (samples)</td>
        <td>2020-12-10T19:00:42.171</td>
        <td>ijfAvuMpluV</td>
      </tr>
      <tr>
        <td>Resistance to Lfx (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Lfx (samples)</td>
        <td>2020-12-10T19:00:41.607</td>
        <td>iM6JWuhj3lg</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>Initial DST (liquid media) - resistance to Mfx (CB) (samples)</td>
        <td>2020-12-10T19:00:42.311</td>
        <td>ipzFvaEa97c</td>
      </tr>
      <tr>
        <td>Emrolled previously treated patients (cumulative)</td>
        <td>DRS enrollments - previously treated patients (cumulative)</td>
        <td>2020-12-10T19:00:19.291</td>
        <td>IQY4krluVlQ</td>
      </tr>
      <tr>
        <td>Samples with subsequent DST result (solid media)</td>
        <td>Samples with subsequent DST result (solid media)</td>
        <td>2020-12-10T19:00:19.439</td>
        <td>IYRukplIKR0</td>
      </tr>
      <tr>
        <td>Resistance to Dlm (samples)</td>
        <td>Initial DST (solid media) - resistance to Dlm (samples)</td>
        <td>2021-01-28T17:12:27.413</td>
        <td>J8c1wHvzxrg</td>
      </tr>
      <tr>
        <td>Days from sample collection to inoculation date</td>
        <td>Days from sample collection in peripheral labs to inoculation date for culture (liquid media) - (0 - 10+) days</td>
        <td>2020-12-10T19:00:43.543</td>
        <td>jcxG1GQfZoh</td>
      </tr>
      <tr>
        <td>Previously treated patients with result for culture (solid media)</td>
        <td>Previously treated patients with result for culture (solid media)</td>
        <td>2020-12-10T19:00:42.633</td>
        <td>jEcL61jz154</td>
      </tr>
      <tr>
        <td>Resistance to Dlm</td>
        <td>Initial DST (solid media) - resistance to Dlm</td>
        <td>2021-01-28T17:12:29.534</td>
        <td>jEEwA8m27lD</td>
      </tr>
      <tr>
        <td>Resistance to Lfx (samples)</td>
        <td>Initial DST (solid media) - resistance to Lfx (samples)</td>
        <td>2020-12-10T19:00:20.267</td>
        <td>JF4IcGSvdKZ</td>
      </tr>
      <tr>
        <td>Lfx - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Lfx</td>
        <td>2020-12-10T19:00:43.702</td>
        <td>jjc1bLPes8H</td>
      </tr>
      <tr>
        <td>Resistance to Emb (samples)</td>
        <td>Initial DST (liquid media) - resistance to Emb (samples)</td>
        <td>2020-12-10T19:00:20.578</td>
        <td>Jje0NRe1NbT</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF test results (samples)</td>
        <td>Xpert MTB/RIF test results (samples)</td>
        <td>2020-12-10T19:00:42.788</td>
        <td>jKhHBRO93cq</td>
      </tr>
      <tr>
        <td>Resistance to Amk</td>
        <td>Subsequent DST (solid media) - resistance to Amk</td>
        <td>2020-12-10T19:00:43.870</td>
        <td>jovCNzeVi4M</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB)</td>
        <td>Initial DST (liquid media) - resistance to Mfx (CB)</td>
        <td>2020-12-10T19:00:44.023</td>
        <td>jpfLJ32aeGt</td>
      </tr>
      <tr>
        <td>Results for culture in liquid media (samples)</td>
        <td>Results for culture (liquid media) (samples)</td>
        <td>2020-12-10T19:00:42.932</td>
        <td>jPqtZEibOnx</td>
      </tr>
      <tr>
        <td>Resistance to Bdq (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Bdq (samples)</td>
        <td>2020-12-10T19:00:20.417</td>
        <td>JRGgjWK15U9</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra test results (samples)</td>
        <td>Xpert MTB/RIF Ultra test results (samples)</td>
        <td>2020-12-10T19:00:20.748</td>
        <td>JrKTgG3HCkb</td>
      </tr>
      <tr>
        <td>Resistance to Bdq</td>
        <td>Initial DST (solid media) - resistance to Bdq</td>
        <td>2020-12-10T19:00:43.096</td>
        <td>jTXvHxr70fc</td>
      </tr>
      <tr>
        <td>Patients with initial DST result (solid media)</td>
        <td>Patients with result for initial DST (solid media)</td>
        <td>2020-12-10T19:00:43.244</td>
        <td>jVz0H7gALIf</td>
      </tr>
      <tr>
        <td>Patients with culture result (liquid media)</td>
        <td>Patients with result for culture (liquid media)</td>
        <td>2020-12-10T19:00:43.387</td>
        <td>jWsixkLlTt7</td>
      </tr>
      <tr>
        <td>Bdq - new patients</td>
        <td>Initial DST (liquid media) - new patients - Bdq</td>
        <td>2020-12-10T19:00:20.909</td>
        <td>JxfNDGLZihK</td>
      </tr>
      <tr>
        <td>Samples with subsequent DST result (liquid media)</td>
        <td>Samples with subsequent DST result (liquid media)</td>
        <td>2020-12-10T19:00:44.300</td>
        <td>k2tU8E5dEJe</td>
      </tr>
      <tr>
        <td>Bdq - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Bdq</td>
        <td>2020-12-10T19:00:21.069</td>
        <td>K6SZfRpy8qY</td>
      </tr>
      <tr>
        <td>Lfx - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Lfx</td>
        <td>2020-12-10T19:00:44.458</td>
        <td>k7Zla8Drzwj</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC)</td>
        <td>Initial DST (solid media) - resistance to Inh (CC)</td>
        <td>2020-12-10T19:00:44.738</td>
        <td>ka97kR73CXU</td>
      </tr>
      <tr>
        <td>Enrolled new patients (cumulative)</td>
        <td>DRS enrollments - new patients (cumulative)</td>
        <td>2020-12-10T19:00:44.876</td>
        <td>kdi7ULxNJzN</td>
      </tr>
      <tr>
        <td>Patients with MTB detected</td>
        <td>LPA (Fq/2LI) - patients with MTB detected</td>
        <td>2020-12-10T19:00:44.595</td>
        <td>kFUtsdrzsEV</td>
      </tr>
      <tr>
        <td>Previously treated patients with result for culture (liquid media)</td>
        <td>Previously treated patients with result for culture (liquid media)</td>
        <td>2020-12-10T19:00:21.224</td>
        <td>KH9PdDr0Q0w</td>
      </tr>
      <tr>
        <td>Resistance to Dlm (samples)</td>
        <td>Initial DST (liquid media) - resistance to Dlm (samples)</td>
        <td>2021-01-28T17:12:27.625</td>
        <td>KJjXSkoWjMs</td>
      </tr>
      <tr>
        <td>Mfx (CB) - new patients</td>
        <td>Initial DST (solid media) - new patients - Mfx (CB)</td>
        <td>2020-12-10T19:00:45.021</td>
        <td>klPI9qiBaJ7</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Mfx (CB) (samples)</td>
        <td>2020-12-10T19:00:45.166</td>
        <td>kneiEKxrJgp</td>
      </tr>
      <tr>
        <td>Inh (CB) - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Inh (CB)</td>
        <td>2020-12-10T19:00:45.314</td>
        <td>kr7ctd10yzK</td>
      </tr>
      <tr>
        <td>New patients with MTB detected</td>
        <td>Xpert MTB/RIF Ultra - new patients with MTB detected</td>
        <td>2020-12-10T19:00:21.574</td>
        <td>Kt4dU1V1dtF</td>
      </tr>
      <tr>
        <td>Resistance to Amk/Cap (samples)</td>
        <td>LPA (Fq/2LI) - resistance to Amk/Cap (samples)</td>
        <td>2020-12-10T19:00:21.725</td>
        <td>KwTMGMSw5zJ</td>
      </tr>
      <tr>
        <td>Resistance to Bdq (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Bdq (samples)</td>
        <td>2020-12-10T19:00:21.896</td>
        <td>KxBQWoRCB03</td>
      </tr>
      <tr>
        <td>New patients with culture result (solid media)</td>
        <td>New patients with result for culture (solid media)</td>
        <td>2020-12-10T19:00:45.469</td>
        <td>l5GNHYa9Nsd</td>
      </tr>
      <tr>
        <td>Resistance to Bdq</td>
        <td>Subsequent DST (liquid media) - resistance to Bdq</td>
        <td>2020-12-10T19:00:45.616</td>
        <td>l97UW74mZiK</td>
      </tr>
      <tr>
        <td>Patients tested by Xpert MTB/RIF</td>
        <td>Patients tested by Xpert MTB/RIF</td>
        <td>2020-12-10T19:00:45.760</td>
        <td>lBcNYF3y4y9</td>
      </tr>
      <tr>
        <td>Samples with subsequent DST inoculation date (liquid media)</td>
        <td>Samples with subsequent DST inoculation date (liquid media)</td>
        <td>2020-12-10T19:00:22.668</td>
        <td>LbqAqZXje61</td>
      </tr>
      <tr>
        <td>Inh (CC) - new patients</td>
        <td>Initial DST (liquid media) - new patients - Inh (CC)</td>
        <td>2020-12-10T19:00:22.832</td>
        <td>LcSUiJ4egVu</td>
      </tr>
      <tr>
        <td>Bdq - new patients</td>
        <td>Initial DST (solid media) - new patients - Bdq</td>
        <td>2020-12-10T19:00:46.538</td>
        <td>ldHjkLk3Ubu</td>
      </tr>
      <tr>
        <td>Samples with culture result (solid media)</td>
        <td>Samples with culture result (solid media)</td>
        <td>2020-12-10T19:00:46.678</td>
        <td>leHYVTzL7P1</td>
      </tr>
      <tr>
        <td>Resistance to Kan (samples)</td>
        <td>LPA (Fq/2LI) - resistance to Kan (samples)</td>
        <td>2020-12-10T19:00:46.832</td>
        <td>leIoVrq7UJ6</td>
      </tr>
      <tr>
        <td>Resistance to Emb</td>
        <td>LPA (Fq/2LI) - resistance to Emb</td>
        <td>2021-02-05T11:59:07.470</td>
        <td>LEUdKDr5L1a</td>
      </tr>
      <tr>
        <td>Amk - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Amk</td>
        <td>2020-12-10T19:00:45.938</td>
        <td>lFfdJDT8vFy</td>
      </tr>
      <tr>
        <td>Progress in sample processing</td>
        <td>Percentage of enrolled patients having taken or undergoing
          a test</td>
        <td>2021-02-05T14:52:40.787</td>
        <td>lH4hJMrZWYs</td>
      </tr>
      <tr>
        <td>Resistance to Amk/Cap</td>
        <td>LPA (Fq/2LI) - resistance to Amk/Cap</td>
        <td>2021-02-05T11:59:07.683</td>
        <td>lhVtzsnOKDu</td>
      </tr>
      <tr>
        <td>Resistance to Emb</td>
        <td>Subsequent DST (liquid media) - resistance to Emb</td>
        <td>2020-12-10T19:00:46.247</td>
        <td>lHXvAIIDEdC</td>
      </tr>
      <tr>
        <td>Inh (CB) - new patients</td>
        <td>Initial DST (solid media) - new patients - Inh (CB)</td>
        <td>2020-12-10T19:00:22.986</td>
        <td>LjSOI8trTcA</td>
      </tr>
      <tr>
        <td>Mfx (CC) - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:23.144</td>
        <td>LjWbJG0O38q</td>
      </tr>
      <tr>
        <td>Resistance to Pza (samples)</td>
        <td>Initial DST (liquid media) - resistance to Pza (samples)</td>
        <td>2020-12-10T19:00:47.120</td>
        <td>lk33yehvMKx</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC)</td>
        <td>Subsequent DST (solid media) - resistance to Mfx (CC)</td>
        <td>2020-12-10T19:00:22.204</td>
        <td>LKnYqCYbSZK</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
        <td>Average number of days from sample collection to LPA (Rif/Inh) test at NRL</td>
        <td>2021-02-05T14:56:49.778</td>
        <td>LO8UDFtOX1a</td>
      </tr>
      <tr>
        <td>Inh (CC) - new patients</td>
        <td>Initial DST (solid media) - new patients - Inh (CC)</td>
        <td>2020-12-10T19:00:22.512</td>
        <td>LPCZqrOtg3V</td>
      </tr>
      <tr>
        <td>Patients with subsequent DST result (solid media)</td>
        <td>Patients with result for subsequent DST (solid media)</td>
        <td>2020-12-10T19:00:47.256</td>
        <td>lqjr3ijnXLz</td>
      </tr>
      <tr>
        <td>Patients with culture result (solid media)</td>
        <td>Patients with result for culture (solid media)</td>
        <td>2020-12-10T19:00:47.419</td>
        <td>lstK4dpi7QV</td>
      </tr>
      <tr>
        <td>Patients with error, invalid or no result</td>
        <td>Xpert MTB/RIF Ultra - patients with error, invalid or no result</td>
        <td>2020-12-10T19:00:47.562</td>
        <td>lyx7VgM9hOG</td>
      </tr>
      <tr>
        <td>Resistance to Emb (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Emb (samples)</td>
        <td>2020-12-10T19:00:46.395</td>
        <td>lZ2mFM2ePmS</td>
      </tr>
      <tr>
        <td>R - new patients</td>
        <td>Initial DST (solid media) - new patients - Rif</td>
        <td>2020-12-10T19:00:23.298</td>
        <td>M7EpQrJdAkN</td>
      </tr>
      <tr>
        <td>Mfx (CC) - new patients</td>
        <td>Initial DST (solid media) - new patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:47.705</td>
        <td>m7O5hwrq0ce</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB)</td>
        <td>Subsequent DST (solid media) - resistance to Inh (CB)</td>
        <td>2020-12-10T19:00:23.762</td>
        <td>MazLayAlMZt</td>
      </tr>
      <tr>
        <td>Patients with MTB detected</td>
        <td>Xpert MTB/RIF - patients with MTB detected</td>
        <td>2020-12-10T19:00:23.911</td>
        <td>MdnAKUS1j8C</td>
      </tr>
      <tr>
        <td>Patients with error, invalid or no result</td>
        <td>Xpert MTB/RIF - patients with error, invalid or no result</td>
        <td>2020-12-10T19:00:48.010</td>
        <td>mepSgyFIhDg</td>
      </tr>
      <tr>
        <td>Resistance to Cfz</td>
        <td>Subsequent DST (solid media) - resistance to Cfz</td>
        <td>2020-12-10T19:00:23.456</td>
        <td>MEr4EVGlmES</td>
      </tr>
      <tr>
        <td>Rif - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Rif</td>
        <td>2020-12-10T19:00:23.608</td>
        <td>MKdKVBf20fU</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Mfx (CC) (samples)</td>
        <td>2020-12-10T19:00:24.100</td>
        <td>MmnpPCsNclV</td>
      </tr>
      <tr>
        <td>Bdq - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Bdq</td>
        <td>2020-12-10T19:00:24.256</td>
        <td>Mngd8Vigd4Y</td>
      </tr>
      <tr>
        <td>Mfx (CB) - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Mfx (CB)</td>
        <td>2020-12-10T19:00:48.300</td>
        <td>mqlNxC7wSrV</td>
      </tr>
      <tr>
        <td>Resistance to Rif</td>
        <td>Initial DST (solid media) - resistance to Rif</td>
        <td>2020-12-10T19:00:48.159</td>
        <td>mqOp1uuJddI</td>
      </tr>
      <tr>
        <td>Resistance to Pza</td>
        <td>Subsequent DST (liquid media) - resistance to Pza</td>
        <td>2020-12-10T19:00:24.413</td>
        <td>MsRE9GlLWdb</td>
      </tr>
      <tr>
        <td>Emb - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Emb</td>
        <td>2021-01-28T17:12:29.731</td>
        <td>mTyUyUzGra9</td>
      </tr>
      <tr>
        <td>Days from sample collection to inoculation date</td>
        <td>Days from sample collection in peripheral labs to inoculation date for culture (solid media) - (0 - 10+) days</td>
        <td>2020-12-10T19:00:48.477</td>
        <td>mvBsrx7Ouv6</td>
      </tr>
      <tr>
        <td>Resistance to Amk (samples)</td>
        <td>Initial DST (solid media) - resistance to Amk (samples)</td>
        <td>2021-01-28T17:12:29.938</td>
        <td>n1CL43NMU9h</td>
      </tr>
      <tr>
        <td>Lzd - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Lzd</td>
        <td>2020-12-10T19:00:48.792</td>
        <td>n1XPz9fsu3y</td>
      </tr>
      <tr>
        <td>Resistance to Rif (samples)</td>
        <td>Initial DST (solid media) - resistance to Rif (samples)</td>
        <td>2020-12-10T19:00:48.945</td>
        <td>n3WNvo7TMeo</td>
      </tr>
      <tr>
        <td>Lzd - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Lzd</td>
        <td>2020-12-10T19:00:49.090</td>
        <td>n62AD2ww4K3</td>
      </tr>
      <tr>
        <td>Pza - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Pza</td>
        <td>2020-12-10T19:00:24.563</td>
        <td>N6aDWfiF17p</td>
      </tr>
      <tr>
        <td>Samples tested by LPA (Rif/Inh)</td>
        <td>Samples with result for LPA (Rif/Inh)</td>
        <td>2020-12-10T19:00:49.666</td>
        <td>naxUYksE2eq</td>
      </tr>
      <tr>
        <td>Inh (CC) - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Inh (CC)</td>
        <td>2020-12-10T19:00:24.725</td>
        <td>Nd7PqCbehde</td>
      </tr>
      <tr>
        <td>Cfz - new patients</td>
        <td>Initial DST (solid media) - new patients - Cfz</td>
        <td>2020-12-10T19:00:49.235</td>
        <td>nDP7wEHhaNJ</td>
      </tr>
      <tr>
        <td>Amk - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Amk</td>
        <td>2020-12-10T19:00:49.822</td>
        <td>ne9D30vUOQ2</td>
      </tr>
      <tr>
        <td>Resistance to Lzd (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Lzd (samples)</td>
        <td>2020-12-10T19:00:24.891</td>
        <td>NiPJOiYsxiQ</td>
      </tr>
      <tr>
        <td>Lzd - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Lzd</td>
        <td>2020-12-10T19:00:49.963</td>
        <td>njD1tVTj84X</td>
      </tr>
      <tr>
        <td>Patients tested by Xpert MTB/RIF Ultra</td>
        <td>Patients tested by Xpert MTB/RIF Ultra</td>
        <td>2020-12-10T19:00:25.034</td>
        <td>NnWyYGrnQNb</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for subsequent DST (solid media)</td>
        <td>Patients with inoculation date for subsequent DST (solid media)</td>
        <td>2020-12-10T19:00:49.384</td>
        <td>nPTiRJBE9NZ</td>
      </tr>
      <tr>
        <td>Samples tested by LPA (Fq/2LI)</td>
        <td>Samples with result for LPA (Fq/2LI)</td>
        <td>2020-12-10T19:00:49.523</td>
        <td>nR4BBVBeTZ7</td>
      </tr>
      <tr>
        <td>Resistance to Lzd (samples)</td>
        <td>Initial DST (liquid media) - resistance to Lzd (samples)</td>
        <td>2020-12-10T19:00:25.184</td>
        <td>NuQW3zdrLf2</td>
      </tr>
      <tr>
        <td>Samples with culture inoculation date (liquid media)</td>
        <td>Samples with culture inoculation date (liquid media)</td>
        <td>2020-12-10T19:00:25.334</td>
        <td>O2mbE0WwCy1</td>
      </tr>
      <tr>
        <td>Mfx (CC) - new patients</td>
        <td>Initial DST (liquid media) - new patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:25.487</td>
        <td>O3HBBg5zrQ4</td>
      </tr>
      <tr>
        <td>New patients with MTB detected</td>
        <td>Xpert MTB/RIF - new patients with MTB detected</td>
        <td>2020-12-10T19:00:50.107</td>
        <td>o6bLNVpJ0cn</td>
      </tr>
      <tr>
        <td>Total enrolled patients (cumulative)</td>
        <td>DRS - Enrollments (cumulative)</td>
        <td>2020-12-10T19:00:50.247</td>
        <td>o7j0HGAyOT6</td>
      </tr>
      <tr>
        <td>Resistance to Amk (samples)</td>
        <td>Initial DST (liquid media) - resistance to Amk (samples)</td>
        <td>2021-01-28T17:12:27.809</td>
        <td>O8gN0OzPTxz</td>
      </tr>
      <tr>
        <td>Resistance to Bdq</td>
        <td>Initial DST (liquid media) - resistance to Bdq</td>
        <td>2020-12-10T19:00:50.945</td>
        <td>oamkDbKVY7J</td>
      </tr>
      <tr>
        <td>Mfx (CC) - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:26.110</td>
        <td>ObmR9NvVeRC</td>
      </tr>
      <tr>
        <td>Samples with subsequent DST inoculation date (solid media)</td>
        <td>Samples with subsequent DST inoculation date (solid media)</td>
        <td>2020-12-10T19:00:25.956</td>
        <td>ObRBFG9XaQZ</td>
      </tr>
      <tr>
        <td>Inh (CC) - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Inh (CC)</td>
        <td>2020-12-10T19:00:50.401</td>
        <td>oBw0wU3yO7C</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for initial DST (liquid media)</td>
        <td>Patients with inoculation date for initial DST (liquid media)</td>
        <td>2020-12-10T19:00:50.575</td>
        <td>oDgNwrOiBVm</td>
      </tr>
      <tr>
        <td>Lzd - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Lzd</td>
        <td>2021-01-28T17:12:27.990</td>
        <td>Of3zi9XgoAu</td>
      </tr>
      <tr>
        <td>Amk/Cap - previously treated patients</td>
        <td>LPA (Fq/2LI) - previously treated patients - Amk/Cap</td>
        <td>2020-12-10T19:00:51.107</td>
        <td>ohQ5OpmpMIR</td>
      </tr>
      <tr>
        <td>Mfx (CB) - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Mfx (CB)</td>
        <td>2020-12-10T19:00:26.404</td>
        <td>OiobLq9yzLX</td>
      </tr>
      <tr>
        <td>Patients with MTB not detected</td>
        <td>LPA (Rif/Inh) - patients with MTB not detected</td>
        <td>2020-12-10T19:00:26.548</td>
        <td>OnfjQrJmd3y</td>
      </tr>
      <tr>
        <td>Cfz - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Cfz</td>
        <td>2020-12-10T19:00:51.256</td>
        <td>onUkoC997zo</td>
      </tr>
      <tr>
        <td>Patients with invalid result</td>
        <td>LPA (Fq/2LI) - patients with invalid result</td>
        <td>2020-12-10T19:01:02.077</td>
        <td>Oq75BjEITeq</td>
      </tr>
      <tr>
        <td>Total enrolled patients (last 12 months, current month)</td>
        <td>DRS - Enrollments (last 12 months, current month)</td>
        <td>2020-12-10T19:00:50.770</td>
        <td>oYJX6cDshdO</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB)</td>
        <td>Initial DST (solid media) - resistance to Inh (CB)</td>
        <td>2020-12-10T19:00:25.814</td>
        <td>OYp1AckDY1K</td>
      </tr>
      <tr>
        <td>Resistance to Pza</td>
        <td>Initial DST (solid media) - resistance to Pza</td>
        <td>2020-12-10T19:00:51.404</td>
        <td>oz3WkbYtzQR</td>
      </tr>
      <tr>
        <td>Enrolled patients with unknown treatment history (cumulative)</td>
        <td>DRS enrollments - patients with unknown treatment history (cumulative)</td>
        <td>2020-12-10T19:00:51.568</td>
        <td>p31TCQDSQsR</td>
      </tr>
      <tr>
        <td>Dlm - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Dlm</td>
        <td>2020-12-10T19:00:51.735</td>
        <td>p496TnooKRY</td>
      </tr>
      <tr>
        <td>Resistance to Cfz</td>
        <td>Subsequent DST (liquid media) - resistance to Cfz</td>
        <td>2020-12-10T19:00:26.710</td>
        <td>P6vL3w0p01K</td>
      </tr>
      <tr>
        <td>Amk - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Amk</td>
        <td>2020-12-10T19:00:51.907</td>
        <td>p9eupZPh9gE</td>
      </tr>
      <tr>
        <td>Missing data report</td>
        <td>DRS - Missing data report</td>
        <td>2020-09-15T12:49:53.676</td>
        <td>PazB6GSITwK</td>
      </tr>
      <tr>
        <td>Emb - new patients</td>
        <td>Initial DST (solid media) - new patients - Emb</td>
        <td>2021-01-28T17:12:30.140</td>
        <td>pgcm0rJkyvE</td>
      </tr>
      <tr>
        <td>Resistance to Lzd</td>
        <td>Subsequent DST (solid media) - resistance to Lzd</td>
        <td>2020-12-10T19:00:26.858</td>
        <td>PHMhhdGBy6u</td>
      </tr>
      <tr>
        <td>Cfz - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Cfz</td>
        <td>2020-12-10T19:00:52.994</td>
        <td>piaFqrKhT4Q</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC)</td>
        <td>Subsequent DST (solid media) - resistance to Inh (CC)</td>
        <td>2020-12-10T19:00:27.009</td>
        <td>PL1gP2my7m4</td>
      </tr>
      <tr>
        <td>Rif - new patients</td>
        <td>Subsequent DST (solid media) - new patients - Rif</td>
        <td>2020-12-10T19:00:27.160</td>
        <td>PLu0C4TeOay</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>Initial DST (solid media) - resistance to Mfx (CB) (samples)</td>
        <td>2020-12-10T19:00:27.319</td>
        <td>PM9PVJ4yyz4</td>
      </tr>
      <tr>
        <td>Resistance to Dlm (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Dlm (samples)</td>
        <td>2021-01-28T17:12:30.340</td>
        <td>ppxfqkBMbG9</td>
      </tr>
      <tr>
        <td>Resistance to Inh</td>
        <td>LPA (Rif/Inh) - resistance to Inh</td>
        <td>2020-12-10T19:00:52.131</td>
        <td>pQBYrLdusMi</td>
      </tr>
      <tr>
        <td>Cfz - new patients</td>
        <td>Initial DST (liquid media) - new patients - Cfz</td>
        <td>2020-12-10T19:00:52.377</td>
        <td>pTumYaD0P0Q</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB)</td>
        <td>Initial DST (liquid media) - resistance to Inh (CB)</td>
        <td>2020-12-10T19:00:27.472</td>
        <td>PW0Z2EweAsF</td>
      </tr>
      <tr>
        <td>Patients with culture inoculation date (solid media)</td>
        <td>Patients with inoculation date for culture (solid media)</td>
        <td>2020-12-10T19:00:52.537</td>
        <td>pWqecnDABin</td>
      </tr>
      <tr>
        <td>Dlm - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Dlm</td>
        <td>2020-12-10T19:00:52.697</td>
        <td>pXn8CZJy39E</td>
      </tr>
      <tr>
        <td>Resistance to Cfz (samples)</td>
        <td>Initial DST (solid media) - resistance to Cfz (samples)</td>
        <td>2020-12-10T19:00:27.656</td>
        <td>PybhgC4XZTw</td>
      </tr>
      <tr>
        <td>Days from sample collection to sample arrival at NRL</td>
        <td>Days from sample collection in peripheral labs to arrival date at NRL - (0 - 10+) days</td>
        <td>2020-12-10T19:00:53.315</td>
        <td>q96JtVS7qYv</td>
      </tr>
      <tr>
        <td>Kan - new patients</td>
        <td>LPA (Fq/2LI) - new patients - Kan</td>
        <td>2020-12-10T19:00:27.821</td>
        <td>QEeBotUbOrT</td>
      </tr>
      <tr>
        <td>Dlm - new patients</td>
        <td>Initial DST (liquid media) - new patients - Dlm</td>
        <td>2020-12-10T19:00:53.516</td>
        <td>qG2g3ZdTHU9</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for initial DST (solid media)</td>
        <td>Patients with inoculation date for initial DST (solid media)</td>
        <td>2020-12-10T19:00:53.684</td>
        <td>qP0IsmPLpry</td>
      </tr>
      <tr>
        <td>Samples with culture inoculation date (solid media)</td>
        <td>Samples with culture inoculation date (solid media)</td>
        <td>2020-12-10T19:00:27.970</td>
        <td>QPmidkANRk0</td>
      </tr>
      <tr>
        <td>Resistance to Rif (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Rif (samples)</td>
        <td>2020-12-10T19:00:28.129</td>
        <td>QThQOSR2R2p</td>
      </tr>
      <tr>
        <td>Pza - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Pza</td>
        <td>2020-12-10T19:00:53.843</td>
        <td>qX7yrDi7mOq</td>
      </tr>
      <tr>
        <td>Resistance to Emb (samples)</td>
        <td>Initial DST (solid media) - resistance to Emb (samples)</td>
        <td>2020-12-10T19:00:28.299</td>
        <td>Qy3on973OWc</td>
      </tr>
      <tr>
        <td>Resistance to Dlm</td>
        <td>Subsequent DST (solid media) - resistance to Dlm</td>
        <td>2021-01-28T17:12:28.183</td>
        <td>R9EJpGiUM9A</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
        <td>Average number of days from sample collection to LPA (Fq/2LI) test at NRL</td>
        <td>2021-02-05T15:00:49.500</td>
        <td>RBNfEOS5n1h</td>
      </tr>
      <tr>
        <td>Emb - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Emb</td>
        <td>2020-12-10T19:00:28.899</td>
        <td>Rc8TYRizjqh</td>
      </tr>
      <tr>
        <td>Mfx (CC) - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:28.752</td>
        <td>RExxXicHhxr</td>
      </tr>
      <tr>
        <td>Bdq - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Bdq</td>
        <td>2020-12-10T19:00:54.021</td>
        <td>rjLCLnYpA1I</td>
      </tr>
      <tr>
        <td>Mfx (CB) - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Mfx (CB)</td>
        <td>2020-12-10T19:00:54.174</td>
        <td>rnTHBV8dv79</td>
      </tr>
      <tr>
        <td>Resistance to Dlm</td>
        <td>Subsequent DST (liquid media) - resistance to Dlm</td>
        <td>2021-01-28T17:12:28.365</td>
        <td>RxK8JDHqUud</td>
      </tr>
      <tr>
        <td>Resistance to Lzd</td>
        <td>Initial DST (solid media) - resistance to Lzd</td>
        <td>2020-12-10T19:00:54.379</td>
        <td>s1MmdQWxnj6</td>
      </tr>
      <tr>
        <td>Emb - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Emb</td>
        <td>2020-12-10T19:00:29.194</td>
        <td>S3yDihOC9Lf</td>
      </tr>
      <tr>
        <td>Inh - previously treated patients</td>
        <td>LPA (Rif/Inh) - previously treated - Inh</td>
        <td>2020-12-10T19:00:54.595</td>
        <td>se2PeR2RKmz</td>
      </tr>
      <tr>
        <td>Resistance to Rif</td>
        <td>Initial DST (liquid media) - resistance to Rif</td>
        <td>2020-12-10T19:00:29.338</td>
        <td>SHlHySH71S2</td>
      </tr>
      <tr>
        <td>Inh (CB) - new patients</td>
        <td>Initial DST (liquid media) - new patients - Inh (CB)</td>
        <td>2020-12-10T19:00:29.493</td>
        <td>SV4CPwttA3l</td>
      </tr>
      <tr>
        <td>Resistance to Fq (samples)</td>
        <td>LPA (Fq/2LI) - resistance to Fq (samples)</td>
        <td>2020-12-10T19:00:29.663</td>
        <td>SWekIBtNWd7</td>
      </tr>
      <tr>
        <td>Samples turn-around time (Cumulative %)</td>
        <td>Samples turn-around time (Cumulative %)</td>
        <td>2020-08-13T12:29:13.845</td>
        <td>SZfv73nGXHE</td>
      </tr>
      <tr>
        <td>Resistance to Amk</td>
        <td>Initial DST (liquid media) - resistance to Amk</td>
        <td>2020-12-10T19:00:29.827</td>
        <td>T0iBCI69Km2</td>
      </tr>
      <tr>
        <td>Cfz - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Cfz</td>
        <td>2020-12-10T19:00:30.007</td>
        <td>T1Zk1rLyysE</td>
      </tr>
      <tr>
        <td>Resistance to Pza (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Pza (samples)</td>
        <td>2020-12-10T19:00:54.842</td>
        <td>t3jOHDviiFd</td>
      </tr>
      <tr>
        <td>Patients with MTB not detected</td>
        <td>LPA (Fq/2LI) - patients with MTB not detected</td>
        <td>2020-12-10T19:00:30.157</td>
        <td>T9baH5KLoyq</td>
      </tr>
      <tr>
        <td>Turn-around time - Xpert MTB/RIF Ultra (Cumulative %)</td>
        <td>Turn-around time Xpert MTB/RIF Ultra (Cumulative %)</td>
        <td>2020-12-10T19:03:53.199</td>
        <td>tcBRmTXHNN7</td>
      </tr>
      <tr>
        <td>Resistance to Emb (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Emb (samples)</td>
        <td>2020-12-10T19:00:54.989</td>
        <td>tOfdO3dkP2H</td>
      </tr>
      <tr>
        <td>Patients with subsequent DST result (liquid media)</td>
        <td>Patients with result for subsequent DST (liquid media)</td>
        <td>2020-12-10T19:00:30.470</td>
        <td>Tr8iuaXmXEN</td>
      </tr>
      <tr>
        <td>Resistance to Lfx</td>
        <td>Initial DST (liquid media) - resistance to Lfx</td>
        <td>2020-12-10T19:00:30.328</td>
        <td>TSDVmBvIneN</td>
      </tr>
      <tr>
        <td>Resistance to Rif</td>
        <td>Subsequent DST (liquid media) - resistance to Rif</td>
        <td>2020-12-10T19:00:55.283</td>
        <td>tvH2WO4uyt1</td>
      </tr>
      <tr>
        <td>Lfx - new patients</td>
        <td>Initial DST (liquid media) - new patients - Lfx</td>
        <td>2020-12-10T19:00:55.136</td>
        <td>tXgkoP5dIbJ</td>
      </tr>
      <tr>
        <td>Previously treated patients with MTB detected</td>
        <td>Xpert MTB/RIF - previously treated patients with MTB detected</td>
        <td>2021-01-28T17:12:30.538</td>
        <td>u3Q5k5dUo8N</td>
      </tr>
      <tr>
        <td>Bdq - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Bdq</td>
        <td>2020-12-10T19:00:30.614</td>
        <td>U6Mb41OYPvp</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB)</td>
        <td>Subsequent DST (liquid media) - resistance to Inh (CB)</td>
        <td>2020-12-10T19:00:55.584</td>
        <td>u6w3chA0T7H</td>
      </tr>
      <tr>
        <td>Amk - new patients</td>
        <td>Initial DST (liquid media) - new patients - Amk</td>
        <td>2020-12-10T19:00:30.759</td>
        <td>UAJZ6hfu31F</td>
      </tr>
      <tr>
        <td>Resistance to Amk (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Amk (samples)</td>
        <td>2021-01-28T17:12:28.547</td>
        <td>Ufb3izlpsLk</td>
      </tr>
      <tr>
        <td>Days from sample collection to sample test date at NRL</td>
        <td>Days from sample collection to sample test date at NRL for Xpert MTB/RIF Ultra - (0 - 10+) days</td>
        <td>2020-12-10T19:00:56.014</td>
        <td>ugHwPgkobfk</td>
      </tr>
      <tr>
        <td>Fq - new patients</td>
        <td>LPA (Fq/2LI) - new patients - Fq</td>
        <td>2020-12-10T19:00:31.213</td>
        <td>UhrAlpevEYj</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC) (samples)</td>
        <td>Initial DST (solid media) - resistance to Mfx (CC) (samples)</td>
        <td>2020-12-10T19:00:31.365</td>
        <td>UkXxLzQCAso</td>
      </tr>
      <tr>
        <td>Bdq - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Bdq</td>
        <td>2020-12-10T19:00:30.921</td>
        <td>ULU6us1uP6h</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB)</td>
        <td>Subsequent DST (solid media) - resistance to Mfx (CB)</td>
        <td>2020-12-10T19:00:31.517</td>
        <td>UmnCZy3mVnB</td>
      </tr>
      <tr>
        <td>Patients with culture result (solid media)</td>
        <td>Patients with result for culture (solid media)</td>
        <td>2020-12-10T19:00:55.778</td>
        <td>uQWxOo4eWRf</td>
      </tr>
      <tr>
        <td>Inh (CB) - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Inh (CB)</td>
        <td>2020-12-10T19:00:56.226</td>
        <td>url5ZeOYYdo</td>
      </tr>
      <tr>
        <td>Dlm - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Dlm</td>
        <td>2020-12-10T19:00:31.666</td>
        <td>UsdQHSjPtWX</td>
      </tr>
      <tr>
        <td>Lfx - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Lfx</td>
        <td>2020-12-10T19:00:56.422</td>
        <td>ut3DEG03LR0</td>
      </tr>
      <tr>
        <td>Rif - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Rif</td>
        <td>2020-12-10T19:00:31.824</td>
        <td>UwArTJbask8</td>
      </tr>
      <tr>
        <td>Resistance to Lzd (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Lzd (samples)</td>
        <td>2020-12-10T19:00:56.662</td>
        <td>v6oY4jwBcT9</td>
      </tr>
      <tr>
        <td>Resistance to Pza (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Pza (samples)</td>
        <td>2020-12-10T19:00:56.830</td>
        <td>v7UvsEI4rSi</td>
      </tr>
      <tr>
        <td>Resistance to Emb</td>
        <td>Subsequent DST (solid media) - resistance to Emb</td>
        <td>2020-12-10T19:00:56.997</td>
        <td>vFjdo58Zxkr</td>
      </tr>
      <tr>
        <td>Rif - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Rif</td>
        <td>2020-12-10T19:00:57.479</td>
        <td>vh6zb8svQtQ</td>
      </tr>
      <tr>
        <td>Inh (CC) - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Inh (CC)</td>
        <td>2020-12-10T19:00:31.976</td>
        <td>VHE1E1MF8mV</td>
      </tr>
      <tr>
        <td>Fq - previously treated patients</td>
        <td>LPA (Fq/2LI) - previously treated patients - Fq</td>
        <td>2020-12-10T19:00:57.148</td>
        <td>vMjeNWMrRj4</td>
      </tr>
      <tr>
        <td>Mfx (CB) - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Mfx (CB)</td>
        <td>2020-12-10T19:00:57.307</td>
        <td>vOGNs1ZENKw</td>
      </tr>
      <tr>
        <td>Turn-around time - (Cumulative %)</td>
        <td>Turn-around time - LPA FQ/2LI (Cumulative %)</td>
        <td>2020-12-10T19:03:52.670</td>
        <td>VQXUgyRIYLC</td>
      </tr>
      <tr>
        <td>Samples with initial DST inoculation date (solid media)</td>
        <td>Samples with initial DST inoculation date (solid media)</td>
        <td>2020-11-16T09:54:29.545</td>
        <td>VSWXYPl2ICa</td>
      </tr>
      <tr>
        <td>Turn-around time - Culture in solid media (Cumulative %)</td>
        <td>Turn-around time - Culture in solid media (Cumulative %)</td>
        <td>2020-08-14T08:25:43.607</td>
        <td>VTxJ4FqPiZ1</td>
      </tr>
      <tr>
        <td>Lfx - new patients</td>
        <td>Initial DST (solid media) - new patients - Lfx</td>
        <td>2020-12-10T19:00:57.638</td>
        <td>w3oL3C68nXe</td>
      </tr>
      <tr>
        <td>Mfx (CC) - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:57.814</td>
        <td>w84CV2ceiJK</td>
      </tr>
      <tr>
        <td>Amk - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Amk</td>
        <td>2020-12-10T19:00:57.967</td>
        <td>w8Byd7sNBmq</td>
      </tr>
      <tr>
        <td>Mfx (CB) - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Mfx (CB)</td>
        <td>2020-12-10T19:00:58.135</td>
        <td>wCz17K0CRyW</td>
      </tr>
      <tr>
        <td>Resistance to Lzd</td>
        <td>Initial DST (liquid media) - resistance to Lzd</td>
        <td>2020-12-10T19:00:58.882</td>
        <td>wl9jNg38cz7</td>
      </tr>
      <tr>
        <td>Resistance to Rif</td>
        <td>Subsequent DST (solid media) - resistance to Rif</td>
        <td>2020-12-10T19:00:58.297</td>
        <td>wOLQDCSW8a6</td>
      </tr>
      <tr>
        <td>Resistance to Emb</td>
        <td>Initial DST (liquid media) - resistance to Emb</td>
        <td>2020-12-10T19:00:32.130</td>
        <td>WTPysmCBftB</td>
      </tr>
      <tr>
        <td>Days from sample collection o sample test date at NRL</td>
        <td>Days from sample collection to sample test date at NRL for Xpert MTB/RIF - (0 - 10+) days</td>
        <td>2020-12-10T19:00:58.478</td>
        <td>wUOoMaMdOjY</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC)</td>
        <td>Initial DST (liquid media) - resistance to Mfx (CC)</td>
        <td>2020-12-10T19:00:59.108</td>
        <td>wv296E9UrGG</td>
      </tr>
      <tr>
        <td>Emb - new patients</td>
        <td>Subsequent DST (liquid media) - new patients - Emb</td>
        <td>2021-01-28T17:12:30.738</td>
        <td>wvcK3HQicCX</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>Initial DST (solid media) - resistance to Inh (CB) (samples)</td>
        <td>2020-12-10T19:00:32.277</td>
        <td>WwPSvH8d1DL</td>
      </tr>
      <tr>
        <td>Days from sample collection to sample test date at NRL</td>
        <td>Days from sample collection to sample test date at NRL for LPA (Rif/Inh) - (0 - 10+) days</td>
        <td>2020-12-10T19:00:58.689</td>
        <td>wXY4PUTXTmR</td>
      </tr>
      <tr>
        <td>Dlm - new patients</td>
        <td>Initial DST (solid media) - new patients - Dlm</td>
        <td>2020-12-10T19:00:32.422</td>
        <td>WzGH9xTfC88</td>
      </tr>
      <tr>
        <td>Resistance to Rif (samples)</td>
        <td>Initial DST (liquid media) - resistance to Rif (samples)</td>
        <td>2020-12-10T19:00:59.511</td>
        <td>x4iYtBG0S7r</td>
      </tr>
      <tr>
        <td>Patients with culture inoculation date (liquid media)</td>
        <td>Patients with inoculation date for culture (liquid media)</td>
        <td>2020-12-10T19:00:32.571</td>
        <td>X6uSXh7tE1z</td>
      </tr>
      <tr>
        <td>Lfx - previously treated patients</td>
        <td>Initial DST (liquid media) - previously treated patients - Lfx</td>
        <td>2020-12-10T19:00:59.856</td>
        <td>xbdjjxp44oH</td>
      </tr>
      <tr>
        <td>Rif - new patients</td>
        <td>LPA (Rif/Inh) - new patients - Rif</td>
        <td>2020-12-10T19:01:00.005</td>
        <td>xcY7uEWjLzG</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to culture inoculation at NRL (liquid media)</td>
        <td>Average number of days from sample collection to culture inoculation (liquid media) at NRL</td>
        <td>2021-02-05T14:53:32.983</td>
        <td>xdOEArjEa8e</td>
      </tr>
      <tr>
        <td>Patients with invalid result</td>
        <td>LPA (Rif/Inh) - patients with invalid result</td>
        <td>2020-12-10T19:01:02.247</td>
        <td>xEFSLe7DvPF</td>
      </tr>
      <tr>
        <td>Enrolled new patients - (last 12 months, current month)</td>
        <td>DRS enrollments - new patients - (last 12 months, current month)</td>
        <td>2020-12-10T19:01:00.302</td>
        <td>xgCWbAaOW1U</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CB) (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Inh (CB) (samples)</td>
        <td>2020-12-10T19:00:32.729</td>
        <td>XgsLr4tC8r0</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB)</td>
        <td>Subsequent DST (liquid media) - resistance to Mfx (CB)</td>
        <td>2020-12-10T19:00:32.873</td>
        <td>XkSbmIgLtVQ</td>
      </tr>
      <tr>
        <td>Turn-around time - (Cumulative %)</td>
        <td>Turn-around time - LPA RIF/INH (Cumulative %)</td>
        <td>2020-12-10T19:03:53.373</td>
        <td>xm0ENkTvUGM</td>
      </tr>
      <tr>
        <td>Mfx (CC) - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Mfx (CC)</td>
        <td>2020-12-10T19:00:59.705</td>
        <td>xNRAnZIHoiI</td>
      </tr>
      <tr>
        <td>Dlm - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Dlm</td>
        <td>2020-12-10T19:01:00.480</td>
        <td>xqReKuS85hm</td>
      </tr>
      <tr>
        <td>Cfz - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Cfz</td>
        <td>2020-12-10T19:01:00.784</td>
        <td>ycFsgydGYQv</td>
      </tr>
      <tr>
        <td>Resistance to Inh (CC) (samples)</td>
        <td>Subsequent DST (liquid media) - resistance to Inh (CC) (samples)</td>
        <td>2020-12-10T19:01:00.628</td>
        <td>yIBx6hllNq8</td>
      </tr>
      <tr>
        <td>Amk - previously treated patients</td>
        <td>Subsequent DST (liquid media) - previously treated patients - Amk</td>
        <td>2020-12-10T19:01:00.935</td>
        <td>ymzubLo1nSE</td>
      </tr>
      <tr>
        <td>Resistance to Lfx</td>
        <td>Subsequent DST (liquid media) - resistance to Lfx</td>
        <td>2020-12-10T19:00:33.162</td>
        <td>Ypto0x4QbZG</td>
      </tr>
      <tr>
        <td>Inh (CB) - previously treated patients</td>
        <td>Subsequent DST (solid media) - previously treated patients - Inh (CB)</td>
        <td>2020-12-10T19:00:33.017</td>
        <td>YQ0QlU6Kxvi</td>
      </tr>
      <tr>
        <td>Patients with culture result (liquid media)</td>
        <td>Patients with result for culture (liquid media)</td>
        <td>2020-12-10T19:01:01.087</td>
        <td>ysMzvrIYK79</td>
      </tr>
      <tr>
        <td>Emb - previously treated patients</td>
        <td>Initial DST (solid media) - previously treated patients - Emb</td>
        <td>2020-12-10T19:00:33.304</td>
        <td>YvBd8YtBoYQ</td>
      </tr>
      <tr>
        <td>Samples with culture result (liquid media)</td>
        <td>Samples with culture result (liquid media)</td>
        <td>2020-12-10T19:01:01.251</td>
        <td>yvpMX7ZOZ1J</td>
      </tr>
      <tr>
        <td>Resistance to Amk</td>
        <td>Subsequent DST (liquid media) - resistance to Amk</td>
        <td>2020-12-10T19:01:01.443</td>
        <td>z7aFwudMAAQ</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CC)</td>
        <td>Subsequent DST (liquid media) - resistance to Mfx (CC)</td>
        <td>2020-12-10T19:00:33.630</td>
        <td>ZgHO5dOyAlw</td>
      </tr>
      <tr>
        <td>Average number of days from sample collection to culture inoculation at NRL (solid media)</td>
        <td>Average number of days from sample collection to culture inoculation (solid media) at NRL</td>
        <td>2021-02-05T14:56:10.547</td>
        <td>ZmrvMWkhiqL</td>
      </tr>
      <tr>
        <td>Mfx (CB) - new patients</td>
        <td>Initial DST (liquid media) - new patients - Mfx (CB)</td>
        <td>2020-12-10T19:01:01.689</td>
        <td>zOGy7fTKh2O</td>
      </tr>
      <tr>
        <td>Patients with initial DST result (liquid media)</td>
        <td>Patients with result for initial DST (liquid media)</td>
        <td>2020-11-13T15:12:47.368</td>
        <td>Zq5jhE1lASV</td>
      </tr>
      <tr>
        <td>Resistance to Lfx (samples)</td>
        <td>Initial DST (liquid media) - resistance to Lfx (samples)</td>
        <td>2020-12-10T19:00:33.949</td>
        <td>Zte7iUlyo6a</td>
      </tr>
      <tr>
        <td>Resistance to Mfx (CB) (samples)</td>
        <td>Subsequent DST (solid media) - resistance to Mfx (CB) (samples)</td>
        <td>2020-12-10T19:00:34.130</td>
        <td>ZwkbWeCIYPF</td>
      </tr>
      <tr>
        <td>Rif - previously treated patients</td>
        <td>LPA (Rif/Inh) - previously treated patients - Rif</td>
        <td>2020-12-10T19:01:01.867</td>
        <td>zxN2vfgQ5Ak</td>
      </tr>
      <tr>
        <td>Days from sample collection to sample test date at NRL</td>
        <td>Days from sample collection to sample test date at NRL for LPA (Fq/2LI) - (0 - 10+) days</td>
        <td>2020-12-10T19:00:34.287</td>
        <td>ZyuEkUrTrCc</td>
      </tr>
      <tr>
        <td>Resistance to Bdq</td>
        <td>Subsequent DST (solid media) - resistance to Bdq</td>
        <td>2020-12-10T19:00:33.477</td>
        <td>ZZ0Ox1hIaFo</td>
      </tr>
    </table>
    <h2 id="maps">Maps</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>RR-TB patients (by health facility)</td>
        <td> </td>
        <td>2020-12-10</td>
        <td>JUbkmvmNxbB</td>
      </tr>
      <tr>
        <td>RR-TB patients resistant to Fq (by health facility)</td>
        <td> </td>
        <td>2020-12-09</td>
        <td>u4FxBzXoiml</td>
      </tr>
      <tr>
        <td>Patients with isoniazid resistant and rifampicin susceptible TB (by health facility)</td>
        <td> </td>
        <td>2020-12-10</td>
        <td>vgIrIjzONuV</td>
      </tr>
    </table>
    <h2 id="eventReports">Event reports</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by Xpert MTB/RIF (last year, current year)</td>
        <td>Patients with multiple samples tested by Xpert MTB/RIF (last year, current year)</td>
        <td>2020-12-10</td>
        <td>fwBQKBqu6Ns</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by LPA FQ/2LI (last year, current year)</td>
        <td>Patients with multiple samples tested by LPA FQ/2LI (last year, current year)</td>
        <td>2020-12-10</td>
        <td>II20o7gabiz</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by LPA RIF/INH (last year, current year)</td>
        <td>Patients with multiple samples tested by LPA RIF/INH (last year, current year)</td>
        <td>2020-12-10</td>
        <td>j5Cp0UMwi6i</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by culture SM (last year, current year)</td>
        <td>Patients with multiple samples tested by culture SM (last year, current year)</td>
        <td>2020-12-10</td>
        <td>jTJdYcjkYtO</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by Initial DST SM (last year, current year)</td>
        <td>Patients with multiple samples tested by Initial DST SM (last year, current year)</td>
        <td>2020-12-10</td>
        <td>kbjk3qOzIIC</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by Initial DST LM (last year, current year)</td>
        <td>Patients with multiple samples tested by Initial DST LM (last year, current year)</td>
        <td>2020-12-10</td>
        <td>M52w6tE1m80</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by culture LM (last year, current year)</td>
        <td>Patients with multiple samples tested by culture LM (last year, current year)</td>
        <td>2020-12-10</td>
        <td>QlqhxnKkycE</td>
      </tr>
      <tr>
        <td>Missing data line list</td>
        <td>DRS - Missing data line list</td>
        <td>2020-12-10</td>
        <td>s66zrjrEKaa</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by Xpert MTB/RIF Ultra (last year, current year)</td>
        <td>Patients with multiple samples tested by Xpert MTB/RIF Ultra (last year, current year)</td>
        <td>2020-12-10</td>
        <td>VFTum2d1lQH</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by Subsequent DST SM (last year, current year)</td>
        <td>Patients with multiple samples tested by Subsequent DST SM (last year, current year)</td>
        <td>2020-12-10</td>
        <td>xvyAxvJ0H1k</td>
      </tr>
      <tr>
        <td>Patients with multiple samples tested by Subsequent DST LM (last year, current year)</td>
        <td>Patients with multiple samples tested by Subsequent DST LM (last year, current year)</td>
        <td>2020-12-10</td>
        <td>ZSc8l1iHQXE</td>
      </tr>
    </table>
    <h2 id="resources">Resources</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Description of indicators (Xpert MTB/RIF Ultra)</td>
        <td>2020-12-10</td>
        <td>bQgaslKTUvu</td>
      </tr>
      <tr>
        <td>Description of indicators (DRS: Culture SM)</td>
        <td>2020-12-10</td>
        <td>dCGOXSZLAJ8</td>
      </tr>
      <tr>
        <td>Description of indicators (DRS: Culture LM)</td>
        <td>2020-12-10</td>
        <td>SEf80hFQPEB</td>
      </tr>
      <tr>
        <td>Description of indicators (Xpert MTB/RIF)</td>
        <td>2020-12-10</td>
        <td>uJeXygGkX3v</td>
      </tr>
    </table>
    <h2 id="userGroups">User Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS data capture</td>
        <td>2021-01-25</td>
        <td>byS9SDFsd9p</td>
      </tr>
      <tr>
        <td>TB DRS access</td>
        <td>2021-01-25</td>
        <td>LHhbGJKXmzz</td>
      </tr>
      <tr>
        <td>TB DRS admin</td>
        <td>2021-01-25</td>
        <td>vN3X85Hxzno</td>
      </tr>
    </table>
    <h2>Users</h2>
    <table>
      <tr>
        <th>Username</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>who</td>
        <td>2020-07-07</td>
        <td>vUeLeQMSwhN</td>
      </tr>
    </table>
  </body>

</html>